<html lang="pt-BR"><head>
  <meta charset="UTF-8">
  <base href="https://www.coffito.gov.br/nsite/wp-content/themes/coffitoV4">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta name="author" content="COFFITO/Gledson Luciano da Silva">
  <title>Conselho Federal de Fisioterapia e Terapia Ocupacional - COFFITO</title>
  <meta name="title" content="Conselho Federal de Fisioterapia e Terapia Ocupacional">
  <meta name="description" content="Conselho Federal de Fisioterapia e Terapia Ocupacional - COFFITO, contendo informações referentes às profissões e aos profissionais de Fisioterapia e Terapia Ocupacional">
  
  <meta property="og:locale" content="pt_BR">
	<meta property="og:type" content="website">
	<meta property="og:title" content="COFFITO">
	<meta property="og:description" content="Conselho Federal de Fisioterapia e Terapia Ocupacional - COFFITO">
	<meta property="og:url" content="https://coffito.gov.br/">
	<meta property="og:site_name" content="COFFITO">
	<meta name="twitter:card" content="summary_large_image">
  
  
  <link rel="stylesheet" href="https://www.coffito.gov.br/nsite/wp-content/themes/coffitoV4/style.css">
  <link id="cssControle" rel="stylesheet" href="">

  <!-- <link rel="stylesheet" type="text/css" href="<//?php bloginfo('template_url'); ?>/css/print.css"  media="print" /> -->
  <!-- <link rel="stylesheet" href="./css/interno.css"> -->
  <link id="cssControle" rel="stylesheet" href="">
  <link href="https://www.coffito.gov.br/nsite/wp-content/themes/coffitoV4/css/fontawesome/css/fontawesome.css" rel="stylesheet">
  <link href="https://www.coffito.gov.br/nsite/wp-content/themes/coffitoV4/css/fontawesome/css/brands.css" rel="stylesheet">
  <link href="https://www.coffito.gov.br/nsite/wp-content/themes/coffitoV4/css/fontawesome/css/solid.css" rel="stylesheet">
  <link rel="shortcut icon" href="https://coffito.gov.br/nsite/wp-content/uploads/2016/07/favicon.png">

<script async="" src="https://www.googletagmanager.com/gtag/js?id=G-P59YF5KLJ6"></script><script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'G-P59YF5KLJ6');
</script></head>
<!-- Google tag (gtag.js) -->


<body>

    <header>
    <section id="container-regionais">
      <div id="menu-regionais">
        <a href="#juca" id="btn-menu-regionais">menu regionais</a>
        <ul>
          <li><a href="https://www.crefito1.org.br/" target="_blank" title="ir para o site CREFITO 1">CREFITO1</a></li>
          <li><a href="https://crefito2.gov.br/" target="_blank" title="ir para o site CREFITO 2">CREFITO2</a></li>
          <li><a href="http://www.crefito3.org.br/" target="_blank" title="ir para o site CREFITO 3">CREFITO3</a></li>
          <li><a href="https://crefito4.org.br/site/" target="_blank" title="ir para o site CREFITO 4">CREFITO4</a></li>
          <li><a href="https://crefito5.org.br/" target="_blank" title="ir para o site CREFITO 5">CREFITO5</a></li>
          <li><a href="https://www.crefito6.org.br/" target="_blank" title="ir para o site CREFITO 6">CREFITO6</a></li>
          <li><a href="https://crefito7.gov.br/" target="_blank" title="ir para o site CREFITO 7">CREFITO7</a></li>
          <li><a href="https://www.crefito8.gov.br/" target="_blank" title="ir para o site CREFITO 8">CREFITO8</a></li>
          <li><a href="https://crefito9.com.br/" target="_blank" title="ir para o site CREFITO 9">CREFITO9</a></li>
          <li><a href="https://crefito10.org.br/portal/" target="_blank" title="ir para o site CREFITO 10">CREFITO10</a></li>
          <li><a href="https://crefito11.gov.br/" target="_blank" title="ir para o site CREFITO 11">CREFITO11</a></li>
          <li><a href="https://crefito12.org.br/" target="_blank" title="ir para o site CREFITO 12">CREFITO12</a></li>
          <li><a href="https://www.crefito13.org.br/" target="_blank" title="ir para o site CREFITO 13">CREFITO13</a></li>
          <li><a href="https://www.crefito14.org.br/" target="_blank" title="ir para o site CREFITO 14">CREFITO14</a></li>
          <li><a href="https://www.crefito15.org.br/" target="_blank" title="ir para o site CREFITO 15">CREFITO15</a></li>
          <li><a href="http://crefito16.gov.br/" target="_blank" title="ir para o site CREFITO 16">CREFITO16</a></li>
          <li><a href="https://crefito17.org.br/" target="_blank" title="ir para o site CREFITO 17">CREFITO17</a></li>
          <li><a href="https://crefito18.org.br/" target="_blank" title="ir para o site CREFITO 18">CREFITO18</a></li>
          <li><a href="https://crefito19.org.br/" target="_blank">CREFITO19</a></li>
          <li><a href="https://crefito20.org.br/cr20/" target="_blank" title="ir para o site CREFITO 20">CREFITO20</a></li>
        </ul>
      </div>
    </section>

    <section id="container-topo">
      <div id="content-topo">
        <div id="content-topo-logo">
          <a title="Conselho Federal de Fisioterapia e Terapia Ocupacional" alt="Conselho Federal de Fisioterapia e Terapia Ocupacional" class="content-topo-logo-link" href="https://www.coffito.gov.br/nsite/"><img src="https://www.coffito.gov.br/nsite/wp-content/themes/coffitoV4/img/coffito-nova-logo.png" title="Conselho Federal de Fisioterapia e Terapia Ocupacional" alt="Conselho Federal de Fisioterapia e Terapia Ocupacional"></a>
          <div>Conselho Federal de Fisioterapia e Terapia Ocupacional</div>
        </div>

        <div id="content-topo-btn-menu">
          <button id="btn-menu-principal" class="btn-action"></button>
        </div>

      </div>
    </section>
    <nav>
      <section id="container-menu" class="btn-action">
        <div class="content-btn-fechar">
          <button class="btn-fecha-menu">Fechar</button>
        </div>
        <div id="content-busca">
          <div id="busca">
            <form role="search" method="get" id="searchform" action="https://www.coffito.gov.br/nsite/">
              <div>
                
				<div>
					<label class="screen-reader-text" for="s">Pesquisar por:</label>
					<input type="text" value=" 474" name="s" id="s">
					<input type="submit" id="searchsubmit" value="Pesquisar">
				</div>
			              </div></form>
            
          </div>
        </div>

        <div id="content-menu">
          <div>
            <nav>
              <h1>Principal</h1>
              <ul>
                <li id="menu-item-3587" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3587"><a href="https://www.coffito.gov.br/nsite/?page_id=3584" title="Comissão de Assuntos Parlamentares">Comissão de Ações Políticas</a></li>
<li id="menu-item-3639" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3639"><a href="https://www.coffito.gov.br/nsite/?page_id=3637">Eleições</a></li>
<li id="menu-item-20196" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-20196"><a target="_blank" href="https://coffito.incorp.tech/">Portal da Transparência</a></li>
<li id="menu-item-33171" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-33171"><a href="https://www.coffito.gov.br/nsite/?page_id=33165">Receita Saúde</a></li>
<li id="menu-item-25478" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25478"><a>Comunicação</a>
<ul class="sub-menu">
	<li id="menu-item-25479" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-25479"><a href="https://www.coffito.gov.br/nsite/?cat=2">Notícias</a></li>
	<li id="menu-item-25480" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25480"><a href="https://www.coffito.gov.br/nsite/?page_id=8188">Eventos</a></li>
	<li id="menu-item-17923" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-17923"><a href="https://www.coffito.gov.br/nsite/?page_id=17920">Contatos</a></li>
	<li id="menu-item-33054" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-33054"><a href="https://www.coffito.gov.br/nsite/?page_id=33052">Manual de Uso da Marca</a></li>
</ul>
</li>
<li id="menu-item-3636" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-3636"><a>Educação</a>
<ul class="sub-menu">
	<li id="menu-item-3634" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3634"><a target="_blank" href="http://psbe.ufrn.br/">Saúde baseada em evidências</a></li>
</ul>
</li>
<li id="menu-item-63" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-63"><a>Legislação</a>
<ul class="sub-menu">
	<li id="menu-item-61" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-61"><a href="https://www.coffito.gov.br/nsite/?page_id=39">Leis e Decretos</a></li>
	<li id="menu-item-62" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-62"><a href="https://www.coffito.gov.br/nsite/?page_id=19">Resoluções</a></li>
	<li id="menu-item-60" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-60"><a href="https://www.coffito.gov.br/nsite/?page_id=41">Acórdãos</a></li>
	<li id="menu-item-7301" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7301"><a href="https://www.coffito.gov.br/nsite/?page_id=7299">Portarias</a></li>
	<li id="menu-item-32901" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-32901"><a href="https://www.coffito.gov.br/nsite/?page_id=32897">Editais</a></li>
</ul>
</li>
<li id="menu-item-25470" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25470"><a>Registro de Títulos</a>
<ul class="sub-menu">
	<li id="menu-item-24992" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-24992"><a href="https://www.coffito.gov.br/nsite/?page_id=5416">Tipos de Títulos</a></li>
	<li id="menu-item-24985" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-24985"><a href="https://www.coffito.gov.br/nsite/?page_id=24979">Conheça os processos para obtenção</a></li>
	<li id="menu-item-24984" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-24984"><a href="https://www.coffito.gov.br/nsite/?page_id=24981">Provas de especialidades</a></li>
</ul>
</li>
<li id="menu-item-15761" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-15761"><a>Transparência e Prestação de Contas</a>
<ul class="sub-menu">
	<li id="menu-item-21950" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-21950"><a target="_blank" href="https://accredit.incorp.tech/incorpweb/portal/relatoriopublicado/?l=12">Informações Contábeis e Financeiras</a></li>
	<li id="menu-item-17739" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-17739"><a href="https://www.coffito.gov.br/nsite/?page_id=17613">Relatório de Gestão</a></li>
</ul>
</li>
              </ul>
            </nav>
          </div>
          <div>
            <nav>
              <h1>Fisioterapia</h1>
              <ul>
                <li id="menu-item-2373" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2373"><a href="https://www.coffito.gov.br/nsite/?page_id=2341">Definição</a></li>
<li id="menu-item-2372" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2372"><a href="https://www.coffito.gov.br/nsite/?page_id=2344">Formação Acadêmica e Profissional</a></li>
<li id="menu-item-2371" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2371"><a href="https://www.coffito.gov.br/nsite/?page_id=2346">Código de Ética</a></li>
<li id="menu-item-2370" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2370"><a href="https://www.coffito.gov.br/nsite/?page_id=2348" title="Código Brasileiro de Ocupações">CBO – Classificação Brasileira de Ocupações</a></li>
<li id="menu-item-2369" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2369"><a href="https://www.coffito.gov.br/nsite/?page_id=2350">Especialidades</a></li>
<li id="menu-item-26190" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-26190"><a href="https://www.coffito.gov.br/nsite/?page_id=26180">Atuação e/ou utilização de técnica</a></li>
<li id="menu-item-2368" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2368"><a href="https://www.coffito.gov.br/nsite/?page_id=2353" title="Referencial Nacional de Procedimentos Fisioterapêuticos">RBPF – Referencial Brasileiro de Procedimentos Fisioterapêuticos</a></li>
<li id="menu-item-23209" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-23209"><a href="https://www.coffito.gov.br/nsite/?page_id=23194" title="Classificação Brasileira de Diagnósticos Fisioterapêuticos">CBDF</a></li>
<li id="menu-item-2367" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2367"><a href="https://www.coffito.gov.br/nsite/?page_id=2355">Jornada de Trabalho</a></li>
<li id="menu-item-2366" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2366"><a href="https://www.coffito.gov.br/nsite/?page_id=2357">Regulamentação</a></li>
<li id="menu-item-2365" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2365"><a href="https://www.coffito.gov.br/nsite/?page_id=2359">Símbolo</a></li>
<li id="menu-item-2364" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2364"><a href="https://www.coffito.gov.br/nsite/?page_id=2361">Parâmetro Assistenciais</a></li>
<li id="menu-item-3580" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3580"><a href="https://www.coffito.gov.br/nsite/?page_id=3578">Sindicatos</a></li>
<li id="menu-item-6991" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6991"><a href="#">Associações</a>
<ul class="sub-menu">
	<li id="menu-item-6990" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6990"><a href="https://www.coffito.gov.br/nsite/?page_id=6988">Associações Conveniadas</a></li>
	<li id="menu-item-6998" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6998"><a href="https://www.coffito.gov.br/nsite/?page_id=6996">Associações de Ensino</a></li>
	<li id="menu-item-7002" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7002"><a href="https://www.coffito.gov.br/nsite/?page_id=6999">Associações de Fisioterapia</a></li>
	<li id="menu-item-7009" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7009"><a href="https://www.coffito.gov.br/nsite/?page_id=7006">Sociedade e Sindicato</a></li>
	<li id="menu-item-7012" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7012"><a href="https://www.coffito.gov.br/nsite/?page_id=7010">Associações Internacionais</a></li>
</ul>
</li>
              </ul>
            </nav>
          </div>
          <div>
            <nav>
              <h1>Terapia Ocupacional</h1>
              <ul>
                <li id="menu-item-3408" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3408"><a href="https://www.coffito.gov.br/nsite/?page_id=3382">Definição</a></li>
<li id="menu-item-3410" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3410"><a href="https://www.coffito.gov.br/nsite/?page_id=3384">Formação Acadêmica e Profissional</a></li>
<li id="menu-item-3407" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3407"><a href="https://www.coffito.gov.br/nsite/?page_id=3386">Código de Ética</a></li>
<li id="menu-item-3406" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3406"><a href="https://www.coffito.gov.br/nsite/?page_id=3388" title="Classificação Brasileira de Ocupações">CBO – Classificação Brasileira de Ocupações</a></li>
<li id="menu-item-3409" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3409"><a href="https://www.coffito.gov.br/nsite/?page_id=3390">Especialidades</a></li>
<li id="menu-item-26193" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-26193"><a href="https://www.coffito.gov.br/nsite/?page_id=26183">Atuação e/ou utilização de técnica</a></li>
<li id="menu-item-3414" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3414"><a href="https://www.coffito.gov.br/nsite/?page_id=3392" title="Referencial Nacional de Honorários de Terapia Ocupacional">RBPTO – Referencial Brasileiro de Procedimentos Terapêuticos Ocupacionais</a></li>
<li id="menu-item-3411" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3411"><a href="https://www.coffito.gov.br/nsite/?page_id=3395">Jornada de Trabalho</a></li>
<li id="menu-item-3415" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3415"><a href="https://www.coffito.gov.br/nsite/?page_id=3397">Regulamentação</a></li>
<li id="menu-item-3416" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3416"><a href="https://www.coffito.gov.br/nsite/?page_id=3399">Brasão</a></li>
<li id="menu-item-3413" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3413"><a href="https://www.coffito.gov.br/nsite/?page_id=3402">Parâmetros Assistenciais</a></li>
<li id="menu-item-3412" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3412"><a href="https://www.coffito.gov.br/nsite/?page_id=3404" title="Lista de Procedimentos da Terapia Ocupacional">LPTO</a></li>
<li id="menu-item-3581" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3581"><a href="https://www.coffito.gov.br/nsite/?page_id=3578">Sindicatos</a></li>
<li id="menu-item-7024" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-7024"><a href="#">Associações</a>
<ul class="sub-menu">
	<li id="menu-item-7025" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7025"><a href="https://www.coffito.gov.br/nsite/?page_id=7013">Associações Conveniadas</a></li>
	<li id="menu-item-7026" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7026"><a href="https://www.coffito.gov.br/nsite/?page_id=7015">Associações Terapia Ocupacional</a></li>
	<li id="menu-item-7027" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7027"><a href="https://www.coffito.gov.br/nsite/?page_id=7019">Associações Profissionais</a></li>
	<li id="menu-item-7028" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7028"><a href="https://www.coffito.gov.br/nsite/?page_id=7017">Sociedade e Sindicato</a></li>
	<li id="menu-item-7029" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7029"><a href="https://www.coffito.gov.br/nsite/?page_id=7021">Associações Internacionais</a></li>
</ul>
</li>
              </ul>
            </nav>
          </div>
          <div>
            <nav>
              <h1>Acesso à Informação</h1>
              <ul>
                <li id="menu-item-25488" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25488"><a>Institucional</a>
<ul class="sub-menu">
	<li id="menu-item-25489" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25489"><a href="https://www.coffito.gov.br/nsite/?page_id=3676">Estrutura Organizacional</a></li>
	<li id="menu-item-25491" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25491"><a href="https://www.coffito.gov.br/nsite/?page_id=9">Competências</a></li>
	<li id="menu-item-25495" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25495"><a href="https://www.coffito.gov.br/nsite/?page_id=25492">Base jurídica da estrutura organizacional e das competências</a></li>
	<li id="menu-item-25497" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25497"><a href="https://www.coffito.gov.br/nsite/?page_id=13">Quem é quem</a></li>
	<li id="menu-item-25508" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25508"><a href="https://www.coffito.gov.br/nsite/?page_id=25506">Perfil profissional</a></li>
	<li id="menu-item-25513" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25513"><a href="https://www.coffito.gov.br/nsite/?page_id=25509">Horários de atendimento</a></li>
	<li id="menu-item-25514" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25514"><a href="https://www.coffito.gov.br/nsite/?page_id=19">Atos Normativos</a></li>
</ul>
</li>
<li id="menu-item-25542" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25542"><a>Ações e Programas</a>
<ul class="sub-menu">
	<li id="menu-item-25537" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25537"><a href="https://www.coffito.gov.br/nsite/?page_id=25524">Programas, projetos e ações, obras e atividades</a></li>
	<li id="menu-item-25536" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25536"><a href="https://www.coffito.gov.br/nsite/?page_id=25526">Carta de Serviços</a></li>
	<li id="menu-item-25535" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25535"><a href="https://www.coffito.gov.br/nsite/?page_id=25528">Concessões de recursos financeiros ou renúncias de receitas</a></li>
	<li id="menu-item-25534" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25534"><a href="https://www.coffito.gov.br/nsite/?page_id=25531">Governança</a></li>
</ul>
</li>
<li id="menu-item-25543" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25543"><a>Participação Social</a>
<ul class="sub-menu">
	<li id="menu-item-25551" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25551"><a href="https://www.coffito.gov.br/nsite/?page_id=25547">Ouvidoria</a></li>
	<li id="menu-item-25554" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25554"><a href="https://www.coffito.gov.br/nsite/?page_id=25552">Audiências e Consultas Públicas</a></li>
	<li id="menu-item-25544" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25544"><a href="https://www.coffito.gov.br/nsite/?page_id=49">Conselhos e Órgãos Colegiados</a></li>
	<li id="menu-item-25545" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25545"><a href="https://www.coffito.gov.br/nsite/?page_id=51">Endereços Regionais</a></li>
	<li id="menu-item-25557" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25557"><a href="https://www.coffito.gov.br/nsite/?page_id=25555">Conferências</a></li>
	<li id="menu-item-25560" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25560"><a href="https://www.coffito.gov.br/nsite/?page_id=25558">Editais de chamamento público</a></li>
</ul>
</li>
<li id="menu-item-25571" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25571"><a>Auditorias</a>
<ul class="sub-menu">
	<li id="menu-item-25575" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25575"><a href="https://www.coffito.gov.br/nsite/?page_id=25567">Prestação de contas</a></li>
	<li id="menu-item-33034" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-33034"><a href="https://accredit.incorp.tech/incorpweb/portal/pagina/?p=19">Rol de Responsáveis</a></li>
	<li id="menu-item-25579" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25579"><a href="https://www.coffito.gov.br/nsite/?page_id=25577">Relatório da CGU</a></li>
	<li id="menu-item-25582" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25582"><a href="https://www.coffito.gov.br/nsite/?page_id=25580">Plano Anual de Atividades de Auditoria Interna (PAINT)</a></li>
	<li id="menu-item-25585" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25585"><a href="https://www.coffito.gov.br/nsite/?page_id=25583">Relatório Anual de Atividades de Auditoria Interna (RAINT)</a></li>
	<li id="menu-item-25588" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25588"><a href="https://www.coffito.gov.br/nsite/?page_id=25586">Ações de supervisão, controle e correição</a></li>
</ul>
</li>
<li id="menu-item-25607" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25607"><a>Receitas e Despesas</a>
<ul class="sub-menu">
	<li id="menu-item-33033" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-33033"><a href="https://accredit.incorp.tech/incorpweb/portal/relatorios/?nomeRelatorio=ComparativoReceitaPrevistaRealizada">Receita Pública</a></li>
	<li id="menu-item-25612" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25612"><a href="https://www.coffito.gov.br/nsite/?page_id=25609">Quadro de detalhamento de programas, por unidade orçamentária</a></li>
	<li id="menu-item-25619" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25619"><a href="https://www.coffito.gov.br/nsite/?page_id=25613">Quadro de execução de despesas, por unidade orçamentária</a></li>
	<li id="menu-item-33019" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-33019"><a target="_blank" href="https://accredit.incorp.tech/incorpweb/portal/listagemdespesa/?l=11">Despesas com diárias e passagens</a></li>
	<li id="menu-item-25621" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25621"><a href="https://www.coffito.gov.br/nsite/?page_id=25617">Notas fiscais eletrônicas</a></li>
</ul>
</li>
<li id="menu-item-25633" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25633"><a>Licitações e Contratos</a>
<ul class="sub-menu">
	<li id="menu-item-25635" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25635"><a href="https://www.coffito.gov.br/nsite/?page_id=3605">Licitações</a></li>
	<li id="menu-item-25634" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25634"><a href="https://www.coffito.gov.br/nsite/?page_id=25631">Contratos</a></li>
</ul>
</li>
<li id="menu-item-25636" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25636"><a>Empregados Públicos</a>
<ul class="sub-menu">
	<li id="menu-item-25644" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25644"><a href="https://www.coffito.gov.br/nsite/?page_id=15753">Empregados</a></li>
	<li id="menu-item-25653" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25653"><a href="https://www.coffito.gov.br/nsite/?page_id=3647">Concurso Público</a></li>
</ul>
</li>
<li id="menu-item-25671" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25671"><a>Serviço de Informação ao Cidadão (SIC)</a>
<ul class="sub-menu">
	<li id="menu-item-25686" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25686"><a href="https://www.coffito.gov.br/nsite/?page_id=25674">Informações sobre o SIC</a></li>
	<li id="menu-item-25687" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25687"><a href="https://www.coffito.gov.br/nsite/?page_id=25678">Modelo de formulário de solicitação de informação e recurso</a></li>
	<li id="menu-item-25688" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25688"><a href="https://www.coffito.gov.br/nsite/?page_id=25680">FalaBR</a></li>
	<li id="menu-item-25689" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25689"><a href="https://www.coffito.gov.br/nsite/?page_id=25684">Relatório Anual da Autoridade de Monitoramento</a></li>
</ul>
</li>
<li id="menu-item-25704" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25704"><a>Dados Abertos</a>
<ul class="sub-menu">
	<li id="menu-item-25705" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25705"><a href="https://www.coffito.gov.br/nsite/?page_id=25696">Planos de Dados Abertos (PDA) vigentes e anteriores, bem como comunicados de eventuais alterações em seus conteúdos.</a></li>
	<li id="menu-item-25706" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25706"><a href="https://www.coffito.gov.br/nsite/?page_id=25698">Disponibilização das bases de dados</a></li>
	<li id="menu-item-25707" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25707"><a href="https://www.coffito.gov.br/nsite/?page_id=25701">Relatórios anual de execução do PDA</a></li>
</ul>
</li>
<li id="menu-item-29005" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-29005"><a href="https://www.coffito.gov.br/nsite/?page_id=29001">Política de Privacidade</a></li>
<li id="menu-item-25692" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-25692"><a href="https://www.coffito.gov.br/nsite/?page_id=25690">FAQ – Perguntas Frequentes</a></li>
              </ul>
            </nav>
          </div>
        </div>
        <div class="content-btn-fechar">
          <button class="btn-fecha-menu">Fechar</button>
        </div>
      </section>
    </nav>
    <section id="container-acessibilidade">
      <div id="content-acessibilidade">
        <div id="bread-crumb">
          <!--<div id="campanha-fita">
            <img src="https://www.coffito.gov.br/nsite/wp-content/themes/coffitoV4/img/fita-azul.png" />
          </div>-->
          <div id="content-bread">
            <a href="https://www.coffito.gov.br/nsite"><i class="fa-solid fa-house"></i></a> »&nbsp; <span class="current">Resultados da pesquisa para " 474"</span> (Page 2)          </div>
        </div>
        <div id="content-topo-acessibilidade">
          <ul>
            <li>
              <a id="diminuir-fonte" data-valor="diminuir" title="Diminuir Fonte">A-</a>
            </li>
            <!-- normal fonte -->
            <li>
              <a id="normal-fonte" data-valor="normal" title="Normal Fonte">A</a>
            </li>
            <!-- AUMENTAR FONTE -->
            <li>
              <a id="aumentar-fonte" data-valor="aumentar" title="Aumentar Fonte">A+</a>
            </li>
            <!--contraste fonte-->
            <li>
              <a id="contraste-fonte" data-valor="contraste" title="Contraste">A</a>
            </li>
            <!--normalcontraste fonte-->
            <li>
              <a id="normalContraste-fonte" data-valor="normalContraste" title="Normal Contraste">A</a>
            </li>
            <li>
              <a id="procura" data-valor="procura" title="pesquisar"><i id="procura2" data-valor="procura" class="fa-solid fa-magnifying-glass"></i></a>
            </li>
          </ul>
        </div>

      </div>
    </section>
  </header><div id="geral">
	<main>
		<section id="container-interno">
						<div id="container-category" class="content-interno">
				
					
						<div id="post-6473" class="divs-interno">
							<article>
								<div class="content-img">
									<div class="box-notdestaque">
										<div class="container-img-noticia">
											<img src=" https://www.coffito.gov.br/nsite/wp-content/uploads/2017/02/sonafe-200x100.jpg">
										</div>
									</div>
								</div>
								<div class="content-data">

									<span class="data">24 de fevereiro de 2017</span>
								</div>
								<div class="content-text">
									<header>
										<h1>VIII Congresso Brasileiro – VI Congresso Internacional da Sociedade Nacional da Fisioterapia Esportiva</h1>
									</header>
									<p>Local: Caldas Novas / GO<br>
Data: 11 a 15 de Outubro de 2017<br>
Mais Informações:&nbsp;http://www.sonafe2017.com.br/site/principal.asp</p>
<p>&nbsp;</p>
<p>Prezados congressistas,</p>
<p>É com enorme prazer que teremos pela primeira vez na história da Sociedade Nacional de Fisioterapia Esportiva-SONAFE, Congresso Nacional e Internacional no coração do Brasil. Foi escolhido para sediar esse grande evento de Fisioterapia Esportiva, uma das cidades mais conhecidas do Centro-Oeste, por ter um dos maiores centros de águas termais naturais do mundo, Caldas Novas.</p>
<p>O congresso ocorrerá exatamente um ano após os jogos olímpicos do Rio 2016, sendo um momento único para trocarmosexperiências de sucesso além de apresentarmos muitas novidades e acontecimentos dos jogos.</p>
<p>O tema central do nosso congresso será “Fisioterapia Esportiva em Movimento”, sendo grande parte da programação voltada para a prevenção, avaliação, tratamento e reabilitação de disfunções do movimento humano. Buscando assim a essência da nossa profissão, a função humana, com foco nas lesões e disfunções inerentes aos esportes e aos exercícios físicos.<br>
A escolha de uma cidade como Caldas Novas vem de encontro ao objetivo desse próximo congresso em buscar aproximar e interagir muito os congressistas, possibilitando o&nbsp;<em>networking,&nbsp;</em>a troca de experiências, o aprendizado prático e científico com os maiores nomes da fisioterapia esportiva do Brasil e do Mundo.</p>
<p>A SONAFE Brasil, a SONAFE Goiás, e o Centro Oeste te aguardam de braços abertos para esse congresso que ficará na história da fisioterapia brasileira.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p align="center">Thiago Vilela Lemos<br>
<strong>Presidente do Congresso</strong></p>
<p align="center">
</p><p align="center"><a href="http://coffito.gov.br/nsite/wp-content/uploads/2017/02/sonafe.jpg"><img fetchpriority="high" decoding="async" class="alignnone size-full wp-image-6474" src="http://coffito.gov.br/nsite/wp-content/uploads/2017/02/sonafe.jpg" alt="sonafe" width="1107" height="287" srcset="https://www.coffito.gov.br/nsite/wp-content/uploads/2017/02/sonafe.jpg 1107w, https://www.coffito.gov.br/nsite/wp-content/uploads/2017/02/sonafe-300x78.jpg 300w, https://www.coffito.gov.br/nsite/wp-content/uploads/2017/02/sonafe-768x199.jpg 768w, https://www.coffito.gov.br/nsite/wp-content/uploads/2017/02/sonafe-1024x265.jpg 1024w, https://www.coffito.gov.br/nsite/wp-content/uploads/2017/02/sonafe-600x156.jpg 600w" sizes="(max-width: 1107px) 100vw, 1107px"></a></p>
<p align="center">
</p><p align="center">

								</p></div>
							</article>

						</div>
					
						<div id="post-5361" class="divs-interno">
							<article>
								<div class="content-img">
									<div class="box-notdestaque">
										<div class="container-img-noticia">
											<img src=" https://www.coffito.gov.br/nsite/wp-content/uploads/2016/10/14718742_1800621260227309_8814742984439811691_n-200x100.png">
										</div>
									</div>
								</div>
								<div class="content-data">

									<span class="data">26 de outubro de 2016</span>
								</div>
								<div class="content-text">
									<header>
										<h1>I Jornada Científica CREFITO 15 – Integrando Saberes</h1>
									</header>
									<p>Data: 28 e 29 de Outubro<br>
Local: Hotel Sheraton, Vitória<br>
Informações:&nbsp;<a href="http://www.crefito15.org.br/" target="_blank">http://www.crefito15.org.br/<br>
I</a>nscrições:&nbsp;<a href="https://goo.gl/dqw9pa" target="_blank">https://goo.gl/dqw9pa</a>.</p>
<p>Com o tema “Integrando Saberes”, a jornada apresenta uma programação variada, com o objetivo de discutir questões atuais da Fisioterapia e da Terapia Ocupacional e trocar experiências entre os profissionais e acadêmicos. Confira abaixo a programação completa e programe-se!<br>
<a href="http://coffito.gov.br/nsite/wp-content/uploads/2016/10/14718742_1800621260227309_8814742984439811691_n.png"><img decoding="async" class="alignnone size-full wp-image-5362" src="http://coffito.gov.br/nsite/wp-content/uploads/2016/10/14718742_1800621260227309_8814742984439811691_n.png" alt="14718742_1800621260227309_8814742984439811691_n" width="800" height="800" srcset="https://www.coffito.gov.br/nsite/wp-content/uploads/2016/10/14718742_1800621260227309_8814742984439811691_n.png 800w, https://www.coffito.gov.br/nsite/wp-content/uploads/2016/10/14718742_1800621260227309_8814742984439811691_n-150x150.png 150w, https://www.coffito.gov.br/nsite/wp-content/uploads/2016/10/14718742_1800621260227309_8814742984439811691_n-300x300.png 300w, https://www.coffito.gov.br/nsite/wp-content/uploads/2016/10/14718742_1800621260227309_8814742984439811691_n-768x768.png 768w, https://www.coffito.gov.br/nsite/wp-content/uploads/2016/10/14718742_1800621260227309_8814742984439811691_n-600x600.png 600w" sizes="(max-width: 800px) 100vw, 800px"></a></p>

								</div>
							</article>

						</div>
					
						<div id="post-5186" class="divs-interno">
							<article>
								<div class="content-img">
									<div class="box-notdestaque">
										<div class="container-img-noticia">
											<img src=" https://www.coffito.gov.br/nsite/wp-content/uploads/2016/09/registro-profissional-200x100.jpg">
										</div>
									</div>
								</div>
								<div class="content-data">

									<span class="data">20 de setembro de 2016</span>
								</div>
								<div class="content-text">
									<header>
										<h1>COFFITO publica nova resolução sobre registro profissional</h1>
									</header>
									<p><a href="http://coffito.gov.br/nsite/wp-content/uploads/2016/09/registro-profissional-e1474405651842.jpg"><img decoding="async" class="centro aligncenter wp-image-5187 size-full" src="http://coffito.gov.br/nsite/wp-content/uploads/2016/09/registro-profissional-e1474405651842.jpg" alt="registro-profissional" width="700" height="700"></a><br>
O COFFITO, em atenção às necessidades dos conselhos regionais, editou as normativas referentes ao Registro Profissional e encerrou a concessão de Licença Temporária de Trabalho (LTT). <a href="https://www.coffito.gov.br/nsite/?p=5186#more-5186" class="more-link">Continue reading <span class="meta-nav">»</span></a></p>

								</div>
							</article>

						</div>
					
						<div id="post-5150" class="divs-interno">
							<article>
								<div class="content-img">
									<div class="box-notdestaque">
										<div class="container-img-noticia">
											<img src=" https://www.coffito.gov.br/nsite/wp-content/uploads/2016/09/intensiva-e-cardio-200x100.jpg">
										</div>
									</div>
								</div>
								<div class="content-data">

									<span class="data">15 de setembro de 2016</span>
								</div>
								<div class="content-text">
									<header>
										<h1>COFFITO publica novos acórdãos sobre a atuação do fisioterapeuta nas áreas de Terapia Intensiva e Cardiorrespiratória</h1>
									</header>
									<p><a href="http://coffito.gov.br/nsite/wp-content/uploads/2016/09/intensiva-e-cardio-e1473951058106.jpg"><img loading="lazy" decoding="async" class="centro aligncenter wp-image-5151 size-full" src="http://coffito.gov.br/nsite/wp-content/uploads/2016/09/intensiva-e-cardio-e1473951058106.jpg" alt="intensiva-e-cardio" width="700" height="700"></a></p>
<p>O COFFITO, em parceria com a Associação Brasileira de Fisioterapia Cardiorrespiratória e Fisioterapia em Terapia Intensiva (ASSOBRAFIR), publicou sete acórdãos relacionados ao trabalho do fisioterapeuta <a href="https://www.coffito.gov.br/nsite/?p=5150#more-5150" class="more-link">Continue reading <span class="meta-nav">»</span></a></p>

								</div>
							</article>

						</div>
					
						<div id="post-3598" class="divs-interno">
							<article>
								<div class="content-img">
									<div class="box-notdestaque">
										<div class="container-img-noticia">
											<img src=" ">
										</div>
									</div>
								</div>
								<div class="content-data">

									<span class="data">15 de abril de 2016</span>
								</div>
								<div class="content-text">
									<header>
										<h1>Associações</h1>
									</header>
									<h2>Associações Conveniadas</h2>
<h2>ACUPUNTURA</h2>
<h3>AFA BRASIL – Associação dos Fisioterapeutas Acupunturistas do Brasil</h3>
<p>Tel.: (47) 3363-4240<br>
Site: <a href="http://www.afabrasil.org.br" target="_blank" rel="noopener noreferrer">www.afabrasil.org.br</a><br>
E-mail: <a href="mailto:neysmith@gmail.com">neysmith@gmail.com</a><br>
Endereço: Rua 2850, número 470 sala 804 – Balneário Camboriú – SC<br>
CEP:88330-363<br>
Presidente – Dr. Ney Peixoto Smith</p>
<h3>SOBRAFISA – Sociedade Brasileira de Fisioterapeutas Acupunturistas</h3>
<p>Tel.: (41) 3225 1844<br>
Site:&nbsp;<a href="http://www.sobrafisa.org.br/" target="_blank" rel="noopener noreferrer">www.sobrafisa.org.br</a><br>
E-mail:&nbsp;<a href="mailto:presidencia@sobrafisa.org.br" target="_blank" rel="noopener noreferrer">sobrafisa@sobrafisa.org.br</a><br>
Endereço: Rua Voluntários da Pátria, nº. 215, 3º. Andar, Centro<br>
Curitiba – PR – CEP 80020-000<br>
Presidente – Dra. Sandra Silvério Lopes</p>
<h2>AQUÁTICA</h2>
<h3>ABFA – Associação Brasileira de Fisioterapia Aquática</h3>
<p>Tel.: (21) 98629-9843<br>
Site: <a href="http://www.abfaquatica.com.br" target="_blank" rel="noopener noreferrer">www.abfaquatica.com.br</a><br>
Email: <a href="mailto:contato@abfaquatica.com.br">contato@abfaquatica.com.br</a><br>
Presidente: Dra. Kesia Medeiros Silva Castro</p>
<h2>DERMATOFUNCIONAL</h2>
<h3>ABRAFIDEF- Associação Brasileira de Fisioterapia Dermatofuncional</h3>
<p>Site: <a href="http://www.abrafidef.org.br" target="_blank" rel="noopener noreferrer">www.abrafidef.org.br</a><br>
E-mail: <a href="abrafidef@abrafidef.org.br" target="_blank" rel="noopener noreferrer">abrafidef@abrafidef.org.br</a>&nbsp;<a href="mailto:secretaria@abrafidef.org.br" target="_blank" rel="noopener noreferrer">secretaria@abrafidef.org.br</a><br>
Endereço: Rua Voluntários da Pátria, 215, 2º andar – Curitiba / PR<br>
CEP: 80710-000<br>
Presidente – Dra. Themis Maria Milan &nbsp;Brochado</p>
<h2>ESPORTIVA</h2>
<h3>SONAFE – Sociedade Nacional de Fisioterapia Esportiva</h3>
<p>Telefone: (11) 4421-4411<br>
Cel/WhatsApp: (11) 98747-0486<br>
Site: <a href="http://www.sonafe.org.br" target="_blank" rel="noopener noreferrer">www.sonafe.org.br</a><br>
E-mail: <a href="mailto:secretaria@sonafe.org.br">secretaria@sonafe.org.br</a><br>
Endereço: Av. Industrial, 780, Sala 713 – Ed Jardim Park Business – Bairro Jardim. CEP: 09080-500 – Santo André/S`P<br>
Presidente – Dr. Rodrigo Ribeiro de Oliveira – Biênio 2022/2023</p>
<h2>NEUROFUNCIONAL CRIANÇA E ADOLESCENTE/ADULTO</h2>
<h3>ABRAFIN -Associação Brasileira de Fisioterapia Neurofuncional</h3>
<p>Telefone: (21)3090-2043<br>
Site: <a href="http://abrafin.org.br/" target="_blank" rel="noopener noreferrer">abrafin.org.br</a><br>
E-mail: <a href="mailto:abrafin@abrafin.org.br">abrafin@abrafin.org.br</a><br>
Endereço: Avenida Rio Branco, 26, Sobreloja, Centro – Rio de janeiro – RJ<br>
CEP: 20090-001<br>
Presidente – Dra. Sibele Melo Knaut</p>
<h2>ONCOLOGIA</h2>
<h3>ABFO – Associação Brasileira de Fisioterapia em Oncologia</h3>
<p>Telefone: (11) 3796-0006<br>
Site: <a href="http://www.abfo.org.br" target="_blank" rel="noopener noreferrer">www.abfo.org.br</a><br>
E-mail: <a href="mailto:abfo@abfo.org.br">abfo@abfo.org.br</a><br>
Endereço: Rua Teodureto Souto, 905, Cambuci São Paulo/SP<br>
CEP: 01539-000<br>
Presidente – Dra. Anke Bergmann</p>
<h2>CANCEROLOGIA</h2>
<h3>SBFC – Sociedade Brasileira de Fisioterapia em Cancerologia</h3>
<p>Tel.: (41) 3361-5016<br>
Site: <a href="http://www.fisioterapia.org.br" target="_blank" rel="noopener noreferrer">www.fisioterapia.org.br<br>
</a>Email: <a href="mailto:sbfc@fisioterapia.org.br" target="_blank" rel="noopener noreferrer">sbfc@fisioterapia.org.br</a><br>
Endereço: Rua Albino Silva, 54 Sala 2A, Edifício Rané<br>
São Francisco – Curitiba/PR<br>
CEP: 80.520.210<br>
Presidente – Dr. Woldir Wosiacki Filho</p>
<h2>OSTEOPATIA</h2>
<h3>ABFO – Associação Brasileira de Fisioterapeutas Osteopatas</h3>
<p>Site: <a href="http://www.osteopatiabrasil.org.br" target="_blank" rel="noopener noreferrer">www.osteopatiabrasil.org.br</a><br>
E-mail:&nbsp;<a href="mailto:secretaria@osteopatiabrasil.org.br">secretaria@osteopatiabrasil.org.br</a><br>
Endereço: Rua Visconde de Taunay, 184&nbsp;– CAMPINAS / SP<br>
CEP: 13023-185<br>
Presidente: Dr. André Chediek</p>
<h2>CARDIOVASCULAR, RESPIRATÓRIA E TERAPIA INTENSIVA</h2>
<h3>ASSOBRAFIR – Associação Brasileira de Fisioterapia Cardiorrespiratória e Fisioterapia em Terapia Intensiva</h3>
<p>Telefone: (11) 5084-5847<br>
Site: <a href="http://www.assobrafir.com.br" target="_blank" rel="noopener noreferrer">www.assobrafir.com.br</a><br>
E-mail: <a href="mailto:assobrafir@assobrafir.com.br">assobrafir@assobrafir.com.br</a><br>
Endereço: Rua Leandro Dupre &nbsp;Nº 41<br>
Vila Clementino – São Paulo/SP<br>
CEP: 04025-010<br>
Presidente – Dr. Flávio Maciel Dias de Andrade</p>
<h2>SAÚDE DA MULHER</h2>
<h3>ABRAFISM – Associação Brasileira de Fisioterapia em Saúde da Mulher</h3>
<p>Telefone/fax: (91) 981104777<br>
Site: <a href="http://www.abrafism.org.br" target="_blank" rel="noopener noreferrer">www.abrafism.org.br</a><br>
E-mail: abrafism@gmail.com<br>
Endereço para contato: Rua dos Tamoios, n°986. Bairro: Jurunas.<br>
Belém- Pará.<br>
CEP 66025540</p>
<p>Presidente –&nbsp; Dra. Lilian Rose de Souza Mascarenhas</p>
<h2>TRABALHO</h2>
<h3>ABRAFIT – Associação Brasileira de Fisioterapia do Trabalho</h3>
<p>Site: <a href="http://www.abrafit.fst.br" target="_blank" rel="noopener noreferrer">www.abrafit.fst.br</a><br>
Telefone: (34) 3236-1649<br>
Endereço: Av. Lazaro Alves Ferreira 474, sala 301<br>
Bairro Santa Mônica &nbsp;– Uberlândia – MG<br>
CEP: 29.164-044<br>
Presidente: Dr.&nbsp;Arquimedes Augusto Penha</p>
<h2>QUIROPRAXIA</h2>
<h3>ANAFIQ – Associação Nacional de Fisioterapia em Quiropraxia</h3>
<p>Telefone: (51) 3066-8940/ (51) 99599-8930<br>
Site: <a href="http://www.quiropraxiabrasil.org" target="_blank" rel="noopener noreferrer">www.quiropraxiabrasil.org</a><br>
E-mail: <a href="mailto:anafiq.secretaria@gmail.com">anafiq.secretaria@gmail.com</a><br>
Endereço: Rua&nbsp;Benjamin Constant, 290 Bairro Ideal, Novo Hamburgo/RS<br>
CEP: 93336-140<br>
Presidente – Dr. Jemerson José Polli Oliveira</p>
<h3><strong>Associação de Fisioterapeutas Quiropraxistas</strong></h3>
<p><strong>Presidente:</strong> André Luiz Nagyidai<br>
<strong>E-mail:</strong> <a href="mailto:andre@phy.com.br">andre@phy.com.br</a><br>
<strong>E-mail da Associação:</strong> <a href="mailto:afqbrasil@outlook.com">afqbrasil@outlook.com</a><br>
<strong>Endereço:</strong>Rua General Mariante, 435, Laranjeiras –<br>
CEP: 22221-100, Rio de Janeiro/RJ</p>
<h2>TRAUMATO-ORTOPÉDICA</h2>
<h3>ABRAFITO – Associação Brasileira de Fisioterapia Traumato-Ortopédica</h3>
<p>Telefone:&nbsp; (48) 9 9844-9901<br>
Site:&nbsp;<a href="http://www.abrafitobr.com.br/" target="_blank" rel="noopener noreferrer">www.abrafitobr.com.br</a><br>
E-mail:&nbsp;<a href="mailto:secretaria@abrafitobr.com.br">secretaria@abrafitobr.com.br</a><br>
Endereço:Rua Moacir Santana 60/104 – Bloco C (Encantado) –<br>
Bairro: Partenon – Porto Alegre RS<br>
CEP: 91530-170<br>
Presidente – Dra. Aline Miranda</p>
<h2>FISIOTERAPIA</h2>
<h3>AFB – Associação de Fisioterapeutas do Brasil</h3>
<p>Telefone: (21) 99982 – 5348 (21) 99529-1235<br>
Site: <a href="http://www.afb.org.br" target="_blank" rel="noopener noreferrer">www.afb.org.br</a><br>
E-mail: <a href="mailto:contato@afb.org.br">contato@afb.org.br</a> / <a href="mailto:comunicacao@afb.org.br">comunicacao@afb.org.br</a><br>
Endereço: Rua&nbsp;Carlos Vasconcelos 111, Tijuca/RJ<br>
CEP: 20521-005<br>
Presidente – Dra. Denise Flávio Botelho</p>
<h2>Associações de Ensino</h2>
<h3>ABENFISIO –&nbsp;Associação Brasileira de Ensino em Fisioterapia</h3>
<p>Site: <a href="http://www.abenfisio.com.br" target="_blank" rel="noopener noreferrer">www.abenfisio.com.br</a><br>
Endereço: Rua Prof. Pedreira de Freitas, 372, Ap 121<br>
CEP: 03312-052 – Tatuapé/SP<br>
Presidente – Dra. Francisca Rego Oliveira de Araújo</p>
<h3>ABENFISIO – Associação Brasileira de Ensino em Fisioterapia – Regional de SC</h3>
<p>Site: <a href="http://www.abenfisio.com.br" target="_blank" rel="noopener noreferrer">www.abenfisio.com.br</a><br>
Endereço: Rua Estilac Leal, 129 apto. 401-108<br>
CEP: 88015-200 – Florianópolis/SC<br>
Presidente – Dr. Sandroval Torres</p>
<h3>ABRAPG-FT – Associação Brasileira de Pesquisa e Pós Graduação em Fisioterapia</h3>
<p>Telefone: (16) 3351 – 8755<br>
Site: <a href="http://www.abrapg-ft.org.br" target="_blank" rel="noopener noreferrer">www.abrapg-ft.org.br</a><br>
Endereço: Rod. Washington Luís – Km 235 – São Carlos/SP<br>
CEP: 13565-905<br>
Presidente – Dirceu Costa (UNINOVE)</p>
<h3>ANEC – Associação Nacional de Educação Católica no Brasil</h3>
<p>Tel.: (16) 3226-5655 / 3226-9421<br>
Fax: (61) 3322-5539<br>
Endereço: SRTV/Sul – Quadra 701 – Conjunto L, Bloco II – Sala 601, Centro Empresarial Assis Chateaubriand – BrasÃ­lia/DF<br>
CEP: 70340-000</p>
<h2>Associações Fisioterapia</h2>
<h2>DIABETES</h2>
<h3>ANAD – Associação Nacional de Assistência ao Diabético</h3>
<p>Telefone: (11) 55572-8985<br>
E-mail: <a href="mailto:faleconosco@anad.org.br">faleconosco@anad.org.br</a><br>
Endereço: Rua Eça de Queiroz, 198, Vila Mariana – São Paulo / SP<br>
CEP: 04011-031</p>
<h2>NEUROFUNCIONAL CRIANÇA E ADOLESCENTE/ADULTO</h2>
<h3>&nbsp;ABRADIMENE – Associação Brasileira para o Desenvolvimento e Divulgação do Conceito Neuroevolutivo Bobath (Neurofuncional)</h3>
<p>Telefone: (51) 3508-8740<br>
WhatsApp: (51) 99361-8460<br>
Site: <a href="http://www.abradimene.org.br" target="_blank" rel="noopener">www.abradimene.org.br</a><br>
E-mail: <a href="contato@abradimene.org.br" target="_blank" rel="noopener">contato@abradimene.org.br</a><br>
Endereço: Rua Dr. Timóteo, 746, Moinhos de Vento, Porto Alegre – RS<br>
CEP 90.570-040<br>
Presidente – Dra. Sonia Manacero</p>
<h2>PILATES</h2>
<h3>AB PILATES – Associação Brasileira de Pilates</h3>
<p>Telefone: (51) 3476-3557</p>
<h2>TERAPIAS HOLÍSTICAS</h2>
<h3>ASBAMTHO – Associação Sino Brasileira de Acupuntura Moxabustão e Terapias Holí­sticas</h3>
<p>Telefone: (21) 2286-3643 / 2539-6805 / 2286-3643<br>
Fax: (21) 2549-6805<br>
Site: <a href="http://www.asbamtho.com.br" target="_blank" rel="noopener noreferrer">www.asbamtho.com.br</a><br>
E-mail: <a href="mailto:asbamtho@gmail.com">asbamtho@gmail.com</a><br>
Endereço: Rua Ipiranga, 88 – Sobrado Laranjeiras – Rio de Janeiro-RJ<br>
CEP: 22231-120</p>
<h2>SOCIEDADE E SINDICATO</h2>
<h3>SBNP – Sociedade Brasileira de Neuropsicologia</h3>
<p>Telefone: (11) 3031-8294 / 3285-6046 / 3285-3407<br>
Site: <a href="mailto:sbnp@sbnp.com.br" target="_blank" rel="noopener noreferrer">sbnp@sbnp.com.br</a><br>
Endereço: Rua dos Macunis, 324 – Pinheiros – São Paulo – SP</p>
<h3>SBOT – Sociedade Brasileira de Ortopedia e Traumatologia</h3>
<p>Telefone: 0800-727-7268<br>
Fax: (11)2137-5418<br>
Endereço: Alameda Lorena, nº 427, 14º andar – Jardim Paulista – São Paulo – SP<br>
CEP: 01424-000</p>
<h3>SINSERCON/BA – Sindicato dos Servidores e Empregados dos conselhos e Ordens de Fiscalização do Execí­cio Profissional</h3>
<p>Telefone: (71)3248-9960<br>
Fax: (71)3248-8708<br>
Endereço: Av. Paulo VI, 486 ,Edf. Empresarial Euler de Menezes, Sala 101, Pituba – Salvador – BA<br>
CEP: 41810-001</p>
<h2>Associações Profissionais</h2>
<h3>ACEFISIO – Associação Cearense de Fisioterapia</h3>
<p>Presidente: Dra. Diana Magda Silva de Castro<br>
Endereço: Av. Visconde do Rio Branco, 2125 loja-04 – Joaquim Távora – Fortaleza – CE<br>
CEP: 600555-171</p>
<h3>AFIRN – Associação dos Fisioterapeutas do Rio Grande do Norte</h3>
<p>Presidente: Dr. Daminhão Ernani de Souza<br>
Endereço: Rua Prof. Zuza, 263 – sala 118 – Cidade Alta – Hotel Samura – Natal – RN<br>
CEP: 59054-795</p>
<h3>AFISC – Associação dos Fisioterapeutas no Estado de Santa Catarina</h3>
<p>Presidente: Dr. Michel Maggi<br>
Endereço: Av. Rio Branco, 380 – apto. 205 – Centro – Florianópolis – SC<br>
CEP: 88015-200</p>
<h3>AFISIO/REC – Associação dos Fisioterapeutas da Região Carbonífera</h3>
<p>Presidente: Dr. Bruno Peruchi<br>
Endereço: Rua Dolário dos Santos, 294 – Centro – Criciúma – SC<br>
CEP: 88802-080</p>
<h3>AFITO – Associação de Fisioterapeutas e Terapeutas Ocupacionais do Sul de Extremo Sul da Bahia</h3>
<p>Presidente – Drª David GuimarÃ£es dos Santos Júnior<br>
Endereço: Rua Adolfo Maron, 96 sala – 101 7º andar – Centro – Itabuna – BA<br>
CEP:34560-000</p>
<h3>AFPS – Associação dos Fisioterapeutas do Planalto Serrano</h3>
<p>Presidente: Dra. Pâmela Mendes<br>
Endereço: Rua João de Castro, 68 sala – 402 – Lage<br>
CEP: 88501-160</p>
<h3>AMF – Associação Mineira de Fisioterapeutas</h3>
<p>Endereço: Rua Tupis, 457 – 7º andar – sala 702, Centro – Belo Horizonte – MG<br>
CEP: 30190-060</p>
<h3>APBFISIO – Associação Paraibana de Fisioterapia</h3>
<p>Presidente: Dr. Wilson Cezar de Vasconcelos Leitão<br>
Endereço: Av. Marcionila da Conceição, 1630 sl – 01/102 – Cabo Branco – JoÃ£o Pessoa – PB</p>
<h3>APERFISIO – Associação Pernambucana de Fisioterapia</h3>
<p>Presidente: Dr. Rogério Azevedo Antunes Pereira<br>
Endereço: Rua Baltazar Passos, 332/302 – Boa viagem – Recife – PE<br>
CEP: 51130-290</p>
<h3>ASFITO – Associação Sergipana de Fisioterapeutas e Terapeutas Ocupacionais</h3>
<p>Presidente – Dr. Lucas Moraes Rego<br>
Endereço: Rua Lagarto, 2000 – São José – Aracaju – SE<br>
CEP:49015-270</p>
<h3>Associação Amazonense de Fisioterapia</h3>
<p>Presidente: Dr. Marcos Siqueira Cortez<br>
Endereço: Rua Barão do Rio Branco, nº 699 – bloco 19, 205, Bairro Flores – Manaus – AM<br>
CEP: 69058-581</p>
<h3>Associação Amazonense de Fisioterapia</h3>
<p>Presidente: Dr. Marcos Siqueira Cortez<br>
Endereço: Rua Barão do Rio Branco, nº 699 – bloco 19, 205, Bairro Flores – Manaus – AM<br>
CEP: 69058-581</p>
<h3>Associação de Blumenau</h3>
<p>Presidente: Dr. Marcelo Schurrub<br>
Endereço: Rua Itajá­, 545 Vostadt – Blumenau – SC<br>
CEP: 89015-200</p>
<h3>Associação de Fisioterapeutas de Campo Grande</h3>
<p>Presidente: Dra. Elaine Aparecida R. Garcia<br>
Endereço: Rua Dollar de Andrae, 129 – São Francisco – Campo Grande – MT<br>
CEP: 79002-321</p>
<h3>Associação de Fisioterapeutas de Dourados</h3>
<p>Presidente: Dra. Solemar Silene Vidigal Guidini<br>
Endereço: Rua João Vicente Ferreira, 1815 – Dourados – Dourados – MT<br>
CEP: 79804-030</p>
<h3>Associação de Fisioterapeutas de Porto Velho</h3>
<p>Presidente: Dr. Marcelo Rubira<br>
Endereço: Av. Brasília, 3062 apto. 502-b – São Cristóvão – Porto Velho – RO<br>
CEP: 78902-500</p>
<h3>Associação de Fisioterapeutas de Primavera do Leste</h3>
<p>Presidente: Dra. Heloisa Carolina Massucato<br>
EndereÃ§o: Rua PoxorÃ©o, 1124 – Jd. Riva – Primavera do Leste – MT<br>
CEP: 78850-000</p>
<h3>Associação de Fisioterapeutas de RondonÃ³polis</h3>
<p>Presidente: Dra. Clorice Pohl M. de Castilho<br>
Endereço: Rua Carlos Chagas Campos nº 121 Cohab – Rondonópolis – MT<br>
CEP: 78740-315</p>
<h3>Associação de Fisioterapeutas de Sorriso</h3>
<p>Presidente: Dr. Gaspar Besbatti de Mello<br>
Endereço: Av. Natalino João Brenscansin, 2239 – Centro – Sorriso – MT<br>
CEP: 78890-000</p>
<h3>Associação de Fisioterapeutas Dermato-Funcional de Campo Grande</h3>
<p>Presidente: Dra. Milena Bassalobre Gonçalves<br>
Endereço: Rua Valério Maria, 617-b – Guanandi – Campo Grande – MT<br>
CEP: 79086-130</p>
<h3>Associação de Fisioterapeutas do Rio Branco</h3>
<p>Presidente: Dr. Rayfran da Silva Alaba<br>
Endereço: Conj. Casa Nova, Quadra C, Casa 07 – São Francisco – Rio Branco – AC<br>
CEP: 69909-240</p>
<h3>Associação dos Fisioterapeutas do Sinop/MT</h3>
<p>Presidente: Dr. Luiz Eduardo Callonti Vieira<br>
Endereço: Rua dos Limoeiros, 178 – Jardim Jacarandás – Sinop – MT<br>
CEP: 78550-000</p>
<h3>COOPERFISIO – Cooperativa dos Fisioterapeutas do Litoral Catarinense</h3>
<p>Presidente: Dr. Marcelo Sanches<br>
Endereço: Rua José Guerreiros Filhos, 181 – Porto Belo – SC<br>
CEP: 88210-000</p>
<h3>FASS – Associação dos Fisioterapeutas do Extremo Oeste, Meio Oeste Catarinense</h3>
<p>Presidente: Dra. Carla di Domenico<br>
Endereço: Rua 07 de Setembro, 74-d apto. 502 – Centro – Chapecó – SC<br>
CEP: 89801-297</p>
<h3>FISIONORTE</h3>
<p>Presidente: Dra. Maria Julia Endler<br>
Endereço? Rua Lourenço Rolando Malucelli, 288 – Monte Clinica – Canoinhas – SC<br>
CEP: 89460-000</p>
<h2>FEDERAÇÕES</h2>
<h3>FENAFITO</h3>
<p>Endereço: Av. Itacira, 2962 – 6º andar – Planalto Paulista – SP<br>
Cep: 04061-003<br>
Telefone: (011) 3337-0045 / 95785-4812<br>
Site: <a href="http://fenafito.com.br/" target="_blank" rel="noopener noreferrer">fenafito.com.br</a><br>
Email: <a href="fenafito@fenafito.com.br" target="_blank" rel="noopener">fenafito@fenafito.com.br</a><br>
Presidente – Edson Stéfani</p>
<h2>INTERNACIONAL</h2>
<h3>A.P.T.O – Associação Portuguesa de Terapeutas Ocupacionais</h3>
<p>Telefone: (21)716 66 57<br>
Email: <a href="mailto:comissoes.congresso@gmail.com" target="_blank" rel="noopener noreferrer">comissoes.congresso@gmail.com</a><br>
Endereço: Estrada de Benfica 589 – 7º andar<br>
Cidade: Lisboa<br>
País: Portugal<br>
Cep: 1500-086</p>
<h3>Associação de Fisioterapeuta do Uruguai</h3>
<p>Presidente: Dra. Mirtha e Pereira Quint¡n<br>
Endereço: M. Fernandez Luna, 2274 apto 002<br>
Cidade: Montevidéu<br>
País: Uruguai</p>
<h3>Colégio de Kinesiologos do Chile</h3>
<p>Presidente: Dr. David Lopez Sanchez<br>
Endereço: Joaquin Dias Garças 090 Casilla 9317<br>
Providencia<br>
Cidade: Santiago<br>
País: Chile</p>
<h3>Confederação Latino-Americana de Fisioterapia e Kinesiologia</h3>
<p>Presidente: Dr. Mabel Yvonne Espinel Gonzalez<br>
Endereço: Carrera 23#47-51 Oficina 608<br>
Cidade: Bogotá<br>
País: Colômbia</p>

								</div>
							</article>

						</div>
					
						<div id="post-2684" class="divs-interno">
							<article>
								<div class="content-img">
									<div class="box-notdestaque">
										<div class="container-img-noticia">
											<img src=" ">
										</div>
									</div>
								</div>
								<div class="content-data">

									<span class="data">30 de outubro de 2015</span>
								</div>
								<div class="content-text">
									<header>
										<h1>Boletim da CAP – Projeto de Lei pretende ampliar rol de profissionais da saúde aptos à realização de Perícia da Previdência Social</h1>
									</header>
									<p data-obsoleto="text-align: center;">
</p><p align="center"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-size:14px;"><img decoding="async" src="http://coffito.gov.br/nsite/wp-content/uploads/images/noticia/2015/BoletimdaCAP.jpg" alt="" data-obsoleto="width: 600px; height: 440px;"></span></span></p>
<p align="center"><span data-obsoleto="font-size:16px;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><strong>Projeto de Lei pretende ampliar rol de profissionais da saúde aptos à realização de Perícia da Previdência Social</strong></span></span></p>
<p>&nbsp;</p>
<p><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-size:14px;">Está em tramitação na Câmara dos Deputados o <a title="" href="http://www.camara.gov.br/proposicoesWeb/fichadetramitacao?idProposicao=474886" target="_blank" rel="noopener"><strong>PL 7200/2010</strong></a>, do deputado Ricardo Berzoini (PT/SP), que <em>altera o § 1º do art. 42 da Lei nº 8.213, de 24 de julho de 1991, e, consequentemente, busca a ampliação da participação dos profissionais de saúde na perícia da Previdência Social</em>.</span></span></p>
<p><span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">O projeto trata da concessão de aposentadoria por invalidez mediante verificação da condição de incapacidade por meio de </span><strong data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">exame pericial a cargo da Previdência Social</strong><span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">, podendo o segurado, às suas expensas, fazer-se acompanhar de médico de sua confiança.</span></p>
<p><span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">Na Comissão de Seguridade Social e Família – CSSF foi aprovado um Substitutivo apresentado pelo deputado Eduardo Barbosa (PSDB/MG), que ampliou o exame pericial para </span><strong data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">multidisciplinar</strong><span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;"> e flexibilizou ao segurado a possibilidade de acompanhamento de profissional de saúde de sua confiança.</span></p>
<p>&nbsp;</p>
<p><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-size:14px;"><strong>Faça sua parte! </strong></span></span></p>
<p><span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">O projeto encontra-se na Comissão de Constituição e Justiça e de Cidadania – CCJC com parecer do deputado Hiran Gonçalves (PMN-RR), </span><u data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">pela injuridicidade, inconstitucionalidade e ausência de boa técnica legislativa do projeto.</u></p>
<p><span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">Desta forma, é necessário que os profissionais se manifestem junto aos parlamentares, membros da CCJC, contrários ao parecer apresentado e favoráveis à aprovação do projeto na forma do parecer da CSSF.</span></p>
<p><span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;"><a href="https://www.coffito.gov.br/nsite/wp-content/uploads/2015/10/Comisso_de_Constituio_e_Justia_e_de_Cidadania.pdf">Clique aqui</a>, veja a relação dos deputados e manifeste a sua opinião!</span></p>
<p>&nbsp;</p>
<p><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-size:14px;"><strong>CAP</strong></span></span></p>
<p><span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">O COFFITO, por meio da Comissão de Assuntos Parlamentares (CAP), acompanha diariamente projetos de lei relacionados direta ou indiretamente com as profissões de Fisioterapia e de Terapia Ocupacional.</span></p>

								</div>
							</article>

						</div>
					
						<div id="post-2518" class="divs-interno">
							<article>
								<div class="content-img">
									<div class="box-notdestaque">
										<div class="container-img-noticia">
											<img src=" ">
										</div>
									</div>
								</div>
								<div class="content-data">

									<span class="data">2 de dezembro de 2014</span>
								</div>
								<div class="content-text">
									<header>
										<h1>Sistema COFFITO/CREFITOs estuda melhorias para as diretrizes curriculares da Fisioterapia</h1>
									</header>
									<p data-obsoleto="text-align: center;">
	<span data-obsoleto="font-size:16px;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="color:#000000;"><strong>Sistema COFFITO/CREFITOs estuda melhorias para as diretrizes curriculares da Fisioterapia</strong></span></span></span></p>
<p data-obsoleto="text-align: center;">
	<strong data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;"><em>Reunião une Comissões de Educação para construir material e apresentá-lo ao INEP</em></strong></p>
<p data-obsoleto="text-align: center;">
	<img decoding="async" alt="" src="http://coffito.gov.br/nsite/wp-content/uploads/images/noticia/DSC_0433_editada.jpg" data-obsoleto="height: 342px; width: 800px;"></p>
<p data-obsoleto="text-align: justify;">
	<span data-obsoleto="font-family: arial, helvetica, sans-serif; font-size: 14px; text-align: justify;">Nos dias 27 e 28 de novembro, em Brasília, a Comissão de Desenvolvimento Científico e Educação do COFFITO (CDCEC) realizou reunião com os representantes dos CREFITOs, da Associação Brasileira de Ensino em Fisioterapia (ABENFISIO), e do Instituto Nacional de Estudos e Pesquisas Educacionais Anísio Teixeira (INEP) para avaliar as diretrizes curriculares e os cursos de Fisioterapia no Brasil, a fim de, posteriormente, construir parecer e apresentá-lo ao Ministério da Educação (MEC). “Podemos implementar várias políticas profissionais, mas o reconhecimento da nossa relevância pela sociedade será definido pela nossa competência.&nbsp; Por isso estamos aqui hoje: para discutir as qualidades, as habilidades e as competências que o profissional deve adquirir durante a formação.”, enfatizou o presidente do COFFITO, Dr. Roberto Mattar Cepeda.</span></p>
<p data-obsoleto="text-align: justify;">
	<span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">Para o membro da CDCEC e presidente do CREFITO-12, Dr. José Wagner Muniz, o Sistema e a Fisioterapia têm pela frente uma missão muito importante, ou seja, a de aproveitar a abertura desse espaço no Ministério da Educação para contribuir com a profissão. “Há quatro anos firmamos um convênio com o MEC, e já podemos nos orgulhar dos progressos alcançados, a exemplo do portal e-MEC e dos atos avaliativos da Fisioterapia. Agora, precisamos participar de maneira mais ativa”, completou.&nbsp;</span></p>
<p data-obsoleto="text-align: justify;">
	<span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">Durante os dois dias de encontro, o grupo abordou os cenários de prática e de estágio durante a formação, contextualizando as diferenças e semelhanças entre as regiões e as instituições. &nbsp;A estrutura das universidades também foi avaliada, principalmente no que tange à relevância de laboratórios específicos, além de, em caráter unânime, a constatação de que o curso de Fisioterapia é presencial, uma vez que a prática supervisionada é imprescindível à formação.</span></p>
<p data-obsoleto="text-align: justify;">
	<span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">A reunião proporcionou o início de uma construção coletiva de indicadores que possibilitará a criação de parâmetros quanti-qualitativos da formação dos futuros fisioterapeutas, egressos de diversas instituições de ensino.&nbsp; Essa interlocução com os regionais e com as associações favorecerá, ainda, a elaboração de um panorama situacional, relativo à formação profissional, que refletirá os contextos sociais da Fisioterapia em cada região do Brasil, traçando, assim, um perfil demográfico desse profissional que ingressará no mercado. &nbsp;</span></p>
<p data-obsoleto="text-align: center;">
	<img decoding="async" alt="" src="http://coffito.gov.br/nsite/wp-content/uploads/images/noticia/2014/DSC_0468_editada.jpg" data-obsoleto="height: 305px; width: 800px;"></p>
<p data-obsoleto="text-align: justify;">
	&nbsp;</p>
<p data-obsoleto="text-align: justify;">
	<strong data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">Lista de presença</strong></p>
<p data-obsoleto="text-align: justify;">
	<span data-obsoleto="font-family: arial, helvetica, sans-serif; font-size: 14px;">Também estiveram presentes na reunião os membros da CDCEC, Dr. Anderson Luís Coelho, Dra. Carla Adriane Pires Ragasson, Dr. Cleber Murilo Pinheiro Sady, Dra. Lilian Rose de Souza Mascarenhas, Dra. Margarete Lovato, Dr. Elias Nasrala Neto, Dra. Rita de Cássia Paula Souza, e Dr. Tarcísio Fulgêncio Alves da Silva; e a convidada da CDCEC, Dra. Leonilde Sousa dos Santos Oliveira. Os regionais foram representados por: Dr. Jorge Luís da Silva Nascimento, do CREFITO-2; Dra. Anadely Aparecida Silva Magalhães, e Dra. Ana Maria Chagas S. Câmara, do CREFITO-4; Dr. Fernando de Mello Prati, e Dra. Vera Striebel, do CREFITO-5; Dr. Ricardo Lotif Araújo, e Dra. Naiza do Nascimento Ferreira, do CREFITO-6; Dr. Abdo Augusto Zeghbi, do CREFITO-8; Dra. Darléa Cristina Gross, do CREFITO-9; Dra. Lila Teixeira de Araújo Jonahú, do CREFITO-12; Dr. Carlos Alberto Eloy Tavares, e Dr. Fernando P. Ferrari, do CREFITO-13; Dr. Marcelino Martins, e Dr. Rafael Victor F. Bonfim, do CREFITO-14; Dra. Sara Lúcia Menezes, do INEP; Dra. Francisca Rêgo O. Araújo, da ABENFISIO; e Dra. Patrícia Rossafa Branco, da Comissão de Recadastramento do COFFITO. &nbsp;</span></p>
<p data-obsoleto="text-align: justify;">
	&nbsp;</p>
<p data-obsoleto="text-align: justify;">
	<span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><strong>Comissão de Desenvolvimento Científico e Educação da Fisioterapia </strong></span></span></span></p>
<p data-obsoleto="text-align: justify;">
	<span data-obsoleto="font-size: 14px; font-family: arial, helvetica, sans-serif;">A Comissão é composta pelos Doutores: Roberto Mattar Cepeda; Anderson Luís Coelho; Augusto Cesinando de Carvalho; Cleber Murilo Pinheiro Sady; Elias Nasrala Neto; José Wagner Cavalcante Muniz; Tarcísio Fulgêncio Alves da Silva; e pelas Doutoras: Carla Adriane Pires Ragasson; Lilian Rose de Souza Mascarenhas; Margarete Lovato; e Rita de Cássia Paula Souza.</span></p>
<p data-obsoleto="text-align: center;">
	<img decoding="async" alt="" class="cke-resize" src="http://coffito.gov.br/nsite/wp-content/uploads/images/noticia/2014/DSC_0474_editada.jpg" data-obsoleto="height: 410px; width: 800px;"></p>
<p data-obsoleto="text-align: justify;">
	&nbsp;</p>
<p>
	<strong><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><a href="https://www.flickr.com/photos/125557377@N07/sets/72157649149730230/" target="_blank" title="">Clique aqui</a> e veja mais fotos do evento.&nbsp;</span></span></strong></p>
<div id="ckimgrsz" data-obsoleto="left: 197.5px; top: 60px;">
<div class="preview">
		&nbsp;</div>
</div>
<div id="ckimgrsz" data-obsoleto="left: 189px; top: 1387px;">
<div class="preview">
		&nbsp;</div>
</div>

								</div>
							</article>

						</div>
					
						<div id="post-3354" class="divs-interno">
							<article>
								<div class="content-img">
									<div class="box-notdestaque">
										<div class="container-img-noticia">
											<img src=" ">
										</div>
									</div>
								</div>
								<div class="content-data">

									<span class="data">1 de agosto de 2014</span>
								</div>
								<div class="content-text">
									<header>
										<h1>PORTARIA FISIOTERAPIA nº 710/2013 – Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Artrite Reumatoide.</h1>
									</header>
									<p>
	<span data-obsoleto="display: none;">&nbsp;</span></p>
<div align="center">
<div align="center">
		<span data-obsoleto="font-size:16px;"><span data-obsoleto="color:#000000;"><strong><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;"><span id="cke_bm_106S" data-obsoleto="display: none;">&nbsp;</span>PORTARIA Nº 710, DE 27 DE JUNHO DE 2013</span></span></strong></span></span></div>
<p align="center">
		&nbsp;</p>
<p data-obsoleto="text-align: right;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Artrite Reumatoide.</span></span></span></span></p>
<p>
		&nbsp;</p>
<p data-obsoleto="text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O Secretário de Atenção à Saúde, no uso de suas atribuições, Considerando a necessidade de se atualizarem parâmetros sobre a artrite reumatoide no Brasil, e de se estabelecerem diretrizes nacionais para diagnóstico, tratamento e acompanhamento dos indivíduos com essa doença;</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Considerando que os Protocolos Clínicos e Diretrizes Terapêuticas (PCDT) são resultado de consenso técnico-científico e formulados dentro de rigorosos parâmetros de qualidade e precisão de indicação; e</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Considerando a avaliação técnica da Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde (CONITEC), do Departamento de Assistência Farmacêutica e Insumos Estratégicos(DAF/SCTIE/MS) e do Departamento de Atenção &nbsp;Especializada (DAE/SAS/MS), resolve:</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
		&nbsp;</p>
<p data-obsoleto="text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Art. 1º Fica aprovado, na forma do Anexo desta Portaria, o Protocolo Clínico e Diretrizes Terapêuticas – Artrite Reumatoide. Parágrafo único. O Protocolo, objeto desta Portaria, que contém o conceito geral da artrite reumatoide, critérios de diagnóstico, critérios de inclusão e de exclusão, tratamento e mecanismos de regulação, controle e avaliação, é de caráter nacional e deve ser utilizado pelas Secretarias de Saúde dos Estados, do Distrito Federal e dos Municípios, na regulação do acesso assistencial, autorização, registro e ressarcimento dos procedimentos correspondentes.</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
		&nbsp;</p>
<p data-obsoleto="text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Art. 2º Fica obrigatória a cientificação ao paciente, ou a seu responsável legal, dos potenciais riscos e efeitos colaterais relacionados ao uso de medicamento preconizado para o tratamento da artrite reumatoide, o que deverá ser formalizado por meio da assinatura do respectivo Termo de Esclarecimento e Responsabilidade, conforme o modelo integrante do Protocolo.</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
		&nbsp;</p>
<p data-obsoleto="text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Art. 3º Os gestores estaduais, distrital e municipais do Sistema Único de Saúde (SUS), conforme sua competência e pactuações, deverão estruturar a Rede Assistencial, definir os serviços referenciais e estabelecer os fluxos para o atendimento dos indivíduos com a doença, em todas as etapas descritas no Anexo desta Portaria.</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
		&nbsp;</p>
<p data-obsoleto="text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Art. 4º Esta Portaria entra em vigor na data de sua publicação.</span></span></span></span></p>
<p>
		&nbsp;</p>
<p align="center">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><strong><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">HELVÉCIO MIRANDA MAGALHÃES JÚNIOR</span></span></strong></span></span></p>
<div>
<p data-obsoleto="margin-left: 5.25pt;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 5.25pt;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><strong><span data-obsoleto="font-family: arial, helvetica, sans-serif;">ANEXO</span></strong></span></span></p>
<p data-obsoleto="margin-left: 5.25pt;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><strong><span data-obsoleto="background-color:#ffffff;">P</span></strong><strong><span data-obsoleto="background-color:#ffffff;">ROTOCOLO&nbsp; CLÍNICO&nbsp; E&nbsp; DIRETRIZES&nbsp; TERAPÊUTICAS&nbsp; ARTRITE&nbsp; REUMATOIDE</span></strong></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">1&nbsp; METODOLOGIA&nbsp; DE&nbsp; BUSCA&nbsp; E&nbsp; AVALIAÇÃO&nbsp; DE&nbsp; LITERATURA</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Em&nbsp; 20/11/2012,&nbsp; foram&nbsp; realizadas&nbsp; buscas&nbsp; nas&nbsp; bases&nbsp; de&nbsp; dados&nbsp; Medline/Pubmed,&nbsp; Embase&nbsp; e&nbsp; Cochrane.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Na&nbsp; base&nbsp; de&nbsp; dados&nbsp; Medline/Pubmed,&nbsp; utilizando-se&nbsp; os&nbsp; termos&nbsp; "Arthritis,&nbsp; Rheumatoid/therapy"[Majr:noexp]&nbsp; &nbsp;&nbsp;AND&nbsp; ("2002/11/24"[PDat]:&nbsp; "2012/11/20"[PDat]&nbsp; AND&nbsp; "humans"[MeSH&nbsp; Terms]&nbsp; AND&nbsp; (Meta-Analysis[ptyp]&nbsp; OR&nbsp; systematic[sb])),&nbsp; foram&nbsp; encontrados&nbsp; 93&nbsp; artigos.&nbsp; Com&nbsp; os&nbsp; termos&nbsp; "Arthritis,&nbsp; Juvenile&nbsp; Rheumatoid/&nbsp; therapy"[Mesh]&nbsp; AND&nbsp; systematic[sb],&nbsp; a&nbsp; busca&nbsp; resultou&nbsp; em&nbsp; 71&nbsp; artigos.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Na&nbsp; base&nbsp; de&nbsp; dados&nbsp; Embase,&nbsp; com&nbsp; os&nbsp; termos&nbsp; 'rheumatoid&nbsp; arthritis'/exp/mj&nbsp; AND&nbsp; 'therapy'/exp/mj&nbsp; AND&nbsp; ([cochrane&nbsp; review]/lim&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">OR&nbsp; [meta&nbsp; analysis]/lim&nbsp; OR&nbsp; [systematic&nbsp; review]/lim)&nbsp; AND&nbsp; [humans]/lim&nbsp; AND&nbsp; [embase]/lim&nbsp; AND&nbsp; [24-11-2002]/sd&nbsp; NOT&nbsp; [20-11-2012]/sd,&nbsp; foram&nbsp; encontrados&nbsp; 58&nbsp; artigos.</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Na&nbsp; base&nbsp; de&nbsp; dados&nbsp; Cochrane,&nbsp; utilizando-se&nbsp; os&nbsp; termos&nbsp; "rheumatoid&nbsp; and&nbsp; arthritis:ti"&nbsp; (com&nbsp; busca&nbsp; limitada&nbsp; ao&nbsp; título),&nbsp; a&nbsp; busca&nbsp; resultou&nbsp; em&nbsp; 67&nbsp; artigos.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Desses&nbsp; 289&nbsp; resultados&nbsp; foram&nbsp; selecionados&nbsp; revisões&nbsp; sistemáticas/&nbsp; meta-análises&nbsp; e&nbsp; ensaios&nbsp; clínicos&nbsp; randomizados&nbsp; mais&nbsp; recentes,&nbsp; sendo&nbsp; excluídos&nbsp; os&nbsp; trabalhos&nbsp; duplicados,&nbsp; os&nbsp; relatos&nbsp; e&nbsp; séries&nbsp; de&nbsp; casos,&nbsp; os&nbsp; estudos&nbsp; de&nbsp; validação,&nbsp; os&nbsp; estudos-&nbsp; piloto,&nbsp; aqueles&nbsp; sobre&nbsp; outras&nbsp; doenças,&nbsp; os&nbsp; com&nbsp; desfechos&nbsp; laboratoriais,&nbsp; os&nbsp; com&nbsp; animais,&nbsp; os&nbsp; com&nbsp; terapias&nbsp; sem&nbsp; base&nbsp; fisiopatológica&nbsp; ou&nbsp; indisponíveis&nbsp; no&nbsp; Brasil,&nbsp; restando&nbsp; 135&nbsp; referências.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Com&nbsp; o&nbsp; objetivo&nbsp; de&nbsp; incluir&nbsp; referências&nbsp; sobre&nbsp; classificação&nbsp; e&nbsp; tratamento&nbsp; bem&nbsp; como&nbsp; sobre&nbsp; epidemiologia&nbsp; e&nbsp; custo-efetividade&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">nacionais&nbsp; da&nbsp; doença&nbsp; também&nbsp; foram&nbsp; realizadas,&nbsp; na&nbsp; mesma&nbsp; data,&nbsp; buscas&nbsp; na&nbsp; base&nbsp; de&nbsp; dados&nbsp; Medline/Pubmed,&nbsp; utilizando-se&nbsp; os&nbsp; termos&nbsp; ((Arthritis,&nbsp; Rheumatoid[MeSH&nbsp; Terms])&nbsp; AND&nbsp; criteria[Title])&nbsp; AND&nbsp; (diagnostic[&nbsp; Title]&nbsp; or&nbsp; classification[Title]).&nbsp; Dessa&nbsp; busca,&nbsp; resultaram&nbsp; 223&nbsp; artigos.</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Com&nbsp; os&nbsp; termos&nbsp; ((Arthritis,&nbsp; Rheumatoid[MeSH&nbsp; Terms])&nbsp; AND&nbsp; recommendations[Title])&nbsp; AND&nbsp; (acr[Title]&nbsp; OR&nbsp; eular[Title]),&nbsp; foram&nbsp; encontrados&nbsp; 16&nbsp; artigos,&nbsp; e&nbsp; com&nbsp; os&nbsp; termos&nbsp; Brazil[All&nbsp; Fields]&nbsp; AND&nbsp; ("Arthritis,&nbsp; Rheumatoid"[MeSH&nbsp; Terms]&nbsp; OR&nbsp; "Arthritis,&nbsp; Rheumatoid"[All&nbsp; Fields]),&nbsp; 324&nbsp; artigos.&nbsp;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial, helvetica, sans-serif;">Desses&nbsp; 563&nbsp; resultados&nbsp; foram&nbsp; excluídos&nbsp; os&nbsp; duplicados,&nbsp; os&nbsp; relatos&nbsp; e&nbsp; séries&nbsp; de&nbsp; casos,&nbsp; os&nbsp; estudos&nbsp; de&nbsp; validação,&nbsp; os&nbsp; estudos-piloto,&nbsp; aqueles&nbsp; sobre&nbsp; outras&nbsp; doenças,&nbsp; os&nbsp; com&nbsp; desfechos&nbsp; laboratoriais,&nbsp; os&nbsp; com&nbsp; animais,&nbsp; os&nbsp; com&nbsp; terapias&nbsp; sem&nbsp; base&nbsp; fisiopatológica&nbsp; ou&nbsp; indisponíveis&nbsp; no&nbsp; Brasil,&nbsp; os&nbsp; com&nbsp; mais&nbsp; de&nbsp; 10&nbsp; anos&nbsp; (exceto&nbsp; estudos&nbsp; epidemiológicos),&nbsp; aqueles&nbsp; em&nbsp; idiomas&nbsp; que&nbsp; não&nbsp; inglês,&nbsp; português&nbsp; e&nbsp; espanhol,&nbsp; restando&nbsp; 34&nbsp; referências.&nbsp;Também&nbsp; foi&nbsp; utilizada&nbsp; como&nbsp; referência&nbsp; na&nbsp; elaboração&nbsp; deste&nbsp; Protocolo&nbsp; a&nbsp; compilação&nbsp; UpToDate,&nbsp; versão&nbsp; 20.8.</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Os&nbsp; critérios&nbsp; de&nbsp; busca&nbsp; adotados&nbsp; foram&nbsp; escolhidos&nbsp; com&nbsp; o&nbsp; objetivo&nbsp; de&nbsp; permitir&nbsp; acesso&nbsp; amplo&nbsp; e&nbsp; focado&nbsp; aos&nbsp; trabalhos&nbsp; de&nbsp; maior&nbsp; relevância,&nbsp; tendo&nbsp; em&nbsp; vista&nbsp; a&nbsp; expressiva&nbsp; quantidade&nbsp; de&nbsp; estudos&nbsp; publicados&nbsp; sobre&nbsp; o&nbsp; tema.&nbsp; Posteriormente&nbsp; à&nbsp; Consulta&nbsp; Pública,&nbsp; a&nbsp; busca&nbsp; adicional&nbsp; de&nbsp; estudos&nbsp; relevantes&nbsp; para&nbsp; o&nbsp; tema&nbsp; também&nbsp; foi&nbsp; realizada,&nbsp; sendo&nbsp; acrescentadas&nbsp; 13&nbsp; referências&nbsp; bibliográficas.</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">2&nbsp; INTRODUÇÃO</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; Artrite&nbsp; reumatoide&nbsp; (AR)&nbsp; é&nbsp; uma&nbsp; doença&nbsp; autoimune,&nbsp; inflamatória,&nbsp; sistêmica&nbsp; e&nbsp; crônica,&nbsp; caracterizada&nbsp; por&nbsp; sinovite&nbsp; periférica&nbsp; e&nbsp; por&nbsp; diversas&nbsp; manifestações&nbsp; extra-articulares.&nbsp; No&nbsp; Brasil,&nbsp; um&nbsp; estudo&nbsp; de&nbsp; 2004&nbsp; mostrou&nbsp; prevalência&nbsp; de&nbsp; 0,46%,&nbsp; representando&nbsp; quase&nbsp; um&nbsp; milhão&nbsp; de&nbsp; pessoas&nbsp; com&nbsp; essa&nbsp; doença,&nbsp; o&nbsp; que&nbsp; confirma&nbsp; o&nbsp; achado&nbsp; do&nbsp; estudo&nbsp; multicêntrico,&nbsp; realizado&nbsp; em&nbsp; 1993,&nbsp; que&nbsp; verificou&nbsp; uma&nbsp; prevalência&nbsp; de&nbsp; AR&nbsp; em&nbsp; adultos&nbsp; variando&nbsp; de&nbsp; 0,2%-1%,&nbsp; nas&nbsp; macrorregiões&nbsp; brasileiras,&nbsp; ocorrendo&nbsp; predominantemente&nbsp; em&nbsp; mulheres&nbsp; entre&nbsp; a&nbsp; quarta&nbsp; e&nbsp; sexta&nbsp; décadas&nbsp; de&nbsp; vida&nbsp; (1-4).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Apesar&nbsp; de&nbsp; a&nbsp; etiopatogenia&nbsp; de&nbsp; AR&nbsp; ainda&nbsp; não&nbsp; ser&nbsp; inteiramente&nbsp; conhecida,&nbsp; muito&nbsp; se&nbsp; avançou&nbsp; no&nbsp; tema&nbsp; nos&nbsp; últimos&nbsp; anos.&nbsp; No&nbsp; início,&nbsp; a&nbsp; observação&nbsp; do&nbsp; aumento&nbsp; da&nbsp; incidência&nbsp; de&nbsp; AR&nbsp; entre&nbsp; familiares,&nbsp; principalmente&nbsp; entre&nbsp; gêmeos&nbsp; monozigóticos,&nbsp; sugeria&nbsp; um&nbsp; componente&nbsp; genético&nbsp; em&nbsp; sua&nbsp; etiopatogênese.&nbsp; Com&nbsp; o&nbsp; avanço&nbsp; dos&nbsp; estudos,&nbsp; foi&nbsp; identificado&nbsp; o&nbsp; antígeno&nbsp; leucocitário&nbsp; humano&nbsp; (human&nbsp; leukocyte&nbsp; antigen&nbsp; –&nbsp; HLA),&nbsp; considerado&nbsp; o&nbsp; principal&nbsp; fator&nbsp; genético&nbsp; no&nbsp; desenvolvimento&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">dessa&nbsp; doença.&nbsp; Diversos&nbsp; alelos&nbsp; de&nbsp; HLA-DRB1&nbsp; vêm&nbsp; sendo&nbsp; associados&nbsp; a&nbsp; AR&nbsp; em&nbsp; populações&nbsp; variadas.&nbsp; Em&nbsp; estudo&nbsp;</span><span data-obsoleto="font-family:arial,helvetica,sans-serif;">brasileiro&nbsp; com&nbsp; pacientes&nbsp; em&nbsp; sua&nbsp; maioria&nbsp; com&nbsp; herança&nbsp; mista,&nbsp; os&nbsp; principais&nbsp; fatores&nbsp; de&nbsp; risco&nbsp; para&nbsp; o&nbsp; desenvolvimento&nbsp; de&nbsp; AR&nbsp;</span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">foram&nbsp; a&nbsp; presença&nbsp; dos&nbsp; alelos&nbsp; HLA-DRB1&nbsp; SE&nbsp; (shared&nbsp; epitope&nbsp; –&nbsp; epitopo&nbsp; compartilhado)&nbsp; e&nbsp; a&nbsp; detecção&nbsp; de&nbsp; anticorpos&nbsp; contra&nbsp; peptídios&nbsp; citrulinados&nbsp; cíclicos&nbsp; (anti-CCP)&nbsp; (5).&nbsp; No&nbsp; entanto,&nbsp; variações&nbsp; fenotípicas&nbsp; e&nbsp; de&nbsp; incidência&nbsp; apontam&nbsp; para&nbsp; fatores&nbsp; ambientais&nbsp; que,&nbsp; além&nbsp; da&nbsp; predisposição&nbsp; genética,&nbsp; contribuem&nbsp; para&nbsp; o&nbsp; surgimento&nbsp; da&nbsp; doença,&nbsp; tais&nbsp; como&nbsp; tabagismo&nbsp; e&nbsp; infecções&nbsp; periodontais&nbsp; (6).</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; AR&nbsp; é&nbsp; bastante&nbsp; variável&nbsp; quanto&nbsp; à&nbsp; apresentação&nbsp; clínica,&nbsp; à&nbsp; gravidade&nbsp; e&nbsp; ao&nbsp; prognóstico.&nbsp; Sua&nbsp; forma&nbsp; clínica&nbsp; mais&nbsp; comum&nbsp; é&nbsp; a&nbsp; poliartrite&nbsp; simétrica&nbsp; de&nbsp; pequenas&nbsp; e&nbsp; grandes&nbsp; articulações&nbsp; com&nbsp; caráter&nbsp; crônico&nbsp; e&nbsp; destrutivo,&nbsp; podendo&nbsp; levar&nbsp; a&nbsp; relevante&nbsp; limitação&nbsp; funcional,&nbsp; comprometendo&nbsp; a&nbsp; capacidade&nbsp; laboral&nbsp; e&nbsp; a&nbsp; qualidade&nbsp; de&nbsp; vida,&nbsp; resultando&nbsp; em&nbsp; significativo&nbsp; impacto&nbsp; pessoal&nbsp; e&nbsp; social,&nbsp; com&nbsp; elevados&nbsp; custos&nbsp; indiretos,&nbsp; segundo&nbsp; estimativas&nbsp; nacionais&nbsp; (7-10).&nbsp; A&nbsp; associação&nbsp; de&nbsp; AR&nbsp; a&nbsp; neutropenia&nbsp; e&nbsp; esplenomegalia,&nbsp; que&nbsp; ocorre&nbsp; mais&nbsp; nos&nbsp; casos&nbsp; de&nbsp; AR&nbsp; de&nbsp; longa&nbsp; evolução,&nbsp; é&nbsp; chamada&nbsp; de&nbsp; Síndrome&nbsp; de&nbsp; Felty.&nbsp; Dados&nbsp; de&nbsp; um&nbsp; estudo&nbsp; brasileiro&nbsp; de&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; inicial&nbsp; sugerem&nbsp; que&nbsp; a&nbsp; apresentação&nbsp; clínica&nbsp; mais&nbsp; comum&nbsp; seja&nbsp; a&nbsp; poliartrite&nbsp; aguda&nbsp; (70%)&nbsp; com&nbsp; sinovite&nbsp; persistente&nbsp; nas&nbsp; mãos&nbsp; (91%)&nbsp; e&nbsp; rigidez&nbsp; matinal&nbsp; prolongada&nbsp; (mais&nbsp; de&nbsp; 2&nbsp; horas)&nbsp; (11).&nbsp; A&nbsp; rigidez&nbsp; matinal&nbsp; pode&nbsp; ser&nbsp; o&nbsp; sintoma&nbsp; inicial&nbsp; e&nbsp; costuma&nbsp; ser&nbsp; um&nbsp; indício&nbsp; de&nbsp; doença&nbsp; ativa.&nbsp; As&nbsp; articulações&nbsp; interfalangianas&nbsp; proximais&nbsp; (IFP)&nbsp; e&nbsp; metacarpofalangianas&nbsp; (MCF)&nbsp; são&nbsp; acometidas&nbsp; em&nbsp; mais&nbsp; de&nbsp; 90%&nbsp; dos&nbsp; casos&nbsp; (12).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; artrite&nbsp; reumatoide&nbsp; juvenil&nbsp; (ARJ)&nbsp; é&nbsp; o&nbsp; nome&nbsp; dado&nbsp; pelo&nbsp; Colégio&nbsp; Americano&nbsp; de&nbsp; Reumatologia&nbsp; à&nbsp; doença&nbsp; articular&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">inflamatória&nbsp; que&nbsp; se&nbsp; inicia&nbsp; antes&nbsp; dos&nbsp; 16&nbsp; anos&nbsp; de&nbsp; idade&nbsp; com&nbsp; duração&nbsp; de&nbsp; pelo&nbsp; menos&nbsp; 6&nbsp; semanas.&nbsp; Há&nbsp; três&nbsp; tipos&nbsp; de&nbsp; ARJ:&nbsp; (a)&nbsp; de&nbsp; início&nbsp; sistêmico&nbsp; (doença&nbsp; de&nbsp; Still),&nbsp; (b)&nbsp; de&nbsp; início&nbsp; poliarticular&nbsp; e&nbsp; (c)&nbsp; de&nbsp; início&nbsp; pauciarticular.&nbsp; O&nbsp; tipo&nbsp; ARJ&nbsp; de&nbsp; início&nbsp; poliarticular&nbsp; apresenta&nbsp; dois&nbsp; subtipos:&nbsp; com&nbsp; fator&nbsp; reumatoide&nbsp; (FR)&nbsp; negativo&nbsp; e&nbsp; com&nbsp; fator&nbsp; reumatoide&nbsp; positivo.&nbsp; Apenas&nbsp; o&nbsp; subtipo&nbsp; poliarticular&nbsp; com&nbsp; FR&nbsp; positivo&nbsp; assemelha-se&nbsp; clinicamente&nbsp; a&nbsp; AR&nbsp; do&nbsp; adulto&nbsp; (13).</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Mais&nbsp; recentemente,&nbsp; a&nbsp; expressão&nbsp; artrite&nbsp; idiopática&nbsp; juvenil&nbsp; (AIJ),&nbsp; criada&nbsp; pela&nbsp; Liga&nbsp; Internacional&nbsp; de&nbsp; Associações&nbsp; para&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">Reumatologia,&nbsp; tem&nbsp; sido&nbsp; utilizada&nbsp; como&nbsp; nomenclatura&nbsp; global&nbsp; para&nbsp; todas&nbsp; as&nbsp; artrites&nbsp; de&nbsp; causa&nbsp; desconhecida&nbsp; que&nbsp; se&nbsp; iniciam&nbsp; antes&nbsp; dos&nbsp; 16&nbsp; anos&nbsp; e&nbsp; que&nbsp; persistem&nbsp; por&nbsp; pelo&nbsp; menos&nbsp; 6&nbsp; semanas.&nbsp; Há&nbsp; sete&nbsp; tipos&nbsp; de&nbsp; AIJ:&nbsp; (a)&nbsp; artrite&nbsp; sistêmica,&nbsp; (b)&nbsp; oligoartrite,&nbsp; (c)&nbsp; poliartrite&nbsp; com&nbsp; FR&nbsp; negativo,&nbsp; (d)&nbsp; poliartrite&nbsp; com&nbsp; FR&nbsp; positivo,&nbsp; (e)&nbsp; artrite&nbsp; psoriásica,&nbsp; (f)&nbsp; artrite&nbsp; relacionada&nbsp; a&nbsp; entesite&nbsp; e&nbsp; (g)&nbsp; outras&nbsp; artrites.&nbsp; Atualmente,&nbsp; a&nbsp; AIJ&nbsp; é&nbsp; a&nbsp; classificação&nbsp; internacional&nbsp; padrão&nbsp; para&nbsp; o&nbsp; diagnóstico&nbsp; das&nbsp; artrites&nbsp; crônicas&nbsp; da&nbsp; infância&nbsp; de&nbsp; causa&nbsp; desconhecida&nbsp; (13).</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; tratamento&nbsp; e&nbsp; o&nbsp; acompanhamento&nbsp; adequados&nbsp; de&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; devem&nbsp; seguir&nbsp; as&nbsp; práticas&nbsp; embasadas&nbsp; em&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">evidências,&nbsp; descritas&nbsp; neste&nbsp; Protocolo&nbsp; (14,&nbsp; 15).</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; identificação&nbsp; da&nbsp; doença&nbsp; em&nbsp; seu&nbsp; estágio&nbsp; inicial&nbsp; e&nbsp; o&nbsp; encaminhamento&nbsp; ágil&nbsp; e&nbsp; adequado&nbsp; para&nbsp; atendimento&nbsp; especializado&nbsp; conferem&nbsp; à&nbsp; Atenção&nbsp; Básica&nbsp; um&nbsp; caráter&nbsp; essencial&nbsp; para&nbsp; um&nbsp; melhor&nbsp; resultado&nbsp; terapêutico&nbsp; e&nbsp; prognóstico&nbsp; dos&nbsp; casos.</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">3&nbsp; CLASSIFICAÇÃO&nbsp; ESTATÍSTICA&nbsp; INTERNACIONAL&nbsp; DE&nbsp; DOENÇAS&nbsp; E&nbsp; PROBLEMAS&nbsp; RELACIONADOS&nbsp; À&nbsp; SAÚDE&nbsp; (CID-10)</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; M05.0&nbsp; Síndrome&nbsp; de&nbsp; Felty</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; M05.1&nbsp; Doença&nbsp; reumatoide&nbsp; do&nbsp; pulmão</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; M05.2&nbsp; Vasculite&nbsp; reumatoide</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; M05.3&nbsp; Artrite&nbsp; reumatoide&nbsp; com&nbsp; comprometimento&nbsp; de&nbsp; outros&nbsp; órgãos&nbsp; e&nbsp; sistemas</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; M05.8&nbsp; Outras&nbsp; artrites&nbsp; reumatoides&nbsp; soropositivas</span></span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; M06.0&nbsp; Artrite&nbsp; reumatoide&nbsp; soronegativa</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; M06.8&nbsp; Outras&nbsp; artrites&nbsp; reumatoides&nbsp; especificadas</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; M08.0&nbsp; Artrite&nbsp; reumatoide&nbsp; juvenil</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">4&nbsp; DIAGNÓSTICO</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; diagnóstico&nbsp; de&nbsp; AR&nbsp; é&nbsp; estabelecido&nbsp; com&nbsp; base&nbsp; em&nbsp; achados&nbsp; clínicos&nbsp; e&nbsp; exames&nbsp; complementares.&nbsp; Nenhum&nbsp; exame&nbsp; isoladamente,&nbsp; seja&nbsp; laboratorial,&nbsp; de&nbsp; imagem&nbsp; ou&nbsp; histopatológico,&nbsp; estabelece&nbsp; o&nbsp; diagnóstico&nbsp; (2,16).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Sem&nbsp; tratamento&nbsp; adequado,&nbsp; o&nbsp; curso&nbsp; da&nbsp; doença&nbsp; é&nbsp; progressivo,&nbsp; determinando&nbsp; deformidades&nbsp; decorrentes&nbsp; da&nbsp; lassidão&nbsp; ou&nbsp; ruptura&nbsp; dos&nbsp; tendões&nbsp; e&nbsp; das&nbsp; erosões&nbsp; articulares.&nbsp; Entre&nbsp; os&nbsp; achados&nbsp; tardios,&nbsp; podem-se&nbsp; identificar&nbsp; desvio&nbsp; ulnar&nbsp; dos&nbsp; dedos&nbsp; ou&nbsp; "dedos&nbsp; em&nbsp; ventania",&nbsp; deformidades&nbsp; em&nbsp; "pescoço&nbsp; de&nbsp; cisne"&nbsp; (hiperextensão&nbsp; das&nbsp; articulações&nbsp; IFP&nbsp; e&nbsp; flexão&nbsp; das&nbsp; interfalangianas&nbsp; distais&nbsp; –&nbsp; IFD),&nbsp; deformidades&nbsp; em&nbsp; "botoeira"&nbsp; (flexão&nbsp; das&nbsp; IFP&nbsp; e&nbsp; hiperextensão&nbsp; das&nbsp; IFD),&nbsp; "mãos&nbsp; em&nbsp; dorso&nbsp; de&nbsp; camelo"&nbsp; (aumento&nbsp; de&nbsp; volume&nbsp; do&nbsp; punho&nbsp; e&nbsp; das&nbsp; articulações&nbsp; MCF&nbsp; com&nbsp; atrofia&nbsp; interóssea&nbsp; dorsal),&nbsp; joelhos&nbsp; valgos&nbsp; (desvio&nbsp; medial),&nbsp; tornozelos&nbsp; valgos&nbsp; (eversão&nbsp; da&nbsp; articulação&nbsp; subtalar),&nbsp; hálux&nbsp; valgo&nbsp; (desvio&nbsp; lateral&nbsp; do&nbsp; hálux),&nbsp; "dedos&nbsp; em&nbsp; martelo"&nbsp; (hiperextensão&nbsp; das&nbsp; articulações&nbsp; metatarsofalangianas&nbsp; –&nbsp; MTF&nbsp; e&nbsp; extensão&nbsp; das&nbsp; IFD),&nbsp; "dedos&nbsp; em&nbsp; crista&nbsp; de&nbsp; galo"&nbsp; (deslocamento&nbsp; dorsal&nbsp; das&nbsp; falanges&nbsp; proximais&nbsp; com&nbsp; exposição&nbsp; da&nbsp; cabeça&nbsp; dos&nbsp; metatarsianos)&nbsp; e&nbsp; pés&nbsp; planos&nbsp; (arco&nbsp; longitudinal&nbsp; achatado)&nbsp; (12).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; acometimento&nbsp; da&nbsp; coluna&nbsp; cervical&nbsp; (C1-C2)&nbsp; com&nbsp; subluxação&nbsp; atlantoaxial&nbsp; geralmente&nbsp; manifesta-se&nbsp; por&nbsp; dor&nbsp; irradiada&nbsp; para&nbsp; a&nbsp; região&nbsp; occipital,&nbsp; perda&nbsp; da&nbsp; lordose&nbsp; fisiológica&nbsp; cervical&nbsp; e&nbsp; resistência&nbsp; à&nbsp; movimentação&nbsp; passiva.&nbsp; Quando&nbsp; sintomas&nbsp; neurológicos,&nbsp; como&nbsp; parestesias&nbsp; periféricas&nbsp; ou&nbsp; perda&nbsp; do&nbsp; controle&nbsp; esfincteriano,&nbsp; surgem,&nbsp; a&nbsp; mortalidade&nbsp; é&nbsp; de&nbsp; 50%&nbsp; em&nbsp; 1&nbsp; ano.&nbsp; A&nbsp; suspeita&nbsp; clínica&nbsp; pode&nbsp; ser&nbsp; comprovada&nbsp; por&nbsp; radiografia&nbsp; de&nbsp; coluna&nbsp; cervical&nbsp; funcional,&nbsp; em&nbsp; que&nbsp; a&nbsp; distância&nbsp; entre&nbsp; o&nbsp; processo&nbsp; odontoide&nbsp; e&nbsp; o&nbsp; arco&nbsp; anterior&nbsp; de&nbsp; C1&nbsp; acima&nbsp; de&nbsp; 3&nbsp; mm&nbsp; (ou&nbsp; entre&nbsp; o&nbsp; processo&nbsp; odontoide&nbsp; e&nbsp; o&nbsp; arco&nbsp; posterior&nbsp; de&nbsp; C1&nbsp; abaixo&nbsp; de&nbsp; 14&nbsp; mm)&nbsp; indica&nbsp; aumento&nbsp; de&nbsp; risco&nbsp; de&nbsp; compressão&nbsp; medular&nbsp; (17,18).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">As&nbsp; manifestações&nbsp; extra-articulares&nbsp; (nódulos&nbsp; reumatoides,&nbsp; vasculite,&nbsp; derrame&nbsp; pleural,&nbsp; episclerite&nbsp; e&nbsp; escleromalacia&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">perfurante,&nbsp; entre&nbsp; outras)&nbsp; correlacionam-se&nbsp; com&nbsp; pior&nbsp; prognóstico.&nbsp; Além&nbsp; da&nbsp; perda&nbsp; de&nbsp; capacidade&nbsp; funcional,&nbsp; pode&nbsp; haver&nbsp; aumento&nbsp; também&nbsp; da&nbsp; mortalidade,&nbsp; o&nbsp; que&nbsp; demonstra&nbsp; a&nbsp; gravidade&nbsp; da&nbsp; doença&nbsp; (17).</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Na&nbsp; avaliação&nbsp; complementar&nbsp; dos&nbsp; pacientes&nbsp; com&nbsp; AR,&nbsp; a&nbsp; titulação&nbsp; de&nbsp; autoanticorpos,&nbsp; tais&nbsp; como&nbsp; FR&nbsp; (sensibilidade&nbsp; de&nbsp; 75%&nbsp; e&nbsp; especificidade&nbsp; de&nbsp; 85%)&nbsp; e&nbsp; anti-CCP&nbsp; (sensibilidade&nbsp; de&nbsp; 75%&nbsp; e&nbsp; especificidade&nbsp; de&nbsp; 95%)&nbsp; tem&nbsp; importância&nbsp; diagnóstica&nbsp; e&nbsp; prognóstica.&nbsp; Em&nbsp; estudo&nbsp; observacional&nbsp; brasileiro,&nbsp; não&nbsp; houve&nbsp; variação&nbsp; na&nbsp; prevalência&nbsp; de&nbsp; FR&nbsp; e&nbsp; anti-CCP&nbsp; ao&nbsp; longo&nbsp; de&nbsp; 3&nbsp; anos&nbsp; de&nbsp; acompanhamento&nbsp; de&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; (19).&nbsp; Recomenda-se&nbsp; a&nbsp; solicitação&nbsp; de&nbsp; anti-CCP&nbsp; apenas&nbsp; para&nbsp; casos&nbsp; em&nbsp; que&nbsp; o&nbsp; FR&nbsp; seja&nbsp; negativo&nbsp; ou&nbsp; quando&nbsp; haja&nbsp; dúvida&nbsp; diagnóstica.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Alguns&nbsp; aspectos&nbsp; clínicos&nbsp; e&nbsp; laboratoriais&nbsp; estão&nbsp; relacionados&nbsp; à&nbsp; progressão&nbsp; mais&nbsp; rápida&nbsp; da&nbsp; destruição&nbsp; articular&nbsp; e&nbsp; devem&nbsp; ser&nbsp; identificados&nbsp; desde&nbsp; o&nbsp; momento&nbsp; do&nbsp; diagnóstico.&nbsp; Os&nbsp; fatores&nbsp; de&nbsp; mau&nbsp; prognóstico&nbsp; são&nbsp; sexo&nbsp; feminino,&nbsp; tabagismo,&nbsp; baixo&nbsp; nível&nbsp; socioeconômico,&nbsp; início&nbsp; da&nbsp; doença&nbsp; em&nbsp; idade&nbsp; mais&nbsp; precoce,&nbsp; FR&nbsp; ou&nbsp; anti-CCP&nbsp; em&nbsp; títulos&nbsp; elevados,&nbsp; provas&nbsp; inflamatórias&nbsp; (velocidade&nbsp; de&nbsp; hemossedimentação&nbsp; ou&nbsp; proteína&nbsp; C&nbsp; reativa)&nbsp; persistentemente&nbsp; elevadas,&nbsp; grande&nbsp; número&nbsp; de&nbsp; articulações&nbsp; edemaciadas,&nbsp; manifestações&nbsp; extra-articulares,&nbsp; elevada&nbsp; atividade&nbsp; inflamatória&nbsp; da&nbsp; doença,&nbsp; presença&nbsp; precoce&nbsp; de&nbsp; erosões&nbsp; na&nbsp; evolução&nbsp; da&nbsp; doença&nbsp; e&nbsp; presença&nbsp; do&nbsp; epítopo&nbsp; compartilhado,&nbsp; este&nbsp; um&nbsp; exame&nbsp; não&nbsp; utilizado&nbsp; na&nbsp; rotina&nbsp; assistencial&nbsp; (16).&nbsp; Critérios&nbsp; de&nbsp; classificação&nbsp; são&nbsp; adotados&nbsp; por&nbsp; pesquisadores&nbsp; para&nbsp; a&nbsp; identificação&nbsp; científica&nbsp; de&nbsp; indivíduos&nbsp; com&nbsp; determinada&nbsp; doença,&nbsp; tal&nbsp; como&nbsp; ocorre&nbsp; em&nbsp; estudos&nbsp; clínicos.&nbsp; Por&nbsp; outro&nbsp; lado,&nbsp; critérios&nbsp; de&nbsp; diagnóstico&nbsp; têm&nbsp; como&nbsp; objetivo&nbsp; auxiliar&nbsp; o&nbsp; médico&nbsp; assistente&nbsp; a&nbsp; identificar&nbsp; esses&nbsp; indivíduos&nbsp; na&nbsp; prática&nbsp; clínica.&nbsp; Com&nbsp; frequência,&nbsp; os&nbsp; critérios&nbsp; de&nbsp; classificação&nbsp; são&nbsp; utilizados&nbsp; também&nbsp; para&nbsp; o&nbsp; diagnóstico.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Com&nbsp; o&nbsp; objetivo&nbsp; de&nbsp; permitir&nbsp; a&nbsp; classificação&nbsp; de&nbsp; indivíduos&nbsp; com&nbsp; AR,&nbsp; foram&nbsp; estabelecidos&nbsp; critérios&nbsp; pelo&nbsp; American&nbsp; College&nbsp; of&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">Rheumatology&nbsp; –&nbsp; ACR&nbsp; em&nbsp; 1987&nbsp; e,&nbsp; mais&nbsp; recentemente,&nbsp; pelo&nbsp; American&nbsp; College&nbsp; of&nbsp; Rheumatology/European&nbsp; League&nbsp; Against&nbsp; Rheumatism&nbsp; –&nbsp; ACR/EULAR&nbsp; em&nbsp; 2010&nbsp; (20-22).&nbsp; As&nbsp; acurácias&nbsp; diagnósticas&nbsp; desses&nbsp; critérios&nbsp; são&nbsp; comparáveis,&nbsp; sendo&nbsp; os&nbsp; últimos&nbsp; mais&nbsp; sensíveis&nbsp; para&nbsp; casos&nbsp; iniciais&nbsp; (23-26).&nbsp; Apesar&nbsp; disso,&nbsp; os&nbsp; critérios&nbsp; de&nbsp; 2010&nbsp; não&nbsp; identificam&nbsp; alguns&nbsp; pacientes&nbsp; classificados&nbsp; pelos&nbsp; critérios&nbsp; de&nbsp; 1987,&nbsp; especialmente&nbsp; aqueles&nbsp; com&nbsp; artrite&nbsp; simétrica&nbsp; soronegativa&nbsp; e&nbsp; limitada&nbsp; a&nbsp; poucas&nbsp; articulações&nbsp; (24,27-32).</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Este&nbsp; Protocolo&nbsp; adota&nbsp; as&nbsp; seguintes&nbsp; recomendações&nbsp; gerais&nbsp; no&nbsp; que&nbsp; se&nbsp; refere&nbsp; ao&nbsp; diagnóstico&nbsp; de&nbsp; AR&nbsp; (2):</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; o&nbsp; diagnóstico&nbsp; de&nbsp; AR&nbsp; deve&nbsp; ser&nbsp; feito&nbsp; considerando-se&nbsp; achados&nbsp; clínicos&nbsp; e&nbsp; exames&nbsp; complementares;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; o&nbsp; diagnóstico&nbsp; diferencial&nbsp; de&nbsp; AR&nbsp; deve&nbsp; ser&nbsp; elaborado&nbsp; com&nbsp; atenção,&nbsp; considerando-se&nbsp; artrites&nbsp; secundárias&nbsp; a&nbsp; infecções,&nbsp; neoplasias&nbsp; e&nbsp; artrite&nbsp; psoriásica,&nbsp; dentre&nbsp; outras;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; a&nbsp; titulação&nbsp; de&nbsp; FR&nbsp; é&nbsp; um&nbsp; exame&nbsp; diagnóstico&nbsp; relevante,&nbsp; mas&nbsp; com&nbsp; sensibilidade&nbsp; e&nbsp; especificidade&nbsp; limitadas&nbsp; na&nbsp; AR&nbsp; inicial;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; a&nbsp; titulação&nbsp; de&nbsp; anticorpos&nbsp; contra&nbsp; peptídios&nbsp; citrulinados&nbsp; cíclicos&nbsp; (anti-CCP)&nbsp; é&nbsp; exame&nbsp; com&nbsp; sensibilidade&nbsp; semelhante&nbsp; à&nbsp; do&nbsp; FR,&nbsp; mas&nbsp; com&nbsp; especificidade&nbsp; superior,&nbsp; especialmente&nbsp; nos&nbsp; casos&nbsp; iniciais&nbsp; de&nbsp; AR,&nbsp; devendo&nbsp; ser&nbsp; utilizado&nbsp; apenas&nbsp; se&nbsp; o&nbsp; FR&nbsp; for&nbsp; negativo&nbsp; ou&nbsp; em&nbsp; caso&nbsp; de&nbsp; dúvida&nbsp; diagnóstica;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; a&nbsp; avaliação&nbsp; por&nbsp; meio&nbsp; de&nbsp; marcadores&nbsp; de&nbsp; atividade&nbsp; inflamatória&nbsp; (velocidade&nbsp; de&nbsp; hemossedimentação&nbsp; e&nbsp; proteína&nbsp; C&nbsp; reativa)</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">deve&nbsp; ser&nbsp; solicitada&nbsp; na&nbsp; suspeita&nbsp; clínica&nbsp; de&nbsp; AR;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; radiografia&nbsp; simples&nbsp; deve&nbsp; ser&nbsp; realizada&nbsp; para&nbsp; avaliação&nbsp; diagnóstica&nbsp; e&nbsp; prognóstica&nbsp; de&nbsp; AR;&nbsp; ultrassonografia&nbsp; e&nbsp; ressonância&nbsp; magnética&nbsp; podem&nbsp; ser&nbsp; solicitadas&nbsp; na&nbsp; AR&nbsp; inicial&nbsp; sem&nbsp; erosões&nbsp; à&nbsp; radiografia;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; algum&nbsp; índice&nbsp; combinado&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; (ICAD)&nbsp; e&nbsp; algum&nbsp; instrumento&nbsp; de&nbsp; medida&nbsp; da&nbsp; capacidade&nbsp; funcional,&nbsp; tal&nbsp; como&nbsp; o&nbsp; Health&nbsp; Assessment&nbsp; Questionnaire&nbsp; (HAQ),&nbsp; devem&nbsp; ser&nbsp; utilizados&nbsp; regularmente&nbsp; no&nbsp; momento&nbsp; do&nbsp; diagnóstico&nbsp; e&nbsp; no&nbsp; monitoramento&nbsp; de&nbsp; AR;&nbsp; &nbsp;&nbsp;e</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; na&nbsp; avaliação&nbsp; inicial&nbsp; de&nbsp; AR,&nbsp; fatores&nbsp; de&nbsp; mau&nbsp; prognóstico&nbsp; devem&nbsp; ser&nbsp; pesquisados.</span></span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Dessa&nbsp; forma,&nbsp; o&nbsp; diagnóstico&nbsp; de&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; deve&nbsp; ser&nbsp; feito&nbsp; considerando-se&nbsp; o&nbsp; tempo&nbsp; de&nbsp; evolução&nbsp; da&nbsp; artrite,&nbsp; a&nbsp; presença&nbsp; de&nbsp; autoanticorpos,&nbsp; a&nbsp; elevação&nbsp; de&nbsp; provas&nbsp; inflamatórias&nbsp; e&nbsp; as&nbsp; alterações&nbsp; compatíveis&nbsp; em&nbsp; exames&nbsp; de&nbsp; imagem,&nbsp; tal&nbsp; como&nbsp; descrito&nbsp; nos&nbsp; critérios&nbsp; de&nbsp; classificação&nbsp; ACR&nbsp; 1987&nbsp; e&nbsp; ACR/EULAR&nbsp; 2010&nbsp; (item&nbsp; 5&nbsp; Critérios&nbsp; de&nbsp; inclusão).</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">5&nbsp; CRITÉRIOS&nbsp; DE&nbsp; INCLUSÃO</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Serão&nbsp; incluídos&nbsp; neste&nbsp; Protocolo&nbsp; os&nbsp; pacientes&nbsp; que&nbsp; preencherem&nbsp; os&nbsp; critérios&nbsp; ACR&nbsp; de&nbsp; 1987&nbsp; ou&nbsp; os&nbsp; critérios&nbsp; ACR/EULAR&nbsp; de</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">2010&nbsp; para&nbsp; classificação&nbsp; de&nbsp; AR&nbsp; (20-22).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Nos&nbsp; critérios&nbsp; ACR&nbsp; são&nbsp; necessários&nbsp; quatro&nbsp; dos&nbsp; sete&nbsp; critérios&nbsp; abaixo&nbsp; para&nbsp; classificar&nbsp; um&nbsp; paciente&nbsp; como&nbsp; tendo&nbsp; artrite&nbsp; reumatoide,&nbsp; sendo&nbsp; que&nbsp; os&nbsp; critérios&nbsp; de&nbsp; 1&nbsp; a&nbsp; 4&nbsp; devem&nbsp; estar&nbsp; presentes&nbsp; em&nbsp; pacientes&nbsp; com&nbsp; história&nbsp; de&nbsp; pelo&nbsp; menos&nbsp; 6&nbsp; semanas&nbsp; de&nbsp; evolução:</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">1.&nbsp; rigidez&nbsp; matinal&nbsp; (nas&nbsp; articulações,&nbsp; com&nbsp; pelo&nbsp; menos&nbsp; 1&nbsp; hora&nbsp; de&nbsp; duração);</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">2.&nbsp; artrite&nbsp; de&nbsp; 3&nbsp; ou&nbsp; mais&nbsp; das&nbsp; seguintes&nbsp; áreas:&nbsp; articulações&nbsp; IFT&nbsp; proximais,&nbsp; articulações&nbsp; MCF,&nbsp; punhos,&nbsp; cotovelos,&nbsp; joelhos,&nbsp; tornozelos&nbsp; e&nbsp; artcilações&nbsp; MTF;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">3.&nbsp; artrite&nbsp; de&nbsp; mãos&nbsp; (punhos,&nbsp; articulações&nbsp; MCF&nbsp; ou&nbsp; IFT&nbsp; proximais);</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">4.&nbsp; artrite&nbsp; simétrica&nbsp; (mesma&nbsp; área&nbsp; em&nbsp; ambos&nbsp; os&nbsp; lados&nbsp; do&nbsp; corpo);</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">5.&nbsp; nódulo&nbsp; reumatoide&nbsp; (presença&nbsp; de&nbsp; 1&nbsp; ou&nbsp; mais&nbsp; nódulos&nbsp; subcutâneos&nbsp; sobre&nbsp; proeminências&nbsp; ósseas&nbsp; ou&nbsp; superfícies&nbsp; extensoras&nbsp; ou&nbsp; regiões&nbsp; periarticulares);</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">6.&nbsp; FR&nbsp; (presente&nbsp; em&nbsp; qualquer&nbsp; título);</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">7.&nbsp; alterações&nbsp; radiográficas&nbsp; (erosões&nbsp; ou&nbsp; descalcificação&nbsp; periarticular&nbsp; em&nbsp; radiografias&nbsp; posteroanteriores&nbsp; de&nbsp; mãos&nbsp; e&nbsp; punhos).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Os&nbsp; critérios&nbsp; ACR/EULAR&nbsp; (pontuação&nbsp; de&nbsp; pelo&nbsp; menos&nbsp; 6&nbsp; em&nbsp; 10)&nbsp; devem&nbsp; estar&nbsp; presentes&nbsp; em&nbsp; pacientes&nbsp; com&nbsp; sinovite&nbsp; clínica&nbsp; em&nbsp; pelo&nbsp; menos&nbsp; uma&nbsp; articulação,&nbsp; que&nbsp; não&nbsp; seja&nbsp; justificada&nbsp; por&nbsp; outra&nbsp; causa):</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">1.&nbsp; envolvimento&nbsp; articular,&nbsp; excluídas&nbsp; as&nbsp; articulações&nbsp; IFT&nbsp; distais&nbsp; de&nbsp; mãos&nbsp; e&nbsp; pés,&nbsp; primeiras&nbsp; MTF&nbsp; e&nbsp; primeiras&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">carpometacárpicas&nbsp; (0-5)</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; 1&nbsp; articulação&nbsp; grande&nbsp; (ombros,&nbsp; cotovelos,&nbsp; quadris,&nbsp; joelhos&nbsp; e&nbsp; tornozelos):&nbsp; 0</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; 2&nbsp; a&nbsp; 10&nbsp; articulações&nbsp; grandes&nbsp; (ombros,&nbsp; cotovelos,&nbsp; quadris,&nbsp; joelhos&nbsp; e&nbsp; tornozelos):&nbsp; 1</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; 1&nbsp; a&nbsp; 3&nbsp; articulações&nbsp; pequenas&nbsp; (articulações&nbsp; MCF,&nbsp; 1a&nbsp; IFT,&nbsp; IFT&nbsp; proximais,&nbsp; 2a&nbsp; a&nbsp; 5a&nbsp; MTF&nbsp; e&nbsp; punhos):&nbsp; 2</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; 4&nbsp; a&nbsp; 10&nbsp; articulações&nbsp; pequenas&nbsp; (articulações&nbsp; MCF,&nbsp; 1ª&nbsp; TF,&nbsp; TF&nbsp; proximais,&nbsp; 2ª&nbsp; a&nbsp; 5ª&nbsp; MTF&nbsp; e&nbsp; punhos):&nbsp; 3</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; mais&nbsp; de&nbsp; 10&nbsp; articulações&nbsp; (pelo&nbsp; menos&nbsp; uma&nbsp; pequena&nbsp; articulação&nbsp; e&nbsp; grandes&nbsp; articulações&nbsp; temporomandibulares,&nbsp; esternoclaviculares&nbsp; e&nbsp; acromioclaviculares):&nbsp; 5&nbsp;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial, helvetica, sans-serif;">2.&nbsp; sorologia&nbsp; (0-3)</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; FR&nbsp; e&nbsp; anti-CCP&nbsp; negativos:&nbsp; 0</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; FR&nbsp; ou&nbsp; anti-CCP&nbsp; positivos&nbsp; em&nbsp; baixos&nbsp; títulos&nbsp; (até&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; limite&nbsp; superior&nbsp; da&nbsp; normalidade):&nbsp; 2</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; FR&nbsp; ou&nbsp; anti-CCP&nbsp; positivos&nbsp; em&nbsp; altos&nbsp; títulos&nbsp; (3&nbsp; vezes&nbsp; acima&nbsp; do&nbsp; limite&nbsp; superior&nbsp; da&nbsp; normalidade):&nbsp; 3</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">3.&nbsp; duração&nbsp; dos&nbsp; sintomas&nbsp; (0-1)</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; menos&nbsp; de&nbsp; 6&nbsp; semanas:&nbsp; 0</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; igual&nbsp; ou&nbsp; superior&nbsp; a&nbsp; 6&nbsp; semanas:&nbsp; 1</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">4.&nbsp; reagentes&nbsp; de&nbsp; fase&nbsp; aguda&nbsp; (0-1)</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; proteína&nbsp; C&nbsp; reativa&nbsp; e&nbsp; velocidade&nbsp; de&nbsp; sedimentação&nbsp; globular&nbsp; normais:&nbsp; 0</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; proteína&nbsp; C&nbsp; reativa&nbsp; ou&nbsp; velocidade&nbsp; de&nbsp; sedimentação&nbsp; globular&nbsp; alteradas:&nbsp; 1</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Os&nbsp; novos&nbsp; critérios&nbsp; de&nbsp; classificação&nbsp; de&nbsp; AR&nbsp; (2010)&nbsp; têm&nbsp; como&nbsp; pré-requisito&nbsp; a&nbsp; exclusão&nbsp; de&nbsp; outras&nbsp; causas&nbsp; de&nbsp; artrite,&nbsp; no&nbsp; entanto&nbsp; a&nbsp; maioria&nbsp; dos&nbsp; estudos&nbsp; clínicos&nbsp; utilizou&nbsp; os&nbsp; critérios&nbsp; anteriores,&nbsp; de&nbsp; 1987.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Assim,&nbsp; com&nbsp; base&nbsp; na&nbsp; importância&nbsp; do&nbsp; reconhecimento&nbsp; precoce&nbsp; e&nbsp; do&nbsp; tratamento&nbsp; adequado&nbsp; dos&nbsp; casos&nbsp; iniciais&nbsp; de&nbsp; AR,&nbsp; optou-&nbsp; se&nbsp; por&nbsp; manter&nbsp; ambos&nbsp; neste&nbsp; Protocolo:&nbsp; os&nbsp; critérios&nbsp; mais&nbsp; estudados&nbsp; (1987)&nbsp; e&nbsp; os&nbsp; mais&nbsp; sensíveis&nbsp; para&nbsp; os&nbsp; casos&nbsp; iniciais&nbsp; (2010).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Para&nbsp; ser&nbsp; classificado&nbsp; como&nbsp; portador&nbsp; de&nbsp; ARJ,&nbsp; o&nbsp; indivíduo&nbsp; deve&nbsp; apresentar&nbsp; artrite&nbsp; de&nbsp; causa&nbsp; desconhecida.&nbsp; Para&nbsp; tanto&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">devem&nbsp; ser&nbsp; excluídas&nbsp; as&nbsp; artrites&nbsp; traumáticas,&nbsp; reacionais,&nbsp; infeciosas,&nbsp; transitórias,&nbsp; paraneoplásicas,&nbsp; vasculares,&nbsp; causadas&nbsp; por&nbsp; doenças&nbsp; de&nbsp; depósito&nbsp; (por&nbsp; exemplo,&nbsp; mucopolissacaridose,&nbsp; doença&nbsp; de&nbsp; Fabry)&nbsp; entre&nbsp; outras.&nbsp; A&nbsp; doença&nbsp; deve&nbsp; ter&nbsp; iniciado&nbsp; antes&nbsp; dos&nbsp; 16&nbsp; anos&nbsp; de&nbsp; idade&nbsp; e&nbsp; a&nbsp; duração&nbsp; dos&nbsp; sintomas&nbsp; deve&nbsp; ser&nbsp; igual&nbsp; ou&nbsp; superior&nbsp; a&nbsp; 6&nbsp; semanas&nbsp; (13).</span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">6&nbsp; CRITÉRIOS&nbsp; DE&nbsp; EXCLUSÃO</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Serão&nbsp; excluídos&nbsp; do&nbsp; uso&nbsp; de&nbsp; medicamento&nbsp; preconizado&nbsp; neste&nbsp; Protocolo&nbsp; os&nbsp; pacientes&nbsp; que&nbsp; apresentarem&nbsp; contraindicação&nbsp; absoluta&nbsp; ao&nbsp; seu&nbsp; respectivo&nbsp; uso&nbsp; (Quadro&nbsp; 1).</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">7&nbsp; CASOS&nbsp; ESPECIAIS</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Serão&nbsp; considerados&nbsp; casos&nbsp; especiais&nbsp; os&nbsp; pacientes&nbsp; com&nbsp; os&nbsp; seguintes&nbsp; diagnósticos:&nbsp; doença&nbsp; reumatoide&nbsp; do&nbsp; pulmão,&nbsp; vasculite&nbsp; reumatoide&nbsp; (diagnosticadas&nbsp; em&nbsp; indivíduos&nbsp; com&nbsp; AR&nbsp; e&nbsp; manifestações&nbsp; compatíveis)&nbsp; e&nbsp; ARJ.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; doença&nbsp; reumatoide&nbsp; do&nbsp; pulmão&nbsp; e&nbsp; vasculite&nbsp; reumatoide&nbsp; são&nbsp; manifestações&nbsp; extra-articulares&nbsp; geralmente&nbsp; graves,&nbsp; tratadas&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">com&nbsp; imunossupressores.</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Pulsoterapia&nbsp; com&nbsp; succinato&nbsp; de&nbsp; metilprednisolona&nbsp; intravenosa,&nbsp; prednisona&nbsp; por&nbsp; via&nbsp; oral,&nbsp; azatioprina&nbsp; por&nbsp; via&nbsp; oral,&nbsp; ciclosporina&nbsp; por&nbsp; via&nbsp; oral&nbsp; e&nbsp; ciclofosfamida&nbsp; intravenosa&nbsp; são&nbsp; opções&nbsp; terapêuticas&nbsp; (33).&nbsp; Em&nbsp; geral,&nbsp; inicia-se&nbsp; com&nbsp; pulsoterapia&nbsp; de&nbsp; metilprednisolona&nbsp; (com&nbsp; ou&nbsp; sem&nbsp; ciclofosfamida,&nbsp; dependendo&nbsp; da&nbsp; gravidade&nbsp; das&nbsp; manifestações&nbsp; da&nbsp; doença).&nbsp; Caso&nbsp; não&nbsp; seja&nbsp; usada&nbsp; ciclofosfamida,&nbsp; pode&nbsp; ser&nbsp; iniciada&nbsp; azatioprina&nbsp; ou&nbsp; ciclosporina&nbsp; em&nbsp; associação&nbsp; à&nbsp; pulsoterapia.</span></span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Posteriormente,&nbsp; realiza-se&nbsp; redução&nbsp; gradual&nbsp; do&nbsp; glicocorticoide,&nbsp; com&nbsp; o&nbsp; objetivo&nbsp; de&nbsp; manter&nbsp; a&nbsp; doença&nbsp; controlada&nbsp; apenas&nbsp; com&nbsp; azatioprina,&nbsp; ciclosporina&nbsp; ou&nbsp; ciclofosfamida&nbsp; de&nbsp; manutenção.</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; tratamento&nbsp; da&nbsp; ARJ&nbsp; segue,&nbsp; em&nbsp; linhas&nbsp; gerais,&nbsp; os&nbsp; mesmos&nbsp; passos&nbsp; da&nbsp; doença&nbsp; no&nbsp; adulto,&nbsp; mas&nbsp; com&nbsp; especificidades:&nbsp; Inicia-&nbsp; se&nbsp; com&nbsp; anti-inflamatórios&nbsp; não&nbsp; esteroides&nbsp; (AINE),&nbsp; sendo&nbsp; o&nbsp; naproxeno&nbsp; o&nbsp; preferencial.</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Raramente,&nbsp; os&nbsp; AINE&nbsp; conseguem&nbsp; controlar&nbsp; isoladamente&nbsp; a&nbsp; artrite.&nbsp; Havendo&nbsp; necessidade&nbsp; de&nbsp; uso&nbsp; de&nbsp; outro&nbsp; medicamento,&nbsp; deve-se&nbsp; optar&nbsp; pelo&nbsp; metotrexato.&nbsp; A&nbsp; sulfassalazina,&nbsp; cloroquina,&nbsp; hidroxicloroquina,&nbsp; leflunomida,&nbsp; azatioprina,&nbsp; ciclosporina,&nbsp; glicocorticoide&nbsp; sistêmico&nbsp; ou&nbsp; intra-articular&nbsp; podem&nbsp; ser&nbsp; indicados&nbsp; a&nbsp; critério&nbsp; clínico.&nbsp; A&nbsp; sulfassalazina&nbsp; não&nbsp; é&nbsp; recomendada&nbsp; para&nbsp; a&nbsp; forma&nbsp; sistêmica.&nbsp; A&nbsp; ciclosporina&nbsp; é&nbsp; preferencialmente&nbsp; recomendada&nbsp; na&nbsp; síndrome&nbsp; de&nbsp; ativação&nbsp; macrofágica,&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">ou&nbsp; linfo-histiocitose&nbsp; hemofagocítica.&nbsp; Na&nbsp; persistência&nbsp; de&nbsp; artrite,&nbsp; após&nbsp; 3&nbsp; a&nbsp; 6&nbsp; meses&nbsp; de&nbsp; tratamento,&nbsp; deve-se&nbsp; iniciar&nbsp; medicamento&nbsp; modificador&nbsp; do&nbsp; curso&nbsp; da&nbsp; doença&nbsp; (MMCD)&nbsp; biológico,&nbsp; entre&nbsp; eles&nbsp; o&nbsp; adalimumabe,&nbsp; etanercepte,&nbsp; infliximabe,&nbsp; abatacepte&nbsp; e&nbsp; tocilizumabe,&nbsp; sendo&nbsp; este&nbsp; último&nbsp; apenas&nbsp; para&nbsp; a&nbsp; forma&nbsp; sistêmica&nbsp; (34-37).&nbsp; A&nbsp; associação&nbsp; de&nbsp; MMCD&nbsp; biológicos&nbsp; não&nbsp; deve&nbsp; ser&nbsp; utilizada&nbsp; (35,38-50).&nbsp; Nos&nbsp; casos&nbsp; de&nbsp; falha&nbsp; ao&nbsp; tratamento&nbsp; com&nbsp; MMCD&nbsp; biológico,&nbsp; deve-se&nbsp; seguir&nbsp; o&nbsp; recomendado&nbsp; no&nbsp; item&nbsp; "Estratégia&nbsp; Terapêutica".</span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">8&nbsp; TRATAMENTO</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; tratamento&nbsp; de&nbsp; AR&nbsp; deve&nbsp; ser&nbsp; iniciado&nbsp; o&nbsp; mais&nbsp; breve&nbsp; possível,&nbsp; uma&nbsp; vez&nbsp; que&nbsp; a&nbsp; terapia&nbsp; medicamentosa&nbsp; intensiva&nbsp; instituída&nbsp; precocemente&nbsp; previne&nbsp; danos&nbsp; estruturais&nbsp; (erosões),&nbsp; melhorando&nbsp; a&nbsp; capacidade&nbsp; funcional&nbsp; (1,10,51,52).&nbsp; O&nbsp; período&nbsp; inicial&nbsp; da&nbsp; doença,&nbsp; principalmente&nbsp; os&nbsp; doze&nbsp; primeiros&nbsp; meses&nbsp; (AR&nbsp; inicial),&nbsp; configura&nbsp; uma&nbsp; janela&nbsp; de&nbsp; oportunidade&nbsp; terapêutica,&nbsp; isto&nbsp; é,&nbsp; um&nbsp; momento&nbsp; em&nbsp; que&nbsp; a&nbsp; intervenção&nbsp; farmacológica&nbsp; efetiva&nbsp; pode&nbsp; mudar&nbsp; o&nbsp; curso&nbsp; da&nbsp; doença&nbsp; (53).&nbsp; Em&nbsp; alguns&nbsp; países,&nbsp; o&nbsp; acompanhamento&nbsp; por&nbsp; reumatologista&nbsp; é&nbsp; uma&nbsp; política&nbsp; assistencial&nbsp; custo-efetiva&nbsp; (54),&nbsp; devendo&nbsp; ser&nbsp; o&nbsp; preferencial.&nbsp; Intervenções&nbsp; educacionais&nbsp; podem&nbsp; ser&nbsp; úteis&nbsp; na&nbsp; implementação&nbsp; de&nbsp; protocolos&nbsp; clínicos&nbsp; para&nbsp; essa&nbsp; doença&nbsp; (55).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">8.1&nbsp; TRATAMENTO&nbsp; NÃO&nbsp; MEDICAMENTOSO</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; tratamento&nbsp; não&nbsp; medicamentoso&nbsp; de&nbsp; AR&nbsp; inclui&nbsp; educação&nbsp; do&nbsp; paciente&nbsp; e&nbsp; de&nbsp; sua&nbsp; família,&nbsp; terapia&nbsp; ocupacional,&nbsp; exercícios,&nbsp; fisioterapia,&nbsp; apoio&nbsp; psicossocial&nbsp; e&nbsp; cirurgia.&nbsp; As&nbsp; evidências&nbsp; de&nbsp; tratamento&nbsp; não&nbsp; medicamentoso&nbsp; são&nbsp; escassas,&nbsp; mas&nbsp; acredita-&nbsp; se&nbsp; que&nbsp; tenha&nbsp; papel&nbsp; importante&nbsp; na&nbsp; melhora&nbsp; clínica&nbsp; e&nbsp; funcional&nbsp; dos&nbsp; pacientes&nbsp; (56-65).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Terapia&nbsp; ocupacional&nbsp; e&nbsp; órteses&nbsp; de&nbsp; punho&nbsp; e&nbsp; dedos&nbsp; têm&nbsp; pouca&nbsp; evidência&nbsp; de&nbsp; validade&nbsp; na&nbsp; AR&nbsp; de&nbsp; longa&nbsp; data&nbsp; (56,66-71).&nbsp; Exercícios&nbsp; contra&nbsp; resistência&nbsp; são&nbsp; seguros&nbsp; e&nbsp; eficazes&nbsp; na&nbsp; AR,&nbsp; melhorando&nbsp; a&nbsp; força&nbsp; muscular&nbsp; e&nbsp; o&nbsp; tempo&nbsp; de&nbsp; deslocamento&nbsp; (72,73).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Exercícios&nbsp; aeróbicos&nbsp; parecem&nbsp; melhorar&nbsp; de&nbsp; forma&nbsp; discreta&nbsp; a&nbsp; qualidade&nbsp; de&nbsp; vida,&nbsp; a&nbsp; capacidade&nbsp; funcional&nbsp; e&nbsp; a&nbsp; dor&nbsp; em&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">pacientes&nbsp; com&nbsp; AR&nbsp; estável,&nbsp; havendo&nbsp; estudos&nbsp; em&nbsp; andamento&nbsp; sobre&nbsp; o&nbsp; tema&nbsp; (74-78).</span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Fisioterapia&nbsp; pode&nbsp; propiciar&nbsp; benefício,&nbsp; havendo&nbsp; ainda&nbsp; grande&nbsp; heterogeneidade&nbsp; de&nbsp; métodos&nbsp; entre&nbsp; os&nbsp; trabalhos&nbsp; disponíveis&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">(79-84).&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Intervenções&nbsp; psicológicas&nbsp; são&nbsp; eficazes&nbsp; no&nbsp; tratamento&nbsp; a&nbsp; curto&nbsp; prazo&nbsp; de&nbsp; AR,&nbsp; especialmente&nbsp; aumentando&nbsp; a&nbsp; atividade&nbsp; física&nbsp; e&nbsp; reduzindo&nbsp; a&nbsp; ansiedade&nbsp; e&nbsp; a&nbsp; depressão&nbsp; (85,&nbsp; 86).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Para&nbsp; a&nbsp; subluxação&nbsp; atlantoaxial,&nbsp; o&nbsp; tratamento&nbsp; cirúrgico&nbsp; parece&nbsp; ser&nbsp; melhor&nbsp; do&nbsp; que&nbsp; o&nbsp; conservador&nbsp; em&nbsp; estudos&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">observacionais&nbsp; (87).</span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Tratamentos&nbsp; cirúrgicos&nbsp; de&nbsp; outras&nbsp; articulações&nbsp; ainda&nbsp; carecem&nbsp; de&nbsp; evidências&nbsp; consistentes&nbsp; (88,89).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; benefício&nbsp; da&nbsp; acupuntura&nbsp; ainda&nbsp; é&nbsp; controverso&nbsp; devido&nbsp; a&nbsp; limitações&nbsp; metodológicas&nbsp; significativas&nbsp; dos&nbsp; estudos&nbsp; realizados&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">(90-92).</span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Terapias&nbsp; alternativas&nbsp; e&nbsp; complementares&nbsp; não&nbsp; apresentam,&nbsp; até&nbsp; o&nbsp; momento,&nbsp; evidências&nbsp; que&nbsp; sustentem&nbsp; a&nbsp; recomendação&nbsp; de&nbsp; seu&nbsp; uso&nbsp; (93-104).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Sinovectomia&nbsp; radioisotópica&nbsp; (radiossinoviórtese)&nbsp; parece&nbsp; apresentar&nbsp; eficácia&nbsp; quando&nbsp; comparada&nbsp; ao&nbsp; uso&nbsp; de&nbsp; glicocorticoide&nbsp; intraarticular,&nbsp; no&nbsp; entanto&nbsp; a&nbsp; heterogeneidade&nbsp; dos&nbsp; poucos&nbsp; estudos&nbsp; disponíveis&nbsp; restringe&nbsp; essa&nbsp; recomendação&nbsp; de&nbsp; tratamento&nbsp; (105,106).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; benefício&nbsp; trazido&nbsp; por&nbsp; modificações&nbsp; nutricionais&nbsp; ainda&nbsp; é&nbsp; incerto,&nbsp; devendo&nbsp; ser&nbsp; considerados&nbsp; seus&nbsp; possíveis&nbsp; eventos&nbsp; adversos,&nbsp; tal&nbsp; como&nbsp; o&nbsp; emagrecimento,&nbsp; que&nbsp; contribuem&nbsp; para&nbsp; o&nbsp; grande&nbsp; número&nbsp; de&nbsp; perdas&nbsp; de&nbsp; acompanhamento&nbsp; nos&nbsp; estudos&nbsp; (107).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Em&nbsp; resumo,&nbsp; para&nbsp; pacientes&nbsp; com&nbsp; AR,&nbsp; inclusive&nbsp; os&nbsp; casos&nbsp; especiais,&nbsp; recomendam-se&nbsp; exercício&nbsp; físico&nbsp; regular,&nbsp; terapia&nbsp; ocupacional,&nbsp; órteses,&nbsp; fisioterapia&nbsp; e&nbsp; terapia&nbsp; psicológica&nbsp; de&nbsp; forma&nbsp; individualizada.</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">8.2&nbsp; TRATAMENTO&nbsp; MEDICAMENTOSO</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; tratamento&nbsp; medicamentoso&nbsp; de&nbsp; AR&nbsp; inclui&nbsp; o&nbsp; uso&nbsp; de&nbsp; antiinflamatórios&nbsp; não&nbsp; esteroides&nbsp; (AINE),&nbsp; glicocorticoides,&nbsp; medicamentos&nbsp; modificadores&nbsp; do&nbsp; curso&nbsp; da&nbsp; doença&nbsp; (MMCD)&nbsp; –&nbsp; sintéticos&nbsp; e&nbsp; biológicos</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; e&nbsp; imunossupressores&nbsp; (1,108).&nbsp; O&nbsp; uso&nbsp; seguro&nbsp; desses&nbsp; fármacos&nbsp; exige&nbsp; o&nbsp; conhecimento&nbsp; de&nbsp; suas&nbsp; contraindicações&nbsp; absolutas&nbsp; (Quadro&nbsp; 1).</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Quadro&nbsp; 1&nbsp; –&nbsp; Contraindicações&nbsp; Absolutas&nbsp; dos&nbsp; Fármacos&nbsp; Utilizados&nbsp; no&nbsp; Tratamento&nbsp; da&nbsp; Artrite&nbsp; Reumatoide&nbsp; (109):</span></span></span></span></p>
<p data-obsoleto="text-align: left;">
			&nbsp;</p>
<table border="1" cellpadding="0" cellspacing="0" data-obsoleto="width: 958px;">
<tbody>
<tr>
<td data-obsoleto="width: 319px; height: 12px;">
<p data-obsoleto="margin-left: 44.4pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">FÁRMACOS</span></span></span></span></p>
</td>
<td data-obsoleto="width: 595px; height: 12px;">
<p data-obsoleto="margin-left: 92.05pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">CONTRA INDICAÇÕES</span></span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Prednisona,&nbsp; succninato&nbsp; de&nbsp; me-&nbsp; tilprednisolona,</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">acetato&nbsp; de&nbsp; metilprednisolona,&nbsp; prednisolona.</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; a&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.&nbsp;&nbsp;</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Naproxeno</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Sangramento&nbsp; gastrointestinal&nbsp; não</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">controlado.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; transaminases/aminotransferases&nbsp; igual</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">ou&nbsp; 3&nbsp; vezes&nbsp; acima&nbsp; do&nbsp; limite&nbsp; superior&nbsp; da&nbsp; normalidade.&nbsp; –&nbsp; Taxa&nbsp; de&nbsp; depuração&nbsp; de&nbsp; creatinina</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">inferior&nbsp; a&nbsp; 30&nbsp; ml/min/1,73m2&nbsp; de&nbsp; superfície&nbsp; corporal&nbsp; na&nbsp; ausência&nbsp; de&nbsp; terapia&nbsp; dialítica&nbsp; crônica.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Metotrexato</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">-Infecção&nbsp; bacteriana&nbsp; com&nbsp; indicação&nbsp; de&nbsp; uso&nbsp; de&nbsp; antibió-tico.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; fúngica&nbsp; ameaçadora&nbsp; à&nbsp; vida.&nbsp; –&nbsp; Infecção&nbsp; por&nbsp; herpes&nbsp; zoster&nbsp; ativa.&nbsp; –&nbsp; Hepatites&nbsp; B&nbsp; ou&nbsp; C&nbsp; agudas.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Gestação,&nbsp; amamentação&nbsp; e&nbsp; concepção&nbsp; (homens&nbsp; e&nbsp; mu-lheres).&nbsp; –&nbsp; Elevação&nbsp; de</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">aminotransferases/transaminases&nbsp; igual&nbsp; ou&nbsp; 3&nbsp; vezes&nbsp; acima&nbsp; do&nbsp; limite&nbsp; superior&nbsp; da&nbsp; normalidade.&nbsp; –&nbsp; Taxa&nbsp; de&nbsp; depuração&nbsp; de&nbsp; creatinina</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">inferior&nbsp; a&nbsp; 30&nbsp; ml/min/1,73m2&nbsp; de&nbsp; superfície&nbsp; corporal&nbsp; na&nbsp; ausência&nbsp; de&nbsp; terapia&nbsp; dialítica&nbsp; crônica.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Sulfassalazina</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Porfiria.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hepatites&nbsp; B&nbsp; ou&nbsp; C&nbsp; agudas.&nbsp; –&nbsp; Artrite&nbsp; reumatoide&nbsp; juvenil,&nbsp; forma&nbsp; sistêmica.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; aminotransferases/transaminases&nbsp; igual&nbsp; ou&nbsp; 3&nbsp; vezes&nbsp; acima&nbsp; do&nbsp; limite&nbsp; superior&nbsp; da&nbsp; normalidade.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Leflunomida</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; bacteriana&nbsp; com&nbsp; indicação&nbsp; de&nbsp; uso&nbsp; de&nbsp; antibió-tico.</span></span></p>
<p>
							&nbsp;</p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; fúngica&nbsp; ameaçadora&nbsp; à&nbsp; vida.&nbsp; –&nbsp; Infecção&nbsp; por&nbsp; herpes&nbsp; zoster&nbsp; ativa.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hepatites&nbsp; B&nbsp; ou&nbsp; C&nbsp; agudas.&nbsp; –&nbsp; Gestação,&nbsp; amamentação&nbsp; e&nbsp; concepção</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">(homens&nbsp; e&nbsp; mulheres).&nbsp; –&nbsp; Elevação&nbsp; de&nbsp; aminotransferases/transaminases&nbsp; igual&nbsp; ou&nbsp; 3&nbsp; vezes&nbsp; acima&nbsp; do&nbsp; limite</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">superior&nbsp; da</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">normalidade.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Taxa&nbsp; de&nbsp; depuração&nbsp; de&nbsp; creatinina&nbsp; inferior&nbsp; a&nbsp; 30&nbsp; ml/min/1,73m2&nbsp; de&nbsp; superfície&nbsp; corporal&nbsp; na&nbsp; ausência&nbsp; de&nbsp; terapia&nbsp; dialítica&nbsp; crô-nica.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Hidroxicloroquina&nbsp; &nbsp;&nbsp;e&nbsp; cloroquina</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Retinopatia.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Adalimumabe,&nbsp; certolizumabe&nbsp; pegol,&nbsp; etanercepte,</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">infliximabe,&nbsp; golimumabe.</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							&nbsp;</p>
<p>
							&nbsp;</p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; bacteriana&nbsp; com&nbsp; indicação&nbsp; de&nbsp; uso&nbsp; de&nbsp; antibiótico.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; fúngica&nbsp; ameaçadora&nbsp; à&nbsp; vida.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; por&nbsp; herpes&nbsp; zoster&nbsp; ativa.&nbsp; –&nbsp; Hepatites&nbsp; B&nbsp; ou&nbsp; C&nbsp; agudas.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Doença&nbsp; linfoproliferativa&nbsp;&nbsp;&nbsp; nos&nbsp; últimos&nbsp; 5&nbsp; anos.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Insuficiência&nbsp; cardíaca&nbsp; congestiva&nbsp; classes&nbsp; III&nbsp; ou&nbsp; IV.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Doença&nbsp; neurológica&nbsp; desmielinizante.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Abatacepte</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; bacteriana&nbsp; com&nbsp; indicação&nbsp; de&nbsp; uso&nbsp; de&nbsp; antibiótico.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; fúngica&nbsp; ameaçadora&nbsp; à&nbsp; vida.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; por&nbsp; herpes&nbsp; zoster&nbsp; ativa.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hepatites&nbsp; B&nbsp; ou&nbsp; C&nbsp; agudas.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Rituximabe</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; bacteriana&nbsp; com&nbsp; indicação&nbsp; de&nbsp; uso&nbsp; de&nbsp; antibiótico.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; fúngica&nbsp; ameaçadora&nbsp; à&nbsp; vida.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; por&nbsp; herpes&nbsp; zoster&nbsp; ativa.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Leucoencefalopatia&nbsp; multifocal&nbsp; progressiva.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hepatites&nbsp; B&nbsp; ou&nbsp; C&nbsp; agudas.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Tocilizumabe</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">-Hipersensibilidade&nbsp; conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; bacteriana&nbsp; com&nbsp; indicação&nbsp; de&nbsp; uso&nbsp; de&nbsp; antibiótico.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; fúngica&nbsp; ameaçadora&nbsp; à&nbsp; vida.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; por&nbsp; herpes&nbsp; zoster&nbsp; ativa.&nbsp; –&nbsp; Hepatites&nbsp; B&nbsp; ou&nbsp; C&nbsp; agudas.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; aminotransferases/transaminases&nbsp; igual&nbsp; ou&nbsp; 3&nbsp; vezes&nbsp; acima&nbsp; do&nbsp; limite&nbsp; superior&nbsp; da&nbsp; normalidade.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Contagem&nbsp; total&nbsp; de&nbsp; neutrófilos&nbsp; inferior&nbsp; a&nbsp; 1.000/mm3.&nbsp; –&nbsp; Contagem&nbsp; total&nbsp; de&nbsp; plaquetas&nbsp; inferior&nbsp; a</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">50.000/mm3.&nbsp; –&nbsp; Risco&nbsp; iminente&nbsp; de&nbsp; perfuração&nbsp; intestinal.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Azatioprina</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; bacteriana&nbsp; com&nbsp; indicação&nbsp; de&nbsp; uso&nbsp; de&nbsp; antibiótico.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; fúngica&nbsp; ameaçadora&nbsp; à&nbsp; vida.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; por&nbsp; herpes&nbsp; zoster&nbsp; ativa.&nbsp; –&nbsp; Hepatites&nbsp; B&nbsp; ou&nbsp; C&nbsp; agudas.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Ciclosporina</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; bacteriana&nbsp; com&nbsp; indicação&nbsp; de&nbsp; uso&nbsp; de&nbsp; antibió-tico.</span></span></p>
<p>
							&nbsp;</p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; fúngica&nbsp; ameaçadora&nbsp; à&nbsp; vida.&nbsp; –&nbsp; Infecção&nbsp; por&nbsp; herpes&nbsp; zoster&nbsp; ativa.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hepatites&nbsp; B&nbsp; ou&nbsp; C&nbsp; agudas.&nbsp; –&nbsp; Hipertensão&nbsp; arterial&nbsp; sistêmica&nbsp; grave&nbsp; não&nbsp; controlada.</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 319px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Ciclofosfamida</span></span></p>
</td>
<td data-obsoleto="width: 595px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hipersensibilidade&nbsp; &nbsp;&nbsp;conhecida&nbsp; ao&nbsp; medicamento,&nbsp; classe&nbsp; ou&nbsp; componentes.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tuberculose&nbsp; sem&nbsp; tratamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; bacteriana&nbsp; com&nbsp; indicação&nbsp; de&nbsp; uso&nbsp; de&nbsp; antibió-tico.</span></span></p>
<p>
							&nbsp;</p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Infecção&nbsp; fúngica&nbsp; ameaçadora&nbsp; à&nbsp; vida.&nbsp; –&nbsp; Infecção&nbsp; por&nbsp; herpes&nbsp; zoster&nbsp; ativa.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Hepatites&nbsp; B&nbsp; ou&nbsp; C&nbsp; agudas.&nbsp; –&nbsp; Cistite&nbsp; hemorrágica.</span></span></p>
</td>
</tr>
</tbody>
</table>
<p>
			&nbsp;</p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Nas&nbsp; várias&nbsp; recomendações&nbsp; de&nbsp; tratamento&nbsp; medicamentoso&nbsp; dos&nbsp; pacientes&nbsp; com&nbsp; AR,&nbsp; o&nbsp; acompanhamento&nbsp; sistemático&nbsp; com&nbsp; progressão&nbsp; de&nbsp; medicamentos&nbsp; em&nbsp; caso&nbsp; de&nbsp; falha&nbsp; terapêutica&nbsp; é&nbsp; considerado&nbsp; estratégia&nbsp; custo-efetiva,&nbsp; uma&nbsp; vez&nbsp; que&nbsp; mantém&nbsp; os&nbsp; pacientes&nbsp; laboralmente&nbsp; ativos,&nbsp; melhorando&nbsp; a&nbsp; capacidade&nbsp; funcional&nbsp; e&nbsp; a&nbsp; qualidade&nbsp; de&nbsp; vida&nbsp; a&nbsp; um&nbsp; custo&nbsp; aceitável&nbsp; para&nbsp; doenças&nbsp; crônicas&nbsp; em&nbsp; estudos&nbsp; realizados&nbsp; em&nbsp; alguns&nbsp; países&nbsp; (110-118).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; administração&nbsp; de&nbsp; MMCD&nbsp; deve&nbsp; ser&nbsp; iniciada&nbsp; no&nbsp; momento&nbsp; do&nbsp; diagnóstico&nbsp; de&nbsp; AR.&nbsp; Avaliações&nbsp; clínicas&nbsp; frequentes,&nbsp; a&nbsp; cada</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">30&nbsp; a&nbsp; 90&nbsp; dias,&nbsp; são&nbsp; recomendadas.&nbsp; Em&nbsp; cada&nbsp; avaliação&nbsp; clínica,&nbsp; o&nbsp; ICAD&nbsp; pode&nbsp; auxiliar&nbsp; o&nbsp; médico&nbsp; no&nbsp; ajuste&nbsp; do&nbsp; tratamento,&nbsp; a&nbsp; ser&nbsp; realizado&nbsp; quando&nbsp; necessário.&nbsp; O&nbsp; objetivo&nbsp; do&nbsp; tratamento&nbsp; é&nbsp; manter&nbsp; a&nbsp; doença&nbsp; em&nbsp; atividade&nbsp; leve&nbsp; ou&nbsp; remissão&nbsp; segundo&nbsp; um&nbsp; ICAD&nbsp; (1,53).&nbsp; Caso&nbsp; contrário,&nbsp; considera-se&nbsp; falha&nbsp; ao&nbsp; tratamento&nbsp; em&nbsp; uso.</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">As&nbsp; falhas&nbsp; terapêuticas&nbsp; aos&nbsp; MMCD&nbsp; biológicos&nbsp; são&nbsp; classificadas&nbsp; em:&nbsp; (a)&nbsp; falha&nbsp; primária,&nbsp; quando&nbsp; o&nbsp; medicamento&nbsp; não&nbsp; atinge&nbsp; o&nbsp; objetivo&nbsp; terapêutico&nbsp; em&nbsp; nenhum&nbsp; momento&nbsp; durante&nbsp; período&nbsp; adequado&nbsp; de&nbsp; observação&nbsp; (de&nbsp; 3&nbsp; a&nbsp; 6&nbsp; meses);&nbsp; ou&nbsp; (b)&nbsp; falha&nbsp; secundária,&nbsp; quando,&nbsp; após&nbsp; resposta&nbsp; satisfatória&nbsp; inicial,&nbsp; há&nbsp; recidiva&nbsp; da&nbsp; doença,&nbsp; com&nbsp; piora&nbsp; da&nbsp; sua&nbsp; atividade.&nbsp; Falha&nbsp; secundária&nbsp; (ou&nbsp; resistência&nbsp; terapêutica&nbsp; adquirida)&nbsp; ocorre&nbsp; quando&nbsp; a&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; moderada&nbsp; ou&nbsp; alta&nbsp; conforme&nbsp; um&nbsp; ICAD&nbsp; após&nbsp; período&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; baixa&nbsp; ou&nbsp; remissão&nbsp; induzida&nbsp; por&nbsp; esse&nbsp; mesmo&nbsp; medicamento.&nbsp; Esta&nbsp; falha&nbsp; tem&nbsp; sido&nbsp; atribuida&nbsp; ao&nbsp; surgimento&nbsp; de&nbsp; anticorpos&nbsp; contra&nbsp; a&nbsp; molécula&nbsp; dos&nbsp; MMCD&nbsp; biológicos,&nbsp; que&nbsp; apresentam&nbsp; maior&nbsp; imunogenecidade&nbsp; do&nbsp; que&nbsp; os&nbsp; MMCD&nbsp; sintéticos&nbsp; (119,120).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Entre&nbsp; os&nbsp; MMCD&nbsp; sintéticos&nbsp; para&nbsp; o&nbsp; tratamento&nbsp; de&nbsp; AR,&nbsp; o&nbsp; metotrexato&nbsp; é&nbsp; o&nbsp; medicamento&nbsp; padrão,&nbsp; devendo&nbsp; ser&nbsp; iniciado&nbsp; tão&nbsp; logo&nbsp; o&nbsp; diagnóstico&nbsp; seja&nbsp; definido&nbsp; (1).&nbsp; Em&nbsp; revisões&nbsp; sistemáticas,&nbsp; o&nbsp; metotrexato&nbsp; foi&nbsp; seguro&nbsp; e&nbsp; eficaz&nbsp; na&nbsp; redução&nbsp; de&nbsp; sintomas,&nbsp; na&nbsp; incapacidade&nbsp; funcional&nbsp; e&nbsp; no&nbsp; dano&nbsp; estrutural,&nbsp; sendo&nbsp; semelhante&nbsp; a&nbsp; leflunomida&nbsp; e&nbsp; superior&nbsp; a&nbsp; outros&nbsp; MMCD&nbsp; sintéticos&nbsp; (121-124).&nbsp; Para&nbsp; otimizar&nbsp; seu&nbsp; perfil&nbsp; de&nbsp; segurança,&nbsp; este&nbsp; fármaco&nbsp; deve&nbsp; ser&nbsp; utilizado&nbsp; preferencialmente&nbsp; com&nbsp; ácido&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">fólico&nbsp; (125-127).</span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; leflunomida&nbsp; é&nbsp; eficaz&nbsp; no&nbsp; controle&nbsp; clínico&nbsp; e&nbsp; radiográfico&nbsp; de&nbsp; AR.&nbsp; Em&nbsp; revisão&nbsp; sistemática&nbsp; com&nbsp; 6&nbsp; ensaios,&nbsp; leflunomida&nbsp; foi&nbsp; superior&nbsp; ao&nbsp; placebo&nbsp; na&nbsp; melhora&nbsp; clínica&nbsp; e&nbsp; radiográfica&nbsp; dos&nbsp; pacientes&nbsp; após&nbsp; 6&nbsp; e&nbsp; 12&nbsp; meses&nbsp; de&nbsp; uso,&nbsp; havendo&nbsp; benefício&nbsp; sustentado&nbsp; com&nbsp; perfil&nbsp; de&nbsp; segurança&nbsp; comparável&nbsp; aos&nbsp; de&nbsp; metotrexato&nbsp; e&nbsp; sulfassalazina&nbsp; após&nbsp; 2&nbsp; anos&nbsp; de&nbsp; acompanhamento&nbsp; (123).&nbsp; Nos&nbsp; casos&nbsp; de&nbsp; toxicidade&nbsp; em&nbsp; que&nbsp; se&nbsp; pretende&nbsp; a&nbsp; reversão&nbsp; farmacológica&nbsp; do&nbsp; efeito&nbsp; da&nbsp; leflunomida,&nbsp; recomenda-se&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">o&nbsp; uso&nbsp; de&nbsp; 50&nbsp; g&nbsp; de&nbsp; carvão&nbsp; ativado,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; a&nbsp; cada&nbsp; 6&nbsp; horas,&nbsp; durante&nbsp; 24&nbsp; horas.</span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; sulfassalazina&nbsp; também&nbsp; é&nbsp; um&nbsp; MMCD&nbsp; sintético&nbsp; eficaz&nbsp; no&nbsp; tratamento&nbsp; de&nbsp; AR,&nbsp; como&nbsp; identificado&nbsp; por&nbsp; Suárez-Almazor&nbsp; e&nbsp; colaboradores&nbsp; (128)&nbsp; em&nbsp; revisão&nbsp; sistemática&nbsp; que&nbsp; incluiu&nbsp; mais&nbsp; de&nbsp; 400&nbsp; pacientes&nbsp; de&nbsp; 6&nbsp; ensaios&nbsp; clínicos&nbsp; randomizados&nbsp; e&nbsp; em&nbsp; que&nbsp; o&nbsp; benefício&nbsp; clínico&nbsp; sobre&nbsp; placebo&nbsp; foi&nbsp; evidenciado&nbsp; e&nbsp; a&nbsp; melhora&nbsp; radiográfica&nbsp; pareceu&nbsp; modesta.</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; hidroxicloroquina&nbsp; apresenta&nbsp; benefício&nbsp; clínico&nbsp; moderado&nbsp; e&nbsp; bom&nbsp; perfil&nbsp; de&nbsp; segurança,&nbsp; sem&nbsp; evidências&nbsp; consistentes&nbsp; de&nbsp; inibição&nbsp; de&nbsp; progressão&nbsp; radiográfica,&nbsp; como&nbsp; demonstrado&nbsp; em&nbsp; revisão&nbsp; sistemática&nbsp; com&nbsp; mais&nbsp; de&nbsp; 500&nbsp; pacientes&nbsp; de&nbsp; 4&nbsp; ensaios&nbsp; clínicos&nbsp; randomizados,&nbsp; identificando&nbsp; benefício&nbsp; clínico&nbsp; moderado&nbsp; e&nbsp; prevalência&nbsp; de&nbsp; eventos&nbsp; adversos&nbsp; comparáveis&nbsp; aos&nbsp; do&nbsp; grupo&nbsp; placebo&nbsp; (129).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">De&nbsp; maneira&nbsp; geral,&nbsp; os&nbsp; MMCD&nbsp; biológicos&nbsp; reduzem&nbsp; a&nbsp; inflamação&nbsp; articular,&nbsp; o&nbsp; dano&nbsp; estrutural&nbsp; e&nbsp; a&nbsp; incapacidade&nbsp; funcional&nbsp; e&nbsp; melhoram&nbsp; a&nbsp; qualidade&nbsp; de&nbsp; vida&nbsp; e,&nbsp; possivelmente,&nbsp; a&nbsp; fadiga&nbsp; (130-134).&nbsp; Não&nbsp; há&nbsp; dados&nbsp; suficientes&nbsp; sobre&nbsp; comparações&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">diretas&nbsp; entre&nbsp; agentes&nbsp; biológicos&nbsp; que&nbsp; permitam&nbsp; definir&nbsp; a&nbsp; superioridade&nbsp; de&nbsp; um&nbsp; agente&nbsp; sobre&nbsp; o&nbsp; outro&nbsp; (135-138).&nbsp; No&nbsp; entanto,&nbsp; um&nbsp; MMCD&nbsp; biológico&nbsp; associado&nbsp; a&nbsp; metotrexato&nbsp; é&nbsp; melhor&nbsp; do&nbsp; que&nbsp; metotrexato&nbsp; isoladamente&nbsp; (139).&nbsp; Os&nbsp; MMCD&nbsp; biológicos&nbsp;não&nbsp; devem&nbsp; ser&nbsp; prescritos&nbsp; de&nbsp; forma&nbsp; associada&nbsp; entre&nbsp; si&nbsp; pelos&nbsp; riscos&nbsp; de&nbsp; eventos&nbsp; adversos&nbsp; graves&nbsp; (135).&nbsp; Há&nbsp; risco&nbsp; de&nbsp; aumento&nbsp; de&nbsp; infecções&nbsp; graves&nbsp; em&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; tratados&nbsp; com&nbsp; MMCD&nbsp; biológicos&nbsp; (140-144).</span></span></span></p>
<p></p></div>
<p data-obsoleto="text-align: justify;">
		&nbsp;</p>
<div>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">No&nbsp; relatório&nbsp; de&nbsp; recomendação&nbsp; da&nbsp; Comissão&nbsp; Nacional&nbsp; de&nbsp; Incorporação&nbsp; de&nbsp; Tecnologias&nbsp; do&nbsp; Sistema&nbsp; Único&nbsp; de&nbsp; Saúde&nbsp; (CONITEC)&nbsp; sobre&nbsp; medicamentos&nbsp; biológicos&nbsp; para&nbsp; o&nbsp; tratamento&nbsp; da&nbsp; AR,&nbsp; publicado&nbsp; em&nbsp; junho&nbsp; de&nbsp; 2012,&nbsp; foram&nbsp; analisados&nbsp; estudos&nbsp; de&nbsp; comparação&nbsp; entre&nbsp; eles.&nbsp; Comparações&nbsp; indiretas&nbsp; entre&nbsp; todos&nbsp; os&nbsp; MMDC&nbsp; biológicos&nbsp; foram&nbsp; realizadas&nbsp; em&nbsp; 3&nbsp; estudos:&nbsp; 2&nbsp; sobre&nbsp; eficácia&nbsp; e&nbsp; 1&nbsp; sobre&nbsp; segurança&nbsp; (145-147).&nbsp; Nos&nbsp; estudos&nbsp; de&nbsp; eficácia,&nbsp; a&nbsp; medida&nbsp; utilizada&nbsp; foi&nbsp; o&nbsp; critério&nbsp; ACR.&nbsp; Esse&nbsp; critério&nbsp; é&nbsp; medida&nbsp; de&nbsp; desfechos&nbsp; em&nbsp; ensaios&nbsp; clínicos&nbsp; e&nbsp; avalia&nbsp; a&nbsp; melhora&nbsp; na&nbsp; contagem&nbsp; de&nbsp; articulações&nbsp; dolorosas&nbsp; e&nbsp; edemaciadas&nbsp; e&nbsp; a&nbsp; melhora&nbsp; em&nbsp; pelo&nbsp; menos&nbsp; 3&nbsp; dos&nbsp; 5&nbsp; parâmetros&nbsp; a&nbsp; seguir:</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; avaliação&nbsp; global&nbsp; da&nbsp; doença&nbsp; pelo&nbsp; paciente;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; avaliação&nbsp; global&nbsp; da&nbsp; doença&nbsp; pelo&nbsp; médico;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; avaliação&nbsp; da&nbsp; dor&nbsp; por&nbsp; meio&nbsp; de&nbsp; escala;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; avaliação&nbsp; física&nbsp; por&nbsp; meio&nbsp; de&nbsp; questionário&nbsp; sobre&nbsp; incapacidade&nbsp; funcional;&nbsp; e</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; melhora&nbsp; em&nbsp; 1&nbsp; das&nbsp; 2&nbsp; provas&nbsp; inflamatórias&nbsp; de&nbsp; fase&nbsp; aguda&nbsp; (velocidade&nbsp; de&nbsp; hemossedimentação&nbsp; ou&nbsp; proteína&nbsp; C&nbsp; reativa).&nbsp; Os&nbsp; critérios&nbsp; ACR&nbsp; 20,&nbsp; ACR&nbsp; 50&nbsp; e&nbsp; ACR&nbsp; 70&nbsp; indicam&nbsp; melhora&nbsp; em&nbsp; 20%,&nbsp; 50%&nbsp; e&nbsp; 70%,&nbsp; respectivamente,&nbsp; na&nbsp; contagem&nbsp; de&nbsp; articulações&nbsp; dolorosas&nbsp; e&nbsp; edemaciadas,&nbsp; e&nbsp; de&nbsp; 20%,&nbsp; 50%&nbsp; e&nbsp; 70%,&nbsp; respectivamente,&nbsp; em&nbsp; pelo&nbsp; menos&nbsp; 3&nbsp; dos&nbsp; 5&nbsp; parâmetros&nbsp; citados.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; estudo&nbsp; de&nbsp; Devine&nbsp; e&nbsp; colaboradores&nbsp; (147)&nbsp; avaliou&nbsp; a&nbsp; resposta&nbsp; terapêutica,&nbsp; em&nbsp; 6&nbsp; meses,&nbsp; medida&nbsp; por&nbsp; ACR&nbsp; 50&nbsp; de&nbsp; 8&nbsp; MMCD&nbsp; biológicos&nbsp; em&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; ativa&nbsp; que&nbsp; haviam&nbsp; apresentado&nbsp; falha&nbsp; de&nbsp; resposta&nbsp; ao&nbsp; tratamento&nbsp; prévio&nbsp; com&nbsp; metotrexato&nbsp; e&nbsp; não&nbsp; encontrou&nbsp; diferença&nbsp; significativa&nbsp; entre&nbsp; eles&nbsp; nesse&nbsp; desfecho.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; estudo&nbsp; de&nbsp; Turkstra&nbsp; e&nbsp; colaboradores&nbsp; (145)&nbsp; avaliou&nbsp; os&nbsp; desfechos&nbsp; de&nbsp; eficácia&nbsp; de&nbsp; ACR&nbsp; 20,&nbsp; ACR&nbsp; 50&nbsp; e&nbsp; ACR&nbsp; 70&nbsp; de&nbsp; 8&nbsp; MMCD&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">biológicos&nbsp; em&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; ativa,&nbsp; apesar&nbsp; de&nbsp; tratamento&nbsp; prévio&nbsp; com&nbsp; MMCD,&nbsp; e&nbsp; mostrou&nbsp; que&nbsp; o&nbsp; certolizumabe&nbsp; pegol&nbsp; pode&nbsp; ser&nbsp; mais&nbsp; eficaz&nbsp; do&nbsp; que&nbsp; os&nbsp; demais.&nbsp; No&nbsp; entanto,&nbsp; os&nbsp; resultados&nbsp; de&nbsp; certolizumabe&nbsp; pegol&nbsp; foram&nbsp; imprecisos&nbsp; (grande&nbsp; intervalo&nbsp; de&nbsp; confiança&nbsp; para&nbsp; a&nbsp; estimativa&nbsp; de&nbsp; efeito),&nbsp; além&nbsp; de&nbsp; haver&nbsp; diferença&nbsp; no&nbsp; momento&nbsp; de&nbsp; ajuste&nbsp; de&nbsp; dose&nbsp; entre&nbsp; os&nbsp; estudos.</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Quanto&nbsp; aos&nbsp; anti-TNF&nbsp; (adalimumabe,&nbsp; certolizumabe&nbsp; pegol,&nbsp; etanercepte,&nbsp; infliximabe&nbsp; e&nbsp; golimumabe),&nbsp; a&nbsp; substituição&nbsp; de&nbsp; um&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">por&nbsp; outro&nbsp; parece&nbsp; oferecer&nbsp; benefício,&nbsp; no&nbsp; entanto&nbsp; a&nbsp; verdadeira&nbsp; magnitude&nbsp; desse&nbsp; efeito&nbsp; bem&nbsp; como&nbsp; o&nbsp; custo-efetividade&nbsp; dessa&nbsp; estratégia&nbsp; precisam&nbsp; ser&nbsp; avaliados&nbsp; em&nbsp; estudos&nbsp; delineados&nbsp; especificamente&nbsp; para&nbsp; essas&nbsp; questões.</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Com&nbsp; relação&nbsp; à&nbsp; segurança,&nbsp; o&nbsp; estudo&nbsp; de&nbsp; Singh&nbsp; e&nbsp; colaboradores&nbsp; (148)&nbsp; encontrou&nbsp; os&nbsp; seguintes&nbsp; resultados&nbsp; para&nbsp; os&nbsp; desfechos&nbsp; avaliados:</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; eventos&nbsp; adversos&nbsp; graves:&nbsp; o&nbsp; certolizumabe&nbsp; pegol&nbsp; foi&nbsp; associado&nbsp; com&nbsp; maior&nbsp; número&nbsp; de&nbsp; eventos&nbsp; adversos&nbsp; graves&nbsp; em&nbsp; comparação&nbsp; com&nbsp; o&nbsp; adalimumabe&nbsp; e&nbsp; o&nbsp; abatacepte,&nbsp; ao&nbsp; passo&nbsp; que&nbsp; o&nbsp; adalimumabe&nbsp; apresentou&nbsp; maior&nbsp; taxa&nbsp; de&nbsp; eventos&nbsp; adversos&nbsp; graves&nbsp; do&nbsp; que&nbsp; o&nbsp; golimumabe.&nbsp; Não&nbsp; houve&nbsp; diferenças&nbsp; estatisticamente&nbsp; significativas&nbsp; entre&nbsp; os&nbsp; outros&nbsp; agentes&nbsp; biológicos&nbsp; para&nbsp; esse&nbsp; desfecho;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; infecções&nbsp; graves:&nbsp; o&nbsp; certolizumabe&nbsp; pegol&nbsp; foi&nbsp; associado&nbsp; com&nbsp; maior&nbsp; incidência&nbsp; em&nbsp; comparação&nbsp; ao&nbsp; abatacepte,&nbsp; adalimumabe,&nbsp; etanercepte,&nbsp; golimumabe&nbsp; e&nbsp; rituximabe;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; total&nbsp; de&nbsp; eventos&nbsp; adversos:&nbsp; não&nbsp; houve&nbsp; diferenças&nbsp; estatisticamente&nbsp; significativas&nbsp; entre&nbsp; os&nbsp; MMCD&nbsp; biológicos;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; abandono&nbsp; devido&nbsp; a&nbsp; eventos&nbsp; adversos:&nbsp; não&nbsp; houve&nbsp; diferenças&nbsp; estatisticamente&nbsp; significativas&nbsp; entre&nbsp; os&nbsp; MMCD&nbsp; biológicos&nbsp; quando&nbsp; utilizados&nbsp; na&nbsp; dose&nbsp; padrão.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; meta-análise&nbsp; envolveu&nbsp; 163&nbsp; ensaios&nbsp; clínicos&nbsp; randomizados&nbsp; com&nbsp; 50.010&nbsp; pacientes&nbsp; e&nbsp; 46&nbsp; estudos&nbsp; de&nbsp; seguimento&nbsp; com</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">11.954&nbsp; pacientes&nbsp; com&nbsp; média&nbsp; de&nbsp; seguimento&nbsp; de&nbsp; 6&nbsp; e&nbsp; 13&nbsp; meses,&nbsp; respectivamente.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; taxa&nbsp; de&nbsp; reativação&nbsp; de&nbsp; tuberculose&nbsp; foi&nbsp; muito&nbsp; alta&nbsp; (razão&nbsp; de&nbsp; chances&nbsp; de&nbsp; 4,68&nbsp; e&nbsp; o&nbsp; NNTH&nbsp; (number&nbsp; needed&nbsp; to&nbsp; treat&nbsp; to&nbsp; harm)&nbsp; de&nbsp; 681.&nbsp; De&nbsp; forma&nbsp; geral,&nbsp; os&nbsp; MMCD&nbsp; biológicos&nbsp; apresentam&nbsp; taxas&nbsp; elevadas&nbsp; de&nbsp; abandono&nbsp; por&nbsp; eventos&nbsp; adversos&nbsp; e&nbsp; o&nbsp; NNTH&nbsp; foi&nbsp; de&nbsp; 30&nbsp; para&nbsp; qualquer&nbsp; efeito&nbsp; adverso.&nbsp; Por&nbsp; exemplo,&nbsp; o&nbsp; certolizumabe&nbsp; associou-se&nbsp; com&nbsp; alto&nbsp; risco&nbsp; de&nbsp; infecções&nbsp; graves,&nbsp; com&nbsp; razão&nbsp; de&nbsp; chances&nbsp; de&nbsp; 3,5&nbsp; e&nbsp; NNTH&nbsp; =17,&nbsp; e&nbsp; o&nbsp; infliximabe&nbsp; com&nbsp; altas&nbsp; taxas&nbsp; de&nbsp; abandono&nbsp; por&nbsp; eventos&nbsp; adversos,&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">com&nbsp; razão&nbsp; de&nbsp; chances&nbsp; de&nbsp; 2&nbsp; e&nbsp; NNTH=12&nbsp; (146).</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Em&nbsp; coorte&nbsp; de&nbsp; 5&nbsp; anos&nbsp; de&nbsp; acompanhamento,&nbsp; os&nbsp; anti-TNF&nbsp; (adalimumabe,&nbsp; etanercepte&nbsp; e&nbsp; infliximabe)&nbsp; não&nbsp; aumentaram&nbsp; o&nbsp; risco&nbsp; de&nbsp; neoplasia&nbsp; sólida&nbsp; em&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; sem&nbsp; história&nbsp; prévia&nbsp; deste&nbsp; tipo&nbsp; de&nbsp; neoplasia&nbsp; (149).&nbsp; Os&nbsp; anti-TNF&nbsp; aumentam&nbsp; o&nbsp; risco&nbsp; de&nbsp; tuberculose,&nbsp; devendo&nbsp; ser&nbsp; realizada,&nbsp; antes&nbsp; do&nbsp; início&nbsp; da&nbsp; terapia,&nbsp; pesquisa&nbsp; de&nbsp; infecção&nbsp; ativa&nbsp; ou&nbsp; de&nbsp; tuberculose&nbsp; latente,&nbsp; para&nbsp; o&nbsp; tratamento&nbsp; apropriado.&nbsp; Além&nbsp; disso,&nbsp; outras&nbsp; possíveis&nbsp; complicações&nbsp; do&nbsp; uso&nbsp; de&nbsp; anti-TNF&nbsp; são&nbsp; disfunção&nbsp; cardíaca,&nbsp; doenças&nbsp; desmielinizantes,&nbsp; fenômenos&nbsp; autoimunes&nbsp; (produção&nbsp; de&nbsp; autoanticorpos),&nbsp; vasculites,&nbsp; doença&nbsp; pulmonar&nbsp; intersticial&nbsp; e&nbsp; possível&nbsp; aumento&nbsp; do&nbsp; risco&nbsp; de&nbsp; linfoma.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Em&nbsp; revisão&nbsp; sistemática&nbsp; com&nbsp; 5&nbsp; ensaios&nbsp; clínicos&nbsp; randomizados&nbsp; controlados&nbsp; por&nbsp; placebo&nbsp; ou&nbsp; por&nbsp; metotrexato&nbsp; com&nbsp; placebo,&nbsp; Ruiz-Garcia&nbsp; e&nbsp; colaboradores&nbsp; (133)&nbsp; estimaram&nbsp; o&nbsp; NNT&nbsp; de&nbsp; certolizumabe&nbsp; pegol&nbsp; em&nbsp; 4&nbsp; para&nbsp; benefício&nbsp; clínico&nbsp; significativo&nbsp; (ACR&nbsp; 50),&nbsp; havendo&nbsp; aumento&nbsp; de&nbsp; eventos&nbsp; adversos&nbsp; sérios,&nbsp; infecções&nbsp; e&nbsp; hipertensão&nbsp; nesse&nbsp; grupo&nbsp; de&nbsp; participantes&nbsp; de&nbsp; forma&nbsp; semelhante&nbsp; à&nbsp; de&nbsp; outros&nbsp; anti-TNF.&nbsp; Em&nbsp; outra&nbsp; revisão&nbsp; sistemática&nbsp; com&nbsp; 4&nbsp; ensaios&nbsp; clínicos&nbsp; randomizados&nbsp; num&nbsp; total&nbsp; de&nbsp; mais&nbsp; de&nbsp; 1.500&nbsp; pacientes,&nbsp; Singh&nbsp; e&nbsp; colaboradores&nbsp; (134)&nbsp; estimaram&nbsp; o&nbsp; NNT&nbsp; de&nbsp; golimumabe&nbsp; em&nbsp; 5&nbsp; para&nbsp; benefício&nbsp; clínico&nbsp; significativo&nbsp; (ACR&nbsp; 50),&nbsp; havendo&nbsp; comparável&nbsp; número&nbsp; de&nbsp; eventos&nbsp; adversos&nbsp; em&nbsp; relação&nbsp; ao&nbsp; grupo&nbsp; placebo&nbsp; a&nbsp; curto&nbsp; prazo.&nbsp; Não&nbsp; houve&nbsp; diferença&nbsp; significativa&nbsp; entre&nbsp; os&nbsp; NNT&nbsp; dos&nbsp; diferentes&nbsp; agentes&nbsp; anti-TNF.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; rituximabe&nbsp; pode&nbsp; ter&nbsp; seu&nbsp; benefício&nbsp; percebido&nbsp; 3&nbsp; a&nbsp; 4&nbsp; meses&nbsp; após&nbsp; a&nbsp; última&nbsp; infusão.&nbsp; Os&nbsp; pacientes&nbsp; com&nbsp; FR&nbsp; ou&nbsp; anti-CCP&nbsp; parecem&nbsp; apresentar&nbsp; melhor&nbsp; resposta&nbsp; ao&nbsp; tratamento&nbsp; com&nbsp; este&nbsp; fármaco.&nbsp; Reações&nbsp; infusionais,&nbsp; em&nbsp; geral&nbsp; leves,&nbsp; podem&nbsp; ocorrer&nbsp; em&nbsp; até&nbsp; 35%&nbsp; dos&nbsp; casos&nbsp; na&nbsp; primeira&nbsp; administração&nbsp; e&nbsp; em&nbsp; cerca&nbsp; de&nbsp; 10%&nbsp; na&nbsp; segunda.&nbsp; Infecções,&nbsp; pneumonia&nbsp; intersticial,&nbsp; neutropenia&nbsp; e&nbsp; trombocitopenia&nbsp; podem&nbsp; ser&nbsp; complicações&nbsp; do&nbsp; tratamento&nbsp; com&nbsp; rituximabe.&nbsp; Os&nbsp; efeitos&nbsp; cardiovasculares&nbsp; deste&nbsp; tratamento&nbsp; ainda&nbsp; estão&nbsp; em&nbsp; estudo&nbsp; (130,135,138,145-&nbsp; 147,150).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; abatacepte&nbsp; mostrou-se&nbsp; eficaz&nbsp; e&nbsp; seguro&nbsp; a&nbsp; curto&nbsp; prazo&nbsp; no&nbsp; tratamento&nbsp; de&nbsp; AR,&nbsp; porém&nbsp; há&nbsp; necessidade&nbsp; de&nbsp; maior&nbsp; tempo&nbsp; de&nbsp; observação&nbsp; para&nbsp; confirmação&nbsp; desse&nbsp; perfil&nbsp; (151,&nbsp; 152).&nbsp; Em&nbsp; revisão&nbsp; sistemática&nbsp; com&nbsp; mais&nbsp; de&nbsp; 2.900&nbsp; pacientes&nbsp; de&nbsp; 7&nbsp; ensaios&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">clínicos&nbsp; randomizados&nbsp; controlados&nbsp; com&nbsp; placebo,&nbsp; Maxwell&nbsp; e&nbsp; colaboradores&nbsp; (151)&nbsp; estimaram&nbsp; o&nbsp; NNT&nbsp; de&nbsp; abatacepte&nbsp; em&nbsp; 5&nbsp; para&nbsp; um&nbsp; benefício&nbsp; clínico&nbsp; significativo&nbsp; (ACR&nbsp; 50),&nbsp; havendo&nbsp; melhora&nbsp; estatística&nbsp; também&nbsp; sobre&nbsp; progressão&nbsp; radiográfica&nbsp; identificada&nbsp; após&nbsp; 12&nbsp; meses&nbsp; de&nbsp; acompanhamento&nbsp; em&nbsp; um&nbsp; estudo.</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; tocilizumabe,&nbsp; a&nbsp; curto&nbsp; prazo,&nbsp; reduz&nbsp; a&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; e&nbsp; melhora&nbsp; a&nbsp; capacidade&nbsp; funcional&nbsp; do&nbsp; doente,&nbsp; havendo,&nbsp; no&nbsp; entanto,&nbsp; aumento&nbsp; significativo&nbsp; nos&nbsp; níveis&nbsp; de&nbsp; colesterol&nbsp; e&nbsp; nos&nbsp; eventos&nbsp; adversos&nbsp; demonstrado&nbsp; nos&nbsp; estudos&nbsp; iniciais&nbsp; (153,154).&nbsp; Em&nbsp; revisão&nbsp; sistemática&nbsp; com&nbsp; mais&nbsp; de&nbsp; 3.300&nbsp; participantes&nbsp; de&nbsp; 8&nbsp; ensaios&nbsp; clínicos&nbsp; randomizados,&nbsp; Singh&nbsp; e&nbsp; colaboradores&nbsp; (153)&nbsp; estimaram&nbsp; uma&nbsp; probabilidade&nbsp; 11&nbsp; vezes&nbsp; maior&nbsp; de&nbsp; os&nbsp; pacientes&nbsp; em&nbsp; uso&nbsp; de&nbsp; tocilizumabe&nbsp; na&nbsp; dose&nbsp; de&nbsp; 8&nbsp; mg/kg&nbsp; atingirem&nbsp; remissão&nbsp; clínica&nbsp; do&nbsp; que&nbsp; os&nbsp; pacientes&nbsp; em&nbsp; uso&nbsp; de&nbsp; placebo,&nbsp; sem&nbsp; um&nbsp; poder&nbsp; suficientemente&nbsp; grande&nbsp; para&nbsp; conhecimento&nbsp; do&nbsp; perfil&nbsp; de&nbsp; segurança&nbsp; a&nbsp; longo&nbsp; prazo.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Outros&nbsp; fármacos,&nbsp; como&nbsp; anakinra,&nbsp; sais&nbsp; de&nbsp; ouro&nbsp; e&nbsp; tacrolimo,&nbsp; têm&nbsp; sido&nbsp; estudados&nbsp; no&nbsp; tratamento&nbsp; de&nbsp; AR,&nbsp; no&nbsp; entanto&nbsp; a&nbsp; desfavorável&nbsp; relação&nbsp; risco-benefício&nbsp; que&nbsp; apresentam&nbsp; nas&nbsp; situações&nbsp; mais&nbsp; frequentes&nbsp; de&nbsp; uso&nbsp; restringe&nbsp; sua&nbsp; aplicabilidade&nbsp; assistencial&nbsp; (138,&nbsp; 155-161).&nbsp; Glicocorticoides&nbsp; sistêmicos&nbsp; (prednisona&nbsp; e&nbsp; prednisolona)&nbsp; associados&nbsp; a&nbsp; MMCD&nbsp; sintéticos&nbsp; ou&nbsp; biológicos,&nbsp; principalmente&nbsp; quando&nbsp; usados&nbsp; no&nbsp; início&nbsp; do&nbsp; tratamento&nbsp; de&nbsp; AR,&nbsp; reduzem&nbsp; sintomas&nbsp; e&nbsp; progressão</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">radiográfica,&nbsp; mesmo&nbsp; depois&nbsp; da&nbsp; suspensão&nbsp; do&nbsp; seu&nbsp; uso&nbsp; (162-167).&nbsp; A&nbsp; prednisolona&nbsp; é&nbsp; o&nbsp; metabólito&nbsp; ativo&nbsp; da&nbsp; prednisona&nbsp; após&nbsp; sua&nbsp; ativação&nbsp; hepática.&nbsp; Com&nbsp; isso,&nbsp; a&nbsp; prednisolona&nbsp; pode&nbsp; ser&nbsp; utilizada&nbsp; preferencialmente&nbsp; em&nbsp; pacientes&nbsp; com&nbsp; doenças&nbsp; hepáticas&nbsp; que&nbsp; diminuam&nbsp; a&nbsp; ativação&nbsp; da&nbsp; prednisona.&nbsp; Além&nbsp; disso,&nbsp; suas&nbsp; apresentações&nbsp; em&nbsp; solução&nbsp; oral&nbsp; permite&nbsp; melhor&nbsp; adequação&nbsp; da&nbsp; dose&nbsp; no&nbsp; tratamento&nbsp; de&nbsp; pacientes&nbsp; pediátricos.&nbsp; A&nbsp; suplementação&nbsp; com&nbsp; cálcio&nbsp; e&nbsp; vitamina&nbsp; D&nbsp; deve&nbsp; ser&nbsp; considerada&nbsp; no&nbsp; caso&nbsp; de&nbsp; uso&nbsp; de&nbsp; glicocorticoide&nbsp; por&nbsp; mais&nbsp; de&nbsp; 3&nbsp; meses,&nbsp; bem&nbsp; como&nbsp; a&nbsp; com&nbsp; bisfosfonados&nbsp; nos&nbsp; pacientes&nbsp; com&nbsp; fatores&nbsp; de&nbsp; risco&nbsp; para&nbsp; fraturas,&nbsp; conforme&nbsp; Protocolo&nbsp; Clínico&nbsp; e&nbsp; Diretrizes&nbsp; Terapêuticas&nbsp; da&nbsp; Osteoporose,&nbsp; do&nbsp; Ministério&nbsp; da&nbsp; Saúde.&nbsp; Glicocorticoide&nbsp; intra-articular&nbsp; pode&nbsp; ser&nbsp; utilizado&nbsp; até&nbsp; 4&nbsp; vezes&nbsp; ao&nbsp; ano&nbsp; nos&nbsp; casos&nbsp; de&nbsp; sinovite&nbsp; persistente&nbsp; de&nbsp; poucas&nbsp; articulações.&nbsp; Na&nbsp; indicação&nbsp; da&nbsp; associação&nbsp; de&nbsp; glicocorticoide&nbsp; e&nbsp; AINE,&nbsp; recomenda-se&nbsp; o&nbsp; uso&nbsp; de&nbsp; inibidor&nbsp; de&nbsp; bomba&nbsp; de&nbsp; próton&nbsp; (por&nbsp; exemplo,&nbsp; omeprazol)&nbsp; para&nbsp; proteção&nbsp; gástrica&nbsp; (1).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Os&nbsp; AINE&nbsp; são&nbsp; superiores&nbsp; a&nbsp; paracetamol&nbsp; no&nbsp; controle&nbsp; sintomático&nbsp; de&nbsp; AR&nbsp; (168).&nbsp; Esses&nbsp; fármacos&nbsp; devem&nbsp; ser&nbsp; usados&nbsp; com&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">cautela&nbsp; nos&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; e&nbsp; história&nbsp; de&nbsp; doença&nbsp; péptica&nbsp; pelo&nbsp; aumento&nbsp; do&nbsp; risco&nbsp; de&nbsp; complicações&nbsp; nessa&nbsp; população&nbsp; (169-171).&nbsp; Em&nbsp; pacientes&nbsp; com&nbsp; insuficiência&nbsp; renal&nbsp; moderada&nbsp; a&nbsp; grave&nbsp; ou&nbsp; doença&nbsp; cardiovascular&nbsp; estabelecida,&nbsp; o&nbsp; se&nbsp; recomenda&nbsp; o&nbsp; uso&nbsp; de&nbsp; AINE&nbsp; (172).&nbsp; O&nbsp; uso&nbsp; combinado&nbsp; de&nbsp; analgésicos,&nbsp; AINE,&nbsp; opioides&nbsp; e&nbsp; neuromoduladores&nbsp; antidepressivos,&nbsp; anticonvulsivantes&nbsp; e&nbsp; relaxantes&nbsp; musculares)&nbsp; não&nbsp; foi&nbsp; superior&nbsp; ao&nbsp; uso&nbsp; isolado&nbsp; de&nbsp; AINE&nbsp; em&nbsp; pacientes&nbsp; com&nbsp; AR,&nbsp; não&nbsp; sendo&nbsp; recomendado&nbsp; neste&nbsp; Protocolo&nbsp; (173-175).&nbsp; Analgésicos&nbsp; opioides&nbsp; em&nbsp; baixas&nbsp; doses&nbsp; e&nbsp; por&nbsp; menos&nbsp; de&nbsp; 6&nbsp; semanas&nbsp; parecem&nbsp;ser&nbsp; eficazes&nbsp; para&nbsp; alguns&nbsp; pacientes&nbsp; com&nbsp; AR,&nbsp; mas&nbsp; os&nbsp; frequentes&nbsp; eventos&nbsp; adversos&nbsp; podem&nbsp; inviabilizar&nbsp; seu&nbsp; uso&nbsp; (176).&nbsp; A</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">indicação&nbsp; de&nbsp; opioides&nbsp; deve&nbsp; seguir&nbsp; as&nbsp; recomendações&nbsp; do&nbsp; Protocolo&nbsp; Clínico&nbsp; e&nbsp; Diretrizes&nbsp; Terapêuticas&nbsp; da&nbsp; Dor&nbsp; Crônica,&nbsp; do</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">Ministério&nbsp; da&nbsp; Saúde.</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; azatioprina&nbsp; e&nbsp; a&nbsp; ciclosporina&nbsp; também&nbsp; apresentam&nbsp; evidência&nbsp; de&nbsp; benefício&nbsp; clínico&nbsp; na&nbsp; AR,&nbsp; no&nbsp; entanto&nbsp; seu&nbsp; uso&nbsp; é&nbsp; bastante&nbsp; limitado&nbsp; em&nbsp; função&nbsp; de&nbsp; eventos&nbsp; adversos&nbsp; de&nbsp; longo&nbsp; prazo&nbsp; e&nbsp; da&nbsp; superioridade&nbsp; terapêutica&nbsp; dos&nbsp; MMCD&nbsp; (177,178).&nbsp; A&nbsp; azatioprina&nbsp; ou&nbsp; a&nbsp; ciclosporina&nbsp; podem&nbsp; ser&nbsp; utilizadas&nbsp; como&nbsp; tratamento&nbsp; de&nbsp; manifestações&nbsp; extra-articulares&nbsp; graves,&nbsp; tais&nbsp; como&nbsp; doença&nbsp; reumatoide&nbsp; do&nbsp; pulmão&nbsp; e&nbsp; vasculite&nbsp; reumatoide&nbsp; (179,180)&nbsp; e&nbsp; nos&nbsp; casos&nbsp; de&nbsp; ARJ.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Pulsoterapia&nbsp; com&nbsp; succinato&nbsp; de&nbsp; metilprednisolona&nbsp; ou&nbsp; de&nbsp; ciclofosfamida&nbsp; deve&nbsp; ser&nbsp; utilizada&nbsp; apenas&nbsp; em&nbsp; caso&nbsp; de&nbsp; manifestações&nbsp; extra-articulares&nbsp; graves&nbsp; (risco&nbsp; de&nbsp; vida&nbsp; ou&nbsp; perda&nbsp; funcional),&nbsp; tais&nbsp; como&nbsp; doença&nbsp; reumatoide&nbsp; do&nbsp; pulmão&nbsp; e&nbsp; vasculite&nbsp; reumatoide&nbsp; (181).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Contraceptivos&nbsp; orais,&nbsp; inclusive&nbsp; estrógenos,&nbsp; não&nbsp; parecem&nbsp; afetar&nbsp; a&nbsp; progressão&nbsp; da&nbsp; doença&nbsp; nem&nbsp; apresentam&nbsp; contraindicações&nbsp; específicas&nbsp; ao&nbsp; uso&nbsp; em&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; (182,&nbsp; 183).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Imunização&nbsp; deve&nbsp; ser&nbsp; recomendada&nbsp; conforme&nbsp; o&nbsp; Programa&nbsp; Nacional&nbsp; de&nbsp; Imunizações,&nbsp; havendo&nbsp; restrição&nbsp; quanto&nbsp; ao&nbsp; uso&nbsp; de&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">vacinas&nbsp; com&nbsp; agentes&nbsp; vivos&nbsp; nos&nbsp; pacientes&nbsp; em&nbsp; terapia&nbsp; imunomoduladora&nbsp; (184).</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Cerca&nbsp; de&nbsp; 50%&nbsp; a&nbsp; 80%&nbsp; das&nbsp; mulheres&nbsp; melhoram&nbsp; da&nbsp; doença&nbsp; durante&nbsp; a&nbsp; gestação&nbsp; e&nbsp; aproximadamente&nbsp; 90%&nbsp; apresentam&nbsp; reativação&nbsp; nos&nbsp; primeiros&nbsp; 3&nbsp; meses&nbsp; após&nbsp; o&nbsp; parto.&nbsp; Alguns&nbsp; medicamentos,&nbsp; como&nbsp; metotrexato&nbsp; e&nbsp; leflunomida,&nbsp; são&nbsp; contraindicados&nbsp; de&nbsp; forma&nbsp; absoluta&nbsp; na&nbsp; gestação&nbsp; e&nbsp; amamentação&nbsp; (categoria&nbsp; X).&nbsp; Azatioprina&nbsp; (categoria&nbsp; D),&nbsp; ciclofosfamida&nbsp; (categoria&nbsp; D)&nbsp; e&nbsp; ciclosporina&nbsp; (categoria&nbsp; C)&nbsp; não&nbsp; devem&nbsp; ser&nbsp; usados&nbsp; na&nbsp; gestação.&nbsp; Glicocorticoides&nbsp; em&nbsp; baixas&nbsp; doses&nbsp; (até&nbsp; 20&nbsp; mg/dia&nbsp; de&nbsp; prednisona)&nbsp; podem&nbsp; ser&nbsp; administrados&nbsp; durante&nbsp; a&nbsp; gestação&nbsp; sem&nbsp; maiores&nbsp; riscos&nbsp; de&nbsp; complicações.&nbsp; Devem&nbsp; ser&nbsp; evitadas&nbsp; doses&nbsp; altas&nbsp; (equivalentes&nbsp; a&nbsp; 1&nbsp; mg/kg/dia&nbsp; de&nbsp; prednisona)&nbsp; na&nbsp; gestação&nbsp; (categoria&nbsp; C).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Os&nbsp; AINE&nbsp; não&nbsp; devem&nbsp; ser&nbsp; utilizados&nbsp; na&nbsp; concepção&nbsp; e&nbsp; no&nbsp; terceiro&nbsp; trimestre&nbsp; pelo&nbsp; risco&nbsp; de&nbsp; complicações&nbsp; na&nbsp; implantação&nbsp; e&nbsp; no&nbsp; desenvolvimento&nbsp; cardiovascular&nbsp; fetal&nbsp; (categoria&nbsp; C).&nbsp; Os&nbsp; anti-TNF&nbsp; parecem&nbsp; seguros&nbsp; na&nbsp; gestação&nbsp; (categoria&nbsp; B),&nbsp; embora&nbsp; os&nbsp; riscos&nbsp; de&nbsp; defeitos&nbsp; congênitos&nbsp; ainda&nbsp; estejam&nbsp; sendo&nbsp; esclarecidos.&nbsp; Abatacepte,&nbsp; rituximabe&nbsp; e&nbsp; tocilizumabe&nbsp; devem&nbsp; ser&nbsp; evitados&nbsp; na&nbsp; gestação&nbsp; e&nbsp; amamentação&nbsp; (categoria&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">C).&nbsp; Hidroxicloroquina,&nbsp; cloroquina&nbsp; e&nbsp; sulfassalazina&nbsp; podem&nbsp; ser&nbsp; indicados&nbsp; com&nbsp; segurança&nbsp; na&nbsp; gestação&nbsp; (categoria&nbsp; B).&nbsp; Durante&nbsp; a&nbsp; amamentação,&nbsp; AINE&nbsp; (exceto&nbsp; ácido&nbsp; acetilsalicílico),&nbsp; glicocorticoide&nbsp; (prednisona&nbsp; até&nbsp; 20&nbsp; mg/dia),&nbsp; sulfassalazina,&nbsp; hidroxicloroquina&nbsp; e&nbsp; cloroquina&nbsp; podem&nbsp; ser&nbsp; empregados.&nbsp; No&nbsp; entanto,&nbsp; para&nbsp; se&nbsp; evitar&nbsp; toxicidade&nbsp; do&nbsp; lactente,&nbsp; azatioprina,&nbsp; ciclosporina,&nbsp; ciclofosfamida,&nbsp; metotrexato&nbsp; e&nbsp; leflunomida&nbsp; não&nbsp; devem&nbsp; ser&nbsp; utilizados&nbsp; (185).</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">8.3&nbsp; ESTRATÉGIA&nbsp; TERAPÊUTICA</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Como&nbsp; definido&nbsp; no&nbsp; relatório&nbsp; de&nbsp; recomendação&nbsp; da&nbsp; Comissão&nbsp; Nacional&nbsp; de&nbsp; Incorporação&nbsp; de&nbsp; Tecnologias&nbsp; do&nbsp; Sistema&nbsp; Único&nbsp; de&nbsp; Saúde&nbsp; (CONITEC)&nbsp; sobre&nbsp; medicamentos&nbsp; biológicos&nbsp; para&nbsp; o&nbsp; tratamento&nbsp; da&nbsp; AR,&nbsp; as&nbsp; estratégias&nbsp; terapêuticas&nbsp; deste&nbsp; Protocolo&nbsp; estão&nbsp; alinhadas&nbsp; ao&nbsp; referido&nbsp; relatório.&nbsp;</span></span></span></span></p>
<p></p></div>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Em&nbsp; qualquer&nbsp; das&nbsp; etapas&nbsp; discriminadas&nbsp; a&nbsp; seguir&nbsp; para&nbsp; o&nbsp; tratamento&nbsp; dos&nbsp; pacientes&nbsp; com&nbsp; AR,&nbsp; prednisona&nbsp; ou&nbsp; prednisolona&nbsp; (até&nbsp; 0,3&nbsp; mg/Kg/dia,&nbsp; por&nbsp; via&nbsp; oral)&nbsp; e&nbsp; AINE&nbsp; (ibuprofeno&nbsp; ou&nbsp; naproxeno)&nbsp; podem&nbsp; ser&nbsp; prescritos&nbsp; para&nbsp; controle&nbsp; sintomático,&nbsp; optando-se&nbsp; pelo&nbsp; uso&nbsp; da&nbsp; menor&nbsp; dose&nbsp; pelo&nbsp; menor&nbsp; tempo&nbsp; possível&nbsp; (162,169).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">PRIMEIRA&nbsp; ETAPA&nbsp; (MMCD&nbsp; sintéticos)</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; metotrexato&nbsp; deve&nbsp; ser&nbsp; a&nbsp; primeira&nbsp; escolha&nbsp; terapêutica.&nbsp; Em&nbsp; situações&nbsp; de&nbsp; contraindicação&nbsp; ao&nbsp; metotrexato,&nbsp; a&nbsp; leflunomida&nbsp; ou&nbsp; a&nbsp; sulfassalazina&nbsp; podem&nbsp; ser&nbsp; a&nbsp; primeira&nbsp; opção.&nbsp; Nos&nbsp; pacientes&nbsp; sem&nbsp; fatores&nbsp; de&nbsp; mau&nbsp; prognóstico&nbsp; (casos&nbsp; leves&nbsp; e&nbsp; com&nbsp; menor&nbsp; risco&nbsp; de&nbsp; apresentar&nbsp; erosões&nbsp; ósseas),&nbsp; os&nbsp; antimaláricos&nbsp; (cloroquina&nbsp; ou&nbsp; hidroxicloroquina)&nbsp; podem&nbsp; passar&nbsp; a&nbsp; ser&nbsp; a&nbsp; primeira&nbsp; opção&nbsp; (111,121).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Em&nbsp; caso&nbsp; de&nbsp; falha&nbsp; da&nbsp; monoterapia&nbsp; inicial,&nbsp; isto&nbsp; é,&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; moderada&nbsp; ou&nbsp; alta&nbsp; após&nbsp; 3&nbsp; meses&nbsp; de&nbsp; tratamento&nbsp; otimizado&nbsp; (doses&nbsp; plenas),&nbsp; recomenda-se&nbsp; tanto&nbsp; a&nbsp; substituição&nbsp; do&nbsp; MMCD&nbsp; sintético&nbsp; por&nbsp; outro&nbsp; MMCD&nbsp; sintético&nbsp; em&nbsp; monoterapia&nbsp; quanto&nbsp; a&nbsp; associação&nbsp; do&nbsp; MMCD&nbsp; sintético&nbsp; em&nbsp; uso&nbsp; a&nbsp; um&nbsp; ou&nbsp; dois&nbsp; MMCD&nbsp; sintéticos.&nbsp; As&nbsp; associações&nbsp; de&nbsp; MMCD&nbsp; sintéticos&nbsp; recomendadas&nbsp; são&nbsp; metotrexato&nbsp; com&nbsp; antimalárico&nbsp; (cloroquina&nbsp; ou&nbsp; hidroxicloroquina),&nbsp; metotrexato&nbsp; com&nbsp; sulfassalazina,&nbsp; metotrexato&nbsp; com&nbsp; antimalárico&nbsp; e&nbsp; sulfassalazina&nbsp; (terapia&nbsp; tríplice)&nbsp; e&nbsp; metotrexato&nbsp; com&nbsp; leflunomida.&nbsp; Dessas&nbsp; associações,&nbsp; a&nbsp; menos&nbsp; usual&nbsp; é&nbsp; a&nbsp; de&nbsp; metotrexato&nbsp; com&nbsp; antimalárico.&nbsp; Para&nbsp; minimização&nbsp; dos&nbsp; riscos&nbsp; de&nbsp; efeitos&nbsp; adversos,&nbsp; recomenda-se&nbsp; a&nbsp; redução&nbsp; da&nbsp; dose&nbsp; do&nbsp; primeiro&nbsp; MMCD&nbsp; sintético&nbsp; no&nbsp; momento&nbsp; da&nbsp; associação&nbsp; ao&nbsp; segundo&nbsp; (111,121).&nbsp; O&nbsp; uso&nbsp; de&nbsp; MMCD&nbsp; biológicos&nbsp; na&nbsp; primeira&nbsp; etapa&nbsp; de&nbsp; tratamento&nbsp; medicamentoso&nbsp; de&nbsp; AR&nbsp; não&nbsp; é&nbsp; recomendado&nbsp; neste&nbsp; Protocolo.&nbsp; SEGUNDA&nbsp; ETAPA&nbsp; (MMCD&nbsp; biológicos)&nbsp; Após&nbsp; 6&nbsp; meses&nbsp; com&nbsp; pelo&nbsp; menos&nbsp; dois&nbsp; esquemas&nbsp; diferentes&nbsp; da&nbsp; primeira&nbsp; etapa&nbsp; e&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; moderada&nbsp; ou&nbsp; alta&nbsp; conforme&nbsp; um&nbsp; ICAD,&nbsp; recomenda-se&nbsp; o&nbsp; início&nbsp; de&nbsp; MMCD&nbsp; biológicos,&nbsp; os&nbsp; quais&nbsp; devem&nbsp; ser&nbsp; utilizados&nbsp; em&nbsp; associação&nbsp; a&nbsp; um&nbsp; MMCD&nbsp; sintético&nbsp; (metotrexato,&nbsp; sulfassalazina&nbsp; ou&nbsp; leflunomida).&nbsp; Apenas&nbsp; para&nbsp; os&nbsp; casos&nbsp; de&nbsp; contraindicação&nbsp; absoluta&nbsp; aos&nbsp; MMCD&nbsp; sintéticos&nbsp; recomenda-se&nbsp; a&nbsp; monoterapia&nbsp; com&nbsp; MMCD&nbsp; biológico.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Pela&nbsp; experiência&nbsp; mundial,&nbsp; o&nbsp; tratamento&nbsp; com&nbsp; MMCD&nbsp; biológicos&nbsp; deve&nbsp; ser&nbsp; iniciado&nbsp; por&nbsp; biológico&nbsp; da&nbsp; classe&nbsp; dos&nbsp; anti-TNF&nbsp; alfa&nbsp; (certolizumabe&nbsp; pegol,&nbsp; golimumabe,&nbsp; infliximabe,&nbsp; etanercepte&nbsp; ou&nbsp; adalimumabe)&nbsp; (130,135,138,141,145,147,151,153).&nbsp; &nbsp;&nbsp;A&nbsp; escolha&nbsp; entre&nbsp; eles&nbsp; no&nbsp; momento&nbsp; da&nbsp; prescrição&nbsp; deve&nbsp; ser&nbsp; realizada&nbsp; considerando&nbsp; os&nbsp; diferentes&nbsp; perfis&nbsp; de&nbsp; toxicidade,&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">eventos&nbsp; adversos&nbsp; ou&nbsp; contraindicações.</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Apenas&nbsp; para&nbsp; os&nbsp; casos&nbsp; de&nbsp; contraindicação&nbsp; absoluta&nbsp; a&nbsp; todos&nbsp; os&nbsp; anti-TNF,&nbsp; recomenda-se&nbsp; a&nbsp; utilização&nbsp; de&nbsp; abatacepte&nbsp; ou&nbsp; tocilizumabe.&nbsp; O&nbsp; uso&nbsp; do&nbsp; rituximabe&nbsp; como&nbsp; primeiro&nbsp; MMCD&nbsp; biológico&nbsp; deve&nbsp; ser&nbsp; reservado&nbsp; somente&nbsp; aos&nbsp; indivíduos&nbsp; com&nbsp; contraindicação&nbsp; absoluta&nbsp; a&nbsp; todos&nbsp; os&nbsp; anti-TNF&nbsp; (e,&nbsp; também,&nbsp; ao&nbsp; abatacepte&nbsp; e&nbsp; tocilizumabe),&nbsp; situação&nbsp; em&nbsp; que&nbsp; deve&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">ser&nbsp; prescrito&nbsp; associado&nbsp; a&nbsp; MMCD&nbsp; sintético,&nbsp; preferencialmente&nbsp; o&nbsp; metotrexato&nbsp; (141).&nbsp; TERCEIRA&nbsp; ETAPA&nbsp; (falha/toxicidade&nbsp; a&nbsp; MMCD&nbsp; biológico).&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Após&nbsp; pelo&nbsp; menos&nbsp; 6&nbsp; meses&nbsp; de&nbsp; terapia&nbsp; com&nbsp; MMCD&nbsp; biológico&nbsp; (exceto&nbsp; o&nbsp; certolizumabe&nbsp; pegol,&nbsp; por&nbsp; 3&nbsp; meses)&nbsp; e&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; moderada&nbsp; ou&nbsp; alta&nbsp; conforme&nbsp; um&nbsp; ICAD,&nbsp; pode&nbsp; ser&nbsp; realizada&nbsp; a&nbsp; substituição&nbsp; por&nbsp; um&nbsp; novo&nbsp; MMCD&nbsp; biológico.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Em&nbsp; caso&nbsp; de&nbsp; falha&nbsp; primária&nbsp; a&nbsp; um&nbsp; anti-TNF,&nbsp; recomenda-se&nbsp; a&nbsp; utilização&nbsp; de&nbsp; um&nbsp; MMCD&nbsp; biológico&nbsp; de&nbsp; outra&nbsp; classe&nbsp; (abatacepte,&nbsp; tocilizumabe&nbsp; ou&nbsp; rituximabe).&nbsp; Em&nbsp; caso&nbsp; falha&nbsp; secundária&nbsp; a&nbsp; um&nbsp; anti-TNF,&nbsp; recomenda-se&nbsp; a&nbsp; troca&nbsp; por&nbsp; um&nbsp; segundo&nbsp; anti-TNF&nbsp; ou&nbsp; por&nbsp; abatacepte,&nbsp; rituximabe&nbsp; ou&nbsp; tocilizumabe,&nbsp; sendo&nbsp; que&nbsp; a&nbsp; escolha&nbsp; entre&nbsp; eles&nbsp; deve&nbsp; respeitar&nbsp; o&nbsp; perfil&nbsp; de&nbsp; segurança&nbsp; de&nbsp; cada&nbsp; medicamento&nbsp; e&nbsp; as&nbsp; peculiaridades&nbsp; de&nbsp; cada&nbsp; paciente,&nbsp; uma&nbsp; vez&nbsp; que&nbsp; não&nbsp; há&nbsp; evidências&nbsp; de&nbsp; superioridade&nbsp; de&nbsp; um&nbsp; medicamento&nbsp; sobre&nbsp; os&nbsp; demais.&nbsp; Quando&nbsp; for&nbsp; feita&nbsp; a&nbsp; opção&nbsp; pela&nbsp; troca&nbsp; por&nbsp; um&nbsp; segundo&nbsp; agente&nbsp; anti-&nbsp; TNF,&nbsp; deve&nbsp; ser&nbsp; dada&nbsp; preferência&nbsp; ao&nbsp; golimumabe,&nbsp; já&nbsp; que&nbsp; apresenta&nbsp; a&nbsp; melhor&nbsp; evidência&nbsp; de&nbsp; uso&nbsp; como&nbsp; segundo&nbsp; agente&nbsp; anti-&nbsp; TNF&nbsp; (141,148,189).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Inexiste&nbsp; estudo&nbsp; metodologicamente&nbsp; bem&nbsp; conduzido&nbsp; para&nbsp; recomendar&nbsp; um&nbsp; terceiro&nbsp; esquema&nbsp; de&nbsp; tratamento&nbsp; com&nbsp; MMCD&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">biológico.</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">No&nbsp; entanto,&nbsp; alguns&nbsp; indivíduos&nbsp; com&nbsp; AR&nbsp; podem&nbsp; não&nbsp; atingir&nbsp; o&nbsp; objetivo&nbsp; do&nbsp; tratamento,&nbsp; ou&nbsp; seja,&nbsp; manter&nbsp; a&nbsp; doença&nbsp; em&nbsp; atividade&nbsp; leve&nbsp; ou&nbsp; em&nbsp; remissão,&nbsp; com&nbsp; os&nbsp; esquemas&nbsp; preconizados&nbsp; neste&nbsp; Protocolo.&nbsp; Somente&nbsp; nestes&nbsp; casos,&nbsp; será&nbsp; permitida&nbsp; troca&nbsp; entre&nbsp; MMCD&nbsp; biológicos,&nbsp; na&nbsp; tentativa&nbsp; de&nbsp; se&nbsp; obter,&nbsp; se&nbsp; não&nbsp; a&nbsp; remissão,&nbsp; pelo&nbsp; menos&nbsp; a&nbsp; baixa&nbsp; atividade&nbsp; da&nbsp; doença.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">8.4&nbsp; FÁRMACOS</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Anti-inflamatórios&nbsp; não&nbsp; esteroides&nbsp; (AINE)</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Ibuprofeno:&nbsp; comprimidos&nbsp; revestidos&nbsp; de&nbsp; 200,&nbsp; 300&nbsp; e&nbsp; 600&nbsp; mg;&nbsp; solução&nbsp; oral&nbsp; de&nbsp; 50&nbsp; mg/ml.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Naproxeno:&nbsp; comprimidos&nbsp; de&nbsp; 250&nbsp; mg&nbsp; ou&nbsp; de&nbsp; 500&nbsp; mg.&nbsp; Glicocorticoides</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Metilprednisolona&nbsp; (acetato)&nbsp; (intra-articular):&nbsp; frasco&nbsp; de&nbsp; 40&nbsp; mg/2&nbsp; ml.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Metilprednisolona&nbsp; (succinato)&nbsp; (intravenoso):&nbsp; frascos&nbsp; de&nbsp; 40,&nbsp; 125,&nbsp; 500&nbsp; ou&nbsp; 1.000&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Prednisona:&nbsp; comprimidos&nbsp; de&nbsp; 5&nbsp; ou&nbsp; 20&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Prednisolona:&nbsp; solução&nbsp; oral&nbsp; de&nbsp; 1&nbsp; e&nbsp; 3&nbsp; mg/ml.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Medicamentos&nbsp; modificadores&nbsp; do&nbsp; curso&nbsp; da&nbsp; doença&nbsp; –&nbsp; sintéticos</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Metotrexato:&nbsp; comprimidos&nbsp; de&nbsp; 2,5&nbsp; mg;&nbsp; frascos&nbsp; de&nbsp; 50&nbsp; mg/2&nbsp; ml.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Sulfassalazina:&nbsp; comprimidos&nbsp; de&nbsp; 500&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Leflunomida:&nbsp; comprimidos&nbsp; de&nbsp; 20&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Hidroxicloroquina:&nbsp; comprimidos&nbsp; de&nbsp; 400&nbsp; mg.-&nbsp; Cloroquina:&nbsp; comprimidos&nbsp; ou&nbsp; cápsulas&nbsp; de&nbsp; 150&nbsp; mg.&nbsp; Medicamentos&nbsp; modificadores&nbsp; do&nbsp; curso&nbsp; da&nbsp; doença&nbsp; –&nbsp; biológicos</span></span></span></span></p>
<div>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Adalimumabe:&nbsp; seringas&nbsp; preenchidas&nbsp; de&nbsp; 40&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Certolizumabe&nbsp; pegol:&nbsp; seringas&nbsp; preenchidas&nbsp; de&nbsp; 200&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Etanercepte:&nbsp; frascos-ampola&nbsp; de&nbsp; 25&nbsp; e&nbsp; 50&nbsp; mg;&nbsp; seringas&nbsp; preenchidas&nbsp; de&nbsp; 50&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Infliximabe:&nbsp; frascos-ampola&nbsp; de&nbsp; 100&nbsp; mg/10ml.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Golimumabe:&nbsp; seringas&nbsp; preenchidas&nbsp; de&nbsp; 50&nbsp; mg.</span></span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Abatacepte:&nbsp; frascos-ampola&nbsp; de&nbsp; 250&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Rituximabe:&nbsp; frascos-ampola&nbsp; de&nbsp; 500&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Tocilizumabe:&nbsp; frascos-ampola&nbsp; de&nbsp; 80&nbsp; mg.&nbsp; Imunossupressores</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Ciclosporina:&nbsp; cápsulas&nbsp; de&nbsp; 10,&nbsp; 25,&nbsp; 50&nbsp; e&nbsp; 100&nbsp; mg;&nbsp; solução&nbsp; oral&nbsp; de&nbsp; 100&nbsp; mg/ml&nbsp; em&nbsp; frascos&nbsp; de&nbsp; 50&nbsp; ml.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Ciclofosfamida:&nbsp; frascos-ampola&nbsp; de&nbsp; 200&nbsp; ou&nbsp; 1.000&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; Azatioprina:&nbsp; comprimidos&nbsp; de&nbsp; 50&nbsp; mg.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">8.5&nbsp; ESQUEMAS&nbsp; DE&nbsp; ADMINISTRAÇÃO&nbsp;</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Ibuprofeno</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Em&nbsp; adultos,&nbsp; devem&nbsp; ser&nbsp; utilizados&nbsp; 600&nbsp; a&nbsp; 2.700&nbsp; mg/dia,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; divididos&nbsp; em&nbsp; três&nbsp; administrações,&nbsp; ou&nbsp; seja,&nbsp; de&nbsp; 8/8&nbsp; horas&nbsp; (utilizar&nbsp; a&nbsp; menor&nbsp; dose&nbsp; pelo&nbsp; menor&nbsp; tempo&nbsp; possível).&nbsp; Considerar&nbsp; o&nbsp; uso&nbsp; de&nbsp; inibidor&nbsp; da&nbsp; bomba&nbsp; de&nbsp; prótons&nbsp; (20&nbsp; mg/dia&nbsp; de&nbsp; omeprazol)&nbsp; para&nbsp; minimizar&nbsp; efeitos&nbsp; gastrointestinais&nbsp; do&nbsp; AINE.&nbsp; Em&nbsp; crianças&nbsp; com&nbsp; mais&nbsp; de&nbsp; 6&nbsp; meses,&nbsp; devem&nbsp; ser&nbsp; utilizados</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">15&nbsp; a&nbsp; 30&nbsp; mg/kg/dia,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; também&nbsp; divididos&nbsp; de&nbsp; 8/8&nbsp; horas&nbsp; e&nbsp; utilizando&nbsp; a&nbsp; menor&nbsp; dose&nbsp; pelo&nbsp; menor&nbsp; tempo&nbsp; possível.&nbsp; Naproxeno</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; com&nbsp; 500&nbsp; a&nbsp; 1.000&nbsp; mg/dia,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; divididos&nbsp; em&nbsp; até&nbsp; duas&nbsp; administrações&nbsp; (utilizar&nbsp; a&nbsp; menor&nbsp; dose&nbsp; pelo&nbsp; menor&nbsp; tempo&nbsp; possível).&nbsp; Em&nbsp; crianças&nbsp; com&nbsp; ou&nbsp; mais&nbsp; de&nbsp; 2&nbsp; anos&nbsp; de&nbsp; idade,&nbsp; devese&nbsp; iniciar&nbsp; com&nbsp; 10&nbsp; mg/kg/dia&nbsp; em&nbsp; duas&nbsp; administrações&nbsp; (dose&nbsp; máxima:&nbsp; &nbsp;&nbsp;1.000&nbsp; mg/dia).</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Considerar&nbsp; o&nbsp; uso&nbsp; de&nbsp; inibidor&nbsp; da&nbsp; bomba&nbsp; de&nbsp; prótons&nbsp; (20&nbsp; mg/dia&nbsp; de&nbsp; omeprazol)&nbsp; para&nbsp; minimizar&nbsp; efeitos&nbsp; gastrointestinais&nbsp; do&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">AINE.</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Metilprednisolona&nbsp; (acetato)</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Devem&nbsp; ser&nbsp; utilizados&nbsp; 40&nbsp; a&nbsp; 80&nbsp; mg,&nbsp; intra&nbsp; ou&nbsp; periarticular,&nbsp; a&nbsp; cada&nbsp; 3&nbsp; meses.&nbsp; Em&nbsp; crianças,&nbsp; deve-se&nbsp; observar&nbsp; a&nbsp; dose&nbsp; de&nbsp; 0,5&nbsp; a</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">1,0&nbsp; mg/kg/articulação.&nbsp; </span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">&nbsp; Metilprednisolona&nbsp; (succinato)</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Devem&nbsp; ser&nbsp; utilizados&nbsp; 1.000&nbsp; mg/dia,&nbsp; por&nbsp; via&nbsp; intravenosa&nbsp; (administrados&nbsp; durante&nbsp; pelo&nbsp; menos&nbsp; 2&nbsp; horas),&nbsp; por&nbsp; 3&nbsp; dias&nbsp; consecutivos&nbsp; (pulsoterapia).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Prednisona/prednisolona</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; com&nbsp; até&nbsp; 0,3&nbsp; mg/kg/dia,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; divididos&nbsp; em&nbsp; duas&nbsp; a&nbsp; três&nbsp; administrações,&nbsp; e&nbsp; reduzir,&nbsp; gradativamente,&nbsp; conforme&nbsp; melhora&nbsp; sintomática&nbsp; (utilizar&nbsp; a&nbsp; menor&nbsp; dose&nbsp; pelo&nbsp; menor&nbsp; tempo&nbsp; possível);&nbsp; excepcionalmente,&nbsp; doses&nbsp; elevadas&nbsp; (1&nbsp; mg/kg/dia),&nbsp; por&nbsp; via&nbsp; oral,&nbsp; devem&nbsp; ser&nbsp; empregadas&nbsp; em&nbsp; caso&nbsp; de&nbsp; manifestações&nbsp; graves.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Metotrexato</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; com&nbsp; 10&nbsp; a&nbsp; 15&nbsp; mg/semana,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; por&nbsp; via&nbsp; subcutânea&nbsp; ou&nbsp; intramuscular,&nbsp; e&nbsp; aumentar&nbsp; 5&nbsp; a&nbsp; 7,5&nbsp; mg/mês&nbsp; até&nbsp; 25&nbsp; mg/semana&nbsp; em&nbsp; três&nbsp; meses&nbsp; de&nbsp; uso.&nbsp; Em&nbsp; crianças,&nbsp; a&nbsp; partir&nbsp; dos&nbsp; 2&nbsp; anos&nbsp; de&nbsp; idade,&nbsp; deve-se&nbsp; iniciar&nbsp; com&nbsp; 5&nbsp; mg/m2/semana,&nbsp; podendo&nbsp; chegar&nbsp; a&nbsp; 15&nbsp; mg/m2/semana.&nbsp; Tanto&nbsp; para&nbsp; adultos&nbsp; quanto&nbsp; para&nbsp; crianças&nbsp; deve-se&nbsp; utilizar&nbsp; a&nbsp; menor&nbsp; dose&nbsp; eficaz&nbsp; e&nbsp; associar&nbsp; a&nbsp; ácido&nbsp; fólico,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; 5&nbsp; a&nbsp; 10&nbsp; mg/semana.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Sulfassalazina</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; com&nbsp; 500&nbsp; mg/dia&nbsp; e,&nbsp; após&nbsp; uma&nbsp; semana,&nbsp; devese&nbsp; aumentar&nbsp; a&nbsp; dose&nbsp; até&nbsp; 2.000&nbsp; a&nbsp; 3.000&nbsp; mg/dia,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; divididos&nbsp; em&nbsp; duas&nbsp; a&nbsp; três&nbsp; administrações.&nbsp; Em&nbsp; crianças,&nbsp; a&nbsp; partir&nbsp; dos&nbsp; 6&nbsp; anos&nbsp; de&nbsp; idade,&nbsp; deve-se&nbsp; iniciar&nbsp; com&nbsp; 10&nbsp; mg/kg/dia&nbsp; em&nbsp; duas&nbsp; administrações&nbsp; e&nbsp; chegar&nbsp; a&nbsp; 30&nbsp; a&nbsp; 50&nbsp; mg/kg/dia&nbsp; em&nbsp; duas&nbsp; administrações&nbsp; (dose&nbsp; máxima&nbsp; 2.000&nbsp; mg/dia).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Leflunomida</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Devem&nbsp; ser&nbsp; utilizados&nbsp; 20&nbsp; mg/dia&nbsp; ou&nbsp; em&nbsp; dias&nbsp; alternados,&nbsp; por&nbsp; via&nbsp; oral. &nbsp;</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">&nbsp; Hidroxicloroquina</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; e&nbsp; manter&nbsp; com&nbsp; 6&nbsp; mg/kg/dia,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; até,&nbsp; no&nbsp; máximo,&nbsp; 400&nbsp; mg/dia.&nbsp;</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">&nbsp; Cloroquina</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; e&nbsp; manter&nbsp; com&nbsp; 4&nbsp; mg/kg/dia,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; até,&nbsp; no&nbsp; máximo,&nbsp; 250&nbsp; mg/dia.&nbsp;</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">&nbsp; Adalimumabe</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; e&nbsp; manter&nbsp; a&nbsp; dose&nbsp; com&nbsp; 40&nbsp; mg,&nbsp; por&nbsp; via&nbsp; subcutânea,&nbsp; duas&nbsp; vezes/mês.&nbsp; Em&nbsp; crianças,&nbsp; a&nbsp; partir&nbsp; dos&nbsp; 4&nbsp; anos&nbsp; de</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">idade,&nbsp; com&nbsp; peso&nbsp; corporal&nbsp; entre&nbsp; 15&nbsp; e&nbsp; 30&nbsp; kg,&nbsp; deve-se&nbsp; administrar&nbsp; 20&nbsp; mg,&nbsp; por&nbsp; via&nbsp; subcutânea,&nbsp; duas&nbsp; vezes/mês;&nbsp; e&nbsp; em&nbsp; crianças,&nbsp; a&nbsp; partir&nbsp; dos&nbsp; 4&nbsp; anos,&nbsp; com&nbsp; peso&nbsp; corporal&nbsp; acima&nbsp; de&nbsp; 30&nbsp; kg,&nbsp; a&nbsp; dose&nbsp; é&nbsp; de&nbsp; 40&nbsp; mg,&nbsp; por&nbsp; via&nbsp; subcutânea,&nbsp; duas&nbsp; vezes/mês.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Certolizumabe&nbsp; pegol</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; com&nbsp; 400&nbsp; mg,&nbsp; por&nbsp; via&nbsp; subcutânea,&nbsp; nas&nbsp; semanas&nbsp; 0,&nbsp; 2&nbsp; e&nbsp; 4;&nbsp; após,&nbsp; manter&nbsp; com&nbsp; 200&nbsp; mg&nbsp; duas&nbsp; vezes/mês&nbsp; ou</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">400&nbsp; mg&nbsp; a&nbsp; cada&nbsp; mês.&nbsp; </span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">&nbsp; Etanercepte</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; e&nbsp; manter&nbsp; a&nbsp; dose&nbsp; com&nbsp; 50&nbsp; mg,&nbsp; por&nbsp; via&nbsp; subcutânea,&nbsp; a&nbsp; cada&nbsp; semana&nbsp; (quatro&nbsp; vezes/mês).&nbsp; Em&nbsp; crianças,&nbsp; a&nbsp; partir&nbsp; dos&nbsp; 2&nbsp; anos&nbsp; de&nbsp; idade,&nbsp; com&nbsp; peso&nbsp; corporal&nbsp; igual&nbsp; ou&nbsp; inferior&nbsp; a&nbsp; 63&nbsp; kg,&nbsp; devese&nbsp; administrar&nbsp; 0,8&nbsp; mg/kg,&nbsp; por&nbsp; via&nbsp; subcutânea,&nbsp; a&nbsp; cada&nbsp; semana&nbsp; (quatro&nbsp; vezes/mês)&nbsp; até&nbsp; a&nbsp; dose&nbsp; máxima&nbsp; de&nbsp; 50&nbsp; mg,&nbsp; por&nbsp; via&nbsp; subcutânea,&nbsp; a&nbsp; cada&nbsp; semana&nbsp; (quatro&nbsp; vezes/mês);&nbsp; em&nbsp; crianças,&nbsp; a&nbsp; partir&nbsp; dos&nbsp; 2&nbsp; anos,&nbsp; com&nbsp; peso&nbsp; corporal&nbsp; superior&nbsp; a&nbsp; 63&nbsp; kg,&nbsp; a&nbsp; dose&nbsp; é&nbsp; de&nbsp; 50&nbsp; mg,&nbsp; por&nbsp; via&nbsp; subcutânea,&nbsp; a&nbsp; cada&nbsp; semana&nbsp; (quatro&nbsp; vezes/mês).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Infliximabe</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; com&nbsp; 3&nbsp; mg/kg/dose,&nbsp; por&nbsp; via&nbsp; intravenosa,&nbsp; nas&nbsp; semanas&nbsp; 0,&nbsp; 2,&nbsp; 6&nbsp; e,&nbsp; após,&nbsp; manter&nbsp; a&nbsp; mesma&nbsp; dose&nbsp; a&nbsp; cada&nbsp; dois&nbsp; meses.&nbsp; Em&nbsp; crianças,&nbsp; a&nbsp; partir&nbsp; dos&nbsp; 6&nbsp; anos&nbsp; de&nbsp; idade,&nbsp; deve-se&nbsp; iniciar&nbsp; com&nbsp; 3&nbsp; mg/kg/dose,&nbsp; por&nbsp; via&nbsp; intravenosa,&nbsp; nas&nbsp; semanas&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">0,&nbsp; 2,&nbsp; 6&nbsp; e,&nbsp; após,&nbsp; manter&nbsp; a&nbsp; mesma&nbsp; dose&nbsp; a&nbsp; cada&nbsp; dois&nbsp; meses.&nbsp; </span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial, helvetica, sans-serif;">Golimumabe</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; e&nbsp; manter&nbsp; a&nbsp; dose&nbsp; com&nbsp; 50&nbsp; mg,&nbsp; por&nbsp; via&nbsp; subcutânea,&nbsp; uma&nbsp; vez/mês.&nbsp; </span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">&nbsp; Abatacepte</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; com&nbsp; 500&nbsp; mg,&nbsp; por&nbsp; via&nbsp; intravenosa,&nbsp; nos&nbsp; pacientes&nbsp; com&nbsp; menos&nbsp; de&nbsp; 60&nbsp; kg,&nbsp; com&nbsp; 750&nbsp; mg&nbsp; nos&nbsp; pacientes&nbsp; com&nbsp; 60&nbsp; a&nbsp; 100&nbsp; kg&nbsp; ou&nbsp; com&nbsp; 1.000&nbsp; mg&nbsp; naqueles&nbsp; com&nbsp; mais&nbsp; de&nbsp; 100&nbsp; kg,&nbsp; nas&nbsp; semanas&nbsp; 0,&nbsp; 2&nbsp; e&nbsp; 4&nbsp; e,&nbsp; após,&nbsp; manter&nbsp; a&nbsp; mesma&nbsp; dose&nbsp; a&nbsp; cada&nbsp; mês.&nbsp; Em&nbsp; crianças,&nbsp; a&nbsp; partir&nbsp; dos&nbsp; 6&nbsp; anos&nbsp; de&nbsp; idade,&nbsp; com&nbsp; peso&nbsp; corporal&nbsp; inferior&nbsp; a&nbsp; 75&nbsp; kg,&nbsp; devese&nbsp; iniciar&nbsp; com&nbsp; 10&nbsp; mg/kg,&nbsp; por&nbsp; via&nbsp; intravenosa,&nbsp; nas&nbsp; semanas&nbsp; 0,&nbsp; 2,&nbsp; 4&nbsp; e,&nbsp; após,&nbsp; manter&nbsp; a&nbsp; mesma&nbsp; dose&nbsp; a&nbsp; cada&nbsp; mês.&nbsp; Em&nbsp; crianças,&nbsp; a&nbsp; partir&nbsp; dos&nbsp; 6&nbsp; anos,&nbsp; com&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">peso&nbsp; corporal&nbsp; entre&nbsp; 75&nbsp; e&nbsp; 100&nbsp; kg,&nbsp; deve-se&nbsp; iniciar&nbsp; com&nbsp; 750&nbsp; mg,&nbsp; por&nbsp; via&nbsp; intravenosa,&nbsp; nas&nbsp; semanas&nbsp; 0,&nbsp; 2,&nbsp; 4&nbsp; e,&nbsp; após,&nbsp; manter&nbsp; a&nbsp; mesma&nbsp; dose&nbsp; a&nbsp; cada&nbsp; mês.&nbsp; Em&nbsp; crianças,&nbsp; a&nbsp; partir&nbsp; dos&nbsp; 6&nbsp; anos,&nbsp; com&nbsp; peso&nbsp; corporal&nbsp; superior&nbsp; a&nbsp; 100&nbsp; kg,&nbsp; deve-se&nbsp; iniciar&nbsp; com&nbsp;1.000&nbsp; mg,&nbsp; por&nbsp; via&nbsp; intravenosa,&nbsp; nas&nbsp; semanas&nbsp; 0,&nbsp; 2,&nbsp; 4&nbsp; e,&nbsp; após,&nbsp; manter&nbsp; com&nbsp; a&nbsp; mesma&nbsp; dose&nbsp; a&nbsp; cada&nbsp; mês.&nbsp; </span></span></span></p>
<p data-obsoleto="text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial, helvetica, sans-serif;">&nbsp; Rituximabe</span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; com&nbsp; 1.000&nbsp; mg,&nbsp; por&nbsp; via&nbsp; intravenosa,&nbsp; nos&nbsp; dias&nbsp; 0&nbsp; e&nbsp; 14&nbsp; e,&nbsp; após,&nbsp; a&nbsp; cada&nbsp; 6&nbsp; ou&nbsp; mais&nbsp; meses,&nbsp; conforme&nbsp; avaliação&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; pelo&nbsp; ICAD,&nbsp; administrando&nbsp; 1.000&nbsp; mg,&nbsp; por&nbsp; via&nbsp; intravenosa,&nbsp; nos&nbsp; dias&nbsp; 0&nbsp; e&nbsp; 14.</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial, helvetica, sans-serif;">&nbsp; Tocilizumabe</span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; e&nbsp; manter&nbsp; a&nbsp; dose&nbsp; com&nbsp; 8&nbsp; mg/kg/dose&nbsp; (dose&nbsp; máxima&nbsp; de&nbsp; 800&nbsp; mg),&nbsp; por&nbsp; via&nbsp; intravenosa,&nbsp; a&nbsp; cada&nbsp; mês.&nbsp; </span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">&nbsp; Ciclosporina</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Em&nbsp; adultos&nbsp; e&nbsp; crianças,&nbsp; deve-se&nbsp; iniciar&nbsp; com&nbsp; 2,5&nbsp; mg/kg/dia,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; em&nbsp; duas&nbsp; administrações,&nbsp; e&nbsp; aumentar&nbsp; 0,5&nbsp; a&nbsp; 0,75&nbsp; mg/kg/dia&nbsp; a&nbsp; cada&nbsp; dois&nbsp; ou&nbsp; três&nbsp; meses,&nbsp; caso&nbsp; não&nbsp; haja&nbsp; resposta,&nbsp; até,&nbsp; no&nbsp; máximo,&nbsp; 4&nbsp; mg/kg/dia.&nbsp; Em&nbsp; caso&nbsp; de&nbsp; surgimento&nbsp; de&nbsp; hipertensão&nbsp; arterial&nbsp; sistêmica&nbsp; ou&nbsp; de&nbsp; elevação&nbsp; de&nbsp; 25%&nbsp; ou&nbsp; mais&nbsp; da&nbsp; creatinina&nbsp; basal&nbsp; (prévia&nbsp; ao&nbsp; início&nbsp; do&nbsp; tratamento),&nbsp; deve-&nbsp; se&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a&nbsp; 50%&nbsp; e,&nbsp; caso&nbsp; se&nbsp; mantenha&nbsp; o&nbsp; efeito&nbsp; adverso,&nbsp; suspender&nbsp; o&nbsp; uso.</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Azatioprina</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Em&nbsp; adultos&nbsp; e&nbsp; crianças,&nbsp; deve-se&nbsp; iniciar&nbsp; com&nbsp; 1&nbsp; mg/kg/dia,&nbsp; por&nbsp; via&nbsp; oral,&nbsp; uma&nbsp; a&nbsp; duas&nbsp; vezes&nbsp; ao&nbsp; dia,&nbsp; e,&nbsp; em&nbsp; caso&nbsp; de&nbsp; não&nbsp; resposta,&nbsp; aumentar&nbsp; 0,5&nbsp; mg/kg/dia&nbsp; a&nbsp; cada&nbsp; mês&nbsp; até&nbsp; 2,5&nbsp; mg/kg/dia&nbsp; (dose&nbsp; máxima).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Ciclofosfamida</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Deve-se&nbsp; iniciar&nbsp; e&nbsp; manter&nbsp; a&nbsp; dose&nbsp; com&nbsp; 600&nbsp; mg/m2,&nbsp; por&nbsp; via&nbsp; intravenosa,&nbsp; em&nbsp; pulsoterapia&nbsp; mensal&nbsp; por&nbsp; 3&nbsp; a&nbsp; 6&nbsp; meses.</span></span></span></span></p>
<p data-obsoleto="margin-left: 80px; text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">8.6&nbsp; TEMPO&nbsp; DE&nbsp; TRATAMENTO&nbsp; (CRITÉRIOS&nbsp; DE&nbsp; INTERRUPÇÃO)</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Não&nbsp; há&nbsp; evidências&nbsp; sobre&nbsp; a&nbsp; melhor&nbsp; estratégia&nbsp; de&nbsp; interrupção&nbsp; de&nbsp; medicamentos&nbsp; para&nbsp; AR.&nbsp; Quando&nbsp; ocorre&nbsp; resposta&nbsp; terapêutica&nbsp; completa,&nbsp; isto&nbsp; é,&nbsp; remissão&nbsp; pelos&nbsp; índices&nbsp; compostos&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença,&nbsp; e&nbsp; sustentada,&nbsp; ou&nbsp; seja,&nbsp; por&nbsp; mais&nbsp; de&nbsp; 6&nbsp; a&nbsp; 12&nbsp; meses,&nbsp; pode-se&nbsp; tentar&nbsp; a&nbsp; retirada&nbsp; gradual&nbsp; dos&nbsp; medicamentos&nbsp; nesta&nbsp; sequência:&nbsp; primeiramente&nbsp; o</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">AINE,&nbsp; seguido&nbsp; pelo&nbsp; glicocorticoide&nbsp; e&nbsp; depois&nbsp; pelo&nbsp; MMCD&nbsp; biológico,&nbsp; mantendo-se&nbsp; o&nbsp; uso&nbsp; de&nbsp; MMCD&nbsp; sintético.&nbsp; Caso&nbsp; haja</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">piora&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença,&nbsp; deve-se&nbsp; reiniciar&nbsp; o&nbsp; esquema&nbsp; terapêutico&nbsp; anterior&nbsp; e&nbsp; seguir&nbsp; as&nbsp; recomendações&nbsp; de&nbsp; dose&nbsp; inicial&nbsp; e&nbsp; de&nbsp; ajuste&nbsp; de&nbsp; doses&nbsp; e&nbsp; troca&nbsp; de&nbsp; medicamentos&nbsp; indicadas&nbsp; neste&nbsp; Protocolo.</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">8.7&nbsp; BENEFÍCIOS&nbsp; ESPERADOS</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; tratamento&nbsp; de&nbsp; AR&nbsp; tem&nbsp; como&nbsp; benefícios&nbsp; esperados&nbsp; reversão&nbsp; da&nbsp; limitação&nbsp; funcional,&nbsp; melhora&nbsp; da&nbsp; qualidade&nbsp; de&nbsp; vida&nbsp; e&nbsp; aumento&nbsp; da&nbsp; sobrevida&nbsp; por&nbsp; meio&nbsp; do&nbsp; controle&nbsp; da&nbsp; atividade&nbsp; de&nbsp; doença,&nbsp; da&nbsp; prevenção&nbsp; das&nbsp; complicações&nbsp; agudas&nbsp; e&nbsp; crônicas&nbsp; e&nbsp; da&nbsp; inibição&nbsp; da&nbsp; progressão&nbsp; dos&nbsp; danos&nbsp; estruturais&nbsp; causados&nbsp; pela&nbsp; doença.</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">9&nbsp; MONITORIZAÇÃO</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Revisões&nbsp; periódicas&nbsp; para&nbsp; avaliação&nbsp; de&nbsp; eficácia&nbsp; e&nbsp; segurança&nbsp; do&nbsp; tratamento&nbsp; devem&nbsp; fazer&nbsp; parte&nbsp; do&nbsp; tratamento&nbsp; dos&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; (118).&nbsp; Inicialmente,&nbsp; os&nbsp; pacientes&nbsp; devem&nbsp; ser&nbsp; avaliados&nbsp; a&nbsp; intervalos&nbsp; menores&nbsp; (1&nbsp; a&nbsp; 3&nbsp; meses).&nbsp; Uma&nbsp; vez&nbsp; atingido&nbsp; o&nbsp; objetivo&nbsp; do&nbsp; tratamento&nbsp; (remissão&nbsp; para&nbsp; AR&nbsp; mais&nbsp; recente&nbsp; e&nbsp; atividade&nbsp; leve&nbsp; de&nbsp; doença&nbsp; para&nbsp; AR&nbsp; de&nbsp; anos&nbsp; de&nbsp; evolução),&nbsp; intervalos&nbsp; maiores&nbsp; podem&nbsp; ser&nbsp; considerados&nbsp; (6&nbsp; a&nbsp; 12&nbsp; meses).&nbsp; No&nbsp; entanto,&nbsp; mesmo&nbsp; sem&nbsp; a&nbsp; necessidade&nbsp; de&nbsp; visitas&nbsp; mais&nbsp; frequentes&nbsp; para&nbsp; avaliação&nbsp; de&nbsp; eficácia,&nbsp; a&nbsp; monitorização&nbsp; de&nbsp; segurança&nbsp; deve&nbsp; ser&nbsp; observada,&nbsp; ou&nbsp; seja,&nbsp; os&nbsp; intervalos&nbsp; dos&nbsp; exames&nbsp; laboratoriais&nbsp; para&nbsp; monitorização&nbsp; dos&nbsp; possíveis&nbsp; efeitos&nbsp; adversos&nbsp; de&nbsp; medicamentos&nbsp; devem&nbsp; ser&nbsp; respeitados&nbsp; (Quadro&nbsp; 2).</span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Quadro&nbsp; 2&nbsp; –&nbsp; Monitorização&nbsp; de&nbsp; Efeitos&nbsp; Adversos&nbsp; no&nbsp; Tratamento&nbsp; de&nbsp; AR:</span></span></span></span></p>
<p>
			&nbsp;</p>
<table border="1" cellpadding="0" cellspacing="0" data-obsoleto="width: 1033px;">
<tbody>
<tr>
<td>
<p data-obsoleto="text-align: center;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">MEDICAMENTO</span></span></p>
</td>
<td>
<p data-obsoleto="text-align: center;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">AVALIAÇÃO</span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p data-obsoleto="text-align: center;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">CONDUTA&nbsp; FRENTE&nbsp; A&nbsp; ALTERAÇÕES</span></span></p>
</td>
</tr>
<tr>
<td colspan="3" data-obsoleto="width: 1010px;">
<p data-obsoleto="text-align: center;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">MMCD&nbsp; sintéticos</span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Metotrexato</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Hemograma,&nbsp; crea<span data-obsoleto="background-color: transparent;">tinina,&nbsp; AST/&nbsp; TGO</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">e&nbsp; ALT/TGP:&nbsp; A&nbsp;<span data-obsoleto="background-color: transparent;">cada&nbsp; 1&nbsp; a&nbsp; 3&nbsp; meses.</span></span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Anemia,&nbsp; leucopenia&nbsp; ou&nbsp; trombocitopenia&nbsp; no<span data-obsoleto="background-color: transparent;">vas&nbsp; ou&nbsp; mais&nbsp; acentuadas:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp;25%&nbsp; a&nbsp; 50%;&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medica-&nbsp; mento&nbsp; se&nbsp; persistirem</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">as&nbsp; alterações.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp;<span data-obsoleto="background-color: transparent;">ALT/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a&nbsp; 50%.&nbsp;</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre <span data-obsoleto="background-color: transparent;">3&nbsp;</span><span data-obsoleto="background-color: transparent;">e&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; suspender&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento&nbsp; até&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN&nbsp; e&nbsp; reiniciar&nbsp; com&nbsp; 50%&nbsp;da&nbsp;dose.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; acima&nbsp; de&nbsp; 5&nbsp; vezes&nbsp; o&nbsp;<span data-obsoleto="background-color: transparent;">LSN:&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento.&nbsp;</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Depuração&nbsp; de&nbsp; creatinina&nbsp; endógena&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">10&nbsp;e&nbsp;50ml/minuto:&nbsp; administrar&nbsp; 50%&nbsp; da&nbsp; dose.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Depuração&nbsp; de&nbsp; creatinina&nbsp; endógena&nbsp; abaixo&nbsp; de&nbsp;<span data-obsoleto="background-color: transparent;">10ml/minuto:&nbsp; evitar&nbsp; uso.</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Sulfassalazina</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Hemograma,&nbsp; AST/TGO&nbsp;<span data-obsoleto="background-color: transparent;">e&nbsp; ALT/&nbsp; TGP:&nbsp; A cada&nbsp; 1&nbsp; a&nbsp; 3&nbsp; meses.</span></span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Anemia,&nbsp; leucopenia&nbsp; ou&nbsp; trombocitopenia&nbsp; novas&nbsp; ou&nbsp; mais&nbsp;<span data-obsoleto="background-color: transparent;">acentuadas:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a &nbsp;50%;&nbsp; interromper&nbsp; o&nbsp; uso&nbsp;do&nbsp; medicamento&nbsp; se&nbsp; persistirem&nbsp; as&nbsp; alterações.&nbsp;</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp;a&nbsp;50%.&nbsp; –&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp;entre&nbsp; 3&nbsp; e&nbsp; 5&nbsp; vezes&nbsp; o</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">LSN:&nbsp; suspender&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento&nbsp; até&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN&nbsp; e&nbsp; reiniciar&nbsp; com&nbsp; 50%&nbsp; da&nbsp; dose.&nbsp;</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; TGO/TGP&nbsp; acima&nbsp; de&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento.</span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Leflunomida</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Hemograma,&nbsp; crea-tinina,&nbsp; AST/&nbsp; TGO&nbsp;<span data-obsoleto="background-color: transparent;">e&nbsp; ALT/TGP:&nbsp; A&nbsp; cada&nbsp; 1&nbsp; a&nbsp; 3&nbsp; meses.</span></span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Anemia,&nbsp; leucopenia&nbsp; ou&nbsp; trombocitopenia&nbsp; no-vas&nbsp; ou&nbsp; mais&nbsp; acentuadas:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp;<span data-obsoleto="background-color: transparent;">medicamento&nbsp; até&nbsp; AST/TGO&nbsp; e&nbsp; 25%&nbsp; a&nbsp; 50%;&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento&nbsp; se&nbsp; persistirem&nbsp;as&nbsp; alterações.&nbsp; –&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp;ALT/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp;LSN:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a&nbsp; 50%.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">3&nbsp; e&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; suspender&nbsp; o&nbsp; uso&nbsp; do&nbsp; ALT/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN&nbsp; e&nbsp; rei-&nbsp; niciar&nbsp; com&nbsp; 50%&nbsp; da&nbsp; dose.&nbsp; –&nbsp; Elevação&nbsp; de&nbsp;AST/TGO&nbsp; e&nbsp;ALT/TGP&nbsp; acima&nbsp; de&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; inter-&nbsp; romper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Depuração&nbsp; de&nbsp; creatinina&nbsp; endógena&nbsp; abaixo&nbsp; de&nbsp; 50ml/minuto:&nbsp; administrar&nbsp; 50%&nbsp; da&nbsp; dose&nbsp; ou&nbsp; suspender,&nbsp; em&nbsp; caso&nbsp; de&nbsp; toxicida-de.</span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Antimaláricos&nbsp; (cloro-quina&nbsp; e&nbsp; hidroxicloro&nbsp; quina)</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Avaliação&nbsp; oftalmológica&nbsp; inicial&nbsp; e&nbsp;<span data-obsoleto="background-color: transparent;">anual&nbsp; após&nbsp; 5&nbsp; anos&nbsp; (ou&nbsp; anualmente&nbsp; se&nbsp; houver&nbsp;</span><span data-obsoleto="background-color: transparent;">fatores&nbsp; de&nbsp; risco&nbsp;</span><span data-obsoleto="background-color: transparent;">para&nbsp; maculopatia,&nbsp; tais&nbsp; como&nbsp; insuficiências&nbsp; renal&nbsp;</span><span data-obsoleto="background-color: transparent;">ou&nbsp;</span><span data-obsoleto="background-color: transparent;">hepática&nbsp; e&nbsp; doses&nbsp; eventualme</span><span data-obsoleto="background-color: transparent;">nte&nbsp; utilizadas acima&nbsp; da&nbsp;</span><span data-obsoleto="background-color: transparent;">dose&nbsp; máxima,&nbsp; que&nbsp; não&nbsp;</span><span data-obsoleto="background-color: transparent;">devem&nbsp; ser&nbsp; utilizadas).&nbsp; Hemograma,&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP:&nbsp; A&nbsp; cada&nbsp; 1&nbsp; a&nbsp;3&nbsp; meses.</span></span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Maculopatia&nbsp; por&nbsp; esses&nbsp; medicamentos:&nbsp;<span data-obsoleto="background-color: transparent;">interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Anemia,&nbsp; leucopenia&nbsp; ou&nbsp; trombocitopenia&nbsp; no-vas&nbsp; ou&nbsp; mais&nbsp; acentuadas:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp;<span data-obsoleto="background-color: transparent;">25%&nbsp; a&nbsp; 50%;&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medica-&nbsp; mento&nbsp; se&nbsp; persistirem&nbsp; as&nbsp; alterações.&nbsp;</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp;LSN:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a&nbsp; 50%.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">3&nbsp; e&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; suspender&nbsp; o&nbsp; uso&nbsp; do&nbsp;medicamento&nbsp; até&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; en-&nbsp; tre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN&nbsp; e&nbsp; reiniciar&nbsp; com&nbsp; 50%&nbsp; da&nbsp; dose.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; TGO/TGP&nbsp; acima&nbsp; de&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; interromper&nbsp; o</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">uso&nbsp; do&nbsp; medicamento.</span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td colspan="3" data-obsoleto="width: 1010px;">
<p data-obsoleto="text-align: center;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">MMCD&nbsp; biológicos</span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Anti-TNF</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Avaliação&nbsp; de&nbsp;<span data-obsoleto="background-color: transparent;">tuberculose&nbsp; latente&nbsp; ou&nbsp; ativa&nbsp; antes&nbsp;</span><span data-obsoleto="background-color: transparent;">do&nbsp; início&nbsp; do&nbsp; trata-mento&nbsp; (anamnese,&nbsp; exame&nbsp;</span><span data-obsoleto="background-color: transparent;">físico,&nbsp; radiografia&nbsp;</span><span data-obsoleto="background-color: transparent;">de&nbsp; tórax&nbsp; e&nbsp; teste&nbsp; tuberculínic</span><span data-obsoleto="background-color: transparent;">o).&nbsp; Hemograma,&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP:&nbsp; A cada&nbsp; 1&nbsp; a&nbsp;3&nbsp; meses.</span></span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tratar&nbsp; tuberculose&nbsp; latente&nbsp; por&nbsp; no&nbsp; mínimo&nbsp;<span data-obsoleto="background-color: transparent;">1&nbsp; mês&nbsp; antes&nbsp; do&nbsp; início&nbsp;do&nbsp; uso&nbsp; desses&nbsp; medicamentos.&nbsp; –&nbsp; Anemia,&nbsp; leucopenia&nbsp; e/ou&nbsp; trombocitopenia&nbsp; &nbsp;&nbsp;novas&nbsp; ou&nbsp; mais&nbsp;acentuadas:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a&nbsp;50%;&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento&nbsp; se&nbsp; persis-tirem&nbsp; as&nbsp; alterações.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp;</span><span data-obsoleto="background-color: transparent;">LSN:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a&nbsp; 50%.&nbsp; –&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp;</span><span data-obsoleto="background-color: transparent;">ALT/TGP&nbsp; entre&nbsp; 3&nbsp; e&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; suspen-&nbsp; der&nbsp; o&nbsp; uso&nbsp; do&nbsp;medicamento&nbsp; até&nbsp; TGO/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN&nbsp; e&nbsp;reiniciar&nbsp; com&nbsp; 50%&nbsp; da&nbsp; dose.&nbsp; –&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; acima&nbsp; de&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento.</span></span></span></p>
</td>
</tr>
<tr>
<td rowspan="2">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Abatacepte</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Avaliação&nbsp; de&nbsp;<span data-obsoleto="background-color: transparent;">tuberculose&nbsp; latente&nbsp; ou&nbsp; ativa&nbsp; antes&nbsp; do&nbsp; iní-cio&nbsp; do&nbsp; tratamento&nbsp; (anamnese,&nbsp; exame&nbsp;</span><span data-obsoleto="background-color: transparent;">físico,&nbsp;</span><span data-obsoleto="background-color: transparent;">radiografia&nbsp;de&nbsp; tórax&nbsp; e&nbsp; teste&nbsp; tuberculínico).&nbsp; Hemograma,&nbsp; AST/TGO&nbsp; e&nbsp;ALT/TGP:&nbsp;A&nbsp; cada&nbsp; 1&nbsp; a&nbsp; 3&nbsp; meses.</span></span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tratar&nbsp; tuberculose&nbsp; latente&nbsp; por&nbsp; no&nbsp; mínimo&nbsp;<span data-obsoleto="background-color: transparent;">1&nbsp; mês&nbsp; antes&nbsp; do&nbsp; início&nbsp;do&nbsp; uso&nbsp; desse&nbsp; medicamento.&nbsp; –&nbsp; Anemia,&nbsp; leucopenia&nbsp; ou&nbsp;trombocitopenia&nbsp; &nbsp;&nbsp;novas&nbsp; ou&nbsp; mais&nbsp; acentuadas:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp;25%&nbsp; a&nbsp; 50%;&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medica-&nbsp; mento&nbsp; se&nbsp; persistirem&nbsp; as&nbsp; alterações.&nbsp;</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp;LSN:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a&nbsp; 50%.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">3&nbsp; e&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; suspender&nbsp; o&nbsp; uso&nbsp; do&nbsp; me-dicamento&nbsp; até&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp;LSN&nbsp; e&nbsp; reiniciar&nbsp; com&nbsp; 50%&nbsp; da&nbsp; dose.-&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; acima&nbsp; de&nbsp; 5&nbsp; vezes&nbsp; o&nbsp;LSN:&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento.</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
<p>
							&nbsp;</p>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							&nbsp;</p>
<p>
							&nbsp;</p>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Rituximabe</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Avaliação&nbsp; de&nbsp; tuberculose&nbsp;<span data-obsoleto="background-color: transparent;">latente&nbsp; ou&nbsp; ativa&nbsp; antes&nbsp; do&nbsp; início&nbsp; do</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">tratamento&nbsp; (anamnese,&nbsp; exame&nbsp; físico,&nbsp; radiografia&nbsp; de&nbsp; tó<span data-obsoleto="background-color: transparent;">rax&nbsp; e&nbsp; teste tuberculínico).&nbsp; Hemograma,&nbsp; AST/TGO&nbsp; e&nbsp;ALT/TGP:&nbsp; A&nbsp; cada&nbsp; 1&nbsp; a&nbsp; 3&nbsp; meses.</span></span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Tratar&nbsp; tuberculose&nbsp; latente&nbsp; por&nbsp; no&nbsp; mínimo&nbsp;<span data-obsoleto="background-color: transparent;">1&nbsp; mês&nbsp; antes&nbsp; do&nbsp; início&nbsp; do&nbsp; uso&nbsp; desse&nbsp; medicamento.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Anemia,&nbsp; leucopenia&nbsp; ou&nbsp; trombocitopenia&nbsp; no-vas&nbsp; ou&nbsp; mais&nbsp; acentuadas:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em 2<span data-obsoleto="background-color: transparent;">5%&nbsp; a&nbsp; 50%;&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medica-&nbsp; mento&nbsp; se&nbsp; persistirem&nbsp; as&nbsp; alterações.&nbsp; –&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp;ALT/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a&nbsp; 50%.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">3&nbsp; e&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; suspender&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento&nbsp; até&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; en-tre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">LSN&nbsp; e&nbsp; reiniciar&nbsp; com&nbsp; 50%&nbsp; da&nbsp; dose.&nbsp; –&nbsp; Elevação&nbsp; de&nbsp; TGO/TGP&nbsp; acima&nbsp; de&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; interromper&nbsp; o&nbsp;<span data-obsoleto="background-color: transparent;">uso&nbsp; do&nbsp; medicamento.</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Tocilizumabe</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Avaliação&nbsp; de&nbsp;<span data-obsoleto="background-color: transparent;">tuberculose&nbsp; latente&nbsp;ou&nbsp; ativa&nbsp; antes&nbsp; do&nbsp; início&nbsp; do&nbsp;</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">tratamento&nbsp; (anamnese,&nbsp; exame&nbsp;<span data-obsoleto="background-color: transparent;">físico,&nbsp; radiografia&nbsp;</span><span data-obsoleto="background-color: transparent;">de&nbsp; tórax&nbsp; e&nbsp; teste&nbsp; tuberculínic</span><span data-obsoleto="background-color: transparent;">o).&nbsp; Hemograma,&nbsp; AST/TGO&nbsp; e&nbsp;ALT/TGP:&nbsp; A&nbsp; cada&nbsp; 1a3&nbsp; meses.&nbsp; Colesterol total,&nbsp; HDL,&nbsp; LDL,&nbsp; triglicerídios:&nbsp; A&nbsp; cada&nbsp; 6&nbsp; a&nbsp; 12&nbsp; meses.</span></span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">-Tratar&nbsp; tuberculose&nbsp; latente&nbsp; por&nbsp; no&nbsp; mínimo&nbsp;<span data-obsoleto="background-color: transparent;">1&nbsp; mês&nbsp; antes&nbsp; do&nbsp; início</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">do&nbsp; uso&nbsp; desse&nbsp; medicamento.</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Neutrófilos&nbsp; entre&nbsp; 500&nbsp; e&nbsp; 1.000/mm3:&nbsp; sus-&nbsp; pender&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento&nbsp; até&nbsp; neutrófilos&nbsp;<span data-obsoleto="background-color: transparent;">acima&nbsp; de&nbsp; 1.000/mm3&nbsp; e&nbsp; reiniciar&nbsp; com&nbsp; 4&nbsp; mg/kg.&nbsp; –&nbsp; Neutrófilos&nbsp; abaixo&nbsp; de&nbsp;500/mm3:&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Plaquetas&nbsp; entre&nbsp; 50.000&nbsp; e&nbsp; 100.000c/mm3:&nbsp; suspender&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento&nbsp; até&nbsp; plaquetas&nbsp;<span data-obsoleto="background-color: transparent;">acima&nbsp; de&nbsp; 100.000/mm3&nbsp; e&nbsp; reiniciar&nbsp; com&nbsp; 4&nbsp; mg/kg.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">-Plaquetas&nbsp; abaixo&nbsp; de&nbsp; 50.000/mm3:&nbsp;<span data-obsoleto="background-color: transparent;">interrom</span><span data-obsoleto="background-color: transparent;">per&nbsp; o&nbsp; uso&nbsp;</span><span data-obsoleto="background-color: transparent;">do&nbsp; medicamento.&nbsp; –&nbsp; Elevação&nbsp; de&nbsp; AST/TGO e&nbsp;</span><span data-obsoleto="background-color: transparent;">ALT/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; para&nbsp; 4 m</span><span data-obsoleto="background-color: transparent;">g/kg.&nbsp; –&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp;ALT/TGP&nbsp; entre&nbsp; 3&nbsp; e&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; suspender&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento&nbsp; até&nbsp; TGO/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN&nbsp; e&nbsp; reiniciar&nbsp; com&nbsp; 4&nbsp; mg/kg.&nbsp; –&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp;ALT/TGP&nbsp; acima&nbsp; de&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevações&nbsp; de&nbsp; colesterol&nbsp; total,&nbsp;<span data-obsoleto="background-color: transparent;">HDL,&nbsp; LDL&nbsp; ou&nbsp; triglicerídios:&nbsp; seguir&nbsp; o&nbsp; Proto-&nbsp; colo&nbsp; Clínico&nbsp; e&nbsp; Diretrizes&nbsp; Terapêuticas&nbsp; de&nbsp; Dislipidemia,&nbsp; do&nbsp; Ministério&nbsp; da&nbsp; Saúde.</span></span></span></p>
</td>
</tr>
<tr>
<td>
						&nbsp;</td>
<td>
						&nbsp;</td>
<td data-obsoleto="width: 500px;">
						&nbsp;</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td colspan="3" data-obsoleto="width: 1010px;">
<p data-obsoleto="text-align: center;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Medicamentos&nbsp; imunossupressores</span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Azatioprina</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Hemograma,&nbsp; AST/TGO&nbsp;<span data-obsoleto="background-color: transparent;">e&nbsp; ALT/&nbsp; TGP:&nbsp; A&nbsp;cada&nbsp; 1&nbsp; a&nbsp; 3&nbsp; meses.</span></span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Anemia,&nbsp; leucopenia&nbsp; ou&nbsp; trombocitopenia&nbsp; novas&nbsp; ou&nbsp; mais&nbsp;<span data-obsoleto="background-color: transparent;">acentuadas:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a&nbsp;50%;&nbsp; interromper&nbsp; o&nbsp; uso&nbsp;do&nbsp; medicamento&nbsp; se&nbsp; persistirem&nbsp; as&nbsp; alterações.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25% a&nbsp;50%.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp;<span data-obsoleto="background-color: transparent;">3&nbsp; e&nbsp; 5&nbsp; vezes&nbsp; o&nbsp;LSN:&nbsp; suspender&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento&nbsp; até&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; entre&nbsp; 1&nbsp; e&nbsp; 3&nbsp; vezes&nbsp; o&nbsp;LSN&nbsp; e&nbsp; reiniciar&nbsp; com&nbsp; 50%&nbsp; da&nbsp; dose.</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; de&nbsp; AST/TGO&nbsp; e&nbsp; ALT/TGP&nbsp; acima&nbsp; de&nbsp; 5&nbsp; vezes&nbsp; o&nbsp; LSN:&nbsp; inter-&nbsp; romper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento.</span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Ciclosporina</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Pressão&nbsp; arterial&nbsp; e&nbsp; creatinina:&nbsp;<span data-obsoleto="background-color: transparent;">A&nbsp; cada&nbsp; 1&nbsp; a&nbsp; 3&nbsp; meses.</span></span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Elevação&nbsp; nova&nbsp; de&nbsp; pressão&nbsp; arterial&nbsp; ou&nbsp; ele-vação&nbsp; de&nbsp; 25%&nbsp; ou&nbsp; mais&nbsp; do&nbsp; valor&nbsp; de&nbsp; creatinina&nbsp; basal&nbsp;<span data-obsoleto="background-color: transparent;">(prévio&nbsp; ao&nbsp; início&nbsp; do&nbsp;medicamento)&nbsp; que&nbsp; se&nbsp; mantêm&nbsp; apesar&nbsp; do&nbsp; ajuste&nbsp; de&nbsp; dose: interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp;medicamento.</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Ciclofosfamia</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Hemograma,&nbsp; exame comum&nbsp; de&nbsp; urina:</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">2 semanas&nbsp; após&nbsp; cada&nbsp; infusão.</span></span></p>
</td>
<td data-obsoleto="width: 500px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">–&nbsp; Anemia,&nbsp; leucopenia&nbsp; e/ou&nbsp; trombocitopenia&nbsp; novas&nbsp; ou&nbsp; mais&nbsp;<span data-obsoleto="background-color: transparent;">acentuadas:&nbsp; reduzir&nbsp; a&nbsp; dose&nbsp; em&nbsp; 25%&nbsp; a &nbsp;</span><span data-obsoleto="background-color: transparent;">50%;&nbsp; interromper&nbsp; o&nbsp; uso&nbsp;do&nbsp; medicamento&nbsp; se&nbsp; persistirem&nbsp;as&nbsp; alterações.&nbsp; –&nbsp; Hematúria&nbsp; devida&nbsp; a&nbsp; cistite&nbsp;hemorrágica:&nbsp; interromper&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento.</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p>
			&nbsp;</p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">MMCD:&nbsp; medicamentos&nbsp; modificadores&nbsp; do&nbsp; curso&nbsp; de&nbsp; doença;&nbsp; AST:&nbsp; aspartato-aminotransferase/TGO:&nbsp; &nbsp;&nbsp;transaminase&nbsp; glutâmico-oxalacética;</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">ALT:&nbsp; alanino-aminotransferase/TGP:&nbsp; &nbsp;&nbsp;transaminase&nbsp; glutâmico-pirúvica;&nbsp; LSN:&nbsp; limite&nbsp; superior&nbsp; da&nbsp; normalidade;&nbsp; HDL:</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">lipoproteína&nbsp; de&nbsp; densidade&nbsp; alta;&nbsp; LDL:&nbsp; lipoproteína&nbsp; de&nbsp; densidade&nbsp; baixa.</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; avaliação&nbsp; sistemática&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; deve&nbsp; fazer&nbsp; parte&nbsp; do&nbsp; acompanhamento&nbsp; dos&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; (2,190).&nbsp; Para&nbsp; tanto,&nbsp; índices&nbsp; compostos&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; (ICAD)&nbsp; devem&nbsp; ser&nbsp; utilizados&nbsp; (Apêndice&nbsp; 1).&nbsp; Os&nbsp; ICAD&nbsp; incluem&nbsp; componentes&nbsp; clínicos&nbsp; e&nbsp; laboratoriais.</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Os&nbsp; principais&nbsp; ICAD&nbsp; são&nbsp; o&nbsp; índice&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; DAS&nbsp; 28&nbsp; (Disease&nbsp; Activity&nbsp; Score&nbsp; 28),&nbsp; o&nbsp; índice&nbsp; simplificado&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; SDAI&nbsp; (Simplified&nbsp; Disease&nbsp; Activity&nbsp; Index)&nbsp; e&nbsp; o&nbsp; índice&nbsp; clínico&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; CDAI&nbsp; (Clinical</span></span></span></span></p>
<p></p></div>
<p data-obsoleto="text-align: justify;">
		&nbsp;</p>
<div>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Disease&nbsp; Activity&nbsp; Index).&nbsp; Com&nbsp; eles&nbsp; é&nbsp; possível&nbsp; estimar&nbsp; a&nbsp; atividade&nbsp; da&nbsp; doença&nbsp; (Quadro&nbsp; 3).&nbsp; Existe&nbsp; boa&nbsp; correlação&nbsp; entre&nbsp; esses&nbsp; ICAD,&nbsp; sendo&nbsp; possível&nbsp; o&nbsp; uso&nbsp; de&nbsp; qualquer&nbsp; um&nbsp; deles&nbsp; isoladamente&nbsp; (53).</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Quadro&nbsp; 3&nbsp; –&nbsp; ICAD&nbsp; Utilizados&nbsp; no&nbsp; Acompanhamento&nbsp; de&nbsp; Pacientes&nbsp; com&nbsp; AR:</span></span></span></span></p>
<p>
			&nbsp;</p>
<table border="1" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td data-obsoleto="width: 54px; height: 24px;">
<p data-obsoleto="margin-left: 7.45pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Índice</span></span></span></span></p>
</td>
<td data-obsoleto="width: 187px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Estado&nbsp; da&nbsp; atividade&nbsp; de&nbsp; doença</span></span></p>
</td>
<td data-obsoleto="width: 135px; height: 24px;">
<p data-obsoleto="margin-left: 23.3pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Pontos&nbsp; de&nbsp; corte</span></span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 54px; height: 48px;">
<p data-obsoleto="margin-left: 8.15pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">DAS</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.9pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">28</span></span></span></span></p>
</td>
<td data-obsoleto="width: 187px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Remissão&nbsp; Baixa</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Moderada&nbsp; Alta</span></span></p>
</td>
<td data-obsoleto="width: 135px; height: 48px;">
<p data-obsoleto="margin-left: 5.1pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Inferior&nbsp; ou&nbsp; igual&nbsp; a&nbsp; 2,6.&nbsp; Superior&nbsp; a&nbsp; 2,6&nbsp; e&nbsp; até&nbsp; 3,2.&nbsp; Superior&nbsp; a&nbsp; 3,2&nbsp; e&nbsp; até&nbsp; 5,1.&nbsp; Superior&nbsp; a&nbsp; 5,1.</span></span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 54px; height: 48px;">
<p data-obsoleto="margin-left: 8.7pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">SDAI</span></span></span></span></p>
</td>
<td data-obsoleto="width: 187px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Remissão</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Baixa&nbsp; Moderada&nbsp; Alta</span></span></p>
</td>
<td data-obsoleto="width: 135px; height: 48px;">
<p data-obsoleto="margin-left: 10.25pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Até&nbsp; 5.&nbsp; Superior&nbsp; a&nbsp; 5&nbsp; e&nbsp; até&nbsp; 20.&nbsp; Superior&nbsp; a&nbsp; 20&nbsp; e&nbsp; até&nbsp; 40.&nbsp; Superior&nbsp; a&nbsp; 40.</span></span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 54px; height: 48px;">
<p data-obsoleto="margin-left: 8.5pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">CDAI</span></span></span></span></p>
</td>
<td data-obsoleto="width: 187px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Remissão&nbsp; Baixa</span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Moderada&nbsp; Alta</span></span></p>
</td>
<td data-obsoleto="width: 135px; height: 48px;">
<p data-obsoleto="margin-left: 5.1pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Até&nbsp; 2,8.&nbsp; Superior&nbsp; a&nbsp; 2,8&nbsp; e&nbsp; até10.</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.1pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Superior&nbsp; a&nbsp; 10&nbsp; e&nbsp; até&nbsp; 22.&nbsp; Superior&nbsp; a&nbsp; 22.</span></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p>
			&nbsp;</p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">DAS&nbsp; 28:&nbsp; índice&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; (28&nbsp; articulações);</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">SDAI:&nbsp; índice&nbsp; simplificado&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença;&nbsp; CDAI:&nbsp; índice&nbsp; clínico&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença.</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Além&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença,&nbsp; a&nbsp; capacidade&nbsp; funcional&nbsp; deve&nbsp; ser&nbsp; periodicamente&nbsp; avaliada.&nbsp; O&nbsp; questionário&nbsp; mais&nbsp; utilizado&nbsp; é&nbsp; o&nbsp; HAQ&nbsp; (Health&nbsp; Assessment&nbsp; Questionnaire;&nbsp; 0-3&nbsp; pontos)&nbsp; e,&nbsp; nos&nbsp; casos&nbsp; de&nbsp; ARJ,&nbsp; o&nbsp; CHAQ&nbsp; (Apêndice&nbsp; 2)&nbsp; (191,192).</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Índices&nbsp; compostos&nbsp; de&nbsp; atividade&nbsp; de&nbsp; doença&nbsp; (DAS&nbsp; 28,&nbsp; SDAI,&nbsp; CDAI)&nbsp; devem&nbsp; ser&nbsp; utilizados&nbsp; a&nbsp; cada&nbsp; consulta;&nbsp; avaliação&nbsp; da</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">capacidade&nbsp; funcional&nbsp; (HAQ)&nbsp; pode&nbsp; ser&nbsp; realizada&nbsp; no&nbsp; mínimo,&nbsp; 1&nbsp; vez&nbsp; por&nbsp; ano.</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Titulações&nbsp; de&nbsp; FR&nbsp; e&nbsp; de&nbsp; anti-CCP&nbsp; só&nbsp; devem&nbsp; ser&nbsp; repetidas&nbsp; dentro&nbsp; dos&nbsp; primeiros&nbsp; dois&nbsp; anos&nbsp; do&nbsp; diagnóstico,&nbsp; caso&nbsp; sejam&nbsp; negativos&nbsp; no&nbsp; início,&nbsp; já&nbsp; que&nbsp; podem&nbsp; se&nbsp; tornar&nbsp; positivos,&nbsp; representando&nbsp; pior&nbsp; prognóstico.</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; intervalo&nbsp; para&nbsp; solicitação&nbsp; de&nbsp; FR&nbsp; e&nbsp; anti-CCP&nbsp; é&nbsp; variável,&nbsp; devendo&nbsp; ser&nbsp; considerado&nbsp; o&nbsp; custo&nbsp; desses&nbsp; exames&nbsp; nessa&nbsp; decisão.&nbsp; Radiografias&nbsp; de&nbsp; mãos&nbsp; e&nbsp; pés&nbsp; e&nbsp; de&nbsp; outras&nbsp; articulações&nbsp; acometidas&nbsp; devem&nbsp; ser&nbsp; realizadas&nbsp; anualmente.</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Atualmente,&nbsp; a&nbsp; principal&nbsp; causa&nbsp; de&nbsp; morte&nbsp; de&nbsp; pacientes&nbsp; com&nbsp; AR&nbsp; são&nbsp; as&nbsp; doenças&nbsp; cardiovasculares&nbsp; (193).&nbsp; A&nbsp; identificação&nbsp; e&nbsp; o</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">controle&nbsp; dos&nbsp; fatores&nbsp; de&nbsp; risco&nbsp; cardiovascular&nbsp; devem&nbsp; fazer&nbsp; parte&nbsp; da&nbsp; rotina&nbsp; assistencial&nbsp; dos&nbsp; pacientes&nbsp; com&nbsp; AR,&nbsp; incluindo&nbsp; o&nbsp; controle&nbsp; rigoroso&nbsp; do&nbsp; processo&nbsp; inflamatório&nbsp; sistêmico&nbsp; (194).</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">10&nbsp; ACOMPANHAMENTO&nbsp; PÓS-TRATAMENTO</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; tratamento&nbsp; de&nbsp; AR&nbsp; deve&nbsp; ser&nbsp; realizado&nbsp; enquanto&nbsp; o&nbsp; paciente&nbsp; dele&nbsp; se&nbsp; beneficiar.&nbsp; Nos&nbsp; raros&nbsp; casos&nbsp; de&nbsp; remissão&nbsp; após&nbsp; interrupção&nbsp; de&nbsp; tratamento,&nbsp; revisões&nbsp; anuais&nbsp; podem&nbsp; ser&nbsp; adotadas.&nbsp; Nessas&nbsp; consultas,&nbsp; além&nbsp; da&nbsp; história&nbsp; e&nbsp; do&nbsp; exame&nbsp; físico,&nbsp; exames&nbsp; como&nbsp; velocidade&nbsp; de&nbsp; hemossedimentação&nbsp; e&nbsp; proteína&nbsp; C&nbsp; reativa&nbsp; podem&nbsp; ser&nbsp; solicitados.&nbsp; Na&nbsp; confirmação&nbsp; de&nbsp; reativação&nbsp; da&nbsp; doença,&nbsp; devem-se&nbsp; as&nbsp; recomendações&nbsp; deste&nbsp; Protocolo&nbsp; voltam&nbsp; a&nbsp; ser&nbsp; aplicáveis.</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">11&nbsp; REGULAÇÃO/CONTROLE/AVALIAÇÃO PELO GESTOR</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Devem&nbsp; ser&nbsp; observados&nbsp; os&nbsp; critérios&nbsp; de&nbsp; inclusão&nbsp; e&nbsp; exclusão&nbsp; de&nbsp; pacientes&nbsp; deste&nbsp; Protocolo,&nbsp; a&nbsp; duração&nbsp; e&nbsp; a&nbsp; monitorização&nbsp; do&nbsp; tratamento&nbsp; bem&nbsp; como&nbsp; a&nbsp; verificação&nbsp; periódica&nbsp; das&nbsp; doses&nbsp; prescritas&nbsp; e&nbsp; dispensadas&nbsp; e&nbsp; a&nbsp; adequação&nbsp; de&nbsp; uso&nbsp; dos&nbsp; medicamentos.</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Recomenda-se&nbsp; que&nbsp; o&nbsp; tratamento&nbsp; de&nbsp; AR&nbsp; seja&nbsp; realizado&nbsp; em&nbsp; serviços&nbsp; especializados,&nbsp; para&nbsp; fins&nbsp; de&nbsp; diagnóstico&nbsp; e&nbsp; de&nbsp; seguimento,&nbsp; que&nbsp; contemplem&nbsp; equipes&nbsp; multiprofissionais&nbsp; para&nbsp; acompanhamento&nbsp; dos&nbsp; pacientes&nbsp; e&nbsp; de&nbsp; suas&nbsp; famílias.&nbsp; Como&nbsp; o&nbsp; controle&nbsp; da&nbsp; doença&nbsp; exige&nbsp; familiaridade&nbsp; com&nbsp; manifestações&nbsp; clínicas&nbsp; próprias,&nbsp; recomenda-se&nbsp; que&nbsp; o&nbsp; médico&nbsp; responsável&nbsp; pelo&nbsp; tratamento&nbsp; tenha&nbsp; experiência&nbsp; e&nbsp; seja&nbsp; treinado&nbsp; nessa&nbsp; atividade,&nbsp; devendo&nbsp; ser&nbsp; preferencialmente&nbsp; reumatologista.</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Para&nbsp; a&nbsp; administração&nbsp; dos&nbsp; MMCD&nbsp; biológicos,&nbsp; recomenda-se&nbsp; a&nbsp; criação&nbsp; de&nbsp; centros&nbsp; de&nbsp; referência&nbsp; para&nbsp; aplicação,&nbsp; com&nbsp; vistas&nbsp; à&nbsp; maior&nbsp; racionalidade&nbsp; do&nbsp; uso&nbsp; e&nbsp; ao&nbsp; monitoramento&nbsp; da&nbsp; efetividade&nbsp; desses&nbsp; medicamentos.</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">12&nbsp; TERMO&nbsp; DE&nbsp; ESCLARECIMENTO&nbsp; E&nbsp; RESPONSABILIDADE&nbsp; (TER)</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">É&nbsp; obrigatória&nbsp; a&nbsp; informação&nbsp; ao&nbsp; paciente&nbsp; ou&nbsp; a&nbsp; seu&nbsp; responsável&nbsp; legal&nbsp; dos&nbsp; benefícios,&nbsp; potenciais&nbsp; riscos&nbsp; e&nbsp; efeitos&nbsp; colaterais&nbsp; relacionados&nbsp; ao&nbsp; uso&nbsp; de&nbsp; medicamento&nbsp; preconizado&nbsp; neste&nbsp; Protocolo.&nbsp; O&nbsp; TER&nbsp; é&nbsp; obrigatório&nbsp; ao&nbsp; se&nbsp; prescrever&nbsp; medicamento&nbsp; do&nbsp; Componente&nbsp; Especializado&nbsp; da&nbsp; Assistência&nbsp; Farmacêutica.</span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">13&nbsp; REFERÊNCIAS&nbsp; BIBLIOGRÁFICAS</span></span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			&nbsp;</p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">1.da&nbsp; Mota&nbsp; LM,&nbsp; Cruz&nbsp; BA,&nbsp; Brenol&nbsp; CV,&nbsp; Pereira&nbsp; IA,&nbsp; Rezende-Fronza&nbsp; LS,&nbsp; Bertolo&nbsp; MB,&nbsp; et&nbsp; al.&nbsp; 2012&nbsp; Brazilian&nbsp; Society&nbsp; of Rheumatology&nbsp; Consensus&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Ver&nbsp; Bras&nbsp; Reumatol.&nbsp; 2012&nbsp; Mar-Apr;52(2):152-74.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">2.da&nbsp; Mota&nbsp; LM,&nbsp; Cruz&nbsp; BA,&nbsp; Brenol&nbsp; CV,&nbsp; Pereira&nbsp; IA,&nbsp; Fronza&nbsp; LS,&nbsp; Bertolo&nbsp; MB,&nbsp; et&nbsp; al.&nbsp; 2011&nbsp; Consensus&nbsp; of&nbsp; the&nbsp; Brazilian&nbsp; Society&nbsp; of Rheumatology&nbsp; for&nbsp; diagnosis&nbsp; and&nbsp; early&nbsp; assessment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Rev&nbsp; Bras&nbsp; Reumatol.&nbsp; 2011&nbsp; May-Jun;51(3):199-219.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">3.Senna&nbsp; ER,&nbsp; De&nbsp; Barros&nbsp; AL,&nbsp; Silva&nbsp; EO,&nbsp; Costa&nbsp; IF,&nbsp; Pereira&nbsp; LV,&nbsp; Ciconelli&nbsp; RM,&nbsp; et&nbsp; al.&nbsp; Prevalence&nbsp; of&nbsp; rheumatic&nbsp; diseases&nbsp; in Brazil:&nbsp; a&nbsp; study&nbsp; using&nbsp; the&nbsp; COPCORD&nbsp; approach.&nbsp; J&nbsp; Rheumatol.&nbsp; 2004&nbsp;&nbsp; Mar;31(3):594-7.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">4.Marques-Neto&nbsp; J,&nbsp; Gonçalves&nbsp; E,&nbsp; Langen&nbsp; L,&nbsp; Cunha&nbsp; M,&nbsp; Radominski&nbsp; S,&nbsp; Oliveira&nbsp; S.&nbsp; Multicentric&nbsp; study&nbsp; of&nbsp; the&nbsp; prevalence&nbsp; of&nbsp; adult&nbsp; rheumatoid&nbsp; arthritis&nbsp; in&nbsp; Brazilian&nbsp; population&nbsp; samples.&nbsp; Rev&nbsp; Bras&nbsp; Reumatol.&nbsp; 1993;33:169-73.</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">5.Usnayo&nbsp; MJ,&nbsp; Andrade&nbsp; LE,&nbsp; Alarcon&nbsp; RT,&nbsp; Oliveira&nbsp; JC,&nbsp; Silva&nbsp; GM,&nbsp; Bendet&nbsp; I,&nbsp; et&nbsp; al.&nbsp; Study&nbsp; of&nbsp; the&nbsp; frequency&nbsp; of&nbsp; HLA-DRB1&nbsp; alleles&nbsp; in&nbsp; Brazilian&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Rev&nbsp; Bras&nbsp; Reumatol.&nbsp; 2011&nbsp; Sep-Oct;51(5):474-83.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">6.Schur&nbsp; P,&nbsp; Firestein&nbsp; G.&nbsp; Pathogenesis&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; UpToDate.&nbsp; Oct,&nbsp; 2012&nbsp; ed2012.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">7.Chermont&nbsp; GC,&nbsp; Kowalski&nbsp; SC,&nbsp; Ciconelli&nbsp; RM,&nbsp; Ferraz&nbsp; MB.&nbsp; Resource&nbsp; utilization&nbsp; and&nbsp; the&nbsp; cost&nbsp; of&nbsp; rheumatoid&nbsp; arthritis&nbsp; in&nbsp; Brazil.&nbsp; Clin&nbsp; Exp&nbsp; Rheumatol.&nbsp; 2008&nbsp; Jan-Feb;26(1):24-31.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">8.Schneider&nbsp; M,&nbsp; Lelgemann&nbsp; M,&nbsp; Baerwald&nbsp; C,&nbsp; Braun&nbsp; J,&nbsp; Hammer&nbsp; M,&nbsp; Kern&nbsp; P,&nbsp; et&nbsp; al.&nbsp; Value&nbsp; of&nbsp; inpatient&nbsp; care&nbsp; in&nbsp; rheumatoid arthritis&nbsp; –&nbsp; An&nbsp; evidence&nbsp; based&nbsp; report.&nbsp; Zeitschrift&nbsp; fur&nbsp; Rheumatologie.&nbsp; 2004;63(5):402-13.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">9.de&nbsp; Azevedo&nbsp; AB,&nbsp; Ferraz&nbsp; MB,&nbsp; Ciconelli&nbsp; RM.&nbsp; Indirect&nbsp; costs&nbsp; of&nbsp; rheumatoid&nbsp; arthritis&nbsp; in&nbsp; Brazil.&nbsp; Value&nbsp; Health.&nbsp; 2008&nbsp; Sep-&nbsp; Oct;11(5):869-77.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">10.Bombardier&nbsp; C,&nbsp; Barbieri&nbsp; M,&nbsp; Parthan&nbsp; A,&nbsp; Zack&nbsp; DJ,&nbsp; Walker&nbsp; V,&nbsp; Macarios&nbsp; D,&nbsp; et&nbsp; al.&nbsp; The&nbsp; relationship&nbsp; between&nbsp; joint&nbsp; damage&nbsp; and&nbsp; functional&nbsp; disability&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2012&nbsp; Jun;71(6):836-44.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">11.da&nbsp; Mota&nbsp; LM,&nbsp; Laurindo&nbsp; IM,&nbsp; dos&nbsp; Santos&nbsp; Neto&nbsp; LL.&nbsp; Demographic&nbsp; and&nbsp; clinical&nbsp; characteristics&nbsp; of&nbsp; a&nbsp; cohort&nbsp; of&nbsp; patients&nbsp; with early&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Rev&nbsp; Bras&nbsp; Reumatol.&nbsp; 2010&nbsp; May-&nbsp; Jun;50(3):235-48.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">12.Venables&nbsp; P,&nbsp; Maini&nbsp; R.&nbsp; Clinical&nbsp; features&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; UpToDate2012.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">13.Lehman&nbsp; T.&nbsp; Classification&nbsp; of&nbsp; juvenile&nbsp; arthritis&nbsp; (JRA/JIA).&nbsp; &nbsp;&nbsp;UpToDate.&nbsp; Sept&nbsp; 4,&nbsp; 2012&nbsp; ed.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">14.Helfenstein&nbsp; M,&nbsp; Jr.,&nbsp; Halpern&nbsp; AS,&nbsp; Bertolo&nbsp; MB.&nbsp; Investigation&nbsp; on&nbsp; Brazilian&nbsp; clinical&nbsp; practices&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; the Brazilian&nbsp; rheumatoid&nbsp; arthritis&nbsp; clinical&nbsp; practices&nbsp; investigation–BRACTICE.&nbsp; J&nbsp; Clin&nbsp; Rheumatol.&nbsp; 2011&nbsp; Jun;17(4&nbsp; Suppl&nbsp; 1):S1-10.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">15.Pincus&nbsp; T,&nbsp; Yazici&nbsp; Y,&nbsp; Sokka&nbsp; T.&nbsp; Are&nbsp; excellent&nbsp; systematic&nbsp; reviews&nbsp; of&nbsp; clinical&nbsp; trials&nbsp; useful&nbsp; for&nbsp; patient&nbsp; care?&nbsp; Nature&nbsp; Clinical Practice&nbsp; Rheumatology.&nbsp; 2008;4(6):294-5.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">16.Venables&nbsp; P,&nbsp; Maini&nbsp; R.&nbsp; Diagnosis&nbsp; and&nbsp; differential&nbsp; diagnosis&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; UpToDate2012.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">17.Schur&nbsp; P,&nbsp; Matteson&nbsp; EL,&nbsp; Turesson&nbsp; C.&nbsp; Overview&nbsp; of&nbsp; the&nbsp; systemic&nbsp; and&nbsp; nonarticular&nbsp; manifestations&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Up-&nbsp; ToDate2012.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">18.Schur&nbsp; P,&nbsp; Currier&nbsp; B.&nbsp; Cervical&nbsp; subluxation&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; UpToDate&nbsp; [serial&nbsp; on&nbsp; the&nbsp; Internet].&nbsp; 2012.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">19.da&nbsp; Mota&nbsp; LM,&nbsp; Santos&nbsp; Neto&nbsp; LL,&nbsp; Pereira&nbsp; IA,&nbsp; Burlingame&nbsp; R.&nbsp; Menard&nbsp; HA,&nbsp; Laurindo&nbsp; IM.&nbsp; Autoantibodies&nbsp; in&nbsp; early&nbsp; rheumatoid&nbsp; arthritis:&nbsp; Brasilia&nbsp; cohort:&nbsp; results&nbsp; of&nbsp; a&nbsp; three-year&nbsp; serial&nbsp; analysis.&nbsp; Rev&nbsp; Bras&nbsp; Reumatol.&nbsp; 2011&nbsp; Dec;51(6):564-71.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">20.Aletaha&nbsp; D,&nbsp; Neogi&nbsp; T,&nbsp; Silman&nbsp; AJ,&nbsp; Funovits&nbsp; J,&nbsp; Felson&nbsp; DT,&nbsp; Bingham&nbsp; CO,&nbsp; 3rd,&nbsp; et&nbsp; al.&nbsp; 2010&nbsp; rheumatoid&nbsp; arthritis&nbsp; classification&nbsp; criteria:&nbsp; &nbsp;&nbsp;an&nbsp; American&nbsp; College&nbsp; of&nbsp; Rheumatology/European&nbsp; League&nbsp; Against&nbsp; Rheumatism&nbsp; collaborative&nbsp; initiative.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2010&nbsp; Sep;69(9):1580-8.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">21.Aletaha&nbsp; D,&nbsp; Neogi&nbsp; T,&nbsp; Silman&nbsp; AJ,&nbsp; Funovits&nbsp; J,&nbsp; Felson&nbsp; DT,&nbsp; Bingham&nbsp; CO,&nbsp; 3rd,&nbsp; et&nbsp; al.&nbsp; 2010&nbsp; Rheumatoid&nbsp; arthritis&nbsp; classification&nbsp; criteria:&nbsp; an&nbsp; American&nbsp; College&nbsp; of&nbsp; Rheumatology/European&nbsp; League&nbsp; Against&nbsp; Rheumatism&nbsp; collaborative&nbsp; initiative.&nbsp; Arthritis&nbsp; Rheum.&nbsp; 2010&nbsp; Sep;62(9):2569-81.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">22.Arnett&nbsp; FC,&nbsp; Edworthy&nbsp; SM,&nbsp; Bloch&nbsp; DA,&nbsp; McShane&nbsp; DJ,&nbsp; Fries&nbsp; JF,&nbsp; Cooper&nbsp; NS,&nbsp; et&nbsp; al.&nbsp; The&nbsp; American&nbsp; Rheumatism&nbsp; Association 1987&nbsp; revised&nbsp; criteria&nbsp; for&nbsp; the&nbsp; classification&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Arthritis&nbsp; Rheum.&nbsp; 1988&nbsp; Mar;31(3):315-24.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">23.Varache&nbsp; S,&nbsp; Cornec&nbsp; D,&nbsp; Morvan&nbsp; J,&nbsp; Devauchelle-Pensec&nbsp; V,&nbsp; Berthelot&nbsp; JM,&nbsp; Le&nbsp; Henaff-Bourhis&nbsp; C,&nbsp; et&nbsp; al.&nbsp; Diagnostic&nbsp; accuracy&nbsp; of&nbsp; ACR/EULAR&nbsp; 2010&nbsp; criteria&nbsp; for&nbsp; rheumatoid&nbsp; arthritis&nbsp; in&nbsp; a&nbsp; 2-year&nbsp; cohort.&nbsp; J&nbsp; Rheumatol.&nbsp; 2011&nbsp; Jul;38(7):1250-7.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">24.Britsemmer&nbsp; K,&nbsp; Ursum&nbsp; J,&nbsp; Gerritsen&nbsp; M,&nbsp; van&nbsp; Tuyl&nbsp; LH,&nbsp; van&nbsp; Schaardenburg&nbsp; D.&nbsp; Validation&nbsp; of&nbsp; the&nbsp; 2010&nbsp; ACR/EULAR classification&nbsp; criteria&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; slight&nbsp; improvement&nbsp; over&nbsp; the&nbsp; 1987&nbsp; ACR&nbsp; criteria.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2011 Aug;70(8):1468-70.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">25.Alves&nbsp; C,&nbsp; Luime&nbsp; JJ,&nbsp; van&nbsp; Zeben&nbsp; D,&nbsp; Huisman&nbsp; AM,&nbsp; Weel&nbsp; AE,&nbsp; Barendregt&nbsp; PJ,&nbsp; et&nbsp; al.&nbsp; Diagnostic&nbsp; performance&nbsp; of&nbsp; the&nbsp; ACR/EULAR&nbsp; 2010&nbsp; criteria&nbsp; for&nbsp; rheumatoid&nbsp; arthritis&nbsp; and&nbsp; two&nbsp; diagnostic&nbsp; algorithms&nbsp; in&nbsp; an&nbsp; early&nbsp; arthritis&nbsp; clinic&nbsp; (REACH).&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2011&nbsp; Sep;70(9):1645-7.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">26.Villeneuve&nbsp; E,&nbsp; Nam&nbsp; J,&nbsp; Emery&nbsp; P.&nbsp; 2010&nbsp; ACR-EULAR&nbsp; classification&nbsp; criteria&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Rev&nbsp; Bras&nbsp; Reumatol. 2010&nbsp; Sep-Oct;50(5):481-3.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">27.Jung&nbsp; SJ,&nbsp; Lee&nbsp; SW,&nbsp; Ha&nbsp; YJ,&nbsp; Lee&nbsp; KH,&nbsp; Kang&nbsp; Y,&nbsp; Park&nbsp; MC,&nbsp; et&nbsp; al.&nbsp; Patients&nbsp; with&nbsp; early&nbsp; arthritis&nbsp; who&nbsp; fulfil&nbsp; the&nbsp; 1987&nbsp; ACR classification&nbsp; criteria&nbsp; for&nbsp; rheumatoid&nbsp; arthritis&nbsp; but&nbsp; not&nbsp; the&nbsp; 2010&nbsp; ACR/EULAR&nbsp; criteria.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2012&nbsp; Jun;71(6):1097- 8.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">28.Fautrel&nbsp; B,&nbsp; Combe&nbsp; B,&nbsp; Rincheval&nbsp; N,&nbsp; Dougados&nbsp; M.&nbsp; Level&nbsp; of&nbsp; agreement&nbsp; of&nbsp; the&nbsp; 1987&nbsp; ACR&nbsp; and&nbsp; 2010&nbsp; ACR/EULAR rheumatoid&nbsp; arthritis&nbsp; classification&nbsp; criteria:&nbsp; an&nbsp; analysis&nbsp; based&nbsp; on&nbsp; ESPOIR&nbsp; cohort&nbsp; data.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2012 Mar;71(3):386-9.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">29.van&nbsp; der&nbsp; Linden&nbsp; MP,&nbsp; Knevel&nbsp; R,&nbsp; Huizinga&nbsp; TW,&nbsp; van&nbsp; der&nbsp; Helm-van&nbsp; Mil&nbsp; AH.&nbsp; Classification&nbsp; of&nbsp; rheumatoid&nbsp; arthritis:&nbsp; comparison&nbsp; of&nbsp; the&nbsp; 1987&nbsp; American&nbsp; College&nbsp; of&nbsp; Rheumatology&nbsp; criteria&nbsp; and&nbsp; the&nbsp; 2010&nbsp; American&nbsp; College&nbsp; of&nbsp; Rheumatology/European&nbsp; League&nbsp; Against&nbsp; Rheumatism&nbsp; criteria.&nbsp; Arthritis&nbsp; Rheum.&nbsp; 2011&nbsp; Jan;63(1):37-42.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">30.Kaneko&nbsp; Y,&nbsp; Kuwana&nbsp; M,&nbsp; Kameda&nbsp; H,&nbsp; Takeuchi&nbsp; T.&nbsp; Sensitivity&nbsp; and&nbsp; specificity&nbsp; of&nbsp; 2010&nbsp; rheumatoid&nbsp; arthritis&nbsp; classification&nbsp; criteria.&nbsp; Rheumatology&nbsp; (Oxford).&nbsp; 2011&nbsp; Jul;50(7):1268-74.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">31.Neogi&nbsp; T,&nbsp; Aletaha&nbsp; D,&nbsp; Silman&nbsp; AJ,&nbsp; Naden&nbsp; RL,&nbsp; Felson&nbsp; DT,&nbsp; Aggarwal&nbsp; R,&nbsp; et&nbsp; al.&nbsp; The&nbsp; 2010&nbsp; American&nbsp; College&nbsp; of&nbsp; Rheumatology/&nbsp; European&nbsp; League&nbsp; Against&nbsp; Rheumatism&nbsp; classification&nbsp; criteria&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; Phase&nbsp; 2&nbsp; methodological&nbsp; report.&nbsp; Arthritis&nbsp; Rheum.&nbsp; 2010&nbsp; Sep;62(9):2582-91.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">32.Funovits&nbsp; J,&nbsp; Aletaha&nbsp; D,&nbsp; Bykerk&nbsp; V,&nbsp; Combe&nbsp; B,&nbsp; Dougados&nbsp; M,&nbsp; Emery&nbsp; P,&nbsp; et&nbsp; al.&nbsp; The&nbsp; 2010&nbsp; American&nbsp; College&nbsp; of&nbsp; Rheumatology/European&nbsp; League&nbsp; Against&nbsp; Rheumatism&nbsp; classification&nbsp; criteria&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; methodological&nbsp; report&nbsp; phase&nbsp; I.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2010&nbsp; Sep;69(9):1589-95.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">33.Lake&nbsp; F.&nbsp; Interstitial&nbsp; lung&nbsp; disease&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; UpToDate.&nbsp; Jun&nbsp; 7,&nbsp; 2011&nbsp; ed.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">34.Lehman&nbsp; AJ.&nbsp; Pauciarticular&nbsp; onset&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis.&nbsp; UpToDate.&nbsp; Apr&nbsp; 23,&nbsp; 2012&nbsp; ed.</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">35.Lehman&nbsp; T.&nbsp; Polyarticular&nbsp; onset&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis:&nbsp; Management.&nbsp; UpToDate.&nbsp; Oct&nbsp; 2,&nbsp; 2012&nbsp; ed.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">36.Lehman&nbsp; AJ.&nbsp; Systemic&nbsp; onset&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis:&nbsp; Treatment.&nbsp; UpToDate.&nbsp; Jun&nbsp; 20,&nbsp; 2012&nbsp; ed.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">37.Tocilizumabe:&nbsp; Bula&nbsp; Profissional&nbsp; de&nbsp; Saúde.&nbsp; 2013.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">38.McMahan&nbsp; R,&nbsp; Balfe&nbsp; LM,&nbsp; Greene&nbsp; L.&nbsp; Summary&nbsp; of&nbsp; AHRQ's&nbsp; Comparative&nbsp; Effectiveness&nbsp; Review&nbsp; of&nbsp; Disease-Modifying Antirheumatic&nbsp; Drugs&nbsp; for&nbsp; Children&nbsp; with&nbsp; Juvenile&nbsp; Idiopathic&nbsp; Arthritis.&nbsp; J&nbsp; Manag&nbsp; Care&nbsp; Pharm.&nbsp; 2012&nbsp; Jan-Feb;18(1&nbsp; Suppl&nbsp; B):1-16.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">39.Klein&nbsp; A,&nbsp; Kaul&nbsp; I,&nbsp; Foeldvari&nbsp; I,&nbsp; Ganser&nbsp; G,&nbsp; Urban&nbsp; A,&nbsp; Horneff&nbsp; G.&nbsp; Efficacy&nbsp; and&nbsp; safety&nbsp; of&nbsp; oral&nbsp; and&nbsp; parenteral&nbsp; methotrexate&nbsp; therapy&nbsp; in&nbsp; children&nbsp; with&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis:&nbsp; an&nbsp; observational&nbsp; study&nbsp; with&nbsp; patients&nbsp; from&nbsp; the&nbsp; German&nbsp; Methotrexate&nbsp; Registry.&nbsp; Arthritis&nbsp; Care&nbsp; Res&nbsp; (Hoboken).&nbsp; 2012&nbsp; Sep;64(9):1349-56.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">40.Kemper&nbsp; AR,&nbsp; Van&nbsp; Mater&nbsp; HA,&nbsp; Coeytaux&nbsp; RR,&nbsp; Williams&nbsp; JW,&nbsp; Jr.,&nbsp; Sanders&nbsp; GD.&nbsp; Systematic&nbsp; review&nbsp; of&nbsp; disease-modifying&nbsp; antirheumatic&nbsp; drugs&nbsp; for&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis.&nbsp; BMC&nbsp; Pediatr.&nbsp; 2012;12:29.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">41.Shenoi&nbsp; S,&nbsp; Wallace&nbsp; CA.&nbsp; Tumor&nbsp; necrosis&nbsp; factor&nbsp; inhibitors&nbsp; in&nbsp; the&nbsp; management&nbsp; of&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis:&nbsp; an&nbsp; evidence-based&nbsp; review.&nbsp; Paediatr&nbsp; Drugs.&nbsp; 2010&nbsp; Dec&nbsp; 1;12(6):367-77.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">42.Gartlehner&nbsp; G,&nbsp; Hansen&nbsp; RA,&nbsp; Jonas&nbsp; BL,&nbsp; Thieda&nbsp; P,&nbsp; Lohr&nbsp; KN.&nbsp; Biologics&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review&nbsp; and&nbsp; critical&nbsp; analysis&nbsp; of&nbsp; the&nbsp; evidence.&nbsp; Clin&nbsp; Rheumatol.&nbsp; 2008&nbsp; Jan;27(1):67-76.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">43.van&nbsp; Rossum&nbsp; MA,&nbsp; van&nbsp; Soesbergen&nbsp; RM,&nbsp; Boers&nbsp; M,&nbsp; Zwinderman&nbsp; AH,&nbsp; Fiselier&nbsp; TJ,&nbsp; Franssen&nbsp; MJ,&nbsp; et&nbsp; al.&nbsp; Long-term&nbsp; outcome&nbsp; of&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis&nbsp; following&nbsp; a&nbsp; placebo-controlled&nbsp; trial:&nbsp; sustained&nbsp; benefits&nbsp; of&nbsp; early&nbsp; sulfasalazine&nbsp; treatment.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2007&nbsp; Nov;66(11):1518-24.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">44.Takken&nbsp; T,&nbsp; Van&nbsp; der&nbsp; Net&nbsp; J,&nbsp; Helders&nbsp; PJ.&nbsp; Methotrexate&nbsp; for&nbsp; treating&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst Rev.&nbsp; 2001(3):CD003129.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">45.Takken&nbsp; T,&nbsp; Van&nbsp; Der&nbsp; Net&nbsp; J,&nbsp; Helders&nbsp; PJ.&nbsp; Methotrexate&nbsp; for&nbsp; treating&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst Rev.&nbsp; 2001(4):CD003129.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">46.Johnson&nbsp; CJ,&nbsp; Reilly&nbsp; KM,&nbsp; Murray&nbsp; KM.&nbsp; Etanercept&nbsp; in&nbsp; juvenile&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Ann&nbsp; Pharmacother.&nbsp; 2001 Apr;35(4):464-&nbsp; 71.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">47.Brooks&nbsp; CD.&nbsp; Sulfasalazine&nbsp; for&nbsp; the&nbsp; management&nbsp; of&nbsp; juvenile&nbsp; rheumatoid&nbsp; arthritis.&nbsp; J&nbsp; Rheumatol.&nbsp; 2001&nbsp; Apr;28(4):845-53.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">48.Giannini&nbsp; EH,&nbsp; Cassidy&nbsp; JT,&nbsp; Brewer&nbsp; EJ,&nbsp; Shaikov&nbsp; A,&nbsp; Maximov&nbsp; A,&nbsp; Kuzmina&nbsp; N.&nbsp; Comparative&nbsp; efficacy&nbsp; and&nbsp; safety&nbsp; of&nbsp; advanced&nbsp; drug&nbsp; therapy&nbsp; in&nbsp; children&nbsp; with&nbsp; juvenile&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Semin&nbsp; Arthritis&nbsp; Rheum.&nbsp; 1993&nbsp; Aug;23(1):34-46.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">49.Brewer&nbsp; EJ,&nbsp; Giannini&nbsp; EH,&nbsp; Kuzmina&nbsp; N,&nbsp; Alekseev&nbsp; L.&nbsp; Penicillamine&nbsp; and&nbsp; hydroxychloroquine&nbsp; in&nbsp; the&nbsp; treatment&nbsp; of&nbsp; severe&nbsp; juvenile&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Results&nbsp; of&nbsp; the&nbsp; U.S.A.-U.S.S.R.&nbsp; doubleblind&nbsp; placebo-controlled&nbsp; trial.&nbsp; N&nbsp; Engl&nbsp; J&nbsp; Med.&nbsp; 1986&nbsp; May 15;314(20):1269-76.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">50.Silverman&nbsp; E,&nbsp; Mouy&nbsp; R,&nbsp; Spiegel&nbsp; L,&nbsp; Jung&nbsp; LK,&nbsp; Saurenmann&nbsp; RK,&nbsp; Lahdenne&nbsp; P,&nbsp; et&nbsp; al.&nbsp; Leflunomide&nbsp; or&nbsp; methotrexate&nbsp; for&nbsp; juvenile&nbsp; rheumatoid&nbsp; arthritis.&nbsp; N&nbsp; Engl&nbsp; J&nbsp; Med.&nbsp; 2005&nbsp; Apr&nbsp; 21;352(16):1655-66.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">51.Boers&nbsp; M,&nbsp; Van&nbsp; Tuyl&nbsp; LHD,&nbsp; Van&nbsp; Den&nbsp; Broek&nbsp; M,&nbsp; Kostense&nbsp; PJ,&nbsp; Allaart&nbsp; CF.&nbsp; Meta-analysis&nbsp; suggests&nbsp; intensive&nbsp; non-biologic&nbsp; combination&nbsp; therapy&nbsp; with&nbsp; step-down&nbsp; prednisolone&nbsp; may&nbsp; also&nbsp; disconnect&nbsp; disease&nbsp; activity&nbsp; and&nbsp; damage&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Arthritis&nbsp; and&nbsp; Rheumatism.&nbsp; 2011;63(10).</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">52.Boers&nbsp; M,&nbsp; van&nbsp; Tuyl&nbsp; L,&nbsp; van&nbsp; den&nbsp; Broek&nbsp; M,&nbsp; Kostense&nbsp; PJ,&nbsp; Allaart&nbsp; CF.&nbsp; Meta-analysis&nbsp; suggests&nbsp; that&nbsp; intensive&nbsp; non-biological&nbsp; combination&nbsp; therapy&nbsp; with&nbsp; step-down&nbsp; prednisolone&nbsp; (COBRA&nbsp; strategy)&nbsp; may&nbsp; also&nbsp; 'disconnect'&nbsp; disease&nbsp; activity&nbsp; and&nbsp; damage&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2012&nbsp; Nov&nbsp; 15.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">53.Schur&nbsp; P,&nbsp; Moreland&nbsp; LW.&nbsp; General&nbsp; principles&nbsp; of&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; UpToDate2012.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">54.Robinson&nbsp; PC,&nbsp; Taylor&nbsp; WJ.&nbsp; Decreasing&nbsp; time&nbsp; to&nbsp; treatment&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; Review&nbsp; of&nbsp; delays&nbsp; in&nbsp; presentation,&nbsp; referral&nbsp; and&nbsp; assessment.&nbsp; International&nbsp; Journal&nbsp; of&nbsp; Clinical&nbsp; Rheumatology.&nbsp; 2011;6(2):173-87.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">55.Lineker&nbsp; SC,&nbsp; Husted&nbsp; JA.&nbsp; Educational&nbsp; interventions&nbsp; for&nbsp; implementation&nbsp; of&nbsp; arthritis&nbsp; clinical&nbsp; practice&nbsp; guidelines&nbsp; in&nbsp; primary&nbsp; care:&nbsp; Effects&nbsp; on&nbsp; health&nbsp; professional&nbsp; behavior.&nbsp; Journal&nbsp; of&nbsp; Rheumatology.&nbsp; 2010;37(8):1562-9.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">56.Vliet&nbsp; Vlieland&nbsp; TP,&nbsp; van&nbsp; den&nbsp; Ende&nbsp; CH.&nbsp; Nonpharmacological&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Curr&nbsp; Opin&nbsp; Rheumatol. 2011&nbsp; May;23(3):259-64.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">57.Silva&nbsp; KN,&nbsp; Mizusaki&nbsp; Imoto&nbsp; A,&nbsp; Almeida&nbsp; GJ,&nbsp; Atallah&nbsp; AN,&nbsp; Peccin&nbsp; MS,&nbsp; Fernandes&nbsp; Moca&nbsp; Trevisani&nbsp; V.&nbsp; Balance&nbsp; training (proprioceptive&nbsp; training)&nbsp; for&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2010(5):CD007648.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">58.Forestier&nbsp; R,&nbsp; Andre-Vert&nbsp; J,&nbsp; Guillez&nbsp; P,&nbsp; Coudeyre&nbsp; E,&nbsp; Lefevre-Colau&nbsp; MM,&nbsp; Combe&nbsp; B,&nbsp; et&nbsp; al.&nbsp; Non-drug&nbsp; treatment&nbsp; (excluding&nbsp; surgery)&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; clinical&nbsp; practice&nbsp; guidelines.&nbsp; Joint&nbsp; Bone&nbsp; Spine.&nbsp; 2009&nbsp; Dec;76(6):691-8.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">59.Falagas&nbsp; ME,&nbsp; Zarkadoulia&nbsp; E,&nbsp; Rafailidis&nbsp; PI.&nbsp; The&nbsp; therapeutic&nbsp; effect&nbsp; of&nbsp; balneotherapy:&nbsp; Evaluation&nbsp; of&nbsp; the&nbsp; evidence&nbsp; from&nbsp; randomized&nbsp; controlled&nbsp; trials.&nbsp; International&nbsp; Journal&nbsp; of&nbsp; Clinical&nbsp; Practice.&nbsp; 2009;63(7):1068-84.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">60.Stucki&nbsp; G,&nbsp; Cieza&nbsp; A,&nbsp; Geyh&nbsp; S,&nbsp; Battistella&nbsp; L,&nbsp; Lloyd&nbsp; J,&nbsp; Symmons&nbsp; D,&nbsp; et&nbsp; al.&nbsp; ICF&nbsp; Core&nbsp; Sets&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Journal&nbsp; of Rehabilitation&nbsp; Medicine,&nbsp; Supplement.&nbsp; 2004(44):87-93.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">61.Riemsma&nbsp; RP,&nbsp; Kirwan&nbsp; JR,&nbsp; Taal&nbsp; E,&nbsp; Rasker&nbsp; JJ.&nbsp; Patient&nbsp; education&nbsp; for&nbsp; adults&nbsp; with&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database Syst&nbsp; Rev.&nbsp; 2003(2):CD003688.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">62.Macfarlane&nbsp; GJ,&nbsp; Paudyal&nbsp; P,&nbsp; Doherty&nbsp; M,&nbsp; Ernst&nbsp; E,&nbsp; Lewith&nbsp; G,&nbsp; MacPherson&nbsp; H,&nbsp; et&nbsp; al.&nbsp; A&nbsp; systematic&nbsp; review&nbsp; of&nbsp; evidence&nbsp; for&nbsp; the&nbsp; effectiveness&nbsp; of&nbsp; practitioner-based&nbsp; complementary&nbsp; and&nbsp; alternative&nbsp; therapies&nbsp; in&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatic&nbsp; diseases:&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Rheumatology&nbsp; (Oxford).&nbsp; 2012&nbsp; Sep;51(9):1707-13.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">63.Takken&nbsp; T,&nbsp; van&nbsp; Brussel&nbsp; M,&nbsp; Engelbert&nbsp; RH,&nbsp; Van&nbsp; der&nbsp; Net&nbsp; J,&nbsp; Kuis&nbsp; W,&nbsp; Helders&nbsp; PJ.&nbsp; Exercise&nbsp; therapy&nbsp; in&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2008(2):CD005954.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">64.Takken&nbsp; T,&nbsp; Van&nbsp; Brussel&nbsp; M,&nbsp; Engelbert&nbsp; RH,&nbsp; Van&nbsp; Der&nbsp; Net&nbsp; J,&nbsp; Kuis&nbsp; W,&nbsp; Helders&nbsp; PJ.&nbsp; Exercise&nbsp; therapy&nbsp; in&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis:&nbsp; a&nbsp; Cochrane&nbsp; Review.&nbsp; Eur&nbsp; J&nbsp; Phys&nbsp; Rehabil&nbsp; Med.&nbsp; 2008&nbsp; Sep;44(3):287-97.</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">65.Epps&nbsp; H,&nbsp; Ginnelly&nbsp; L,&nbsp; Utley&nbsp; M,&nbsp; Southwood&nbsp; T,&nbsp; Gallivan&nbsp; S,&nbsp; Sculpher&nbsp; M,&nbsp; et&nbsp; al.&nbsp; Is&nbsp; hydrotherapy&nbsp; cost-effective?&nbsp; A&nbsp; randomised&nbsp; controlled&nbsp; trial&nbsp; of&nbsp; combined&nbsp; hydrotherapy&nbsp; programmes&nbsp; compared&nbsp; with&nbsp; physiotherapy&nbsp; land&nbsp; techniques&nbsp; in&nbsp; children&nbsp; with&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis.&nbsp; Health&nbsp; Technol&nbsp; Assess.&nbsp; 2005&nbsp; Oct;9(39):iii-iv,&nbsp; ix-x,&nbsp; 1-59.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">66.Tuntland&nbsp; H,&nbsp; Kjeken&nbsp; I,&nbsp; Nordheim&nbsp; LV,&nbsp; Falzon&nbsp; L,&nbsp; Jamtvedt&nbsp; G,&nbsp; Hagen&nbsp; KB.&nbsp; Assistive&nbsp; technology&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2009(4):CD006729.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">67.Oldfield&nbsp; V,&nbsp; Felson&nbsp; DT.&nbsp; Exercise&nbsp; therapy&nbsp; and&nbsp; orthotic&nbsp; devices&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; evidence-based&nbsp; review.&nbsp; Curr&nbsp; Opin Rheumatol.&nbsp; 2008&nbsp; May;20(3):353-9.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">68.Metsios&nbsp; GS,&nbsp; Stavropoulos-Kalinoglou&nbsp; A,&nbsp; van&nbsp; Zanten&nbsp; JJCSV,&nbsp; Treharne&nbsp; GJ,&nbsp; Panoulas&nbsp; VF,&nbsp; Douglas&nbsp; KMJ,&nbsp; et&nbsp; al.&nbsp; Rheumatoid&nbsp; arthritis,&nbsp; cardiovascular&nbsp; disease&nbsp; and&nbsp; physical&nbsp; exercise:&nbsp; A&nbsp; systematic&nbsp; review.&nbsp; Rheumatology.&nbsp; 2008;47(3):239-48.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">69.Steultjens&nbsp; EM,&nbsp; Dekker&nbsp; J,&nbsp; Bouter&nbsp; LM,&nbsp; van&nbsp; Schaardenburg&nbsp; D,&nbsp; van&nbsp; Kuyk&nbsp; MA,&nbsp; van&nbsp; den&nbsp; Ende&nbsp; CH.&nbsp; Occupational&nbsp; therapy&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2004(1):CD003114.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">70.Egan&nbsp; M,&nbsp; Brosseau&nbsp; L,&nbsp; Farmer&nbsp; M,&nbsp; Ouimet&nbsp; MA,&nbsp; Rees&nbsp; S,&nbsp; Wells&nbsp; G,&nbsp; et&nbsp; al.&nbsp; Splints/orthoses&nbsp; in&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2003(1):CD004018.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">71.Steultjens&nbsp; EM,&nbsp; Dekker&nbsp; J,&nbsp; Bouter&nbsp; LM,&nbsp; van&nbsp; Schaardenburg&nbsp; D,&nbsp; van&nbsp; Kuyk&nbsp; MA,&nbsp; van&nbsp; den&nbsp; Ende&nbsp; CH.&nbsp; Occupational&nbsp; therapy&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review.&nbsp; Arthritis&nbsp; Rheum.&nbsp; 2002&nbsp; Dec&nbsp; 15;47(6):672-85.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">72.Baillet&nbsp; A,&nbsp; Vaillant&nbsp; M,&nbsp; Guinot&nbsp; M,&nbsp; Juvin&nbsp; R,&nbsp; Gaudin&nbsp; P.&nbsp; Efficacy&nbsp; of&nbsp; resistance&nbsp; exercises&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; meta-&nbsp; analysis&nbsp; of&nbsp; randomized&nbsp; controlled&nbsp; trials.&nbsp; Rheumatology&nbsp; (Oxford).&nbsp; 2012&nbsp; Mar;51(3):519-27.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">73.Wessel&nbsp; J.&nbsp; The&nbsp; effectiveness&nbsp; of&nbsp; hand&nbsp; exercises&nbsp; for&nbsp; persons&nbsp; with&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review.&nbsp; J&nbsp; Hand&nbsp; Ther. 2004&nbsp; Apr-Jun;17(2):174-80.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">74.Baillet&nbsp; A,&nbsp; Zeboulon&nbsp; N,&nbsp; Gossec&nbsp; L,&nbsp; Combescure&nbsp; C,&nbsp; Bodin&nbsp; LA,&nbsp; Juvin&nbsp; R,&nbsp; et&nbsp; al.&nbsp; Efficacy&nbsp; of&nbsp; cardiorespiratory&nbsp; aerobic&nbsp; exercise&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; meta-analysis&nbsp; of&nbsp; randomized&nbsp; controlled&nbsp; trials.&nbsp; Arthritis&nbsp; Care&nbsp; Res&nbsp; (Hoboken).&nbsp; 2010 Jul;62(7):984-92.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">75.Hurkmans&nbsp; E,&nbsp; Van&nbsp; Der&nbsp; Giesen&nbsp; FJ,&nbsp; Vliet&nbsp; Vlieland&nbsp; TPM,&nbsp; Schoones&nbsp; J,&nbsp; Van&nbsp; Den&nbsp; Ende&nbsp; ECHM.&nbsp; Home-based&nbsp; exercise&nbsp; therapy&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; of&nbsp; Systematic&nbsp; Reviews.&nbsp; 2009(2).</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">76.Hurkmans&nbsp; E,&nbsp; van&nbsp; der&nbsp; Giesen&nbsp; FJ,&nbsp; Vliet&nbsp; Vlieland&nbsp; TP,&nbsp; Schoones&nbsp; J,&nbsp; Van&nbsp; den&nbsp; Ende&nbsp; EC.&nbsp; Dynamic&nbsp; exercise&nbsp; programs (aerobic&nbsp; capacity&nbsp; and/or&nbsp; muscle&nbsp; strength&nbsp; training)&nbsp; in&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev. 2009(4):CD006853.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">77.Cairns&nbsp; AP,&nbsp; McVeigh&nbsp; JG.&nbsp; A&nbsp; systematic&nbsp; review&nbsp; of&nbsp; the&nbsp; effects&nbsp; of&nbsp; dynamic&nbsp; exercise&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Rheumatol&nbsp; Int. 2009&nbsp; Dec;30(2):147-58.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">78.Conn&nbsp; VS,&nbsp; Hafdahl&nbsp; AR,&nbsp; Minor&nbsp; MA,&nbsp; Nielsen&nbsp; PJ.&nbsp; Physical&nbsp; Activity&nbsp; Interventions&nbsp; Among&nbsp; Adults&nbsp; with&nbsp; Arthritis:&nbsp; Meta-&nbsp; Analysis&nbsp; of&nbsp; Outcomes.&nbsp; Seminars&nbsp; in&nbsp; Arthritis&nbsp; and&nbsp; Rheumatism.&nbsp; 2008;37(5):307-&nbsp; 16.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">79.Hurkmans&nbsp; EJ,&nbsp; Jones&nbsp; A,&nbsp; Li&nbsp; LC,&nbsp; Vliet&nbsp; Vlieland&nbsp; TP.&nbsp; Quality&nbsp; appraisal&nbsp; of&nbsp; clinical&nbsp; practice&nbsp; guidelines&nbsp; on&nbsp; the&nbsp; use&nbsp; of&nbsp; physiotherapy&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review.&nbsp; Rheumatology&nbsp; (Oxford).&nbsp; 2011&nbsp; Oct;50(10):1879-88.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">80.Greene&nbsp; B,&nbsp; Lim&nbsp; SS.&nbsp; The&nbsp; role&nbsp; of&nbsp; physical&nbsp; therapy&nbsp; in&nbsp; management&nbsp; of&nbsp; patients&nbsp; with&nbsp; osteoarthritis&nbsp; and&nbsp; rheumatoid&nbsp; arthritis. Bulletin&nbsp; on&nbsp; the&nbsp; Rheumatic&nbsp; Diseases.&nbsp; 2003;52(4).</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">81.Brosseau&nbsp; L,&nbsp; Judd&nbsp; MG,&nbsp; Marchand&nbsp; S,&nbsp; Robinson&nbsp; VA,&nbsp; Tugwell&nbsp; P,&nbsp; Wells&nbsp; G,&nbsp; et&nbsp; al.&nbsp; Transcutaneous&nbsp; electrical&nbsp; nerve&nbsp; stimulation&nbsp; (TENS)&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis&nbsp; in&nbsp; the&nbsp; hand.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev. 2003(3):CD004377.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">82.Robinson&nbsp; V,&nbsp; Brosseau&nbsp; L,&nbsp; Casimiro&nbsp; L,&nbsp; Judd&nbsp; M,&nbsp; Shea&nbsp; B,&nbsp; Wells&nbsp; G,&nbsp; et&nbsp; al.&nbsp; Thermotherapy&nbsp; for&nbsp; treating&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2002(2):CD002826.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">83.Casimiro&nbsp; L,&nbsp; Brosseau&nbsp; L,&nbsp; Robinson&nbsp; V,&nbsp; Milne&nbsp; S,&nbsp; Judd&nbsp; M,&nbsp; Well&nbsp; G,&nbsp; et&nbsp; al.&nbsp; Therapeutic&nbsp; ultrasound&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2002(3):CD003787.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">84.Brosseau&nbsp; LU,&nbsp; Pelland&nbsp; LU,&nbsp; Casimiro&nbsp; LY,&nbsp; Robinson&nbsp; VI,&nbsp; Tugwell&nbsp; PE,&nbsp; Wells&nbsp; GE.&nbsp; Electrical&nbsp; stimulation&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2002(2):CD003687.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">85.Knittle&nbsp; K,&nbsp; Maes&nbsp; S,&nbsp; de&nbsp; Gucht&nbsp; V.&nbsp; Psychological&nbsp; interventions&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; examining&nbsp; the&nbsp; role&nbsp; of&nbsp; self-regulation&nbsp; with&nbsp; a&nbsp; systematic&nbsp; review&nbsp; and&nbsp; meta-analysis&nbsp; of&nbsp; randomized&nbsp; controlled&nbsp; trials.&nbsp; Arthritis&nbsp; Care&nbsp; Res&nbsp; (Hoboken).&nbsp; 2010 Oct;62(10):1460-72.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">86.Dissanayake&nbsp; RK,&nbsp; Bertouch&nbsp; JV.&nbsp; Psychosocial&nbsp; interventions&nbsp; as&nbsp; adjunct&nbsp; therapy&nbsp; for&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review.&nbsp; Int&nbsp; J&nbsp; Rheum&nbsp; Dis.&nbsp; 2010&nbsp; Oct;13(4):324-34.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">87.Wolfs&nbsp; JF,&nbsp; Kloppenburg&nbsp; M,&nbsp; Fehlings&nbsp; MG,&nbsp; van&nbsp; Tulder&nbsp; MW,&nbsp; Boers&nbsp; M,&nbsp; Peul&nbsp; WC.&nbsp; Neurologic&nbsp; outcome&nbsp; of&nbsp; surgical&nbsp; and&nbsp; conservative&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; cervical&nbsp; spine&nbsp; subluxation:&nbsp; a&nbsp; systematic&nbsp; review.&nbsp; Arthritis&nbsp; Rheum.&nbsp; 2009&nbsp; Dec 15;61(12):1743-52.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">88.Jacobs&nbsp; WC,&nbsp; Clement&nbsp; DJ,&nbsp; Wymenga&nbsp; AB.&nbsp; Retention&nbsp; versus&nbsp; sacrifice&nbsp; of&nbsp; the&nbsp; posterior&nbsp; cruciate&nbsp; ligament&nbsp; in&nbsp; total&nbsp; knee&nbsp; replacement&nbsp; for&nbsp; treatment&nbsp; of&nbsp; osteoarthritis&nbsp; and&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2005(4):CD004803.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">89.Jacobs&nbsp; W,&nbsp; Anderson&nbsp; P,&nbsp; Limbeek&nbsp; J,&nbsp; Wymenga&nbsp; A.&nbsp; Mobile&nbsp; bearing&nbsp; vs&nbsp; fixed&nbsp; bearing&nbsp; prostheses&nbsp; for&nbsp; total&nbsp; knee&nbsp; arthroplasty&nbsp; for&nbsp; post-operative&nbsp; functional&nbsp; status&nbsp; in&nbsp; patients&nbsp; with&nbsp; osteoarthritis&nbsp; and&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev. 2004(2):CD003130.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">90.Wang&nbsp; C,&nbsp; de&nbsp; Pablo&nbsp; P,&nbsp; Chen&nbsp; X,&nbsp; Schmid&nbsp; C,&nbsp; McAlindon&nbsp; T.&nbsp; Acupuncture&nbsp; for&nbsp; pain&nbsp; relief&nbsp; in&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis: a&nbsp; systematic&nbsp; review.&nbsp; Arthritis&nbsp; Rheum.&nbsp; 2008&nbsp; Sep&nbsp; 15;59(9):1249-56.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">91.Lee&nbsp; MS,&nbsp; Shin&nbsp; BC,&nbsp; Ernst&nbsp; E.&nbsp; Acupuncture&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review.&nbsp; Rheumatology&nbsp; (Oxford).&nbsp; 2008 Dec;47(12):1747-53.</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">92.Casimiro&nbsp; L,&nbsp; Barnsley&nbsp; L,&nbsp; Brosseau&nbsp; L,&nbsp; Milne&nbsp; S,&nbsp; Robinson&nbsp; VA,&nbsp; Tugwell&nbsp; P,&nbsp; et&nbsp; al.&nbsp; Acupuncture&nbsp; and&nbsp; electroacupuncture&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2005(4):CD003788.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">93.Macfarlane&nbsp; GJ,&nbsp; El-Metwally&nbsp; A,&nbsp; De&nbsp; Silva&nbsp; V,&nbsp; Ernst&nbsp; E,&nbsp; Dowds&nbsp; GL,&nbsp; Moots&nbsp; RJ.&nbsp; Evidence&nbsp; for&nbsp; the&nbsp; efficacy&nbsp; of&nbsp; complementary&nbsp; and&nbsp; alternative&nbsp; medicines&nbsp; in&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review.&nbsp; Rheumatology&nbsp; (Oxford).&nbsp; 2011 Sep;50(9):1672-&nbsp; 83.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">94.Haaz&nbsp; S,&nbsp; Bartlett&nbsp; SJ.&nbsp; Yoga&nbsp; for&nbsp; Arthritis:&nbsp; A&nbsp; Scoping&nbsp; Review.&nbsp; Rheumatic&nbsp; Disease&nbsp; Clinics&nbsp; of&nbsp; North&nbsp; America.&nbsp; 2011;37(1):33-46.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">95.Ernst&nbsp; E,&nbsp; Posadzki&nbsp; P.&nbsp; Complementary&nbsp; and&nbsp; alternative&nbsp; medicine&nbsp; for&nbsp; rheumatoid&nbsp; arthritis&nbsp; and&nbsp; osteoarthritis:&nbsp; an&nbsp; overview&nbsp; of&nbsp; systematic&nbsp; reviews.&nbsp; Curr&nbsp; Pain&nbsp; Headache&nbsp; Rep.&nbsp; 2011&nbsp; Dec;15(6):431-7.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">96.Cameron&nbsp; M,&nbsp; Gagnier&nbsp; JJ,&nbsp; Chrubasik&nbsp; S.&nbsp; Herbal&nbsp; therapy&nbsp; for&nbsp; treating&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev. 2011(2):CD002948.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">97.Lee&nbsp; MS,&nbsp; Pittler&nbsp; MH,&nbsp; Ernst&nbsp; E.&nbsp; Tai&nbsp; chi&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; Systematic&nbsp; review.&nbsp; Rheumatology.&nbsp; 2007;46(11):1648-51.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">98.Park&nbsp; J,&nbsp; Ernst&nbsp; E.&nbsp; Ayurvedic&nbsp; medicine&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review.&nbsp; Semin&nbsp; Arthritis&nbsp; Rheum.&nbsp; 2005 Apr;34(5):705-13.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">99.Christie&nbsp; A,&nbsp; Fongen&nbsp; C.&nbsp; Tai&nbsp; Chi&nbsp; may&nbsp; be&nbsp; safe&nbsp; through&nbsp; ineffective&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; Commentary.&nbsp; Australian&nbsp; Journal&nbsp; of&nbsp; Physiotherapy.&nbsp; 2005;51(4):267.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">100.Brosseau&nbsp; L,&nbsp; Robinson&nbsp; V,&nbsp; Wells&nbsp; G,&nbsp; Debie&nbsp; R,&nbsp; Gam&nbsp; A,&nbsp; Harman&nbsp; K,&nbsp; et&nbsp; al.&nbsp; Low&nbsp; level&nbsp; laser&nbsp; therapy&nbsp; (Classes&nbsp; I,&nbsp; II&nbsp; and&nbsp; III)&nbsp; for&nbsp; treating&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2005(4):CD002049.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">101.Han&nbsp; A,&nbsp; Robinson&nbsp; V,&nbsp; Judd&nbsp; M,&nbsp; Taixiang&nbsp; W,&nbsp; Wells&nbsp; G,&nbsp; Tugwell&nbsp; P.&nbsp; Tai&nbsp; chi&nbsp; for&nbsp; treating&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane Database&nbsp; Syst&nbsp; Rev.&nbsp; 2004(3):CD004849.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">102.Brien&nbsp; S,&nbsp; Lachance&nbsp; L,&nbsp; Lewith&nbsp; GT.&nbsp; Are&nbsp; the&nbsp; therapeutic&nbsp; effects&nbsp; of&nbsp; homeopathy&nbsp; attributed&nbsp; to&nbsp; the&nbsp; consultation,&nbsp; the&nbsp; homeopathic&nbsp; remedy,&nbsp; or&nbsp; both?&nbsp; A&nbsp; protocol&nbsp; for&nbsp; a&nbsp; future&nbsp; exploratory&nbsp; feasibility&nbsp; trial&nbsp; in&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Journal&nbsp; of&nbsp; Alternative&nbsp; and&nbsp; Complementary&nbsp; Medicine.&nbsp; 2004;10(3):499-502.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">103.Verhagen&nbsp; AP,&nbsp; Bierma-Zeinstra&nbsp; SM,&nbsp; Cardoso&nbsp; JR,&nbsp; de&nbsp; Bie&nbsp; RA,&nbsp; Boers&nbsp; M,&nbsp; de&nbsp; Vet&nbsp; HC.&nbsp; Balneotherapy&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2003(4):CD000518.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">104.Walach&nbsp; H.&nbsp; Homeopathy&nbsp; in&nbsp; rheumatoid&nbsp; arthritis&nbsp; –&nbsp; No&nbsp; evidence&nbsp; for&nbsp; its&nbsp; superiority&nbsp; to&nbsp; placebo.&nbsp; Forschende Komplementarmedizin&nbsp; und&nbsp; Klassische&nbsp; Naturheilkunde.&nbsp; 2002;9(6):363-5.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">105.van&nbsp; der&nbsp; Zant&nbsp; FM,&nbsp; Boer&nbsp; RO,&nbsp; Moolenburgh&nbsp; JD,&nbsp; Jahangier&nbsp; ZN,&nbsp; Bijlsma&nbsp; HJWJ,&nbsp; Jacobs&nbsp; HJWG.&nbsp; Radiation&nbsp; synovectomy&nbsp; with&nbsp; 90yttrium,&nbsp; 186rhenium&nbsp; and&nbsp; 169erbium:&nbsp; A&nbsp; systematic&nbsp; literature&nbsp; review&nbsp; &nbsp;&nbsp;ith&nbsp; meta-analyses.&nbsp; Clinical&nbsp; and&nbsp; Experimental&nbsp; Rheumatology.&nbsp; 2009;27(1):130-9.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">106.Kampen&nbsp; WU,&nbsp; Voth&nbsp; M,&nbsp; Pinkert&nbsp; J,&nbsp; Krause&nbsp; A.&nbsp; Therapeutic&nbsp; status&nbsp; of&nbsp; radiosynoviorthesis&nbsp; of&nbsp; the&nbsp; knee&nbsp; with&nbsp; yttrium&nbsp; [90Y] colloid&nbsp; in&nbsp; rheumatoid&nbsp; arthritis&nbsp; and&nbsp; related&nbsp; indications.&nbsp; Rheumatology.&nbsp; 2007;46(1):16-24.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">107.Hagen&nbsp; KB,&nbsp; Byfuglien&nbsp; MG,&nbsp; Falzon&nbsp; L,&nbsp; Olsen&nbsp; SU,&nbsp; Smedslund&nbsp; G.&nbsp; Dietary&nbsp; interventions&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane Database&nbsp; Syst&nbsp; Rev.&nbsp; 2009(1):CD006400.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">108.Smolen&nbsp; JS,&nbsp; Landewe&nbsp; R,&nbsp; Breedveld&nbsp; FC,&nbsp; Dougados&nbsp; M,&nbsp; Emery&nbsp; P,&nbsp; Gaujoux-Viala&nbsp; C,&nbsp; et&nbsp; al.&nbsp; EULAR&nbsp; recommendations&nbsp; for&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis&nbsp; with&nbsp; synthetic&nbsp; and&nbsp; biological&nbsp; disease-modifying&nbsp; antirheumatic&nbsp; drugs.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2010&nbsp; Jun;69(6):964-75.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">109.Furst&nbsp; DE,&nbsp; Keystone&nbsp; EC,&nbsp; Braun&nbsp; J,&nbsp; Breedveld&nbsp; FC,&nbsp; Burmester&nbsp; GR,&nbsp; De&nbsp; Benedetti&nbsp; F,&nbsp; et&nbsp; al.&nbsp; Updated&nbsp; consensus&nbsp; statement&nbsp; on&nbsp; biological&nbsp; agents&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatic&nbsp; diseases,&nbsp; 2011.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2012&nbsp; Apr;71&nbsp; Suppl&nbsp; 2:i2-45.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">110.Schoels&nbsp; M,&nbsp; Wong&nbsp; J,&nbsp; Scott&nbsp; DL,&nbsp; Zink&nbsp; A,&nbsp; Richards&nbsp; P,&nbsp; &nbsp;&nbsp;Landewe&nbsp; R,&nbsp; et&nbsp; al.&nbsp; Economic&nbsp; aspects&nbsp; of&nbsp; treatment&nbsp; options&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; literature&nbsp; review&nbsp; informing&nbsp; the&nbsp; EULAR&nbsp; recommendations&nbsp; for&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2010&nbsp; Jun;69(6):995-1003.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">111.Hazlewood&nbsp; GS,&nbsp; Barnabe&nbsp; CCM,&nbsp; Tomlinson&nbsp; GA,&nbsp; Marshall&nbsp; D,&nbsp; Bombardier&nbsp; C.&nbsp; The&nbsp; comparative&nbsp; efficacy&nbsp; and&nbsp; toxicity&nbsp; of&nbsp; initial&nbsp; disease-modifying&nbsp; anti-rheumatic&nbsp; drug&nbsp; choices&nbsp; for&nbsp; patients&nbsp; with&nbsp; moderate-&nbsp; severe&nbsp; early&nbsp; rheumatoid&nbsp; arthritis:&nbsp; A&nbsp; bayesian&nbsp; network&nbsp; metaanalysis.&nbsp; Arthritis&nbsp; and&nbsp; Rheumatism.&nbsp; 2011;63(10).</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">112.Fitzpatrick&nbsp; R,&nbsp; Buchan&nbsp; S.&nbsp; Optimising&nbsp; methotrexate&nbsp; therapy&nbsp; and&nbsp; reducing&nbsp; total&nbsp; treatment&nbsp; costs&nbsp; in&nbsp; rheumatoid&nbsp; arthritis. Rheumatology.&nbsp; 2011;50:iii66.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">113.Kuriya&nbsp; B,&nbsp; Arkema&nbsp; EV,&nbsp; Bykerk&nbsp; VP,&nbsp; Keystone&nbsp; EC.&nbsp; Efficacy&nbsp; of&nbsp; initial&nbsp; methotrexate&nbsp; monotherapy&nbsp; versus&nbsp; combination&nbsp; therapy&nbsp; with&nbsp; a&nbsp; biological&nbsp; agent&nbsp; in&nbsp; early&nbsp; rheumatoid&nbsp; arthritis:&nbsp; A&nbsp; metaanalysis&nbsp; of&nbsp; clinical&nbsp; and&nbsp; radiographic&nbsp; remission.&nbsp; Annals&nbsp; of&nbsp; the&nbsp; Rheumatic&nbsp; Diseases.&nbsp; 2010;69(7):1298-304.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">114.Knevel&nbsp; R,&nbsp; Schoels&nbsp; M,&nbsp; Huizinga&nbsp; TW,&nbsp; Aletaha&nbsp; D,&nbsp; Burmester&nbsp; GR,&nbsp; Combe&nbsp; B,&nbsp; et&nbsp; al.&nbsp; Current&nbsp; evidence&nbsp; for&nbsp; a&nbsp; strategic&nbsp; approach&nbsp; to&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis&nbsp; with&nbsp; disease-modifying&nbsp; antirheumatic&nbsp; drugs:&nbsp; a&nbsp; systematic&nbsp; literature&nbsp; review&nbsp; informing&nbsp; the&nbsp; EULAR&nbsp; recommendations&nbsp; for&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2010 Jun;69(6):987-94.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">115.Katchamart&nbsp; W,&nbsp; Trudeau&nbsp; J,&nbsp; Phumethum&nbsp; V,&nbsp; Bombardier&nbsp; C.&nbsp; Methotrexate&nbsp; monotherapy&nbsp; versus&nbsp; methotrexate&nbsp; combination&nbsp; therapy&nbsp; with&nbsp; non-biologic&nbsp; disease&nbsp; modifying&nbsp; anti-rheumatic&nbsp; drugs&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2010(4):CD008495.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">116.Deighton&nbsp; C,&nbsp; O'Mahony&nbsp; R,&nbsp; Tosh&nbsp; J,&nbsp; Turner&nbsp; C,&nbsp; Rudolf&nbsp; M.&nbsp; Management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis:&nbsp; summary&nbsp; of&nbsp; NICE guidance.&nbsp; BMJ.&nbsp; 2009;338:b702.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">117.Launois&nbsp; R,&nbsp; Le&nbsp; Moine&nbsp; JG,&nbsp; Huynh&nbsp; TMT.&nbsp; Mixed&nbsp; treatment&nbsp; comparison,&nbsp; cost-effectiveness&nbsp; analysis&nbsp; and&nbsp; budget&nbsp; impact&nbsp; model&nbsp; in&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis&nbsp; after&nbsp; failure&nbsp; of&nbsp; conventional&nbsp; DMARD&nbsp; therapy&nbsp; using&nbsp; comprehensive&nbsp; bayesian&nbsp; decision&nbsp; analytical&nbsp; modelling.&nbsp; Value&nbsp; in&nbsp; Health.&nbsp; 2012;15(4):A50.</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">118.Katchamart&nbsp; W,&nbsp; Bombardier&nbsp; C.&nbsp; Systematic&nbsp; monitoring&nbsp; of&nbsp; disease&nbsp; activity&nbsp; using&nbsp; an&nbsp; outcome&nbsp; measure&nbsp; improves&nbsp; outcomes&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; J&nbsp; Rheumatol.&nbsp; 2010&nbsp; Jul;37(7):1411-5.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">119.Rubbert-Roth&nbsp; A,&nbsp; Finckh&nbsp; A.&nbsp; Treatment&nbsp; options&nbsp; in&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis&nbsp; failing&nbsp; initial&nbsp; TNF&nbsp; inhibitor&nbsp; therapy:&nbsp; a&nbsp; critical&nbsp; review.&nbsp; Arthritis&nbsp; Res&nbsp; Ther.&nbsp; 2009;11&nbsp; Suppl&nbsp; 1:S1.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">120.Emery&nbsp; P.&nbsp; Optimizing&nbsp; outcomes&nbsp; in&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis&nbsp; and&nbsp; an&nbsp; inadequate&nbsp; response&nbsp; to&nbsp; anti-TNF treatment.&nbsp; Rheumatology&nbsp; (Oxford).&nbsp; 2012&nbsp; Jul;51&nbsp; Suppl&nbsp; 5:v22-30.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">121.Gaujoux-Viala&nbsp; C,&nbsp; Smolen&nbsp; JS,&nbsp; Landewe&nbsp; R,&nbsp; Dougados&nbsp; M,&nbsp; Kvien&nbsp; TK,&nbsp; Mola&nbsp; EM,&nbsp; et&nbsp; al.&nbsp; Current&nbsp; evidence&nbsp; for&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis&nbsp; with&nbsp; synthetic&nbsp; disease-modifying&nbsp; antirheumatic&nbsp; drugs:&nbsp; a&nbsp; systematic&nbsp; literature&nbsp; review&nbsp; informing&nbsp; the&nbsp; EULAR&nbsp; recommendations&nbsp; for&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2010 Jun;69(6):1004-9.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">122.Smolen&nbsp; JS,&nbsp; Emery&nbsp; P,&nbsp; Kalden&nbsp; JR,&nbsp; Van&nbsp; Riel&nbsp; PLCM,&nbsp; Dougados&nbsp; M,&nbsp; Strand&nbsp; CV,&nbsp; et&nbsp; al.&nbsp; The&nbsp; efficacy&nbsp; of&nbsp; leflunomide&nbsp; monotherapy&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; Towards&nbsp; the&nbsp; goals&nbsp; of&nbsp; disease&nbsp; modifying&nbsp; antirheumatic&nbsp; drug&nbsp; therapy.&nbsp; Journal&nbsp; of&nbsp; Rheumatology.&nbsp; 2004;31(7&nbsp; SUPPL.&nbsp; 1):13-20.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">123.Osiri&nbsp; M,&nbsp; Shea&nbsp; B,&nbsp; Robinson&nbsp; V,&nbsp; Suarez-Almazor&nbsp; M,&nbsp; Strand&nbsp; V,&nbsp; Tugwell&nbsp; P,&nbsp; et&nbsp; al.&nbsp; Leflunomide&nbsp; for&nbsp; treating&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2003(1):CD002047.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">124.Suarez-Almazor&nbsp; ME,&nbsp; Belseck&nbsp; E,&nbsp; Shea&nbsp; B,&nbsp; Wells&nbsp; G, Tugwell&nbsp; P.&nbsp; Methotrexate&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2000(2):CD000957.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">125.Miehle&nbsp; W,&nbsp; Tomiak&nbsp; C.&nbsp; Fixed&nbsp; sequential&nbsp; supplementation&nbsp; with&nbsp; folic&nbsp; acid&nbsp; during&nbsp; methotrexate&nbsp; therapy.&nbsp; Aktuelle Rheumatologie.&nbsp; 2005;30(4):254-65.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">126.Morgan&nbsp; SL,&nbsp; Baggott&nbsp; JE.&nbsp; Folate&nbsp; supplementation&nbsp; during&nbsp; Methotrexate&nbsp; therapy&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Clinical&nbsp; and Experimental&nbsp; Rheumatology.&nbsp; 2010;28(5&nbsp; SUPPL.&nbsp; 61):S102-S9.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">127.Ortiz&nbsp; Z,&nbsp; Shea&nbsp; B,&nbsp; Suarez&nbsp; Almazor&nbsp; M,&nbsp; Moher&nbsp; D,&nbsp; Wells&nbsp; G,&nbsp; Tugwell&nbsp; P.&nbsp; Folic&nbsp; acid&nbsp; and&nbsp; folinic&nbsp; acid&nbsp; for&nbsp; reducing&nbsp; side&nbsp; effects&nbsp; in&nbsp; patients&nbsp; receiving&nbsp; methotrexate&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2000(2):CD000951.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">128.Suarez-Almazor&nbsp; ME,&nbsp; Belseck&nbsp; E,&nbsp; Shea&nbsp; B,&nbsp; Wells&nbsp; G,&nbsp; Tugwell&nbsp; P.&nbsp; Sulfasalazine&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane Database&nbsp; Syst&nbsp; Rev.&nbsp; 2000(2):CD000958.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">129.Suarez-Almazor&nbsp; ME,&nbsp; Belseck&nbsp; E,&nbsp; Shea&nbsp; B,&nbsp; Homik&nbsp; J,&nbsp; Wells&nbsp; G,&nbsp; Tugwell&nbsp; P.&nbsp; Antimalarials&nbsp; for&nbsp; treating&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2000(4):CD000959.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">130.Scott&nbsp; DL.&nbsp; Biologics-based&nbsp; therapy&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Clinical&nbsp; Pharmacology&nbsp; and&nbsp; Therapeutics. 2012;91(1):30-43.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">131.Leff&nbsp; L.&nbsp; Emerging&nbsp; new&nbsp; therapies&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; What's&nbsp; next&nbsp; for&nbsp; the&nbsp; patient?&nbsp; Journal&nbsp; of&nbsp; Infusion&nbsp; Nursing. 2006;29(6):326-37.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">132.Chauffier&nbsp; K,&nbsp; Salliot&nbsp; C,&nbsp; Berenbaum&nbsp; F,&nbsp; Sellam&nbsp; J.&nbsp; Effect&nbsp; of&nbsp; biotherapies&nbsp; on&nbsp; fatigue&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; A&nbsp; systematic&nbsp; review&nbsp; of&nbsp; the&nbsp; literature&nbsp; and&nbsp; meta-analysis.&nbsp; Rheumatology.&nbsp; 2012;51(1):60-8.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">133.Ruiz&nbsp; Garcia&nbsp; V,&nbsp; Jobanputra&nbsp; P,&nbsp; Burls&nbsp; A,&nbsp; Cabello&nbsp; JB,&nbsp; Galvez&nbsp; Munoz&nbsp; JG,&nbsp; Saiz&nbsp; Cuenca&nbsp; ES,&nbsp; et&nbsp; al.&nbsp; Certolizumab&nbsp; pegol (CDP870)&nbsp; for&nbsp; rheumatoid&nbsp; arthritis&nbsp; in&nbsp; adults.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2011(2):CD007649.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">134.Singh&nbsp; JA,&nbsp; Noorbaloochi&nbsp; S,&nbsp; Singh&nbsp; G.&nbsp; Golimumab&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev. 2010(1):CD008341.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">135.Donahue&nbsp; KE,&nbsp; Jonas&nbsp; DE,&nbsp; Hansen&nbsp; RA,&nbsp; Roubey&nbsp; R,&nbsp; Jonas&nbsp; B,&nbsp; Lux&nbsp; LJ,&nbsp; et&nbsp; al.&nbsp; Drug&nbsp; Therapy&nbsp; for&nbsp; Rheumatoid&nbsp; Arthritis&nbsp; in Adults:&nbsp; An&nbsp; Update&nbsp; [Internet].&nbsp; Comparative&nbsp; Effectiveness&nbsp; Reviews.&nbsp; 2012&nbsp; Apr;55.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">136.Brodszky&nbsp; V.&nbsp; Efficacy&nbsp; of&nbsp; the&nbsp; biological&nbsp; treatments&nbsp; based&nbsp; on&nbsp; ACR70&nbsp; response&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; Indirect&nbsp; comparison&nbsp; and&nbsp; meta-regression&nbsp; using&nbsp; Bayes-model.&nbsp; Orvosi&nbsp; Hetilap.&nbsp; 2011;152(23):919-28.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">137.Pentek&nbsp; M,&nbsp; Gulacsi&nbsp; L,&nbsp; Ersek&nbsp; K,&nbsp; Baji&nbsp; P,&nbsp; Boncz&nbsp; I,&nbsp; Orlewska&nbsp; E,&nbsp; et&nbsp; al.&nbsp; Comparison&nbsp; of&nbsp; recently&nbsp; registered&nbsp; biological&nbsp; drugs&nbsp; with&nbsp; available&nbsp; therapies&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; Methodological&nbsp; issues&nbsp; to&nbsp; consider&nbsp; for&nbsp; meta-analysis.&nbsp; Value&nbsp; in&nbsp; Health.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">2010;13(7):A303.&nbsp; 138.Singh&nbsp; JA,&nbsp; Christensen&nbsp; R,&nbsp; Wells&nbsp; GA,&nbsp; Suarez-Almazor&nbsp; ME,&nbsp; Buchbinder&nbsp; R,&nbsp; Lopez-Olivo&nbsp; MA,&nbsp; et&nbsp; al.&nbsp; Biologics&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; an&nbsp; overview&nbsp; of&nbsp; Cochrane&nbsp; reviews.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2009(4):CD007848.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">139.Orme&nbsp; ME,&nbsp; Fotheringham&nbsp; I,&nbsp; Mitchell&nbsp; SA,&nbsp; Spurden&nbsp; D,&nbsp; Bird&nbsp; A.&nbsp; Systematic&nbsp; review&nbsp; and&nbsp; network&nbsp; meta-analysis&nbsp; of combination&nbsp; therapy&nbsp; for&nbsp; methotrexate-experienced,&nbsp; rheumatoid&nbsp; arthritis&nbsp; patients:&nbsp; Analysis&nbsp; of&nbsp; american&nbsp; college&nbsp; of&nbsp; rheumatology&nbsp; criteria&nbsp; scores&nbsp; 20,&nbsp; 50&nbsp; and&nbsp; 70.&nbsp; Arthritis&nbsp; and&nbsp; Rheumatism.&nbsp; 2011;63(10).</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">140.Cormier&nbsp; H,&nbsp; Barnetche&nbsp; T,&nbsp; Schaeverbeke&nbsp; T.&nbsp; The&nbsp; risk&nbsp; of&nbsp; serious&nbsp; infection&nbsp; with&nbsp; and&nbsp; without&nbsp; anti-tnf&nbsp; therapy&nbsp; in&nbsp; rheumatoid&nbsp; arthritis&nbsp; and&nbsp; ankylosing&nbsp; spondylitis:&nbsp; A&nbsp; meta-analysis.&nbsp; Arthritis&nbsp; and&nbsp; Rheumatism.&nbsp; 2011;63(10).</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">141.Nam&nbsp; JL,&nbsp; Winthrop&nbsp; KL,&nbsp; van&nbsp; Vollenhoven&nbsp; RF,&nbsp; Pavelka&nbsp; K,&nbsp; Valesini&nbsp; G,&nbsp; Hensor&nbsp; EM,&nbsp; et&nbsp; al.&nbsp; Current&nbsp; evidence&nbsp; for&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis&nbsp; with&nbsp; biological&nbsp; disease-modifying&nbsp; antirheumatic&nbsp; drugs:&nbsp; a&nbsp; systematic&nbsp; literature&nbsp; review&nbsp; informing&nbsp; the&nbsp; EULAR&nbsp; recommendations&nbsp; for&nbsp; the&nbsp; management&nbsp; of&nbsp; RA.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2010&nbsp; Jun;69(6):976-86.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">142.Bernatsky&nbsp; S,&nbsp; Habel&nbsp; Y,&nbsp; Rahme&nbsp; E.&nbsp; Observational&nbsp; studies&nbsp; of&nbsp; infections&nbsp; in&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; metaanalysis&nbsp; of&nbsp; tumor&nbsp; necrosis&nbsp; factor&nbsp; antagonists.&nbsp; J&nbsp; Rheumatol.&nbsp; 2010&nbsp; May;37(5):928-31.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">143.Mealy&nbsp; NE,&nbsp; Bayes&nbsp; M.&nbsp; Infliximab.&nbsp; Drugs&nbsp; of&nbsp; the&nbsp; Future.&nbsp; 2005;30(8):845-6.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">144.Cunnane&nbsp; G,&nbsp; Doran&nbsp; M,&nbsp; Bresnihan&nbsp; B.&nbsp; Infections&nbsp; and&nbsp; biological&nbsp; therapy&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Best&nbsp; Practice&nbsp; and Research:&nbsp; Clinical&nbsp; Rheumatology.&nbsp; 2003;17(2):345-63.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">145.Turkstra&nbsp; E,&nbsp; Ng&nbsp; SK,&nbsp; Scuffham&nbsp; PA.&nbsp; A&nbsp; mixed&nbsp; treatment&nbsp; comparison&nbsp; of&nbsp; the&nbsp; short-term&nbsp; efficacy&nbsp; of&nbsp; biologic&nbsp; disease&nbsp; modifying&nbsp; anti-rheumatic&nbsp; drugs&nbsp; in&nbsp; established&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Curr&nbsp; Med&nbsp; Res&nbsp; Opin.&nbsp; 2011&nbsp; Oct;27(10):1885-97.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">146.Singh&nbsp; JA,&nbsp; Wells&nbsp; GA,&nbsp; Christensen&nbsp; R,&nbsp; Tanjong&nbsp; Ghogomu&nbsp; E,&nbsp; Maxwell&nbsp; L,&nbsp; Macdonald&nbsp; JK,&nbsp; et&nbsp; al.&nbsp; Adverse&nbsp; effects&nbsp; of&nbsp; biologics:&nbsp; a&nbsp; network&nbsp; meta-analysis&nbsp; and&nbsp; Cochrane&nbsp; overview.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2011(2):CD008794.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">147.Devine&nbsp; EB,&nbsp; Alfonso-Cristancho&nbsp; R,&nbsp; Sullivan&nbsp; SD.&nbsp; Effectiveness&nbsp; of&nbsp; biologic&nbsp; therapies&nbsp; for&nbsp; rheumatoid&nbsp; arthritis:&nbsp; an&nbsp; indirect comparisons&nbsp; approach.&nbsp; Pharmacotherapy.&nbsp; 2011&nbsp; Jan;31(1):39-51.</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">148.Malottki&nbsp; K,&nbsp; Barton&nbsp; P,&nbsp; Tsourapas&nbsp; A,&nbsp; Uthman&nbsp; AO,&nbsp; Liu&nbsp; Z,&nbsp; Routh&nbsp; K,&nbsp; et&nbsp; al.&nbsp; Adalimumab,&nbsp; etanercept,&nbsp; infiximab,&nbsp; rituximab&nbsp; and&nbsp; abatacept&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis&nbsp; after&nbsp; the&nbsp; failure&nbsp; of&nbsp; a&nbsp; tumour&nbsp; necrosis&nbsp; factor&nbsp; inhibitor:&nbsp; A&nbsp; systematic&nbsp; review&nbsp; and&nbsp; economic&nbsp; evaluation.&nbsp; Health&nbsp; Technology&nbsp; Assessment.&nbsp; 2011;15(14):1-300.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">149.Mercer&nbsp; LK,&nbsp; Galloway&nbsp; JB,&nbsp; Low&nbsp; ASL,&nbsp; Watson&nbsp; KD,&nbsp; Lunt&nbsp; M,&nbsp; Dixon&nbsp; WG.&nbsp; The&nbsp; risk&nbsp; of&nbsp; solid&nbsp; cancer&nbsp; in&nbsp; patients&nbsp; receiving&nbsp; antitumour&nbsp; necrosis&nbsp; factor&nbsp; therapy&nbsp; for&nbsp; rheumatoid&nbsp; arthritis&nbsp; for&nbsp; up&nbsp; to&nbsp; 5&nbsp; years:&nbsp; Results&nbsp; from&nbsp; the&nbsp; british&nbsp; society&nbsp; for&nbsp; rheumatology&nbsp; biologics&nbsp; register.&nbsp; Arthritis&nbsp; and&nbsp; Rheumatism.&nbsp; 2011;63(10).</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">150.Novikova&nbsp; DS,&nbsp; Popkova&nbsp; TV,&nbsp; Nasonov&nbsp; EL.&nbsp; The&nbsp; effect&nbsp; of&nbsp; anti-B-cell&nbsp; therapy&nbsp; on&nbsp; the&nbsp; development&nbsp; of&nbsp; atherosclerosis&nbsp; in&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Current&nbsp; Pharmaceutical&nbsp; Design.&nbsp; 2012;18(11):1512-8.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">151.Maxwell&nbsp; L,&nbsp; Singh&nbsp; JA.&nbsp; Abatacept&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2009(4):CD007277.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">152.Parchamazad&nbsp; P,&nbsp; Ghazvini&nbsp; P,&nbsp; Honeywell&nbsp; M,&nbsp; Treadwell&nbsp; P.&nbsp; Abatacept&nbsp; (CTLA4-Ig,&nbsp; Orencia):&nbsp; An&nbsp; investigational&nbsp; biological&nbsp; compound&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; P&nbsp; and&nbsp; T.&nbsp; 2005;30(11):633-8+43+69.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">153.Singh&nbsp; JA,&nbsp; Beg&nbsp; S,&nbsp; Lopez-Olivo&nbsp; MA.&nbsp; Tocilizumab&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev. 2010(7):CD008331.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">154.Nishimoto&nbsp; N,&nbsp; Ito&nbsp; K,&nbsp; Takagi&nbsp; N.&nbsp; Safety&nbsp; and&nbsp; efficacy&nbsp; profiles&nbsp; of&nbsp; tocilizumab&nbsp; monotherapy&nbsp; in&nbsp; Japanese&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis:&nbsp; meta-analysis&nbsp; of&nbsp; six&nbsp; initial&nbsp; trials&nbsp; and&nbsp; five&nbsp; long-term&nbsp; extensions.&nbsp; Mod&nbsp; Rheumatol.&nbsp; 2010&nbsp; Jun;20(3):222-32.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">155.Mertens&nbsp; M,&nbsp; Singh&nbsp; JA.&nbsp; Anakinra&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2009(1):CD005121.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">156.Clark&nbsp; P,&nbsp; Tugwell&nbsp; P,&nbsp; Bennet&nbsp; K,&nbsp; Bombardier&nbsp; C,&nbsp; Shea&nbsp; B,&nbsp; Wells&nbsp; G,&nbsp; et&nbsp; al.&nbsp; Injectable&nbsp; gold&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2000(2):CD000520.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">157.Suarez-Almazor&nbsp; ME,&nbsp; Spooner&nbsp; CH,&nbsp; Belseck&nbsp; E,&nbsp; Shea&nbsp; B.&nbsp; Auranofin&nbsp; versus&nbsp; placebo&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; CochraneDatabase&nbsp; Syst&nbsp; Rev.&nbsp; 2000(2):CD002048.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">158.Suarez-Almazor&nbsp; ME,&nbsp; Spooner&nbsp; C,&nbsp; Belseck&nbsp; E.&nbsp; Penicillamine&nbsp; for&nbsp; treating&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst Rev.&nbsp; 2000(4):CD001460.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">159.Lee&nbsp; YH,&nbsp; Woo&nbsp; JH,&nbsp; Choi&nbsp; SJ,&nbsp; Ji&nbsp; JD,&nbsp; Bae&nbsp; SC,&nbsp; Song&nbsp; GG.&nbsp; Tacrolimus&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; active&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review&nbsp; and&nbsp; meta-analysis&nbsp; of&nbsp; randomized&nbsp; controlled&nbsp; trials.&nbsp; Scand&nbsp; J&nbsp; Rheumatol.&nbsp; 2010&nbsp; Aug;39(4):271-8.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">160.Richards&nbsp; BL,&nbsp; Whittle&nbsp; SL,&nbsp; Buchbinder&nbsp; R.&nbsp; Neuromodulators&nbsp; for&nbsp; pain&nbsp; management&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; CochraneDatabase&nbsp; Syst&nbsp; Rev.&nbsp; 2012;1:CD008921.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">161.Ichim&nbsp; TE,&nbsp; Zheng&nbsp; X,&nbsp; Suzuki&nbsp; M,&nbsp; Kubo&nbsp; N,&nbsp; Zhang&nbsp; X,&nbsp; Min&nbsp; LR,&nbsp; et&nbsp; al.&nbsp; Antigen-specific&nbsp; therapy&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Expert&nbsp; Opinion&nbsp; on&nbsp; Biological&nbsp; Therapy.&nbsp; 2008;8(2):191-9.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">162.Bijlsma&nbsp; JWJ.&nbsp; Disease&nbsp; control&nbsp; with&nbsp; glucocorticoid&nbsp; th&nbsp; erapy&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Rheumatology&nbsp; (United&nbsp; Kingdom). 2012;51(SUPPL.4):iv9-iv13.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">163.Gorter&nbsp; SL,&nbsp; Bijlsma&nbsp; JW,&nbsp; Cutolo&nbsp; M,&nbsp; Gomez-Reino&nbsp; J,&nbsp; Kouloumas&nbsp; M,&nbsp; Smolen&nbsp; JS,&nbsp; et&nbsp; al.&nbsp; Current&nbsp; evidence&nbsp; for&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis&nbsp; with&nbsp; glucocorticoids:&nbsp; a&nbsp; systematic&nbsp; literature&nbsp; review&nbsp; informing&nbsp; the&nbsp; EULAR&nbsp; recommendations&nbsp; for&nbsp; the&nbsp; management&nbsp; of&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2010&nbsp; Jun;69(6):1010-4.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">164.Dernis&nbsp; E,&nbsp; Ruyssen-Witrand&nbsp; A,&nbsp; Mouterde&nbsp; G,&nbsp; Maillefert&nbsp; JF,&nbsp; Tebib&nbsp; J,&nbsp; Cantagrel&nbsp; A,&nbsp; et&nbsp; al.&nbsp; Use&nbsp; of&nbsp; glucocorticoids&nbsp; in&nbsp; rheumatoid&nbsp; arthritis&nbsp; –&nbsp; Pratical&nbsp; modalities&nbsp; of&nbsp; glucocorticoid&nbsp; therapy:&nbsp;&nbsp; Recommendations&nbsp; for&nbsp; clinical&nbsp; practice&nbsp; based&nbsp; on&nbsp; data&nbsp; from&nbsp; the&nbsp; literature&nbsp; and&nbsp; expert&nbsp; opinion.&nbsp; Joint&nbsp; Bone&nbsp; Spine.&nbsp; 2010;77(5):451-7.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">165.Kirwan&nbsp; JR,&nbsp; Bijlsma&nbsp; JW,&nbsp; Boers&nbsp; M,&nbsp; Shea&nbsp; BJ.&nbsp; Effects&nbsp; of&nbsp; glucocorticoids&nbsp; on&nbsp; radiological&nbsp; progression&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2007(1):CD006356.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">166.Wallen&nbsp; M,&nbsp; Gillies&nbsp; D.&nbsp; Intra-articular&nbsp; steroids&nbsp; and&nbsp; splints/rest&nbsp; for&nbsp; children&nbsp; with&nbsp; juvenile&nbsp; idiopathic&nbsp; arthritis&nbsp; and&nbsp; adults with&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2006(1):CD002824.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">167.Gotzsche&nbsp; PC,&nbsp; Johansen&nbsp; HK.&nbsp; Short-term&nbsp; low-dose&nbsp; corticosteroids&nbsp; vs&nbsp; placebo&nbsp; and&nbsp; nonsteroidal&nbsp; antiinflammatory&nbsp; drugs&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2004(3):CD000189.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">168.Wienecke&nbsp; T,&nbsp; Gotzsche&nbsp; PC.&nbsp; Paracetamol&nbsp; versus&nbsp; nonsteroidal&nbsp; anti-inflammatory&nbsp; drugs&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2004(1):CD003789.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">169.Radner&nbsp; H,&nbsp; Ramiro&nbsp; S,&nbsp; Buchbinder&nbsp; R,&nbsp; Landewe&nbsp; RB,&nbsp; van&nbsp; der&nbsp; Heijde&nbsp; D,&nbsp; Aletaha&nbsp; D.&nbsp; Pain&nbsp; management&nbsp; for&nbsp; inflammatory&nbsp; arthritis&nbsp; (rheumatoid&nbsp; arthritis,&nbsp; psoriatic&nbsp; arthritis,&nbsp; ankylosing&nbsp; spondylitis&nbsp; and&nbsp; other&nbsp; spondylarthritis)&nbsp; and&nbsp; gastrointestinal&nbsp; or&nbsp; liver&nbsp; comorbidity.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2012;1:CD008951.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">170.Colebatch&nbsp; AN,&nbsp; Marks&nbsp; JL,&nbsp; Edwards&nbsp; CJ.&nbsp; Safety&nbsp; of&nbsp; nonsteroidal&nbsp; anti-inflammatory&nbsp; drugs,&nbsp; including&nbsp; aspirin&nbsp; and&nbsp; paracetamol&nbsp; (acetaminophen)&nbsp; in&nbsp; people&nbsp; receiving&nbsp; methotrexate&nbsp; for&nbsp; inflammatory&nbsp; arthritis&nbsp; (rheumatoid&nbsp; arthritis,&nbsp; ankylosing&nbsp; spondylitis,&nbsp; psoriatic&nbsp; arthritis,&nbsp; other&nbsp; spondyloarthritis).&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2011(11):CD008872.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">171.Garner&nbsp; S,&nbsp; Fidan&nbsp; D,&nbsp; Frankish&nbsp; R,&nbsp; Judd&nbsp; M,&nbsp; Shea&nbsp; B,&nbsp; Towheed&nbsp; T,&nbsp; et&nbsp; al.&nbsp; Celecoxib&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane Database&nbsp; Syst&nbsp; Rev.&nbsp; 2002(4):CD003831.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">172.Marks&nbsp; JL,&nbsp; Colebatch&nbsp; AN,&nbsp; Buchbinder&nbsp; R,&nbsp; Edwards&nbsp; CJ.&nbsp; Pain&nbsp; management&nbsp; for&nbsp; rheumatoid&nbsp; arthritis&nbsp; and&nbsp; cardiovascular&nbsp; or&nbsp; renal&nbsp; comorbidity.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2011(10):CD008952.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">173.Ramiro&nbsp; S,&nbsp; Radner&nbsp; H,&nbsp; van&nbsp; der&nbsp; Heijde&nbsp; D,&nbsp; van&nbsp; Tubergen&nbsp; A,&nbsp; Buchbinder&nbsp; R,&nbsp; Aletaha&nbsp; D,&nbsp; et&nbsp; al.&nbsp; Combination&nbsp; therapy&nbsp; for&nbsp; pain&nbsp; management&nbsp; in&nbsp; inflammatory&nbsp; arthritis&nbsp; (rheumatoid&nbsp; arthritis,&nbsp; ankylosing&nbsp; spondylitis,&nbsp; psoriatic&nbsp; arthritis,&nbsp; other&nbsp; spondyloarthritis).&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2011(10):CD008886.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">174.Richards&nbsp; BL,&nbsp; Whittle&nbsp; SL,&nbsp; Buchbinder&nbsp; R.&nbsp; Antidepressants&nbsp; for&nbsp; pain&nbsp; management&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane Database&nbsp; Syst&nbsp; Rev.&nbsp; 2011(11):CD008920.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">175.Richards&nbsp; BL,&nbsp; Whittle&nbsp; SL,&nbsp; Buchbinder&nbsp; R.&nbsp; Muscle&nbsp; relaxants&nbsp; for&nbsp; pain&nbsp; management&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane Database&nbsp; Syst&nbsp; Rev.&nbsp; 2012;1:CD008922.</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">176.Whittle&nbsp; SL,&nbsp; Richards&nbsp; BL,&nbsp; Husni&nbsp; E,&nbsp; Buchbinder&nbsp; R.&nbsp; Opioid&nbsp; therapy&nbsp; for&nbsp; treating&nbsp; rheumatoid&nbsp; arthritis&nbsp; pain.&nbsp; Cochrane Database&nbsp; Syst&nbsp; Rev.&nbsp; 2011(11):CD003113.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">177.Wells&nbsp; G,&nbsp; Haguenauer&nbsp; D,&nbsp; Shea&nbsp; B,&nbsp; Suarez-Almazor&nbsp; ME,&nbsp; Welch&nbsp; VA,&nbsp; Tugwell&nbsp; P.&nbsp; Cyclosporine&nbsp; for&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2000(2):CD001083.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">178.Suarez-Almazor&nbsp; ME,&nbsp; Spooner&nbsp; C,&nbsp; Belseck&nbsp; E.&nbsp; Azathioprine&nbsp; for&nbsp; treating&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst Rev.&nbsp; 2000(4):CD001461.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">179.Whelan&nbsp; P,&nbsp; Atone&nbsp; J.&nbsp; Treatment&nbsp; of&nbsp; rheumatoid&nbsp; vasculitis.&nbsp; UpToDate&nbsp; [serial&nbsp; on&nbsp; the&nbsp; Internet].&nbsp; 2012.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">180.Lake&nbsp; F.&nbsp; Interstitial&nbsp; lung&nbsp; disease&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; UpToDate&nbsp; [serial&nbsp; on&nbsp; the&nbsp; Internet].&nbsp; 2012.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">181.Suarez-Almazor&nbsp; ME,&nbsp; Belseck&nbsp; E,&nbsp; Shea&nbsp; B,&nbsp; Wells&nbsp; G,&nbsp; Tugwell&nbsp; P.&nbsp; Cyclophosphamide&nbsp; for&nbsp; treating&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Cochrane&nbsp; Database&nbsp; Syst&nbsp; Rev.&nbsp; 2000(4):CD001157.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">182.Li&nbsp; RHW,&nbsp; Gebbie&nbsp; AE,&nbsp; Wong&nbsp; RWS,&nbsp; Ng&nbsp; EHY,&nbsp; Glasier&nbsp; AF,&nbsp; Ho&nbsp; PC.&nbsp; The&nbsp; use&nbsp; of&nbsp; sex&nbsp; hormones&nbsp; in&nbsp; women&nbsp; with&nbsp; rheumatological&nbsp; diseases.&nbsp; Hong&nbsp; Kong&nbsp; Medical&nbsp; Journal.&nbsp; 2011;17(6):487-91.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">183.Farr&nbsp; SL,&nbsp; Folger&nbsp; SG,&nbsp; Paulen&nbsp; ME,&nbsp; Curtis&nbsp; KM.&nbsp; Safety&nbsp; of&nbsp; contraceptive&nbsp; methods&nbsp; for&nbsp; women&nbsp; with&nbsp; rheumatoid&nbsp; arthritis:&nbsp; a&nbsp; systematic&nbsp; review.&nbsp; Contraception.&nbsp; 2010;82(1):64-71.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">184.Sikora&nbsp; A.&nbsp; Efficacy&nbsp; of&nbsp; vaccination&nbsp; in&nbsp; connective&nbsp; tissue&nbsp; diseases:&nbsp; Systemic&nbsp; lupus&nbsp; erythematosus&nbsp; (SLE)&nbsp; and&nbsp; rheumatoid&nbsp; arthritis&nbsp; (RA)&nbsp; –&nbsp; Review&nbsp; of&nbsp; the&nbsp; literature.&nbsp; Central-European&nbsp; Journal&nbsp; of&nbsp; Immunology.&nbsp; 2004;29(1):35-8.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">185.Bermas&nbsp; B.&nbsp; Rheumatoid&nbsp; arthritis&nbsp; and&nbsp; pregnancy.&nbsp; UpTo-&nbsp; Date2012.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">186.Finckh&nbsp; A,&nbsp; Ciurea&nbsp; A,&nbsp; Brulhart&nbsp; L,&nbsp; Moller&nbsp; B,&nbsp; Walker&nbsp; UA,&nbsp; Courvoisier&nbsp; D,&nbsp; et&nbsp; al.&nbsp; Which&nbsp; subgroup&nbsp; of&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis&nbsp; benefits&nbsp; from&nbsp; switching&nbsp; to&nbsp; rituximab&nbsp; versus&nbsp; alternative&nbsp; antitumour&nbsp; necrosis&nbsp; factor&nbsp; (TNF)&nbsp; agents&nbsp; after&nbsp; previous&nbsp; failure&nbsp; of&nbsp; an&nbsp; anti-&nbsp; TNF&nbsp; agent?&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2010&nbsp; Feb;69(2):387-93.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">187.Hyrich&nbsp; KL,&nbsp; Lunt&nbsp; M,&nbsp; Watson&nbsp; KD,&nbsp; Symmons&nbsp; DP,&nbsp; Silman&nbsp; AJ.&nbsp; Outcomes&nbsp; after&nbsp; switching&nbsp; from&nbsp; one&nbsp; anti-tumor&nbsp; necrosis&nbsp; factor&nbsp; alpha&nbsp; agent&nbsp; to&nbsp; a&nbsp; second&nbsp; anti-tumor&nbsp; necrosis&nbsp; factor&nbsp; alpha&nbsp; agent&nbsp; in&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis:&nbsp; results&nbsp; from&nbsp; a&nbsp; large&nbsp; UK&nbsp; national&nbsp; cohort&nbsp; study.&nbsp; Arthritis&nbsp; Rheum.&nbsp; 2007&nbsp; Jan;56(1):13-20.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">188.Karlsson&nbsp; JA,&nbsp; Kristensen&nbsp; LE,&nbsp; Kapetanovic&nbsp; MC,&nbsp; Gulfe&nbsp; A,&nbsp; Saxne&nbsp; T,&nbsp; Geborek&nbsp; P.&nbsp; Treatment&nbsp; response&nbsp; to&nbsp; a&nbsp; second&nbsp; or&nbsp; third TNFinhibitor&nbsp; in&nbsp; RA:&nbsp; results&nbsp; from&nbsp; the&nbsp; South&nbsp; Swedish&nbsp; Arthritis&nbsp; Treatment&nbsp; Group&nbsp; Register.&nbsp; Rheumatology&nbsp; (Oxford).&nbsp; 2008 Apr;47(4):507-13.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">189.Smolen&nbsp; JS,&nbsp; Kay&nbsp; J,&nbsp; Doyle&nbsp; MK,&nbsp; Landewe&nbsp; R,&nbsp; Matteson&nbsp; EL,&nbsp; Wollenhaupt&nbsp; J,&nbsp; et&nbsp; al.&nbsp; Golimumab&nbsp; in&nbsp; patients&nbsp; with&nbsp; active&nbsp; rheumatoid&nbsp; arthritis&nbsp; after&nbsp; treatment&nbsp; with&nbsp; tumour&nbsp; necrosis&nbsp; factor&nbsp; alpha&nbsp; inhibitors&nbsp; (GO-AFTER&nbsp; study):&nbsp; a&nbsp; multicentre,&nbsp; randomised,&nbsp; doubleblind,&nbsp; placebo-controlled,&nbsp; phase&nbsp; III&nbsp; trial.&nbsp; Lancet.&nbsp; 2009&nbsp; Jul&nbsp; 18;374(9685):210-21.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">190.Barton&nbsp; JL,&nbsp; Criswell&nbsp; LA,&nbsp; Kaiser&nbsp; R,&nbsp; Chen&nbsp; YH,&nbsp; Schillinger&nbsp; D.&nbsp; Systematic&nbsp; review&nbsp; and&nbsp; metaanalysis&nbsp; of&nbsp; patient&nbsp; self-report&nbsp; versus&nbsp; trained&nbsp; assessor&nbsp; joint&nbsp; counts&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; Journal&nbsp; of&nbsp; Rheumatology.&nbsp; 2009;36(12):2635-41.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">191.Ferraz&nbsp; MB,&nbsp; Oliveira&nbsp; LM,&nbsp; Araujo&nbsp; PM,&nbsp; Atra&nbsp; E,&nbsp; Tugwell&nbsp; P.&nbsp; Crosscultural&nbsp; reliability&nbsp; of&nbsp; the&nbsp; physical&nbsp; ability&nbsp; dimension&nbsp; of&nbsp; the&nbsp; health&nbsp; assessment&nbsp; questionnaire.&nbsp; J&nbsp; Rheumatol.&nbsp; 1990&nbsp; Jun;17(6):813-7.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">192.Len&nbsp; C,&nbsp; Goldenberg&nbsp; J,&nbsp; Ferraz&nbsp; MB,&nbsp; Hilario&nbsp; MO,&nbsp; Oliveira&nbsp; LM,&nbsp; Sacchetti&nbsp; S.&nbsp; Crosscultural&nbsp; reliability&nbsp; of&nbsp; the&nbsp; Childhood Health&nbsp; Assessment&nbsp; Questionnaire.&nbsp; J&nbsp; Rheumatol.&nbsp; 1994&nbsp; Dec;21(12):2349-52.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">193.Venables&nbsp; P,&nbsp; Maini&nbsp; R.&nbsp; Disease&nbsp; outcome&nbsp; and&nbsp; functional&nbsp; capacity&nbsp; in&nbsp; rheumatoid&nbsp; arthritis.&nbsp; UpToDate.&nbsp; Oct,&nbsp; 2012&nbsp; ed.</span></span></span></p>
<p data-obsoleto="text-align: left; margin-left: 40px;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial,helvetica,sans-serif;">194.Peters&nbsp; MJ,&nbsp; Symmons&nbsp; DP,&nbsp; McCarey&nbsp; D,&nbsp; Dijkmans&nbsp; BA,&nbsp; Nicola&nbsp; P,&nbsp; Kvien&nbsp; TK,&nbsp; et&nbsp; al.&nbsp; EULAR&nbsp; evidence-based&nbsp; recommendations&nbsp; for&nbsp; cardiovascular&nbsp; risk&nbsp; management&nbsp; in&nbsp; patients&nbsp; with&nbsp; rheumatoid&nbsp; arthritis&nbsp; and&nbsp; other&nbsp; forms&nbsp; of&nbsp; inflammatory&nbsp; arthritis.&nbsp; Ann&nbsp; Rheum&nbsp; Dis.&nbsp; 2010&nbsp; Feb;69(2):325-31.</span></span></span></p>
<p data-obsoleto="text-align: justify;">
			&nbsp;</p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">APÊNDICE&nbsp; 1</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">ÍNDICES&nbsp; COMPOSTOS&nbsp; DA&nbsp; ATIVIDADE&nbsp; DE&nbsp; DOENÇA&nbsp; (ICAD)&nbsp; DAS&nbsp; 28:&nbsp; Disease&nbsp; Activity&nbsp; Score,&nbsp; 28&nbsp; joints&nbsp; (0,49&nbsp; a&nbsp; 9,07)</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; DAS&nbsp; 28&nbsp; é&nbsp; um&nbsp; ICAD&nbsp; calculado&nbsp; a&nbsp; partir&nbsp; de&nbsp; quatro&nbsp; variáveis:</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(1)&nbsp; número&nbsp; de&nbsp; articulações&nbsp; dolorosas&nbsp; entre&nbsp; 28&nbsp; pré-estabelecidas&nbsp; (dolorosas28:&nbsp; interfalangianas&nbsp; proximais,&nbsp; metacarpofalangianas,&nbsp; punhos,&nbsp; cotovelos,&nbsp; ombros&nbsp; e&nbsp; joelhos),&nbsp; (2)&nbsp; número&nbsp; de&nbsp; articulações&nbsp; edemaciadas&nbsp; entre&nbsp; 28&nbsp; pré-&nbsp; estabelecidas&nbsp; (edemaciadas28:&nbsp; interfalangianas&nbsp; proximais,&nbsp; metacarpofalangianas,&nbsp; punhos,&nbsp; cotovelos,&nbsp; ombros&nbsp; e&nbsp; joelhos),&nbsp; (3)&nbsp; velocidade&nbsp; de&nbsp; hemossedimentação&nbsp; –&nbsp; VHS&nbsp; ou&nbsp; velocidade&nbsp; de&nbsp; sedimentação&nbsp; globular&nbsp; ?&nbsp; VSG&nbsp; em&nbsp; mm/h&nbsp; e&nbsp; (4)&nbsp; Escala&nbsp; Visual&nbsp; Analógica&nbsp; de&nbsp; Saúde&nbsp; Global&nbsp; segundo&nbsp; o&nbsp; paciente&nbsp; (EVAp:&nbsp; 0&nbsp; a&nbsp; 100&nbsp; mm).</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; fórmula&nbsp; do&nbsp; DAS&nbsp; 28&nbsp; é:&nbsp; 0,56&nbsp; x&nbsp; raiz&nbsp; quadrada(dolorosas28)&nbsp; +&nbsp; 0,28&nbsp; x&nbsp; raiz&nbsp; quadrada(edemaciadas28)&nbsp; +&nbsp; 0,70&nbsp; x&nbsp; ln(VHS)&nbsp; +&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">0,014&nbsp; x&nbsp; EVAp.</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">SDAI:&nbsp; Simplified&nbsp; Disease&nbsp; Activity&nbsp; Score&nbsp; (0,1&nbsp; a&nbsp; 86)&nbsp; O&nbsp; SDAI&nbsp; é&nbsp; um&nbsp; ICAD&nbsp; calculado&nbsp; a&nbsp; partir&nbsp; de&nbsp; cinco&nbsp; variáveis:</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(1)&nbsp; número&nbsp; de&nbsp; articulações&nbsp; dolorosas&nbsp; entre&nbsp; 28&nbsp; pré-estabelecidas&nbsp; (interfalangianas&nbsp; proximais,&nbsp; metacarpofalangianas,&nbsp; punhos,&nbsp; cotovelos,&nbsp; ombros&nbsp; e&nbsp; joelhos),&nbsp; (2)&nbsp; número&nbsp; de&nbsp; articulações&nbsp; edemaciadas&nbsp; entre&nbsp; 28&nbsp; pré-estabelecidas&nbsp; (interfalangianas&nbsp; proximais,&nbsp; metacarpofalangianas,&nbsp; punhos,&nbsp; cotovelos,&nbsp; ombros&nbsp; e&nbsp; joelhos),&nbsp; (3)&nbsp; proteína&nbsp; C&nbsp; reativa&nbsp; (PCR&nbsp; de</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">0,1&nbsp; a&nbsp; 10&nbsp; mg/dl),&nbsp; (4)&nbsp; Escala&nbsp; Visual&nbsp; Analógica&nbsp; de&nbsp; Atividade&nbsp; de&nbsp; Doença&nbsp; segundo&nbsp; o&nbsp; paciente&nbsp; (EVAp:&nbsp; 0&nbsp; a&nbsp; 10&nbsp; cm)&nbsp; e&nbsp; (5)&nbsp; Escala</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Visual&nbsp; Analógica&nbsp; de&nbsp; Atividade&nbsp; de&nbsp; Doença&nbsp; segundo&nbsp; o&nbsp; médico&nbsp; (EVAm:&nbsp; 0&nbsp; a&nbsp; 10&nbsp; cm).&nbsp; A&nbsp; fórmula&nbsp; do&nbsp; SDAI&nbsp; é:&nbsp; dolorosas28&nbsp; +&nbsp; edemaciadas28&nbsp; +&nbsp; PCR&nbsp; +&nbsp; EVAp&nbsp; +&nbsp; EVAm.&nbsp; CDAI:&nbsp; Clinical&nbsp; Disease&nbsp; Activity&nbsp; Score&nbsp; (0&nbsp; a&nbsp; 76)</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">O&nbsp; CDAI&nbsp; é&nbsp; um&nbsp; ICAD&nbsp; calculado&nbsp; a&nbsp; partir&nbsp; de&nbsp; quatro&nbsp; variáveis:</span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(1)&nbsp; número&nbsp; de&nbsp; articulações&nbsp; dolorosas&nbsp; entre&nbsp; 28&nbsp; pré-estabelecidas&nbsp; (interfalangianas&nbsp; proximais,&nbsp; metacarpofalangianas,&nbsp; punhos,&nbsp; cotovelos,&nbsp; ombros&nbsp; e&nbsp; joelhos),&nbsp; (2)&nbsp; número&nbsp; de&nbsp; articulações&nbsp; edemaciadas&nbsp; entre&nbsp; 28&nbsp; pré-estabelecidas&nbsp; (interfalangianas&nbsp; proximais,&nbsp; metacarpofalangianas,&nbsp; punhos,&nbsp; cotovelos,&nbsp; ombros&nbsp; e&nbsp; joelhos),&nbsp; (3)&nbsp; Escala&nbsp; Visual&nbsp; Analógica&nbsp; de&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">Atividade&nbsp; de&nbsp; Doença&nbsp; segundo&nbsp; o&nbsp; paciente&nbsp; (EVAp:&nbsp; 0&nbsp; a&nbsp; 10&nbsp; cm)&nbsp; e&nbsp; (4)&nbsp; Escala&nbsp; Visual&nbsp; Analógica&nbsp; de&nbsp; Atividade&nbsp; de&nbsp; Doença&nbsp; segundo&nbsp; o&nbsp; médico&nbsp; (EVAm:&nbsp; 0&nbsp; a&nbsp; 10&nbsp; cm).</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			&nbsp;</p>
<p></p></div>
<div>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; fórmula&nbsp; do&nbsp; CDAI&nbsp; é:&nbsp; dolorosas28&nbsp; +&nbsp; edemaciadas28&nbsp; +&nbsp; EVAp&nbsp; +&nbsp; EVAm.</span></span></span></span></p>
<p>
			&nbsp;</p>
<p data-obsoleto="margin-left: 11.25pt;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">APÊNDICE&nbsp; 2</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">AVALIAÇÃO&nbsp; DE&nbsp; CAPACIDADE&nbsp; FUNCIONAL&nbsp; Health&nbsp; Assessment&nbsp; Questionnaire&nbsp; –&nbsp; HAQ&nbsp; (0&nbsp; a&nbsp; 3)</span></span></span></span></p>
<p>
			&nbsp;</p>
<table border="1" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">No.</span></span></p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Atividade</span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Sem&nbsp; dificuldade</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Com&nbsp; alguma&nbsp; dificuldade</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Com&nbsp; muita&nbsp; di-ficuldade</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Incapaz&nbsp; de&nbsp; fazer</span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Vestir-se,&nbsp; inclusive&nbsp; amarrar&nbsp; os&nbsp; cordões&nbsp;<span data-obsoleto="background-color: transparent;">dos&nbsp; seus</span></span></span></p>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">sapatos,&nbsp; abotoar&nbsp; as&nbsp; suas&nbsp; roupas?</span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">01</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Lavar&nbsp; sua&nbsp; cabeça&nbsp; e&nbsp; os&nbsp;<span data-obsoleto="background-color: transparent;">seus&nbsp; cabelos?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">02</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Levantar-se&nbsp; de&nbsp; uma&nbsp;<span data-obsoleto="background-color: transparent;">maneira&nbsp; ereta&nbsp; de&nbsp; uma&nbsp; cadeira&nbsp; de &nbsp;encosto&nbsp; reto&nbsp; e&nbsp; sem&nbsp; braços?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">03</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Deitar-se&nbsp; e&nbsp; levantar-se&nbsp; da&nbsp; cama?</span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">04</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Cortar&nbsp; um&nbsp; pedaço&nbsp; de&nbsp; carne?</span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">05</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Levar&nbsp; à&nbsp; boca&nbsp; um&nbsp; copo&nbsp; ou&nbsp; uma&nbsp; xíca<span data-obsoleto="background-color: transparent;">ra&nbsp;cheia&nbsp; de&nbsp; café,&nbsp; leite&nbsp; ou&nbsp; água?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">06</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Abrir&nbsp; um&nbsp; saco&nbsp; de&nbsp; leite&nbsp; comum?</span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">07</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Caminhar&nbsp; em&nbsp; lugares&nbsp; planos?</span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">08</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Subir&nbsp; cinco&nbsp; degraus?</span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">09</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Lavar&nbsp; seu&nbsp; corpo&nbsp; inteiro&nbsp; e&nbsp;<span data-obsoleto="background-color: transparent;">secá-lo&nbsp; após&nbsp; o&nbsp; banho?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">10</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Tomar&nbsp; um&nbsp; banho&nbsp;<span data-obsoleto="background-color: transparent;">de&nbsp; chuveiro?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">11</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Sentar-se&nbsp; e&nbsp; levantar-se&nbsp;<span data-obsoleto="background-color: transparent;">de&nbsp; um&nbsp; vaso&nbsp; sanitário?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">12</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Levantar&nbsp; os&nbsp; braços&nbsp; e&nbsp;<span data-obsoleto="background-color: transparent;">pegar&nbsp; um&nbsp; objeto&nbsp; de&nbsp; mais&nbsp; ou&nbsp; menos&nbsp; 2,5&nbsp; quilos,&nbsp; que&nbsp;está&nbsp; posicionado&nbsp; um&nbsp; pouco&nbsp;acima&nbsp; de&nbsp; sua&nbsp; cabeça?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">13</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Curvar-se&nbsp; para&nbsp; pegar&nbsp; suas&nbsp; roupas&nbsp; no&nbsp;<span data-obsoleto="background-color: transparent;">chão?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">14</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Segurar-se&nbsp; em&nbsp; pé&nbsp; no&nbsp; ônibus&nbsp; ou&nbsp; no&nbsp;<span data-obsoleto="background-color: transparent;">metrô?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">15</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Abrir&nbsp; potes&nbsp; ou&nbsp; vidros&nbsp; de&nbsp;<span data-obsoleto="background-color: transparent;">conserva&nbsp; que&nbsp; tenham&nbsp; sido&nbsp;previamente&nbsp; abertos?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">16</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Abrir&nbsp; e&nbsp; fechar&nbsp; torneiras?</span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">17</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Fazer&nbsp; compras&nbsp; na&nbsp; redondeza&nbsp; onde mora?</span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Entrar&nbsp; e&nbsp; sair&nbsp; de&nbsp;<span data-obsoleto="background-color: transparent;">um&nbsp; ônibus?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">19</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 405px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Realizar&nbsp; tarefas&nbsp; tais c<span data-obsoleto="background-color: transparent;">omo usar a vassoura&nbsp;para&nbsp; varrer&nbsp; e&nbsp; o&nbsp; rodo&nbsp; para&nbsp; puxar&nbsp; água?</span></span></span></p>
</td>
<td data-obsoleto="width: 212px;">
<p>
							&nbsp;</p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">20</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
</tbody>
</table>
<p>
			&nbsp;</p>
<p data-obsoleto="margin-left: 11.25pt;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">&nbsp;Avaliação&nbsp; dos&nbsp; Escores&nbsp; do&nbsp; HAQ:</span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">média&nbsp; aritmética&nbsp; dos&nbsp; maiores&nbsp; escores&nbsp; de&nbsp; cada&nbsp; componente</span></span></span></span></p>
<p>
			&nbsp;</p>
<table border="1" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td>
<p data-obsoleto="text-align: center;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componentes</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Perguntas</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Maior&nbsp; escore</span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 1&nbsp; (vestir-se).</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Perguntas&nbsp; 1&nbsp; e&nbsp; 2.</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 2&nbsp; (levantar-se).</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Perguntas&nbsp; 3&nbsp; e&nbsp; 4.</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 3&nbsp; (alimentar-se).</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Perguntas&nbsp; 5,&nbsp; 6&nbsp; e&nbsp; 7.</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 4&nbsp; (caminhar).</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Perguntas&nbsp; 8&nbsp; e&nbsp; 9.</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 5&nbsp; (higiene&nbsp; pessoal).</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Perguntas&nbsp; 10,&nbsp; 11&nbsp; e&nbsp; 12.</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 6&nbsp; (alcançar&nbsp; objetos).</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Perguntas&nbsp; 13&nbsp; e&nbsp; 14.</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 7&nbsp; (apreender&nbsp; objetos).</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Perguntas&nbsp; 15,&nbsp; 16&nbsp; e&nbsp; 17.</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 8&nbsp; (outras&nbsp; atividades).</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Perguntas&nbsp; 18,&nbsp; 19&nbsp; e&nbsp; 20.</span></span></p>
</td>
<td>
<p>
							&nbsp;</p>
</td>
</tr>
</tbody>
</table>
<p>
			&nbsp;</p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; fórmula&nbsp; do&nbsp; HAQ&nbsp; é&nbsp; calculada&nbsp; a&nbsp; partir&nbsp; dos&nbsp; maiores&nbsp; escores&nbsp; de&nbsp; cada&nbsp; componente:&nbsp; somatório&nbsp; dos&nbsp; maiores&nbsp; escores&nbsp; de&nbsp; cada&nbsp; componente&nbsp; (o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 1&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 2&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 3&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 4&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 5&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 6&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 7&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 8)&nbsp; dividido&nbsp; por&nbsp; 8.&nbsp; Childhood&nbsp; Assessment&nbsp; Questionnaire&nbsp; –&nbsp; CHAQ&nbsp; (0&nbsp; a&nbsp; 3)</span></span></span></span></p>
<p>
			&nbsp;</p>
<table border="1" cellpadding="0" cellspacing="0" data-obsoleto="width: 736px;">
<tbody>
<tr>
<td data-obsoleto="width: 15px; height: 60px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">No.</span></span></p>
</td>
<td>
<p data-obsoleto="text-align: center;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Atividade</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Sem&nbsp; dificuldade</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Com&nbsp; alguma dificuldade</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Com muita &nbsp;dificuldade</span></span></p>
</td>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Incapaz&nbsp; de&nbsp;fazer</span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 48px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 158px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Vestir-se,&nbsp; inclusive&nbsp; amarrar&nbsp; os&nbsp; cordões&nbsp; dos&nbsp; seus&nbsp; sapatos,&nbsp; abotoar&nbsp; as&nbsp; suas&nbsp; roupas?</span></span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 48px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 129px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">01</span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 48px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 112px; height: 48px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 48px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 158px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Lavar&nbsp; a&nbsp; sua&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">cabeça &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; e&nbsp;os&nbsp;seus&nbsp; cabelos?</span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 48px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 129px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">02</span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 48px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 112px; height: 48px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 12px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 158px; height: 12px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Retirar&nbsp; as&nbsp; meias?</span></span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 12px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 129px; height: 12px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">03</span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 12px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 112px; height: 12px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 12px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 158px; height: 12px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Cortas&nbsp; as&nbsp; unhas?</span></span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 12px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 129px; height: 12px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">04</span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 12px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 112px; height: 12px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 36px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 158px; height: 36px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Levantar-se&nbsp; de&nbsp; uma&nbsp; ca-&nbsp; deira&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">baixa&nbsp; ou&nbsp; do&nbsp; chão?</span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 36px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 129px; height: 36px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">05</span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 36px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 112px; height: 36px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 36px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 158px; height: 36px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Entrar&nbsp; e&nbsp; sair&nbsp; da&nbsp; cama&nbsp; ou&nbsp; ficar&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">em&nbsp; pé&nbsp; em&nbsp; um&nbsp; berço?</span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 36px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 129px; height: 36px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">06</span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 36px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 112px; height: 36px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 24px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 158px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Cortar&nbsp; sua&nbsp; própria&nbsp; carne?</span></span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 24px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 129px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">07</span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 24px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 112px; height: 24px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 36px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 158px; height: 36px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Levar&nbsp; uma&nbsp; xícara&nbsp; ou&nbsp; um</span></span></span></span></p>
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">copo&nbsp; até&nbsp; a&nbsp; boca?</span></span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 36px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 129px; height: 36px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">08</span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 36px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 112px; height: 36px;">
<p>
							&nbsp;</p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 24px;">
<p>
							&nbsp;</p>
</td>
<td data-obsoleto="width: 59px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Abrir uma caixa nova de cereais?</span></span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">09</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 59px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Caminhar&nbsp;</span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif; background-color: transparent;">em&nbsp;</span><span data-obsoleto="font-family: arial, helvetica, sans-serif; background-color: transparent;">lugares&nbsp;</span><span data-obsoleto="font-family: arial, helvetica, sans-serif; background-color: transparent;">planos?</span></span></span></span></p>
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">10</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 15px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 59px; height: 13px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Subir&nbsp; cinco degraus</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 50px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 13px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">11</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 31px;">
<p data-obsoleto="margin-left: 5.25pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Lavar&nbsp; o&nbsp; corpo&nbsp; inteiro&nbsp; e&nbsp; secá-lo&nbsp; após&nbsp; o&nbsp; banho?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 31px;">
<p data-obsoleto="margin-left: 5.25pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">12</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 60px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 60px;">
<p data-obsoleto="margin-left: 5pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Tomar&nbsp; um&nbsp; banho&nbsp; de&nbsp; banheira&nbsp; –&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">entrar &nbsp;e sair?</span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 60px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 60px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">13</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 60px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 60px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 48px;">
<p data-obsoleto="margin-left: 5pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Sentar-se&nbsp; e&nbsp; levantar-se&nbsp; de&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">um&nbsp; vaso&nbsp; sanitário&nbsp; ou&nbsp; de&nbsp; um&nbsp; penico?</span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">14</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 13px;">
<p data-obsoleto="margin-left: 5pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Escovar&nbsp; os&nbsp; dentes?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 13px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">15</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 19px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 19px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Pentear/escovar &nbsp;o&nbsp; cabelo?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 19px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 19px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">16</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 19px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 19px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 72px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 72px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Levantar&nbsp; os&nbsp; braços&nbsp; e&nbsp; pegar&nbsp; um&nbsp; objeto&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">como&nbsp; um&nbsp; jogo&nbsp; grande&nbsp; ou&nbsp;livros posicionados&nbsp; pouco&nbsp; aci-ma&nbsp; da&nbsp; cabeça?</span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 72px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 72px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">17</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 72px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 72px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Curvar-se&nbsp; para&nbsp; pegar&nbsp; suas</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">roupas&nbsp; ou&nbsp; um&nbsp; pedaço&nbsp; de</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">papel&nbsp; no&nbsp; chão?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">18</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Vestir&nbsp; uma&nbsp; malha&nbsp; por&nbsp; cima&nbsp; da&nbsp; cabeça?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">19</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Virar&nbsp; a&nbsp; cabeça&nbsp; e&nbsp; olhar&nbsp; sobre&nbsp; o&nbsp; ombro?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">20</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Escrever&nbsp; ou&nbsp; desenhar&nbsp; com</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">uma&nbsp; caneta&nbsp; ou&nbsp; um&nbsp; lápis?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">21</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 36px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 36px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Abrir&nbsp; as&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif; background-color: transparent;">portas&nbsp;</span><span data-obsoleto="font-family: arial, helvetica, sans-serif; background-color: transparent;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; de&nbsp;</span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">carro?</span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 36px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 36px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">22</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 36px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 36px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 31px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Abrir&nbsp; tampas&nbsp; de&nbsp; rosca&nbsp; de&nbsp; potes&nbsp; já&nbsp; abertos&nbsp; antes?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 31px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">23</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Abrir&nbsp; e&nbsp; fechar&nbsp; torneiras?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">24</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 31px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Abrir&nbsp; portas&nbsp; quando&nbsp; tem&nbsp; que&nbsp; virar&nbsp; a&nbsp; maçaneta?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 31px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">25</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 31px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Levar&nbsp; recados&nbsp; e&nbsp; fazer&nbsp; compras n</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">as&nbsp; redondezas&nbsp; de&nbsp; onde&nbsp; mora?</span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">26</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Entrar&nbsp; e&nbsp; sair&nbsp; de&nbsp; um&nbsp; carro, carro&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">de&nbsp; brinquedo&nbsp; ou&nbsp; ônibus escolar?</span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 48px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">27</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 48px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Andar&nbsp; de&nbsp; bicicleta&nbsp; ou&nbsp; triciclo?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 24px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">28</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 70px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 70px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Ajudar&nbsp; em&nbsp; tarefas&nbsp; caseiras</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(lavar&nbsp; pratos,&nbsp; retirar&nbsp; o&nbsp; lixo,&nbsp; aspirar,&nbsp; limpar&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">o&nbsp; quintal,&nbsp; fazer&nbsp; a&nbsp; cama,&nbsp; limpar&nbsp; o&nbsp; quarto)?</span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 70px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 70px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">29</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 70px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 70px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 19px; height: 12px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 154px; height: 12px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Correr&nbsp; e&nbsp; brincar?</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 46px; height: 12px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 129px; height: 12px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">30</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 63px; height: 12px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
<td data-obsoleto="width: 112px; height: 12px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p>
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Avaliação&nbsp; dos&nbsp; Escores&nbsp; do&nbsp; CHAQ:</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">média&nbsp; aritmética&nbsp; dos&nbsp; maiores&nbsp; escores&nbsp; de&nbsp; cada&nbsp; componente</span></span></span></span></span></p>
<p>
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<table border="1" cellpadding="0" cellspacing="0" data-obsoleto="width: 626px;">
<tbody>
<tr>
<td data-obsoleto="width: 191px; height: 12px;">
<p data-obsoleto="margin-left: 47.4pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Componente</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 165px; height: 12px;">
<p data-obsoleto="margin-left: 19.35pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Perguntas</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 205px; height: 12px;">
<p data-obsoleto="margin-left: 22.15pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Maior&nbsp; escore</span></span></span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 1&nbsp; (vestir-se).</span></span></p>
</td>
<td data-obsoleto="width: 165px; height: 13px;">
<p data-obsoleto="margin-left: 16.05pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Perguntas&nbsp; 1&nbsp; a&nbsp; 4.</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 205px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 2&nbsp; (levantar-se).</span></span></p>
</td>
<td data-obsoleto="width: 165px; height: 13px;">
<p data-obsoleto="margin-left: 16.05pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Perguntas&nbsp; 5&nbsp; e&nbsp; 6.</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 205px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 3&nbsp; (alimentar-se).</span></span></p>
</td>
<td data-obsoleto="width: 165px; height: 13px;">
<p data-obsoleto="margin-left: 16.05pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Perguntas&nbsp; 7&nbsp; a&nbsp; 9.</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 205px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 4&nbsp; (caminhar)<span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">.</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 165px; height: 12px;">
<p data-obsoleto="margin-left: 11.75pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Perguntas&nbsp; 10&nbsp; e&nbsp; 11.</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 205px; height: 12px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 5&nbsp; (higiene&nbsp; pessoal).</span></span></p>
</td>
<td data-obsoleto="width: 165px; height: 12px;">
<p data-obsoleto="margin-left: 11.75pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Perguntas&nbsp; 12&nbsp; a&nbsp; 16.</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 205px; height: 12px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 6&nbsp; (alcançar).</span></span></p>
</td>
<td data-obsoleto="width: 165px; height: 12px;">
<p data-obsoleto="margin-left: 11.75pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Perguntas&nbsp; 17&nbsp; a&nbsp; 20.</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 205px; height: 12px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 7&nbsp; (apreender&nbsp; objetos).</span></span></p>
</td>
<td data-obsoleto="width: 165px; height: 13px;">
<p data-obsoleto="margin-left: 11.75pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Perguntas&nbsp; 21&nbsp; a&nbsp; 25.</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 205px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
<tr>
<td>
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Componente&nbsp; 8&nbsp; (outras&nbsp; atividades).</span></span></p>
</td>
<td data-obsoleto="width: 165px; height: 13px;">
<p data-obsoleto="margin-left: 11.75pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Perguntas&nbsp; 26&nbsp; a&nbsp; 30.</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 205px; height: 13px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p>
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">A&nbsp; fórmula&nbsp; do&nbsp; CHAQ&nbsp; é&nbsp; calculada&nbsp; a&nbsp; partir&nbsp; dos&nbsp; maiores&nbsp; escores&nbsp; de&nbsp; cada&nbsp; componente:&nbsp; somatório&nbsp; dos&nbsp; maiores&nbsp; escores&nbsp; de&nbsp; cada&nbsp; componente&nbsp; (o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 1&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 2&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 3&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 4&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 5&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 6&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 7&nbsp; mais&nbsp; o&nbsp; maior&nbsp; escore&nbsp; do&nbsp; componente&nbsp; 8)&nbsp; dividido&nbsp; por&nbsp; 8.</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family: arial, helvetica, sans-serif;">&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">TERMO&nbsp; DE&nbsp; ESCLARECIMENTO&nbsp; E&nbsp; RESPONSABILIDADE</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Naproxeno,&nbsp; Cloroquina,&nbsp; Hidroxicloroquina,&nbsp; Sulfassalazina,&nbsp; Metotrexato,&nbsp; Azatioprina,&nbsp; Ciclosporina,&nbsp; Leflunomida,&nbsp; Metilprednisolona,&nbsp; Adalimumabe,&nbsp; Certolizumabe&nbsp; Pegol,&nbsp; Etanercepte,&nbsp; Infliximabe,&nbsp; Golimumabe,&nbsp; Abatacepte,&nbsp; Rituximabe&nbsp; e&nbsp; Tocilizumabe.</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 10.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Eu,&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(nome&nbsp; do(a)&nbsp; paciente),&nbsp; declaro&nbsp; ter&nbsp; sido&nbsp; informado(a)&nbsp; claramente&nbsp; sobre&nbsp; benefícios,&nbsp; riscos,&nbsp; contraindicações&nbsp; e&nbsp; principais&nbsp; efeitos&nbsp; adversos&nbsp; relacionados&nbsp; ao&nbsp; uso&nbsp; de&nbsp; naproxeno,&nbsp; cloroquina,&nbsp; hidroxicloroquina,&nbsp; sulfassalazina,&nbsp; metotrexato,&nbsp; azatioprina,&nbsp; ciclosporina,&nbsp; leflunomida,&nbsp; metilprednisolona,&nbsp; adalimumabe,&nbsp; certolizumabe&nbsp; pegol,&nbsp; etanercepte,&nbsp; infliximabe,&nbsp; golimumabe,&nbsp; abatacepte,&nbsp; rituximabe&nbsp; e&nbsp; tocilizumabe,&nbsp; indicados&nbsp; para&nbsp; o&nbsp; tratamento&nbsp; da&nbsp; artrite&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">reumatoide.</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Os&nbsp; termos&nbsp; médicos&nbsp; foram&nbsp; explicados&nbsp; e&nbsp; todas&nbsp; as&nbsp; dúvidas&nbsp; foram&nbsp; esclarecidas&nbsp; pelo&nbsp; médico &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(nome&nbsp; do&nbsp; médico&nbsp; que&nbsp; prescreve).</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Expresso&nbsp; também&nbsp; minha&nbsp; concordância&nbsp; e&nbsp; espontânea&nbsp; vontade&nbsp; em&nbsp; submeter-me&nbsp; ao&nbsp; referido&nbsp; tratamento,&nbsp; assumindo&nbsp; a&nbsp; responsabilidade&nbsp; e&nbsp; os&nbsp; riscos&nbsp; pelos&nbsp; eventuais&nbsp; efeitos&nbsp; indesejáveis.&nbsp; Assim,&nbsp; declaro&nbsp; que&nbsp; fui&nbsp; claramente&nbsp; informado(a)&nbsp; de&nbsp; que&nbsp; o(s)&nbsp; medicamento(s)&nbsp; que&nbsp; passo&nbsp; a&nbsp; receber&nbsp; pode(m)&nbsp; trazer&nbsp; os&nbsp; seguintes&nbsp; benefícios:</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; prevenção&nbsp; das&nbsp; complicações&nbsp; da&nbsp; doença;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; controle&nbsp; da&nbsp; atividade&nbsp; da&nbsp; doença;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; melhora&nbsp; da&nbsp; capacidade&nbsp; de&nbsp; realizar&nbsp; atividades&nbsp; funcionais;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; melhora&nbsp; da&nbsp; qualidade&nbsp; de&nbsp; vida.</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Fui&nbsp; também&nbsp; claramente&nbsp; informado(a)&nbsp; a&nbsp; respeito&nbsp; das&nbsp; seguintes&nbsp; contraindicações,&nbsp; potenciais&nbsp; efeitos&nbsp; colaterais&nbsp; e&nbsp; riscos:</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; os&nbsp; riscos&nbsp; na&nbsp; gestação&nbsp; e&nbsp; na&nbsp; amamentação&nbsp; já&nbsp; são&nbsp; conhecidos;&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">portanto,&nbsp; caso&nbsp; engravide,&nbsp; devo&nbsp; avisar&nbsp; imediatamente&nbsp; o&nbsp; médico;</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; medicamentos&nbsp; classificados&nbsp; na&nbsp; gestação&nbsp; como&nbsp; categoria&nbsp; B&nbsp; (estudos&nbsp; em&nbsp; animais&nbsp; não&nbsp; mostraram&nbsp; anormalidades&nbsp; nos&nbsp; descendentes,&nbsp; porém&nbsp; não&nbsp; há&nbsp; estudos&nbsp; em&nbsp; humanos;&nbsp; risco&nbsp; para&nbsp; o&nbsp; bebê&nbsp; muito&nbsp; improvável):&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">infliximabe,&nbsp; etanercepte,&nbsp; adalimumabe&nbsp; e&nbsp; sulfassalazina&nbsp; (no&nbsp; primeiro&nbsp; trimestre);</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; medicamentos&nbsp; classificados&nbsp; na&nbsp; gestação&nbsp; como&nbsp; categoria&nbsp; C&nbsp; (estudos&nbsp; em&nbsp; animais&nbsp; mostraram&nbsp; anormalidades&nbsp; nos&nbsp; descendentes,&nbsp; porém&nbsp; não&nbsp; há&nbsp; estudos&nbsp; em&nbsp; humanos;&nbsp; o&nbsp; risco&nbsp; para&nbsp; o&nbsp; bebê&nbsp; não&nbsp; pode&nbsp; ser&nbsp; descartado,&nbsp; mas&nbsp; um&nbsp; benefício&nbsp; potencial&nbsp; pode&nbsp; ser&nbsp; maior&nbsp; do&nbsp; que&nbsp; os&nbsp; riscos):&nbsp; cloroquina,&nbsp; hidroxicloroquina,&nbsp; ciclosporina,&nbsp; metilprednisolona,&nbsp; abatacepte,&nbsp; rituximabe,&nbsp; tocilizumabe,&nbsp; golimumabe;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; medicamento&nbsp; classificado&nbsp; na&nbsp; gestação&nbsp; como&nbsp; categoria&nbsp; D&nbsp; (há&nbsp; evidências&nbsp; de&nbsp; riscos&nbsp; ao&nbsp; feto,&nbsp; mas&nbsp; um&nbsp; benefício&nbsp; potencial&nbsp; pode&nbsp; ser&nbsp; maior&nbsp; do&nbsp; que&nbsp; os&nbsp; riscos)&nbsp; sulfassalazina&nbsp; (no&nbsp; terceiro&nbsp; trimestre)&nbsp; e&nbsp; azatioprina;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; medicamentos&nbsp; classificados&nbsp; na&nbsp; gestação&nbsp; como&nbsp; categoria&nbsp; X&nbsp; (estudos&nbsp; em&nbsp; animais&nbsp; ou&nbsp; em&nbsp; humanos&nbsp; claramente&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">monstraram&nbsp; risco&nbsp; para&nbsp; o&nbsp; bebê&nbsp; que&nbsp; suplantam&nbsp; quaisquer&nbsp; potenciais&nbsp; benefícios,&nbsp; sendo&nbsp; contraindicados&nbsp; na&nbsp; gestação):&nbsp;leflunomida&nbsp; e&nbsp; metotrexato;</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; do&nbsp; naproxeno:&nbsp; dor&nbsp; abdominal,&nbsp; sede,&nbsp; constipação,&nbsp; diarreia,&nbsp; dispneia,&nbsp; náuseas,&nbsp; estomatite,&nbsp; azia,&nbsp; sonolência,&nbsp; vertigens,&nbsp; enxaquecas,&nbsp; tontura,&nbsp; erupções&nbsp; cutâneas,&nbsp; prurido,&nbsp; sudorese,&nbsp; ocorrência&nbsp; de&nbsp; distúrbios&nbsp; auditivos&nbsp; e&nbsp; visuais,&nbsp; palpitações,&nbsp; edemas,&nbsp; dispepsia&nbsp; e&nbsp; púrpura;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; da&nbsp; azatioprina:&nbsp; diminuição&nbsp; das&nbsp; células&nbsp; brancas,&nbsp; vermelhas&nbsp; e&nbsp; plaquetas&nbsp; do&nbsp; sangue,&nbsp; náuseas,&nbsp; vômitos,</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">diarreia,&nbsp; dor&nbsp; abdominal,&nbsp; fezes&nbsp; com&nbsp; sangue,&nbsp; problemas&nbsp; no&nbsp; fígado,&nbsp; febre,&nbsp; calafrios,&nbsp; diminuição&nbsp; de&nbsp; apetite,&nbsp; vermelhidão&nbsp; de&nbsp; pele,&nbsp; perda&nbsp; de&nbsp; cabelo,&nbsp; aftas,&nbsp; dores&nbsp; nas&nbsp; juntas,&nbsp; problemas&nbsp; nos&nbsp; olhos&nbsp; (retinopatia),&nbsp; falta&nbsp; de&nbsp; ar,&nbsp; pressão&nbsp; baixa;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; de&nbsp; cloroquina&nbsp; e&nbsp; hidroxicloroquina:&nbsp; distúrbios&nbsp; visuais&nbsp; com&nbsp; visão&nbsp; borrada&nbsp; e&nbsp; fotofobia,&nbsp; edema&nbsp; macular,&nbsp; pigmentação&nbsp; anormal,&nbsp; retinopatia,&nbsp; atrofia&nbsp; do&nbsp; disco&nbsp; óptico,&nbsp; escotomas,&nbsp; diminuição&nbsp; da&nbsp; acuidade&nbsp; visual&nbsp; e&nbsp; nistagmo;&nbsp; outras&nbsp; reações:&nbsp; problemas&nbsp; emocionais,&nbsp; dores&nbsp; de&nbsp; cabeça,&nbsp; tonturas,&nbsp; movimentos&nbsp; involuntários,&nbsp; cansaço,&nbsp; branqueamento&nbsp; e&nbsp; queda&nbsp; de&nbsp; cabelos,&nbsp; mudanças&nbsp; da&nbsp; cor&nbsp; da&nbsp; pele&nbsp; e&nbsp; alergias&nbsp; leves&nbsp; a&nbsp; graves,&nbsp; náuseas,&nbsp; vômitos,&nbsp; perda&nbsp; de&nbsp; apetite,&nbsp; desconforto&nbsp; abdominal,&nbsp; diarreia,&nbsp; parada&nbsp; na&nbsp; produção&nbsp; de&nbsp; sangue&nbsp; pela&nbsp; medula&nbsp; óssea&nbsp; (anemia&nbsp; aplásica),&nbsp; parada&nbsp; na&nbsp; produção&nbsp; de&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">células&nbsp; brancas&nbsp; pela&nbsp; medula&nbsp; óssea&nbsp; (agranulocitose),&nbsp; diminuição&nbsp; de&nbsp; células&nbsp; brancas&nbsp; do&nbsp; sangue&nbsp; e&nbsp; de&nbsp; plaquetas,&nbsp; destruição&nbsp; das&nbsp; células&nbsp; do&nbsp; sangue&nbsp; (hemólise);</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">reações&nbsp; raras:&nbsp; miopatia,&nbsp; paralisia,&nbsp; zumbido&nbsp; e&nbsp; surdez;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; da&nbsp; sulfassalazina:&nbsp; dores&nbsp; de&nbsp; cabeça,&nbsp; aumento&nbsp; da&nbsp; sensibilidade&nbsp; aos&nbsp; raios&nbsp; solares,&nbsp; alergias&nbsp; de&nbsp; pele&nbsp; graves,&nbsp; dores&nbsp; abdominais,&nbsp; náuseas,&nbsp; vômitos,&nbsp; perda&nbsp; de&nbsp; apetite,&nbsp; diarreia,&nbsp; hepatite,&nbsp; dificuldade&nbsp; para&nbsp; engolir,&nbsp; diminuição&nbsp; do&nbsp; número&nbsp; dos&nbsp; glóbulos&nbsp; brancos&nbsp; no&nbsp; sangue,&nbsp; parada&nbsp; na&nbsp; produção&nbsp; de&nbsp; sangue&nbsp; pela&nbsp; medula&nbsp; óssea&nbsp; (anemia&nbsp; aplásica),&nbsp; anemia&nbsp; por&nbsp; destruição&nbsp; aumentada&nbsp; dos&nbsp; glóbulos&nbsp; vermelhos&nbsp; do&nbsp; sangue&nbsp; (anemia&nbsp; hemolítica),&nbsp; diminuição&nbsp; do&nbsp; número&nbsp; de&nbsp; plaquetas&nbsp; no&nbsp; sangue,&nbsp; falta&nbsp; de&nbsp; ar&nbsp; associada&nbsp; a&nbsp; tosse&nbsp; e&nbsp; febre&nbsp; (pneumonite&nbsp; intersticial),&nbsp; dores&nbsp; articulares,&nbsp; cansaço&nbsp; e&nbsp; reações&nbsp; alérgicas;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; da&nbsp; ciclosporina:&nbsp; disfunção&nbsp; renal,&nbsp; tremores,&nbsp; aumento&nbsp; da&nbsp; quantidade&nbsp; de&nbsp; pelos&nbsp; no&nbsp; corpo,&nbsp; pressão&nbsp; alta,&nbsp; hipertrofia&nbsp; gengival,&nbsp; aumento&nbsp; dos&nbsp; níveis&nbsp; de&nbsp; colesterol&nbsp; e&nbsp; triglicerídios,&nbsp; formigamentos,&nbsp; dor&nbsp; no&nbsp; peito,&nbsp; infarto&nbsp; do&nbsp; miocárdio,&nbsp; batimentos&nbsp; rápidos&nbsp; do&nbsp; coração,&nbsp; convulsões,&nbsp; confusão,&nbsp; ansiedade,&nbsp; depressão,&nbsp; fraqueza,&nbsp; dores&nbsp; de&nbsp; cabeça,&nbsp; unhas&nbsp; e&nbsp; cabelos&nbsp; quebradiços,&nbsp; coceira,&nbsp; espinhas,&nbsp; náusea,&nbsp; vômitos,&nbsp; perda&nbsp; de&nbsp; apetite,&nbsp; gastrite,&nbsp; úlcera&nbsp; péptica,&nbsp; soluços,&nbsp; inflamação&nbsp; na&nbsp; boca,&nbsp; dificuldade&nbsp; para&nbsp; engolir,&nbsp; hemorragias,&nbsp; inflamação&nbsp; do&nbsp; pâncreas,&nbsp; prisão&nbsp; de&nbsp; ventre,&nbsp; desconforto&nbsp; abdominal,&nbsp; síndrome&nbsp; hemolíticourêmica,&nbsp; diminuição&nbsp; das&nbsp; células&nbsp; brancas&nbsp; do&nbsp; sangue,&nbsp; linfoma,&nbsp; calorões,&nbsp; hiperpotassemia,&nbsp; hipomagnesemia,&nbsp; hiperuricemia,&nbsp; toxicidade&nbsp; para&nbsp; os&nbsp; músculos,&nbsp; disfunção&nbsp; respiratória,&nbsp; sensibilidade&nbsp; aumentada&nbsp; a&nbsp; temperatura&nbsp; e&nbsp; reações&nbsp; alérgicas,&nbsp; toxicidade&nbsp; renal&nbsp; e&nbsp; hepática&nbsp; e&nbsp; ginecomastia;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; da&nbsp; metiprednisolona:&nbsp; retenção&nbsp; de&nbsp; líquidos,&nbsp; aumento&nbsp; da&nbsp; pressão&nbsp; arterial,&nbsp; problemas&nbsp; no&nbsp; coração,&nbsp; fraqueza&nbsp; nos&nbsp; músculos,&nbsp; problema&nbsp; nos&nbsp; ossos&nbsp; (osteoporose),&nbsp; problemas&nbsp; de&nbsp; estômago&nbsp; (úlceras),&nbsp; inflamação&nbsp; do&nbsp; pâncreas&nbsp; (pancreatite),&nbsp; dificuldade&nbsp; de&nbsp; cicatrização&nbsp; de&nbsp; feridas,&nbsp; pele&nbsp; fina&nbsp; e&nbsp; frágil,&nbsp; irregularidades&nbsp; na&nbsp; menstruação,&nbsp; e&nbsp; manifestação&nbsp; de&nbsp; diabetes&nbsp; melito;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; do&nbsp; metotrexato:&nbsp; convulsões,&nbsp; encefalopatia,&nbsp; febre,&nbsp; calafrios,&nbsp; sonolência,&nbsp; queda&nbsp; de&nbsp; cabelo,&nbsp; espinhas,&nbsp; furúnculos,&nbsp; alergias&nbsp; de&nbsp; pele&nbsp; leves&nbsp; a&nbsp; graves,&nbsp; sensibilidade&nbsp; à&nbsp; luz,&nbsp; alterações&nbsp; da&nbsp; pigmentação&nbsp; da&nbsp; pele&nbsp; e&nbsp; de&nbsp; mucosas,&nbsp; náuseas,&nbsp; vômitos,&nbsp; perda&nbsp; de&nbsp; apetite,&nbsp; inflamação&nbsp; da&nbsp; boca,&nbsp; úlceras&nbsp; de&nbsp; trato&nbsp; gastrointestinal,&nbsp; hepatite,&nbsp; cirrose&nbsp; e&nbsp; necrose&nbsp; hepática,&nbsp; diminuição&nbsp; das&nbsp; células&nbsp; brancas&nbsp; do&nbsp; sangue&nbsp; e&nbsp; das&nbsp; plaquetas,&nbsp; insuficiência&nbsp; renal,&nbsp; fibrose&nbsp; pulmonar&nbsp; e&nbsp; diminuição&nbsp; das&nbsp; defesas&nbsp; imunológicas&nbsp; do&nbsp; organismo&nbsp; com&nbsp; ocorrência&nbsp; de&nbsp; infecções;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; da&nbsp; leflunomida:&nbsp; pressão&nbsp; alta,&nbsp; dor&nbsp; no&nbsp; peito,&nbsp; palpitações,&nbsp; aumento&nbsp; do&nbsp; número&nbsp; de&nbsp; batimentos&nbsp; do&nbsp; coração,&nbsp; vasculite,&nbsp; varizes,&nbsp; edema,&nbsp; infeccções&nbsp; respiratórias,&nbsp; sangramento&nbsp; nasal,&nbsp; diarreia,&nbsp; hepatite,&nbsp; náuseas,&nbsp; vômitos,&nbsp; perda&nbsp; de&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">apetite,&nbsp; gastrite,&nbsp; gastroenterite,&nbsp; dor&nbsp; abdominal,&nbsp; azia,&nbsp; gazes,&nbsp; ulcerações&nbsp; na&nbsp; boca,&nbsp; pedra&nbsp; na&nbsp; vesícula,&nbsp; prisão&nbsp; de&nbsp; ventre,&nbsp; desconforto&nbsp; abdominal,&nbsp; sangramento&nbsp; nas&nbsp; fezes,&nbsp; candidíase&nbsp; oral,&nbsp; aumento&nbsp; das&nbsp; glândulas&nbsp; salivares,&nbsp; boca&nbsp; seca,&nbsp; alterações&nbsp; dentárias,&nbsp; distúrbios&nbsp; do&nbsp; paladar,&nbsp; infecções&nbsp; do&nbsp; trato&nbsp; geniturinário,&nbsp; ansiedade,&nbsp; depressão,&nbsp; fraqueza,&nbsp; dores&nbsp; de&nbsp; cabeça,&nbsp; tonturas,&nbsp; febre,&nbsp; sonolência,&nbsp; distúrbios&nbsp; do&nbsp; sono,&nbsp; formigamentos,&nbsp; alteração&nbsp; da&nbsp; cor&nbsp; e&nbsp; queda&nbsp; de&nbsp; cabelo,&nbsp; alergias&nbsp; de&nbsp; pele,&nbsp; coceira,&nbsp; pele&nbsp; seca,&nbsp; espinhas,&nbsp; hematomas,&nbsp; alterações&nbsp; das&nbsp; unhas,&nbsp; alterações&nbsp; da&nbsp; cor&nbsp; da&nbsp; pele,&nbsp; úlceras&nbsp; de&nbsp; pele,&nbsp; hipopotassemia,&nbsp; diabetes&nbsp; melito,&nbsp; hiperlipidemia,&nbsp; hipertireoidismo,&nbsp; desordens&nbsp; menstruais,&nbsp; dores&nbsp; pelo&nbsp; corpo,&nbsp; alteração&nbsp; da&nbsp; visão,&nbsp; anemia,&nbsp; infecções&nbsp; e&nbsp; alteração&nbsp; da&nbsp; voz;</span></span></span></p>
<p></p></div>
<div>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; de&nbsp; adalimumabe,&nbsp; etanercepte,&nbsp; infliximabe,&nbsp; certolizumabe&nbsp; pegol&nbsp; e&nbsp; golimumabe:&nbsp; reações&nbsp; no&nbsp; local&nbsp; da&nbsp; aplicação&nbsp; da&nbsp; injeção&nbsp; como&nbsp; dor&nbsp; e&nbsp; coceiras,&nbsp; dor&nbsp; de&nbsp; cabeça,&nbsp; tosse,&nbsp; náuseas,&nbsp; vômitos,&nbsp; febre,&nbsp; cansaço,&nbsp; alteração&nbsp; na&nbsp; pressão&nbsp; arterial;&nbsp; reações&nbsp; mais&nbsp; graves:</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">infecções&nbsp; oportunísticas&nbsp; fúngicas&nbsp; e&nbsp; bacterianas&nbsp; do&nbsp; trato&nbsp; respiratório&nbsp; superior,&nbsp; como&nbsp; faringite,&nbsp; rinite,&nbsp; laringite,&nbsp; tuberculose,&nbsp; histoplasmose,&nbsp; aspergilose&nbsp; e&nbsp; nocardiose,&nbsp; podendo,&nbsp; em&nbsp; casos&nbsp; raros,&nbsp; ser&nbsp; fatal;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; de&nbsp; abatacepte&nbsp; e&nbsp; rituximabe:&nbsp; reações&nbsp; no&nbsp; local&nbsp; da&nbsp; aplicação&nbsp; da&nbsp; injeção&nbsp; ou&nbsp; reações&nbsp; alérgicas&nbsp; durante&nbsp; ou&nbsp; após&nbsp; a&nbsp; infusão,&nbsp; dor&nbsp; de&nbsp; cabeça,&nbsp; nasofaringite,&nbsp; enjoos&nbsp; e&nbsp; risco&nbsp; aumentado&nbsp; a&nbsp; uma&nbsp; variedade&nbsp; de&nbsp; infecções,&nbsp; como&nbsp; herpes-&nbsp; zóster,&nbsp; infecção&nbsp; urinária,&nbsp; gripe,&nbsp; pneumonia,&nbsp; bronquite&nbsp; e&nbsp; infecção&nbsp; localizada.&nbsp; A&nbsp; tuberculose&nbsp; pode&nbsp; ser&nbsp; reativada&nbsp; ou&nbsp; iniciada&nbsp; com&nbsp; o&nbsp; uso&nbsp; do&nbsp; medicamento&nbsp; e&nbsp; aumento&nbsp; de&nbsp; risco&nbsp; para&nbsp; alguns&nbsp; tipos&nbsp; de&nbsp; câncer&nbsp; (abatacepte).&nbsp; O&nbsp; vírus&nbsp; da&nbsp; hepatite&nbsp; B&nbsp; pode&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">ser&nbsp; reativado&nbsp; (rituximabe);</span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; efeitos&nbsp; adversos&nbsp; do&nbsp; tocilizumabe:&nbsp; reações&nbsp; no&nbsp; local&nbsp; da&nbsp; aplicação&nbsp; da&nbsp; injeção&nbsp; e&nbsp; durante&nbsp; a&nbsp; infusão,&nbsp; alergias,&nbsp; coceira,&nbsp; urticária,&nbsp; dor&nbsp; de&nbsp; cabeça,&nbsp; tonturas,&nbsp; aumento&nbsp; da&nbsp; pressão&nbsp; sanguínea,&nbsp; tosse,&nbsp; falta&nbsp; de&nbsp; ar,&nbsp; feridas&nbsp; na&nbsp; boca,&nbsp; aftas,&nbsp; dor&nbsp; abdominal&nbsp; e&nbsp; risco&nbsp; aumentado&nbsp; a&nbsp; uma&nbsp; variedade&nbsp; de&nbsp; infecções,&nbsp; como&nbsp; infecções&nbsp; de&nbsp; vias&nbsp; aéreas&nbsp; superiores,&nbsp; celulite,&nbsp; herpes&nbsp; simples&nbsp; e&nbsp; herpes-zóster,&nbsp; alterações&nbsp; nos&nbsp; exames&nbsp; laboratoriais&nbsp; (aumento&nbsp; das&nbsp; enzimas&nbsp; do&nbsp; fígado,&nbsp; bilirrubinas,&nbsp; aumento&nbsp; do&nbsp; colesterol&nbsp; e&nbsp; triglicerídios);</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; alguns&nbsp; medicamentos&nbsp; biológicos&nbsp; aumentam&nbsp; o&nbsp; risco&nbsp; de&nbsp; tuberculose,&nbsp; devendo&nbsp; ser&nbsp; realizada&nbsp; antes&nbsp; do&nbsp; início&nbsp; do&nbsp; tratamento&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">pesquisa&nbsp; de&nbsp; infecção&nbsp; ativa&nbsp; ou&nbsp; de&nbsp; tuberculose&nbsp; latente,&nbsp; para&nbsp; tratamento&nbsp; apropriado;</span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; medicamentos&nbsp; contraindicados&nbsp; em&nbsp; casos&nbsp; de&nbsp; hipersensibilidade&nbsp; (alergia)&nbsp; aos&nbsp; fármacos&nbsp; ou&nbsp; aos&nbsp; componentes&nbsp; da&nbsp; fórmula;</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">–&nbsp; o&nbsp; risco&nbsp; de&nbsp; ocorrência&nbsp; de&nbsp; efeitos&nbsp; adversos&nbsp; aumenta&nbsp; com&nbsp; a&nbsp; superdosagem.</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Estou&nbsp; ciente&nbsp; de&nbsp; que&nbsp; este(s)&nbsp; medicamento(s)&nbsp; somente&nbsp; pode(m)&nbsp; ser&nbsp; utilizado(s)&nbsp; por&nbsp; mim,&nbsp; comprometendo-me&nbsp; a&nbsp; devolvê-&nbsp; lo(s)&nbsp; caso&nbsp; não&nbsp; queira&nbsp; ou&nbsp; não&nbsp; possa&nbsp; utilizá-lo(s)&nbsp; ou&nbsp; se&nbsp; o&nbsp; tratamento&nbsp; for&nbsp; interrompido.</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Sei&nbsp; também&nbsp; que&nbsp; continuarei&nbsp; a&nbsp; ser&nbsp; atendido(a)&nbsp; inclusive&nbsp; em&nbsp; caso&nbsp; de&nbsp; desistir&nbsp; da&nbsp; usar&nbsp; o(s)&nbsp; medicamento(s).</span></span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Autorizo&nbsp; o&nbsp; Ministério&nbsp; da&nbsp; Saúde&nbsp; e&nbsp; as&nbsp; Secretarias&nbsp; de&nbsp; Saúde&nbsp; a&nbsp; fazerem&nbsp; uso&nbsp; de&nbsp; informações&nbsp; relativas&nbsp; ao&nbsp; meu&nbsp; tratamento,&nbsp; desde&nbsp; que&nbsp; assegurado&nbsp; o&nbsp; anonimato.</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; Sim&nbsp; (&nbsp; )&nbsp; Não</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Meu&nbsp; tratamento&nbsp; constará&nbsp; de&nbsp; um&nbsp; ou&nbsp; mais&nbsp; dos&nbsp; seguintes&nbsp; medicamentos:&nbsp; (&nbsp; )&nbsp; naproxeno</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; cloroquina</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; hidroxicloroquina</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; sulfassalazina</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; metotrexato</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; azatioprina</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; ciclosporina</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; leflunomida</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; metilprednisolona</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; adalimumabe</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; certolizumabe&nbsp; pegol</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; etanercepte</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; infliximabe</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; golimumabe</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; abatacepte</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; rituximabe</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 11.25pt; text-align: justify;">
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">(&nbsp; )&nbsp; tocilizumabe</span></span></span></span></span></p>
<p>
			<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<table border="1" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td colspan="3" data-obsoleto="width: 274px; height: 12px;">
<p data-obsoleto="margin-left: 5.1pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Local:&nbsp; Data:</span></span></span></span></span></p>
</td>
</tr>
<tr>
<td colspan="3" data-obsoleto="width: 274px; height: 12px;">
<p data-obsoleto="margin-left: 5.1pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Nome&nbsp; do&nbsp; paciente:</span></span></span></span></span></p>
</td>
</tr>
<tr>
<td colspan="3" data-obsoleto="width: 274px; height: 13px;">
<p data-obsoleto="margin-left: 5.1pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Cartão&nbsp; Nacional&nbsp; de&nbsp; Saúde:</span></span></span></span></span></p>
</td>
</tr>
<tr>
<td colspan="3" data-obsoleto="width: 274px; height: 13px;">
<p data-obsoleto="margin-left: 5.1pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Nome&nbsp; do&nbsp; responsável&nbsp; legal:</span></span></span></span></span></p>
</td>
</tr>
<tr>
<td colspan="3" data-obsoleto="width: 274px; height: 13px;">
<p data-obsoleto="margin-left: 16.55pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Documento&nbsp; de&nbsp; identificação&nbsp; do&nbsp; responsável&nbsp; legal:</span></span></span></span></span></p>
</td>
</tr>
<tr>
<td colspan="3" data-obsoleto="width: 274px; height: 24px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 5.1pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Assinatura&nbsp; do&nbsp; paciente&nbsp; ou&nbsp; do&nbsp; responsável&nbsp; legal</span></span></span></span></span></p>
</td>
</tr>
<tr>
<td data-obsoleto="width: 178px; height: 13px;">
<p data-obsoleto="margin-left: 30.8pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Médico&nbsp; responsável:</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 52px; height: 13px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">CRM:</span></span></span></span></span></p>
</td>
<td data-obsoleto="width: 44px; height: 13px;">
<p data-obsoleto="margin-left: 4.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">UF:</span></span></span></span></span></p>
</td>
</tr>
<tr>
<td colspan="3" data-obsoleto="width: 274px; height: 36px;">
<p>
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 46.8pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Assinatura&nbsp; e&nbsp; carimbo&nbsp; do&nbsp; médico</span></span></span></span></span></p>
<p data-obsoleto="margin-left: 49.95pt;">
							<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Data:</span></span></span></span></span></p>
</td>
</tr>
</tbody>
</table></div>
<p>	<br clear="all"></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">Observação:&nbsp; Este&nbsp; Termo&nbsp; é&nbsp; obrigatório&nbsp; ao&nbsp; se&nbsp; solicitar&nbsp; o&nbsp; fornecimento&nbsp; de&nbsp; medicamento&nbsp; do&nbsp; Componente&nbsp; Especializado&nbsp; da&nbsp; Assistência&nbsp; Farmacêutica&nbsp; e&nbsp; deverá&nbsp; ser&nbsp; preenchido&nbsp; em&nbsp; duas&nbsp; vias:&nbsp; uma&nbsp; será&nbsp; arquivada&nbsp; na&nbsp; farmácia,&nbsp; e&nbsp; a&nbsp; outra,&nbsp; entregue&nbsp; ao&nbsp; usuário&nbsp; ou&nbsp; a&nbsp; seu&nbsp; responsável&nbsp; legal.</span></span></span></span></span></p>
<p data-obsoleto="text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">NOTA&nbsp; 1&nbsp; –&nbsp; A&nbsp; administração&nbsp; intravenosa&nbsp; de&nbsp; metilprednisolona&nbsp; é&nbsp; compatível&nbsp; com&nbsp; o&nbsp; procedimento&nbsp; 03.03.02.001-6&nbsp; –&nbsp; Pulsoterapia&nbsp; I&nbsp; (por&nbsp; aplicação),&nbsp; da&nbsp; Tabela&nbsp; de&nbsp; Procedimentos,&nbsp; Medicamentos,&nbsp; Órteses,&nbsp; Próteses&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">e&nbsp; Materiais&nbsp; do&nbsp; SUS.</span></span></span></p>
<p data-obsoleto="text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">NOTA&nbsp; 2&nbsp; –&nbsp; A&nbsp; administração&nbsp; intravenosa&nbsp; de&nbsp; ciclofosfamida&nbsp; é&nbsp; compatível&nbsp; com&nbsp; o&nbsp; procedimento&nbsp; 03.03.02.002-4&nbsp; –&nbsp; Pulsoterapia&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">II&nbsp; (por&nbsp; aplicação),&nbsp; da&nbsp; Tabela&nbsp; de&nbsp; Procedimentos,&nbsp; Medicamentos,&nbsp; Órteses,&nbsp; Próteses&nbsp; e&nbsp; Materiais&nbsp; do&nbsp; SUS.</span></span></span></p>
<p data-obsoleto="text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;</span></span></span></p>
<p data-obsoleto="margin-left: 5.25pt; text-align: justify;">
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;"><span data-obsoleto="background-color:#ffffff;">NOTA&nbsp; 3&nbsp; –&nbsp; A&nbsp; administração&nbsp; intra-articular&nbsp; de&nbsp; metilprednisolona&nbsp; é&nbsp; compatível&nbsp; com&nbsp; o&nbsp; procedimento&nbsp; 03.03.09.003-0&nbsp; –&nbsp; Infiltração&nbsp; de&nbsp; substâncias&nbsp; em&nbsp; cavidade&nbsp; sinovial,&nbsp; da&nbsp; Tabela&nbsp; de&nbsp; Procedimentos,&nbsp; Medicamentos,&nbsp;</span></span></span><span data-obsoleto="font-family: arial, helvetica, sans-serif;">Órteses,&nbsp; Próteses&nbsp; e&nbsp; Materiais&nbsp; do&nbsp; SUS.</span></span></span></p>
<div>
		<span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-family:arial,helvetica,sans-serif;">&nbsp;<span id="cke_bm_106E" data-obsoleto="display: none;">&nbsp;</span></span></span></span></div>
</div>
<p>
	<span data-obsoleto="display: none;">&nbsp;</span></p>

								</div>
							</article>

						</div>
					
						<div id="post-2396" class="divs-interno">
							<article>
								<div class="content-img">
									<div class="box-notdestaque">
										<div class="container-img-noticia">
											<img src=" ">
										</div>
									</div>
								</div>
								<div class="content-data">

									<span class="data">24 de junho de 2014</span>
								</div>
								<div class="content-text">
									<header>
										<h1>COFFITO mostra importância da Fisioterapia e da Terapia Ocupacional no CONASEMS</h1>
									</header>
									<p align="center"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-size:18px;"><strong>COFFITO mostra importância da Fisioterapia e da Terapia Ocupacional no CONASEMS</strong></span></span></p>
<p align="center"><span data-obsoleto="color:#000000;"><span data-obsoleto="font-size:14px;"><em>Profissionais aproveitam evento para exemplificar suas atuações e atraem atenção de gestores municipais</em></span></span></p>
<p align="center"><span data-obsoleto="color:#000000;"><img decoding="async" src="http://coffito.gov.br/nsite/wp-content/uploads/images/10427266_10202847122671630_8842196069247441295_n.jpg" alt=""></span><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Mostrar a importância do trabalho desenvolvido por fisioterapeutas e por terapeutas ocupacionais e auxiliar gestores públicos na inserção da Fisioterapia e da Terapia Ocupacional, por meio de políticas públicas, nos municípios, foram as estratégias adotadas pelo COFFITO durante o XXX Congresso Nacional de Secretarias Municipais de Saúde (Conasems) e o XI Congresso Brasileiro de Saúde, Cultura de Paz e Não Violência, realizados de 1º a 4 de junho, na cidade de Serra, ES, que receberam cerca de 5 mil visitantes.</span></span></p>
<div><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Parceiro de longa data desses eventos, o COFFITO, apoiado pelos Regionais, levou profissionais de todo o Brasil para contextualizar e exemplificar a amplitude das profissões de Fisioterapia e de Terapia Ocupacional. Para a terapeuta ocupacional e auditora do SUS, Dra. Lauriluci Farias Lopes de Albuquerque, responsável pelo atendimento aos gestores de saúde, foi possível constatar que ainda é necessário mostrar as diversas áreas de atuação das profissões, bem como explicar projetos de saúde a que o munícipio pode aderir e, por intermédio dessas ações, contratar fisioterapeutas e terapeutas ocupacionais. Ainda que muitos gestores pouco conhecessem o trabalho das citadas profissões, Lauriluci pôde constatar que o Plano Viver Sem Limites já era realidade em alguns municípios e destacou um deles em que havia uma gestora fisioterapeuta.</span></span></div>
<div></div>
<div><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Durante o evento, foi realizado cadastro com nome e contato dos gestores que visitaram o estande. A partir desse cadastro, no dia 10 de junho, foram enviados pelo COFFITO materiais que visam subsidiar a inclusão do fisioterapeuta e do terapeuta ocupacional no Núcleo de Apoio à Saúde da Família (Nasf) do Governo Federal.</span></span></div>
<div></div>
<div><strong><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Fisioterapia&nbsp;</span></span></strong></div>
<div></div>
<div><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Para a coordenadora de Fisioterapia do Conasems e conselheira do COFFITO, Dra. Elineth da Conceição da S. Braga, a ação serviu para ressaltar que o atendimento de Fisioterapia não está restrito ao setor terciário, ou seja, à recuperação. Segundo ela, em conversa com os gestores, parte do trabalho é direcionado à atuação do fisioterapeuta na prevenção. “O estande do COFFITO já virou tradição e, aproveitando isso, neste ano, levamos as diversas atribuições do fisioterapeuta, principalmente nas especialidades, como Fisioterapia do Trabalho, Fisioterapia Dermatofuncional, Fisioterapia Esportiva e Fisioterapia em Osteopatia, que poderiam ser utilizadas na prevenção”, ressaltou.</span></span></div>
<div></div>
<div><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">De acordo com a Dra. Elineth, cabe ressaltar que neste ano já foi possível constatar resultados do trabalho de divulgação das profissões junto aos gestores, pois, em mais de uma oportunidade, os secretários de saúde mencionaram que, após orientações do COFFITO, em edições passadas do Conasems, conseguiram inserir fisioterapeutas e terapeutas ocupacionais em seus municípios.</span></span></div>
<div></div>
<div><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Para demonstrar as especialidades da Fisioterapia, quem passou pelo estande recebeu atendimento em osteopatia, orientações sobre postura no ambiente de trabalho e tratamentos da área dermatofuncional. Ainda, de forma descontraída, antes da realização das palestras, o Dr. Jefferson de Freitas Ferla, fisioterapeuta, realizou momentos de ginástica laboral. Porém o diferencial esteve no fato de que esse profissional não usou o tradicional jaleco branco e, sim, roupa e maquiagem de Charles Chaplin.</span></span></div>
<div></div>
<div><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Aproveitando a fantasia e lado cômico do personagem, Jefferson passeou pelo local em uma cadeira de rodas e mostrou aos gestores as dificuldades de acessibilidade usualmente enfrentadas por pessoas com deficiência. “Às vezes, o local possuía rampa de acessibilidade, mas algo estava na frente e impedia a passagem. Outras, a rampa era tão íngreme que exigia um imenso esforço físico para passar por ela”, ressaltou.</span></span></div>
<div></div>
<div><strong><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Terapia Ocupacional</span></span></strong></div>
<div></div>
<div><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">A Terapia Ocupacional, por sua vez, aproveitou o espaço para mostrar o trabalho com as tecnologias assistidas e adaptações. De acordo com a coordenadora da Terapia Ocupacional e vice-presidente do COFFITO, Dra. Luziana Maranhão, durante o evento, os gestores puderam vivenciar novas experiências, por meio da simulação de uma incapacidade. &nbsp;“Imobilizamos o braço dominante com uma tipoia e ensinamos, com adaptações, o retorno às atividades cotidianas, tanto na parte de alimentação como na de higiene pessoal. Por meio das Atividades de Vida Diária (AVD), enfatizamos a importância do trabalho da Terapia Ocupacional”, destacou.</span></span></div>
<div></div>
<div><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Ainda segundo a Dra. Luziana, ao conversar com os gestores, foi possível perceber que existe grande trabalho referente à Terapia Ocupacional, seja na divulgação da profissão, seja na pouca oferta de terapeutas ocupacionais em todo o país. Para ela, o evento serviu como forma de subsidiar o trabalho que vem sendo realizado pelo Conselho Federal em prol da abertura de novos cursos de Terapia Ocupacional. “Reforçamos as ações de divulgação para que os gestores conheçam a Terapia Ocupacional e vejam a necessidade de inclusão desse profissional no município, resultando em benefícios aos usuários e mostrando à sociedade e ao governo a necessidade da abertura de mais cursos no Brasil.” No estande, os terapeutas ocupacionais aplicaram testes cognitivos, de memória e voltados ao desempenho na área de saúde do trabalhador, tendo significativa adesão dos participantes do evento.</span></span></div>
<div></div>
<div><strong><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">Agradecimento</span></span></strong></div>
<div></div>
<div><span data-obsoleto="font-size:14px;"><span data-obsoleto="color:#000000;">O COFFITO agradece a colaboração dos profissionais e dos CREFITOs no que tange à participação no XXX Congresso Nacional de Secretarias Municipais de Saúde (Conasems). “O apoio do Sistema, que nos auxiliou no envio de profissionais e de materiais de divulgação, e a união das categorias contribuíram imensamente para o sucesso de mais esta edição do Conasems. Neste ano, começamos a evidenciar ainda mais os resultados que essas participações trazem. Nosso estande foi visitado pelos gestores e secretários municipais de saúde de todo o Brasil; as especialidades das nossas profissões estão sendo mais reconhecidas nacionalmente”, enfatizou o presidente do COFFITO, Dr. Roberto Mattar Cepeda.&nbsp;</span></span></div>
<p data-obsoleto="text-align: justify;">
</p><p data-obsoleto="text-align: justify;">
</p><p>&nbsp;</p>

								</div>
							</article>

						</div>
					
						<div id="post-3012" class="divs-interno">
							<article>
								<div class="content-img">
									<div class="box-notdestaque">
										<div class="container-img-noticia">
											<img src=" ">
										</div>
									</div>
								</div>
								<div class="content-data">

									<span class="data">15 de maio de 2014</span>
								</div>
								<div class="content-text">
									<header>
										<h1>RESOLUÇÃO COFFITO nº 254/2003 – Prorrogado o prazo para acolhimento de títulos concedidos pela Sociedade Brasileira de Fisioterapia Respiratória para fins de registro no Coffito e dá outras providências</h1>
									</header>
									<p style="text-align: center;" data-obsoleto="text-align: center;"><span data-obsoleto="font-size:16px;"><strong>RESOLUÇÃO Nº. 254, DE </strong><strong>2 DE OUTUBRO DE 2003</strong></span></p>
<p style="text-align: center;" data-obsoleto="text-align: center;">(DOU Nº 193, DE 06.10.03, SEÇÃO I, PÁG.151)</p>
<p data-obsoleto="text-align: right;">Prorrogado o prazo para acolhimento de títulos concedidos pela Sociedade Brasileira de Fisioterapia Respiratória para fins de registro no Coffito e dá outras providências. <a href="https://www.coffito.gov.br/nsite/?p=3012#more-3012" class="more-link">Continue reading <span class="meta-nav">»</span></a></p>

								</div>
							</article>

						</div>
					
			</div>
			<div id="paginacao">

				<a class="prev page-numbers" href="https://www.coffito.gov.br/nsite/?s=+474&amp;paged=1">« Anterior</a>
<a class="page-numbers" href="https://www.coffito.gov.br/nsite/?s=+474&amp;paged=1">1</a>
<span aria-current="page" class="page-numbers current">2</span>
<a class="page-numbers" href="https://www.coffito.gov.br/nsite/?s=+474&amp;paged=3">3</a>
<a class="next page-numbers" href="https://www.coffito.gov.br/nsite/?s=+474&amp;paged=3">Próximo »</a>
			</div>
		</section>
	</main>
	<footer>
<section id="container-rodape">
    <div id="content-rodape">
      <div class="btn-rodape">
            <a id="btnLink" title="ir para o topo" href="#container-topo">
              <!-- <img title="ir para o topo" alt="ir para o topo" src="./img/setaTop.png"/> -->
            </a>
            <span>topo</span>
      </div>
      <div id="content-rodape-ms">
		<a href="https://whatsapp.com/channel/0029Vb4FZ7xElagnZMndzH3K " target="_blank" title="whatsapp"> <i class="fa-brands fa-whatsapp"></i></a>
        <a href="https://www.facebook.com/Coffitooficial/" target="_blank" title="facebook"> <i class="fa-brands fa-facebook"></i></a>
        <a href="https://www.youtube.com/channel/UCz9pTR7-65dqctZ5i0WfaRw" target="_blank" title="youtube"><i class="fa-brands fa-youtube"></i></a>
        <!--<a href="https://twitter.com/@coffito_oficial" target="_blank" title="twitter"><i class="fa-brands fa-twitter"></i></a>-->
        <a href="https://www.instagram.com/coffito" target="_blank" title="instagram"><i class="fa-brands fa-instagram"></i></a>
        <a href="https://www.tiktok.com/@coffito?_t=ZM-8v9TPLASs6B&amp;_r=1" target="_blank" title="TikTok"><i class="fa-brands fa-tiktok"></i></a>
      </div>
      <div id="content-rodape-info">
        <address>
          <ul class="listaEndereco">
            <li>Conselho Federal de Fisioterapia e Terapia Ocupacional - COFFITO</li>
 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<li>Sede: SIA Trecho 17, 810 - Parque Ferroviário.</li>
            <li>CEP: 71200-260 - Brasília - DF.</li>
            <li>Telefone: <a href="tel:(61)3035-7120">(61)3035-7120</a></li>
			<li>Horário de funcionamento: 08h00 as 18h00 de segunda a sexta.</li>
			<li>Horário de funcionamento do protocolo: 09h00 as 17h00 de segunda a sexta.</li>
            <li>
              <hr>
            </li>
            <li>CNPJ: 00.487.140/0001-36</li>
          </ul>
        </address>
        <hr>
      </div>
      <h2 id="btn-contato">Contatos</h2>
      <div id="content-rodape-contato">
        <table>
          <thead>
            <tr>
              <th>Regional</th>
              <th>Telefone</th>
              <th>E-mail</th>
              <th>Site</th>
            </tr>
          </thead>
          <tfoot>
          </tfoot>
          <tbody>
            <tr>
              <td rowspan="1">Ouvidoria - COFFITO</td>
              <td><a href="tel:(61) 3035-7120">(61) 3035-7120</a></td>
              <td><a href="https://www.coffito.gov.br/nsite/?page_id=25547">Fala.BR</a></td>
              <td><a href="https://coffito.gov.br" target="_blank">www.coffito.gov.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-1 - (PE, PB, AL e RN)</td>
              <td><a href="tel:(81) 3081-5000">(81) 3081-5000</a></td>
              <td><a href="mailto:crefito1@crefito1.org.br">crefito1@crefito1.org.br</a></td>
              <td><a href="https://www.crefito1.org.br" target="_blank">www.crefito1.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-2 - (RJ)</td>
              <td><a href="tel:(21) 2169-2169">(21) 2169-2169</a></td>
              <td><a href="mailto:faleconosco@crefito2.org.br ">faleconosco@crefito2.org.br </a></td>
              <td><a href="https://crefito2.gov.br/" target="_blank">www.crefito2.gov.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-3 - (SP)</td>
              <td><a href="tel:(11) 3252-2255">(11) 3252-2255</a></td>
              <td><a href="mailto:">-</a></td>
              <td><a href="https://www.crefito3.org.br/" target="_blank">www.crefito3.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-4 - (MG)</td>
              <td><a href="tel:(31) 3218-7400">(31) 3218-7400</a> / <a href="tel:(31)99584-5961">(31) 99584-5961</a></td>
              <td><a href="mailto: crefito4@crefito4.gov.br">crefito4@crefito4.gov.br</a></td>
              <td><a href="https://crefito4.gov.br" target="_blank">www.crefito4.gov.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-5 - (RS)</td>
              <td><a href="tel:(51) 3334-6586">(51) 3334-6586</a></td>
              <td><a href="mailto:atendimento@crefito5.org.br">atendimento@crefito5.org.br</a></td>
              <td><a href="https://www.crefito5.org.br/" target="_blank">www.crefito5.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-6 - (CE)</td>
              <td><a href="tel:(85) 3241-1456">(85) 3241-1456</a></td>
              <td><a href="mailto: crefito6@crefito6.org.br"> crefito6@crefito6.org.br</a></td>
              <td><a href="https://crefito6.org.br/" target="_blank">www.crefito6.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-7 - (BA)</td>
              <td><a href="tel:(71) 3341-4271">(71) 3341-4271</a></td>
              <td><a href="mailto:">-</a></td>
              <td><a href="https://crefito7.gov.br/" target="_blank">www.crefito7.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-8 - (PR)</td>
              <td><a href="tel:0800-645-2009">0800-645-2009</a> / <a href="tel:(41) 3264-8097">(41) 3264-8097</a></td>
              <td><a href="mailto:">-</a></td>
              <td><a href="https://www.crefito8.gov.br/" target="_blank">www.crefito8.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-9 - (MT)</td>
              <td><a href="tel:(65) 3644-4272">(65) 3644-4272</a></td>
              <td><a href="mailto:">-</a></td>
              <td><a href="https://www.crefito9.org.br/" target="_blank">www.crefito9.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-10 - (SC)</td>
              <td><a href="tel:(48) 3225-3329">(48) 3225-3329</a></td>
              <td><a href="mailto:crefito10@crefito10.org.br">crefito10@crefito10.org.br</a></td>
              <td><a href="https://crefito10.org.br/" target="_blank">www.crefito10.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-11 - (DF)</td>
              <td><a href="tel:(61) 3225-3700">(61) 3225-3700</a></td>
              <td><a href="mailto:atendimento@crefito11.gov.br">atendimento@crefito11.gov.br</a></td>
              <td><a href="https://crefito11.gov.br/" target="_blank">www.crefito11.gov.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-12 - (PA, TO e AP)</td>
              <td><a href="tel:(91) 3249-1787">(91) 3249-1787</a> / <a href="tel:(91) 3259-1653">(91) 3259-1653</a> / <a href="tel:(91) 98814-0213">(91) 98814-0213</a></td>
              <td><a href="mailto:crefito12@crefito12.org.br">crefito12@crefito12.org.br</a></td>
              <td><a href="https://crefito12.org.br/" target="_blank">www.crefito12.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-13 - (MS)</td>
              <td><a href="tel:(67) 3321-4558">(67) 3321-4558</a></td>
              <td><a href="mailto:crefito13@crefito13.org.br">crefito13@crefito13.org.br</a></td>
              <td><a href="https://www.crefito13.org.br" target="_blank">www.crefito13.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-14 - (PI)</td>
              <td><a href="tel:(86) 3216-6030">(86) 3216-6030</a></td>
              <td><a href="mailto:secretaria@crefito14.org.br">secretaria@crefito14.org.br</a></td>
              <td><a href="https://www.crefito14.org.br" target="_blank">www.crefito14.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-15 - (ES)</td>
              <td><a href="tel:(27) 3227-6616">(27) 3227-6616</a></td>
              <td><a href="mailto:crefito15@crefito15.org.br">crefito15@crefito15.org.br</a></td>
              <td><a href="https://www.crefito15.org.br" target="_blank">www.crefito15.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-16 - (MA)</td>
              <td><a href="tel:(98) 3304-7779">(98) 3304-7779</a> / <a href="tel:(98) 3304-7774">(98) 3304-7774</a></td>
              <td><a href="mailto:crefito16@crefito16.gov.br">crefito16@crefito16.gov.br</a></td>
              <td><a href="https://www.crefito16.gov.br" target="_blank">www.crefito16.gov.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-17 - (SE)</td>
              <td><a href="tel:(79) 3024-2476">(79) 3024-2476</a></td>
              <td><a href="mailto:">-</a></td>
              <td><a href="https://crefito17.org.br/" target="_blank">www.crefito17.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-18 - (RO e AC)</td>
              <td><a href="tel:(69) 3229-6960">(69) 3229-6960</a></td>
              <td><a href="mailto:">-</a></td>
              <td><a href="https://crefito18.org.br/" target="_blank">www.crefito18.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-19 - (GO)</td>
              <td><a href="tel:(62) 3945-6842"></a>(62) 3945-6842</td>
              <td><a href="mailto:atendimento@crefito19.org.br">atendimento@crefito19.org.br</a></td>
              <td><a href="https://crefito19.org.br" target="_blank">www.crefito19.org.br</a></td>
            </tr>
            <tr>
              <td rowspan="1">CREFITO-20 - (AM e RR)</td>
              <td><a href="tel:(92) 3213-5856"></a>(92) 3213-5856</td>
              <td><a href="mailto:secretaria@crefito20.org.br">secretaria@crefito20.org.br</a></td>
              <td><a href="https://crefito20.org.br/" target="_blank">www.crefito20.org.br</a></td>
            </tr>
          </tbody>
        </table>
        <div class="btn-rodape">
            <a id="btnLink2" title="ir para o topo" href="#container-topo">
              <!-- <img title="ir para o topo" alt="ir para o topo" src="./img/setaTop.png"/> -->
            </a>
            <span>topo</span>
      </div>
      </div>
    </div>
  </section>
</footer>

<script src="https://www.coffito.gov.br/nsite/wp-content/themes/coffitoV4/js/geral.js"></script></div>

</body></html>